fgen-10q_20190630.htm

0001564590-19-030812.txt : 20190808 0001564590-19-030812.hdr.sgml : 20190808 20190808162154 ACCESSION NUMBER: 0001564590-19-030812 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190808 DATE AS OF CHANGE: 20190808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FIBROGEN INC CENTRAL INDEX KEY: 0000921299 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36740 FILM NUMBER: 191009861 BUSINESS ADDRESS: STREET 1: 409 ILLINOIS STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-978-1200 MAIL ADDRESS: STREET 1: 409 ILLINOIS STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94158 10-Q 1 fgen-10q_20190630.htm 10-Q fgen-10q_20190630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36740

FIBROGEN, INC.

(Exact name of registrant as specified in its charter)

Delaware

77-0357827

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

409 Illinois Street
San Francisco, CA		94158
(Address of Principal Executive Offices)		(Zip Code)

(415) 978-1200

Registrant’s telephone number, including area code:

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.01 par value	FGEN	The Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☑	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes ☐ No ☑

The number of shares of common stock outstanding as of July 31, 2019 was 86,915,996.

FIBROGEN, INC.

TABLE OF CONTENTS

		Page
PART I—FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (Unaudited)	2
	Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018 (Unaudited)	2
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2019 and 2018 (Unaudited)	3
	Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2019 and 2018 (Unaudited)	4
	Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2019 and 2018 (Unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2019 and 2018 (Unaudited)	7
	Notes to the Condensed Consolidated Financial Statements (Unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	40
Item 4.	Controls and Procedures	40

PART II—OTHER INFORMATION

Item 1.	Legal Proceedings	41
Item 1A.	Risk Factors	41
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	83
Item 3.	Defaults Upon Senior Securities	83
Item 4.	Mine Safety Disclosures	83
Item 5.	Other Information	83
Item 6.	Exhibits	84
	Signatures	85

Table of Contents

FIBROGEN, INC.

PART I—FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited)

	June 30, 2019			December 31, 2018
Assets
Current assets:
Cash and cash equivalents	$	74,587		$	89,258
Short-term investments		586,174			532,144
Accounts receivable ($4,311 and $47,210 from a related party)		6,453			63,684
Inventories		1,981			—
Prepaid expenses and other current assets ($127,981 and $0 from a related party)		136,596			4,929
Total current assets		805,791			690,015

Restricted time deposits		4,145			4,145
Long-term investments		10,915			55,820
Property and equipment, net		44,865			127,198
Finance lease right-of-use assets		44,536			—
Other assets		4,814			3,420
Total assets	$	915,066		$	880,598

Liabilities, stockholders’ equity and non-controlling interests
Current liabilities:
Accounts payable	$	4,060		$	9,139
Accrued and other current liabilities ($781 and $444 to a related party)		66,545			66,123
Deferred revenue		136			13,771
Finance lease liabilities, current		12,071			—
Total current liabilities		82,812			89,033

Long-term portion of lease obligations		1,342			97,157
Product development obligations		16,846			16,798
Deferred rent		—			3,038
Deferred revenue, net of current		102,926			136,109
Finance lease liabilities, non-current		43,780			—
Other long-term liabilities		19,058			9,993
Total liabilities		266,764			352,128

Commitments and Contingencies

Stockholders’ equity:
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2019 and December 31, 2018		—			—
Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2019 and December 31, 2018; 86,847 and 85,432 shares issued and outstanding at June 30, 2019 and December 31, 2018		868			854
Additional paid-in capital		1,265,783			1,226,453
Accumulated other comprehensive loss		(462	)		(2,281	)
Accumulated deficit		(637,158	)		(715,827	)
Total stockholders’ equity		629,031			509,199
Non-controlling interests		19,271			19,271
Total equity		648,302			528,470
Total liabilities, stockholders’ equity and non-controlling interests	$	915,066		$	880,598

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Revenue:
License revenue (includes $117,470, $14,323, $117,470 and $14,323 from a related party)	$	150,581		$	14,323		$	150,581		$	14,323
Development and other revenue (includes $17,223, $6,145, $22,082 and $11,317 from a related party)		40,985			29,629			64,848			61,553
Total revenue		191,566			43,952			215,429			75,876

Operating expenses:
Research and development		52,008			52,138			102,505			109,112
Selling, general and administrative		26,739			15,055			48,948			30,605
Total operating expenses		78,747			67,193			151,453			139,717
Income (loss) from operations		112,819			(23,241	)		63,976			(63,841	)

Interest and other, net
Interest expense		(736	)		(2,750	)		(1,507	)		(5,519	)
Interest income and other, net		4,125			2,645			8,303			4,717
Total interest and other, net		3,389			(105	)		6,796			(802	)

Income (loss) before income taxes		116,208			(23,346	)		70,772			(64,643	)
Provision for income taxes		205			75			180			174
Net income (loss)	$	116,003		$	(23,421	)	$	70,592		$	(64,817	)

Net income (loss) per share:
Basic	$	1.34		$	(0.28	)	$	0.82		$	(0.78	)
Diluted	$	1.26		$	(0.28	)	$	0.77		$	(0.78	)
Weighted average number of common shares used to calculate net income (loss) per share:
Basic		86,445			83,750			86,077			83,309
Diluted		91,728			83,750			92,069			83,309

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019		2018
Net income (loss)	$	116,003		$	(23,421	)	$	70,592	$	(64,817	)
Other comprehensive income (loss):
Foreign currency translation adjustments		(180	)		958			111		431
Available-for-sale investments:
Unrealized gain on investments, net of tax effect		655			53			1,097		3
Other comprehensive income, net of taxes		475			1,011			1,208		434
Comprehensive income (loss)	$	116,478		$	(22,410	)	$	71,800	$	(64,383	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(In thousands, except share data)

(Unaudited)

	For The Three Month Period
	Common Stock				Additional Paid-in		Accumulated Other Comprehensive			Accumulated			Non Controlling
	Shares		Amount		Capital		Loss			Deficit			Interests		Total
Balance at March 31, 2019		86,129,564	$	861	$	1,242,460	$	(937	)	$	(753,161	)	$	19,271	$	508,494
Net income		—		—		—		—			116,003			—		116,003
Change in unrealized gain or loss on investments		—		—		—		655			—			—		655
Foreign currency translation adjustments		—		—		—		(180	)		—			—		(180	)
Shares issued from stock plans, net of payroll taxes paid		717,508		7		5,681		—			—			—		5,688
Stock-based compensation		—		—		17,642		—			—			—		17,642
Balance at June 30, 2019		86,847,072	$	868	$	1,265,783	$	(462	)	$	(637,158	)	$	19,271	$	648,302

Balance at March 31, 2018		83,420,625	$	834	$	1,173,109	$	(3,622	)	$	(670,803	)	$	19,271	$	518,789
Net loss		—		—		—		—			(23,421	)		—		(23,421	)
Change in unrealized gain or loss on investments		—		—		—		53			—			—		53
Foreign currency translation adjustments		—		—		—		958			—			—		958
Shares issued from stock plans, net of payroll taxes paid		762,219		8		5,184		—			—			—		5,192
Stock-based compensation		—		—		13,231		—			—			—		13,231
Balance at June 30, 2018		84,182,844	$	842	$	1,191,524	$	(2,611	)	$	(694,224	)	$	19,271	$	514,802

Table of Contents

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (CONTINUED)

(In thousands, except share data)

(Unaudited)

	For The Six Month Period
	Common Stock				Additional Paid-in		Accumulated Other Comprehensive			Accumulated			Non Controlling
	Shares		Amount		Capital		Loss			Deficit			Interests		Total
										(Note 1)
Balance at December 31, 2018		85,432,102	$	854	$	1,226,453	$	(2,281	)	$	(715,827	)	$	19,271	$	528,470
Impact of adoption of ASC 842 (Note 1)		—		—		—		—			8,688			—		8,688
Impact of change in accounting principle upon adoption of ASU 2018-02 (Note 1)		—		—		—		611			(611	)		—		—
Net income		—		—		—		—			70,592			—		70,592
Change in unrealized gain or loss on investments		—		—		—		1,097			—			—		1,097
Foreign currency translation adjustments		—		—		—		111			—			—		111
Shares issued from stock plans, net of payroll taxes paid		1,414,970		14		5,258		—			—			—		5,272
Stock-based compensation		—		—		34,072		—			—			—		34,072
Balance at June 30, 2019		86,847,072	$	868	$	1,265,783	$	(462	)	$	(637,158	)	$	19,271	$	648,302

Balance at December 31, 2017		82,498,128	$	825	$	1,160,094	$	(1,795	)	$	(630,657	)	$	19,271	$	547,738
Impact of change in accounting principle upon adoption of ASU 2016-01		—		—		—		(1,250	)		1,250			—		—
Net loss		—		—		—		—			(64,817	)		—		(64,817	)
Change in unrealized gain or loss on investments		—		—		—		3			—			—		3
Foreign currency translation adjustments		—		—		—		431			—			—		431
Shares issued from stock plans, net of payroll taxes paid		1,684,716		17		7,321		—			—			—		7,338
Stock-based compensation		—		—		24,109		—			—			—		24,109
Balance at June 30, 2018		84,182,844	$	842	$	1,191,524	$	(2,611	)	$	(694,224	)	$	19,271	$	514,802

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six Months Ended June 30,
	2019			2018
Operating activities
Net income (loss)	$	70,592		$	(64,817	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation		5,523			3,083
Amortization of finance lease right-of-use assets		5,140			—
Net amortization of premium and discount on investments		(2,457	)		463
Unrealized loss (gain) on cash equivalents and short-term equity investments		(59	)		1,127
Loss (gain) on disposal of property and equipment		(10	)		53
Stock-based compensation		34,072			24,109
Realized foreign currency gain		—			(1,074	)
Realized gain on sales of available-for-sale securities		—			(87	)
Changes in operating assets and liabilities:
Accounts receivable		57,231			(21,737	)
Inventories		(1,981	)		—
Prepaid expenses and other current assets		(131,803	)		(13,197	)
Other assets		(200	)		(722	)
Accounts payable		(5,079	)		(2,287	)
Accrued and other liabilities		917			(13,371	)
Deferred revenue		(46,818	)		20,370
Lease obligations		—			25
Accrued interest for finance lease liabilities		241			—
Other long-term liabilities		8,519			1,135
Net cash used in operating activities		(6,172	)		(66,927	)

Investing activities
Purchases of property and equipment		(2,206	)		(3,705	)
Proceeds from sale of property and equipment		—			184
Purchases of available-for-sale securities and term deposit		(105,511	)		(98	)
Proceeds from sales of available-for-sale securities		—			8,167
Proceeds from maturities of investments		100,000			25,390
Net cash provided by (used in) investing activities		(7,717	)		29,938

Financing activities
Repayments of finance lease liabilities		(5,850	)		—
Repayments of lease obligations		(202	)		(201	)
Cash paid for payroll taxes on restricted stock unit releases		(8,065	)		(10,005	)
Proceeds from issuance of common stock		13,337			17,343
Net cash provided by (used in) financing activities		(780	)		7,137
Effect of exchange rate change on cash and cash equivalents		(2	)		(3	)
Net decrease in cash and cash equivalents		(14,671	)		(29,855	)
Total cash and cash equivalents at beginning of period		89,258			673,658
Total cash and cash equivalents at end of period	$	74,587		$	643,803

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

FIBROGEN, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.	Significant Accounting Policies

Description of Operations

FibroGen, Inc. (“FibroGen” or the “Company”), incorporated in 1993 in Delaware and headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China (“China”), is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (“HIF”), connective tissue growth factor (“CTGF”) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase (“HIF-PH”) activity, completing Phase 3 clinical development worldwide for the treatment of anemia in chronic kidney disease (“CKD”), with a New Drug Application (“NDA”) now approved by the National Medical Products Administration (“NMPA”) in China. The Company and its collaboration partners AstraZeneca AB (“AstraZeneca”) and Astellas Pharma Inc. (“Astellas”) are in the process of preparing an NDA for submission to the United States (“U.S.”) Food and Drug Administration (“FDA”) and a Marketing Authorization Application (“MAA”) for submission to the European Medicines Agency (“EMA”) this year. Astellas submitted an NDA for the treatment of anemia in CKD patients on dialysis in Japan in September 2018, which is currently under review by the Pharmaceuticals and Medical Devices Agency (“PMDA”). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (“MDS”). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (“IPF”), and advancing towards Phase 3 for the treatment of pancreatic cancer. Pamrevlumab is also currently in a Phase 2 trial for Duchenne muscular dystrophy (“DMD”). FibroGen is also developing a biosynthetic cornea in China.

Basis of Presentation and Principles of Consolidation

The condensed consolidated financial statements include the accounts of FibroGen, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. (“FibroGen China”). All inter-company transactions and balances have been eliminated in consolidation. The Company operates in one segment — the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.

The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2018 (“2018 Form 10-K”).

The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2018 Form 10-K, except for the following:

Leases

The Company determines if an arrangement is a lease at inception date when it is given control of the underlying assets. The Company elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of 12 months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.

The Company’s building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (“ASC”) 842 - Leases (“ASC 842”) are accounted for as finance leases under the requirements of ASC 842.

Lease right-of-use (“ROU”) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As its leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company will reassess the incremental borrowing rate periodically for application to any new leases or lease modifications or if any company-specific or general business conditions warrant.

Table of Contents

Lease ROU assets include any lease payments made and initial direct costs incurred. The Company has lease agreements with lease and non-lease components. The Company generally accounts for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability.

The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms.

Regarding leases denominated in a foreign currency, the related ROU assets and the corresponding ROU asset amortization costs are remeasured using the exchange rate in effect at the date of initial recognition; the related lease liabilities are remeasured using the exchange rate in effect at the end of the reporting period; the lease costs and interest expenses related to lease liability accretion are remeasured using average exchange rates for the reporting period.

Finance leases are included in finance lease ROU assets, finance lease liabilities, current and non-current on the Company’s consolidated balance sheets. Operating leases are included in other assets, accrued and other current liabilities, and other long-term liabilities on the Company’s consolidated balance sheets.

Inventories

Inventories are stated at the lower of cost and net realizable value. The cost of inventories are determined using full absorption and standard costing, which approximates cost based on a first-in, first-out method. The Company reviews the standard costs of raw materials, work-in-process and finished goods periodically, and at least annually, to ensure that its inventories approximate current actual costs. The cost of inventories includes direct material costs, direct labor and manufacturing overhead. The Company regularly reviews the need to adjust the carrying value of excess and obsolete inventories to their estimated net realizable value, if less than cost, based primarily on its estimated forecast of product demand and product expiration period.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue and deferred revenue, estimates of accruals related to clinical trial costs, valuation allowances for deferred tax assets, and valuation and recognition of stock-based compensation. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company’s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented.

Net Income (Loss) per Share

The following is a reconciliation of the basic and diluted net income (loss) per share calculation for the periods presented (in thousands, except per share data):

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019		2018
Net income (loss)	$	116,003	$	(23,421	)	$	70,592	$	(64,817	)
Weighted average shares used to compute net income (loss) per share:
Basic		86,445		83,750			86,077		83,309
Dilutive effect of potential common shares		5,283		—			5,992		—
Diluted		91,728		83,750			92,069		83,309

Net income (loss) per share:
Basic	$	1.34	$	(0.28	)	$	0.82	$	(0.78	)
Diluted	$	1.26	$	(0.28	)	$	0.77	$	(0.78	)

Diluted shares did not include 4.4 million and 3.4 million securities for the three and six months ended June 30, 2019, and 8.8 million and 8.7 million securities for the three and six months ended June 30, 2018, respectively, as they were anti-dilutive.

Table of Contents

Recently Issued and Adopted Accounting Guidance

ASC 842

The Company adopted the above guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment at the beginning of the first quarter of 2019. The Company elected the optional transition method under the guidance, which allowed it to continue applying previous lease guidance (ASC 840) for the comparative prior year periods presentation in the year of adoption. Accordingly, the Company recognized a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.

In addition, the Company elected the package of transitional practical expedients permitted under the transition guidance under ASC 842, which among other things allows the Company to carry forward its historical lease classification, and not to reassess initial direct costs for any existing leases. Meanwhile, the Company did not elect the hindsight practical expedient because it has limited number of leases, lease terms are straightforward, and most of its lease renewals are undefined until negotiated.

In addition, the Company has elected the short term accounting policy practical expedient and does not apply the balance sheet recognition requirements for short-term leases (excluding expenses relating to leases with a lease term of one month or less), by class of underlying asset to which the right of use relates. The Company has not elected the non-lease components practical expedient, and therefore accounts for each lease component separately from the non-lease components.

Upon adoption of ASC 842, the Company classified its existing building leases that were previously accounted for as build-to-suit arrangements as finance leases, and applied the transition guidance. Accordingly, the Company derecognized the assets and liabilities previously recognized under ASC 840 build-to-suit guidance. In addition, as a result of applying the transition guidance, the Company also recorded an adjustment to the accumulated depreciation of related leasehold improvements to reflect a change in estimated useful life from the building life to the shorter of the building life and remaining lease term. Differences between the assets and liabilities derecognized were recorded to the opening balance of retained earnings.

Table of Contents

The impacts to the select line items from the Company’s condensed consolidated balance sheet upon adoption of the ASC 842 guidance are as follows (in thousands):

Balance Sheet Line Item	Nature of Adjustment	New Lease Guidance Adoption Adjustment
Assets
Property and equipment, net	Derecognition - build-to-suit lease assets - building shell, cost	$	(53,880	)
	Derecognition - build-to-suit lease assets - building shell, accumulated depreciation		13,476
	Change of useful life - leasehold improvements, accumulated depreciation		(38,877	)
Finance lease right-of-use assets	Recognition - finance lease ROU assets		49,597
Other assets	Recognition - operating lease ROU assets		730
Liabilities
Accrued and other current liabilities	Derecognition - deferred rent, current		(619	)
	Derecognition - build-to-suit lease liabilities, current		(545	)
	Recognition - operating lease liabilities, current		404
Finance lease liabilities, current	Recognition - finance lease liabilities, current		11,499
Long-term portion of lease obligations	Derecognition - build-to-suit lease liabilities, non-current		(95,613	)
Deferred rent	Derecognition - deferred rent, non-current		(3,038	)
Finance lease liabilities, non-current	Recognition - finance lease liabilities, non-current		49,884
Other long-term liabilities	Recognition - operating lease liabilities, non-current		250
Stockholders’ equity
Accumulated deficit	Cumulative decrease to accumulated deficit	$	8,688

The adoption of this guidance did not have a material impact to the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the six months ended June 30, 2019.

ASU 2018-02

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This guidance allows for the reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects arising from the reduction of the U.S. federal statutory income tax rate from 35% to 21%. This guidance was effective for annual reporting period beginning after December 15, 2018, including interim periods. The Company adopted this guidance on January 1, 2019 using the modified retrospective approach. The impacts, based on the aggregate portfolio approach, to the Company’s accumulated other comprehensive loss and accumulated deficit upon adoption of this guidance are as follows (in thousands):

	Accumulated Other Comprehensive Loss			Accumulated Deficit
Balance at December 31, 2018	$	(2,281	)	$	(715,827	)
Impact of change in accounting principle upon adoption of ASU 2018-02		611			(611	)
Opening balance as of January 1, 2019	$	(1,670	)	$	(716,438	)

The adoption of this guidance had no impact to the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the six months ended June 30, 2019.

Table of Contents

SEC Disclosure Requirement

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, “Disclosure Update and Simplification,” amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements. Under the amendments, the changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. This analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is presented. This final rule was effective as of November 5, 2018. Accordingly, the Company included the condensed consolidated statements of changes in stockholders’ equity in Form 10-Q starting the first quarter of 2019.

ASU 2018-07

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This guidance expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance was effective for annual reporting period beginning after December 15, 2018, including interim periods. The Company adopted this guidance on January 1, 2019, and the adoption of this guidance had no impact to the Company’s consolidated financial statements.

Recently Issued Accounting Guidance Not Yet Adopted

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance should be applied either retrospectively or prospectively, and is effective for annual reporting period beginning after December 15, 2019 including interim periods, with early adoption permitted. The Company is currently evaluating the impact on its consolidated financial statements upon the adoption of this guidance.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. This guidance amends existing fair value measurement disclosure requirements by adding, changing, or removing certain disclosures. This guidance is effective for annual reporting period beginning after December 15, 2019 including interim periods, with early adoption permitted. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently in April 2019, the FASB issued amendments to the guidance, ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and in May 2019, ASU 2019-05, Financial Instruments – Credit Losses (Topic 326): Targeted Transition Relief. This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. ASU 2019-04 clarifies that equity instruments without readily determinable fair values for which an entity has elected the measurement alternative should be remeasured to fair value as of the date that an observable transaction occurred. ASU 2019-05 provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. The amendments should be applied on either a prospective transition or modified-retrospective approach depending on the subtopic. This guidance is effective for the annual reporting period beginning after December 15, 2019, including interim periods within that reporting period. The Company does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.

Table of Contents

2.	Collaboration Agreements

Astellas Agreements

Japan Agreement

In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (“Japan Agreement”). Under this agreement, Astellas paid license fees and other consideration totaling $40.1 million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5 million in potential milestone payments, comprised of (i) up to $22.5 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii) up to $95.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii) up to approximately $15.0 million in milestone payments upon the achievement of specified commercial sales milestone. The aggregate amount of such consideration received through June 30, 2019 totals $77.6 million.

Europe Agreement

In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (“Europe Agreement”). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). Under the Europe Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $425.0 million in potential milestone payments, comprised of (i) up to $90.0 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii) up to $335.0 million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of such consideration received through June 30, 2019 totals $410.0 million.

In the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of chemotherapy induced anemia (“CIA”). AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas. For revenue recognition purposes, the Company concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the end of 2023 to allow for development of this indication.

During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiac event (“MACE”) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA during their fiscal year 2019, which ends on March 31, 2020, following the Company’s NDA submission to the FDA. The Company evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $129.5 million was recognized as revenue during the period from performance obligations satisfied or partially satisfied as of June 30, 2019. According to the Europe Agreement, these milestone payments are not billable to Astellas until the submission of an MAA, therefore this $130.0 million was recorded as an unbilled contract asset as of June 30, 2019.

Table of Contents

AstraZeneca Agreements

U.S./Rest of World (“RoW”) Agreement

Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (“U.S./RoW Agreement”). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i) up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events, $15.0 million of which was received in 2015 as a result of the finalization of its two audited pre-clinical carcinogenicity study reports, (ii) up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii) up to $160.0 million in milestone payments related to activity by potential competitors and (iv) up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of such consideration received through June 30, 2019 totals $389.0 million.

As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company’s NDA submission to the FDA. The Company evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the U.S./ RoW Agreement in the second quarter of 2019, of which $41.6 million was recognized as revenue during the period from performance obligations satisfied or partially satisfied as of June 30, 2019. According to the U.S/RoW Agreement, this milestone payment is not billable to AstraZeneca until the Company has submitted the NDA, therefore this $50.0 million was recorded as an unbilled contract asset as of June 30, 2019.

China Agreement

Effective July 30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (“China Agreement”). Under the terms of the China Agreement, AstraZeneca paid upfront, non-contingent and non-refundable payments totaling $28.2 million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i) up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii) up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii) up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined) and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of such consideration received through June 30, 2019 totals $55.2 million.

As mentioned above, in the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of CIA. AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas. In addition to CIA, in December 2018, anemia of chronic inflammation (“ACI”) and multiple myeloma (“MM”) have been approved for development by AstraZeneca and is expected to be fully funded by them. For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, ACI and MM under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications.

On December 17, 2018, FibroGen (China) Medical Technology Development Co., Ltd. (“FibroGen Beijing”), received marketing authorization from the NMPA for roxadustat, a first-in-class HIF-PH inhibitor, for the treatment of anemia caused by CKD in patients on dialysis. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. On December 29, 2018, FibroGen Beijing received First Manufacturing Approval for a Product in the Field in the Territory, which allows production for Phase IV clinical studies, patients’ early experience programs, donation programs, as well as to supply products for testing and assessments required prior to launch. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. These milestones payments were received in the first quarter of 2019.

Table of Contents

Summary of Revenue Recognized Under the Collaboration Agreements

The table below summarizes the accounting treatment for the various performance obligations pursuant to each of the Astellas and AstraZeneca agreements. License amounts identified below are included in the “License revenue” line item in the condensed consolidated statements of operations. All other elements identified below are included in the “Development and other revenue” line item in the condensed consolidated statements of operations.

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
Japan	License revenue	$	—	$	14,323	$	—	$	14,323
	Development revenue	$	369	$	1,142	$	615	$	1,591

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

Japan Agreement	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019		Total Consideration Through June 30, 2019
License	$	74,089	$	—	$	74,089
Development revenue		14,523		136		14,659
Total license and development revenue	$	88,612	$	136	$	88,748

The revenue recognized under the Japan Agreement for the three months ended June 30, 2019 included an immaterial amount resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Japan Agreement includes $0.5 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
Europe	License revenue	$	117,470	$	—	$	117,470	$	—
	Development revenue	$	16,854	$	5,003	$	21,467	$	9,726

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

Europe Agreement	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019			Total Consideration Through June 30, 2019
License	$	487,951	$	—		$	487,951
Development revenue		224,304		2,019			226,323
Total license and development revenue	$	712,255	$	2,019	*	$	714,274

_______________________________________________________________________________________________________

Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of June 30, 2019, prepaid expenses and other current assets included a net unbilled contract asset of $128.0 million related to the Europe Agreement, which represents the net of the above-mentioned unbilled contract asset of $130.0 million, and $2.0 million of deferred revenue presented above.

Table of Contents

The revenue recognized under the Europe Agreement for the three months ended June 30, 2019 included an increase in revenue of $129.2 million resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Europe Agreement includes $9.4 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
U.S. / RoW and China	License revenue	$	33,111	$	—	$	33,111	$	—
	Development revenue		23,762		23,479		42,766		50,202
	China performance obligation	$	—	$	—	$	—	$	—

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):

U.S. / RoW and China Agreements	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019			Total Consideration Through June 30, 2019
License	$	327,275	$	—		$	327,275
Co-development, information sharing & committee services		451,402		16,342			467,744
China performance obligation		—		136,584			136,584
Total license and development revenue	$	778,677	$	152,926	*	$	931,603

_______________________________________________________________________________________________________

Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of June 30, 2019, long-term deferred revenue included $102.9 million related to the U.S./RoW and China Agreement, which represents the net of $152.9 million of deferred revenue presented above and the above-mentioned $50.0 million unbilled contract asset.

The revenue recognized under the U.S./RoW Agreement for the three months ended June 30, 2019 included an increase in revenue of $41.9 million resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $149.4 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period, except for amounts allocated to the China performance obligation, which are expected to be recognized in a pattern consistent with estimated deliveries of the commercial drug product.

Other Revenues

Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for all periods presented.

Deferred Revenue

Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company’s collaboration partners for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. The long term portion of deferred revenue represents amounts to be recognized after one year through the end of the non-contingent performance period of the underlying performance obligations.

Table of Contents

Deferred revenue includes amounts allocated to the China unit of accounting under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China. As of December 31, 2018, such deferred revenue was included in long-term deferred revenue. As of June 30, 2019, following receipt of the Chinese Good Manufacturing Practices license by FibroGen Beijing in the second quarter of 2019, approximately $0.5 million of the related deferred revenue was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized as a result of the transfer of control of commercial drug product in China.

3.	Fair Value Measurements

The fair values of the Company’s financial assets that are measured on a recurring basis are as follows (in thousands):

	June 30, 2019
	Level 1		Level 2		Level 3		Total
US treasury notes and bills	$	350,891	$	125,263	$	—	$	476,154
Bond and mutual funds		10,677		—		—		10,677
Equity investments		237		—		—		237
Money market funds		33,804		—		—		33,804
Term deposit		—		80,000		—		80,000
Certificate of deposit		—		30,021		—		30,021
Total	$	395,609	$	235,284	$	—	$	630,893

	December 31, 2018
	Level 1		Level 2		Level 3		Total
US treasury notes and bills	$	292,317	$	224,953	$	—	$	517,270
Bond and mutual funds		10,484		—		—		10,484
Equity investments		234		—		—		234
Money market funds		541		—		—		541
Term deposit		—		80,000		—		80,000
Certificate of deposit		—		29,910		—		29,910
Total	$	303,576	$	334,863	$	—	$	638,439

Our Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs.

The fair values of the Company’s financial liabilities that are carried at historical cost are as follows (in thousands):

	June 30, 2019
	Level 1		Level 2		Level 3		Total
Lease obligations	$	—	$	—	$	1,745	$	1,745

	December 31, 2018
	Level 1		Level 2		Level 3		Total
Lease obligations	$	—	$	—	$	98,105	$	98,105

The fair values of the Company’s financial liabilities were derived by using an income approach, which required Level 3 inputs such as discounted estimated future cash flows.

As of December 31, 2018, the Company had $96.2 million in lease obligations related to its building leases under build-to-suit arrangements. Upon the adoption of ASC 842 as of January 1, 2019, using the modified retrospective transition method, the Company derecognized these liabilities previously recognized under ASC 840 build-to-suit designation. Refer to Note 1 for details.

The remaining balance of $1.7 million as of June 30, 2019 under lease obligations is related to an expansion option in the Company’s long-term property lease with Shorenstein Properties LLC (“Alexandria” or “landlord”). This expansion option allowed the Company to occupy part of an adjacent building within 31 months of the lease commencement date in 2008. In 2012, the Company gave notice to its landlord that it would not exercise this expansion option, which resulted in a $5.0 million payment liability to the landlord that is financed over the remaining lease term to 2023.

Table of Contents

There were no transfers of assets or liabilities between levels for any of the periods presented.

Leases

The Company currently has two building leases treated as finance leases.

In 2006, the Company entered into a long-term property lease with Alexandria for its corporate headquarters in San Francisco, California, with an initial term of 15 years, scheduled to expire in 2023. The Company has an option to extend the lease for an additional 10 years through 2033. The lease contract provides for a fixed annual rent, with scheduled increases of two percent that occur on each anniversary of the rent commencement date. This lease requires the Company to pay all costs of ownership, operation, and maintenance of the premises, including without limitation all operating costs, insurance costs, and taxes.

In 2013, the Company entered into a long-term property lease with Beijing Economic-Technological Development Area (“BDA”) Management Committee for a pilot plant located in Beijing Yizhuang Biomedical Park (“BYBP”) of BDA. The building is leased for an initial lease term of eight years, scheduled to expire in 2021. Renewal options are not specified within the lease contract. The lease contract provides for fixed quarterly rent payments, with scheduled increases that occur as detailed in the lease contract. This lease requires the Company to pay all operating and maintenance costs, and a fixed amount for property management fees.

The Company currently has five additional real estate leases for space within a building, which are treated as operating leases. These leases have lease terms ranging from two to four years. These lease contracts provide for fixed quarterly rent payments, and require the Company to pay operating and maintenance costs, and a fixed amount for property management fees.

In addition, the Company has several immaterial lease arrangements for office equipment, scientific devices and automobile leases, with contracted lease terms ranging from two to five years, treated as finance leases or operating leases, respectively.

The Company’s lease assets and related lease liabilities were as follows (in thousands):

	Balance Sheet Line Item	June 30, 2019
Assets
Finance:
Right-of-use assets - cost		$	49,676
Accumulated amortization			(5,140	)
Finance lease right-of-use assets, net	Finance lease right-of-use assets		44,536
Operating:
Right-of-use assets - cost			1,212
Accumulated amortization			(273	)
Operating lease right-of-use assets, net	Other assets		939
Total lease assets		$	45,475

Liabilities
Current:
Finance lease liabilities	Finance lease liabilities, current	$	12,071
Operating lease liabilities	Accrued and other current liabilities		591
Non-current:
Finance lease liabilities	Finance lease liabilities, non-current		43,780
Operating lease liabilities	Other long-term liabilities		346
Total lease liabilities		$	56,788

Table of Contents

The components of lease expense were as follows (in thousands):

	Statement of Operations Line Item	Three Months Ended June 30, 2019			Six Months Ended June 30, 2019
Finance lease cost:
Amortization of right-of-use assets	Selling, general and administrative expenses	$	2,571		$	5,140
Interest on lease liabilities	Interest expense		609			1,249
Operating lease cost	Research and development, Selling, general and administrative expenses		163			289
Sublease income	Selling, general and administrative expenses		(237	)		(824	)
Total lease cost		$	3,106		$	5,854

Supplemental cash flow information related to leases were as follows (in thousands):

	Six Months Ended June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	191
Operating cash flows from finance leases		1,053
Financing cash flows from finance leases		5,850
Right-of-use assets obtained in exchange for new lease liabilities:
Finance leases		49,676
Operating leases	$	1,212

Lease term and discount rate were as follows at June 30, 2019:

	June 30, 2019
Weighted-average remaining lease term (years):
Finance leases		4.1
Operating leases		1.4
Weighted-average discount rate:
Finance leases		4.43	%
Operating leases		4.74	%

Maturities of lease liabilities are as follows:

Year Ending	Finance Leases			Operating Leases
2019 (Remaining six month period)	$	7,002		$	313
2020		14,089			507
2021		13,678			134
2022		13,878			19
2023		12,523			—
Total future lease payments		61,170			973
Less: Interest		(5,319	)		(36	)
Present value of lease liabilities	$	55,851		$	937

Table of Contents

The following information was previously disclosed under ASC 840 as of December 31, 2018:

Future minimum lease payments under all non-cancelable operating lease obligations as of December 31, 2018 were as follows (in thousands):

Year Ending	Operating Leases
2019	$	444
2020		232
2021		25
2022		16
2023		—
Total minimum payments	$	717

Future minimum lease payments, on a consolidated basis, under the Company’s facility lease financing obligations as of December 31, 2018 were as follows (in thousands):

Year Ending	Lease financing obligations
2019	$	14,379
2020		14,664
2021		14,179
2022		14,335
2023		12,872
Total minimum payments	$	70,429

5.	Balance Sheet Components

Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Cash	$	40,783	$	38,783
US treasury notes and bills		—		49,934
Money market funds		33,804		541
Total cash and cash equivalents	$	74,587	$	89,258

At June 30, 2019 and December 31, 2018, a total of $26.0 million and $21.9 million, respectively, of the Company’s cash and cash equivalents were held outside of the U.S. in its foreign subsidiaries to be used primarily for its China operations.

Table of Contents

Investments

The Company’s investments consist of available-for-sale debt investments, marketable equity investments, a term deposit and a certificate of deposit. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands):

	June 30, 2019
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
US treasury notes and bills	$	475,126	$	1,028	$	—		$	476,154
Term deposit		80,000		—		—			80,000
Certificates of deposit		30,000		21		—			30,021
Bond and mutual funds		10,602		75		—			10,677
Equity investments		125		112		—			237
Total investments	$	595,853	$	1,236	$	—		$	597,089

	December 31, 2018
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
US treasury notes and bills	$	467,296	$	109	$	(69	)	$	467,336
Term deposit		80,000		—		—			80,000
Certificates of deposit		30,000		—		(90	)		29,910
Bond and mutual funds		10,464		20		—			10,484
Equity investments		125		109		—			234
Total investments	$	587,885	$	238	$	(159	)	$	587,964

At June 30, 2019, all of the available-for-sale investments had contractual maturities within one year. The Company periodically reviews its available-for-sale investments and term deposit for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the three and six months ended June 30, 2019 and 2018, the Company did not recognize any other-than-temporary impairment loss.

Inventories

Inventories consisted of the following (in thousands):

	June 30, 2019
Raw materials	$	797
Work-in-progress		1,035
Finished goods		149
Total inventories	$	1,981

The Company started capitalizing inventory costs in June 2019 when FibroGen China began productions of roxadustat for commercial sales purposes. There was no provision to write-down excess and obsolete inventory for the three months ended June 30, 2019.

Prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Unbilled contract assets	$	180,000		$	—
Deferred revenues from associated contracts		(52,019	)		—
Net unbilled contract assets		127,981			—
Prepaid assets		4,716			2,705
Other current assets		3,899			2,224
Total prepaid expenses and other current assets	$	136,596		$	4,929

Table of Contents

The unbilled contract assets as of June 30, 2019 were related to two regulatory milestones totaling $130.0 million under the Europe Agreement with Astellas associated with the planned MAA submission in Europe, and a $50.0 million regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the planned NDA submission in the U.S. See Note 2 for details.

Property and Equipment

Property and equipment consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Leasehold improvements	$	101,250		$	101,200
Building shell		—			53,880
Laboratory equipment		16,754			16,405
Machinery		8,461			8,382
Computer equipment		6,655			6,473
Furniture and fixtures		5,778			5,690
Construction in progress		1,888			367
Total property and equipment	$	140,786		$	192,397
Less: accumulated depreciation		(95,921	)		(65,199	)
Property and equipment, net	$	44,865		$	127,198

As of December 31, 2018, the Company had $53.9 million building shell cost and $13.5 million accumulated depreciation related to its building leases under build-to-suit arrangements. Upon the adoption of ASC 842 as of January 1, 2019, using the modified retrospective transition method, the Company derecognized these assets previously recognized under ASC 840 build-to-suit designation. Up to December 31, 2018, the leasehold improvements related to these building leases were depreciated over the life of the building under ASC 840. Upon the adoption of ASC 842, these leasehold improvements should have a useful life based on the lease term. As a result, at the adoption date, the Company recorded a cumulative adjustment of $38.9 million to the accumulated depreciation for these leasehold improvements so that their net balance equals the undepreciated amount had the useful life of the leasehold improvements always been equal to the lease terms. Refer to Note 1 for details.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Preclinical and clinical trial accruals	$	41,104	$	35,413
Payroll and related accruals		14,001		21,430
Property taxes and other		1,778		1,095
Professional services		3,588		2,648
Other		6,074		5,537
Total accrued liabilities	$	66,545	$	66,123

6.	Stock-Based Compensation

Stock-based compensation expense was allocated to research and development and selling, general and administrative expense as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Research and development	$	10,450	$	7,894	$	20,028	$	14,264
Selling, general and administrative		7,192		5,337		14,044		9,845
Total stock-based compensation expense	$	17,642	$	13,231	$	34,072	$	24,109

Table of Contents

The assumptions used to estimate the fair value of stock options granted and purchases under the Company’s 2014 Employee Share Purchase Plan (“ESPP”) using the Black-Scholes option valuation model were as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Stock Options
Expected term (in years)		5.3			5.4			5.3			5.4
Expected volatility		68.2	%		67.5	%		67.9	%		67.8	%
Risk-free interest rate		2.0	%		2.8	%		2.5	%		2.7	%
Expected dividend yield		—			—			—			—
Weighted average estimated fair value	$	24.40		$	31.35		$	33.20		$	32.12

ESPPs
Expected term (in years)	0.5 - 2.0			0.5 - 2.0			0.5 - 2.0			0.5 - 2.0
Expected volatility	48.1 - 62.1		%	47.3 - 75.3		%	48.1 - 62.1		%	47.3 - 75.3		%
Risk-free interest rate	1.3 - 2.9		%	0.8 - 2.6		%	1.3 - 2.9		%	0.8 - 2.6		%
Expected dividend yield		—			—			—			—
Weighted average estimated fair value	$	19.07		$	15.25		$	19.65		$	13.67

7.	Income Taxes

The provisions for income taxes for the three and six months ended June 30, 2019 and 2018 were due to foreign taxes.

Based upon the weight of available evidence, which includes its historical operating performance, reported cumulative net losses since inception, the Company has established and continues to maintain a full valuation allowance against its deferred tax assets as it does not currently believe that realization of those assets is more likely than not.

8.	Related Party Transactions

Astellas is an equity investor in the Company and considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $134.7 million and $139.6 million for the three and six months ended June 30, 2019, respectively, and $20.5 million and $25.6 million for the three and six months ended June 30, 2018, respectively.

The Company recorded expense related to collaboration agreements with Astellas of $0.8 million and $0.2 million during the three months ended June 30, 2019 and 2018, respectively, and $1.3 million and $0.7 million during the six months ended June 30, 2019 and 2018.

As of June 30, 2019 and December 31, 2018, accounts receivable from Astellas were $4.3 million and $47.2 million, respectively, and amounts due to Astellas were $0.8 million and $0.4 million, respectively. The accounts receivable from Astellas as of December 31, 2018 included $43.8 million related to the delivery of roxadustat API to Astellas during the fourth quarter of 2018, pursuant to an amendment to the Japan Agreement that will allow Astellas to manufacture roxadustat drug product for commercialization in Japan. This amount was received during the first quarter of 2019.

Prepaid expenses and other current assets as of June 30, 2019 included $128.0 million of net unbilled contract asset, representing a $130.0 million unbilled contract asset related to two regulatory milestones under the Europe Agreement with Astellas associated with the planned MAA submission to the EMA, net of $2.0 million of associated deferred revenue. See Note 2 for details. According to the Europe Agreement, this $130.0 million is not billable to Astellas until the submission of an MAA, therefore the net contract asset was included in the prepaid expenses and other current assets line on the Company’s condensed consolidated balance sheet as of June 30, 2019. There was no such contract asset balance as of December 31, 2018.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and in our Securities and Exchange Commission (“SEC”) filings, including our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on February 27, 2019.

FORWARD-LOOKING STATEMENTS

The following discussion and information contained elsewhere in this Quarterly Report on Form 10-Q contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), Section 27A of the Securities Act of 1933, as amended (“Securities Act”) and within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors,” set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. New risks emerge from time to time, and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q and are cautioned not to place undue reliance on such forward-looking statements.

BUSINESS OVERVIEW

We were incorporated in 1993 in Delaware and are headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China (“China”), is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. We apply our pioneering expertise in hypoxia-inducible factor (“HIF”), connective tissue growth factor (“CTGF”) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, our most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase (“HIF-PH”) activity, completing Phase 3 clinical development worldwide for the treatment of anemia in chronic kidney disease (“CKD”), with a New Drug Application (“NDA”) now approved by the National Medical Products Administration (“NMPA”) in China. We and our collaboration partners AstraZeneca AB (“AstraZeneca”) and Astellas Pharma Inc. (“Astellas”) are in the process of preparing an NDA for submission to the United States (“U.S.”) Food and Drug Administration (“FDA”) and a Marketing Authorization Application (“MAA”) for submission to the European Medicines Agency (“EMA”) this year. Astellas submitted an NDA for the treatment of anemia in CKD patients on dialysis in Japan in September 2018, which is currently under review by the Pharmaceuticals and Medical Devices Agency (“PMDA”). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (“MDS”). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (“IPF”), and advancing towards Phase 3 for the treatment of pancreatic cancer. Pamrevlumab is also currently in a Phase 2 trial for Duchenne muscular dystrophy (“DMD”). We are also developing a biosynthetic cornea in China.

Table of Contents

Financial Highlights

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019		2018
	(in thousands, except for per share data)
Result of Operations
Revenue	$	191,566	$	43,952		$	215,429	$	75,876
Operating expenses	$	78,747	$	67,193		$	151,453	$	139,717
Net income (loss)	$	116,003	$	(23,421	)	$	70,592	$	(64,817	)
Net income (loss) per share - basic	$	1.34	$	(0.28	)	$	0.82	$	(0.78	)
Net income (loss) per share - diluted	$	1.26	$	(0.28	)	$	0.77	$	(0.78	)

						June 30, 2019		December 31, 2018
						(in thousands)
Balance Sheet
Cash and cash equivalents						$	74,587	$	89,258
Short-term and long-term investments						$	597,089	$	587,964
Accounts receivable						$	6,453	$	63,684

Our revenue for the three and six months ended June 30, 2019 increased compared to the same periods a year ago. Our revenue for the current year periods primarily consisted of the recognition of $129.5 million of two regulatory milestones totaling $130.0 million that were included in the transaction price during the second quarter of 2019 when these milestones became probable of being achieved. These milestones are associated with the planned MAA submission to the EMA under the collaboration agreement with Astellas for roxadustat as a treatment for dialysis and non-dialysis CKD patients. In addition, the revenue recognized during the current year periods included the recognition of $41.6 million of a $50.0 million regulatory milestone that was included in the transaction price during the second quarter of 2019 when this milestone became probable of being achieved. This milestone is associated with the planned NDA submission to the FDA under the collaboration agreement with AstraZeneca for roxadustat as a treatment for dialysis and non-dialysis CKD patients. As comparison, our revenue for the prior year period included the recognition of $14.9 million of a $15.0 million regulatory milestone associated with NDA submission in Japan under the collaboration agreement with Astellas for roxadustat for the treatment of anemia in Japan that was included in the transaction price during the second quarter of 2018 when this milestone became probable of being achieved. The increases were partially offset by a decrease in co-development billings related to the development of roxadustat as a result of the substantial completion of Phase 3 trials for roxadustat.

Operating expenses for the three months ended June 30, 2019 increased compared to the same period a year ago primarily due to $9.2 million higher outside service expenses related to co-promotional activities and scientific contract expenses, $4.4 million higher stock-based compensation related to the cumulative impact of stock option grant activities, $2.6 million amortization of finance lease right-of-use (“ROU”) assets related to the adoption of lease accounting guidance under Accounting Standards Codification (“ASC”) 842 - Leases (“ASC 842”) and $1.1 million higher depreciation expenses due to the change in estimated useful life for our leasehold improvements as a result of the adoption of ASC 842. The increases were partially offset by $3.4 million lower clinical trial expenses related to lower activities for roxadustat offset by higher activities for pamrevlumab, and $2.5 million lower drug development expenses associated with drug substance manufacturing activities related to pamrevlumab.

Operating expenses for the six months ended June 30, 2019 increased compared to the same period a year ago primarily due to $11.4 million higher outside service expenses related to co-promotional activities and scientific contract expenses, $10.0 million higher stock-based compensation related to the cumulative impact of stock option grant activities, $5.2 million amortization of finance lease ROU assets related to the adoption of lease accounting guidance under ASC 842, $2.3 million higher depreciation expenses due to the change in estimated useful life for our leasehold improvements as a result of the adoption of ASC 842 and $1.8 million higher employee-related expenses resulting from higher average compensation level. The increases were partially offset by $11.7 million lower clinical trial expenses related to lower activities for roxadustat offset by higher activities for pamrevlumab, $6.2 million lower drug development expenses associated with drug substance manufacturing activities related to pamrevlumab.

Table of Contents

During the three months ended June 30, 2019, we had a net income of $116.0 million, or net income per basic share of $1.34, and net income per diluted share of $1.26, as compared to a net loss of $23.4 million for the same period a year ago, due to an increase in revenue partially offset by an increase in operating expenses. During the six months ended June 30, 2019, we had a net income of $70.6 million, or net income per basic share of $0.82, and net income per diluted share of $0.77, as compared to a net loss of $64.8 million for the same period a year ago, due to an increase in revenue partially offset by an increase in operating expenses.

Cash and cash equivalents, investments and accounts receivable totaled $678.1 million at June 30, 2019, a decrease of $62.8 million from December 31, 2018, primarily due to the cash used in operations, partially offset by the accounts receivable at December 31, 2018 collected during the year.

Programs

Roxadustat for the Treatment of Anemia in Chronic Kidney Disease

Roxadustat is our most advanced product candidate, an oral small molecule inhibitor of HIF-PH activity that acts by stimulating the body’s natural pathway of erythropoiesis, or red blood cell production. We received our first NDA approval in China for roxadustat for the treatment of anemia caused by CKD in dialysis patients in December of 2018.

We have reported top line efficacy data from individual studies and safety data for the pooled non-dialysis population and the pooled dialysis population, as well as the incident dialysis subpopulation, from the roxadustat Phase 3 trials intended to support our NDA in the U.S. and MAA in the European Union (“EU”) for the treatment of anemia in CKD.

In our pre-NDA meeting with the FDA, we reached agreement on the content to be included in our NDA submission package for roxadustat for treatment of anemia in CKD, including the cardiovascular safety analyses for both CKD-dialysis and CKD-non-dialysis. The agreement for non-dialysis is an approach to account for the differential dropout between roxadustat and placebo observed in our Phase 3 studies. We are confident we have sufficient data for FDA review of our NDA in both CKD dialysis and CKD non-dialysis and we are planning to submit the NDA in October of 2019. Our partner Astellas is planning for an MAA submission to the EMA during the second half of their fiscal year 2019, which ends on March 31, 2020.

In China, we have secured regulatory approval of our commercial active pharmaceutical ingredient (“API”) plant in Cangzhou, Hebei. We have subsequently produced commercial batches of API and shipped commercial drug product. Roxadustat is currently approved for the treatment of anemia in CKD patients on dialysis. We expect non-dialysis CKD patients to be added to the roxadustat label in the third quarter of 2019.

In Japan, Astellas submitted an NDA for roxadustat for the treatment of anemia in CKD patients on dialysis in September 2018, which is currently under review by the PMDA. We expect an approval decision on the Japan dialysis NDA in the second half of 2019. Astellas has announced it expects the second non-dialysis study in Japan to be completed in 2019.

Roxadustat for the Treatment of Anemia in Myelodysplastic Syndromes

In addition to anemia in CKD, we are continuing to enroll the 156-patient double-blind, placebo-controlled portion of our global Phase 3 clinical study of roxadustat in transfusion-dependent, lower risk MDS patients. The primary endpoint is the proportion of patients who achieve transfusion independence.

In China, we continue to enroll the open-label portion of our Phase 2/3 clinical trial to evaluate the safety and efficacy of roxadustat in non-transfusion dependent, lower risk MDS patients with anemia. After the open-label portion we expect to begin the 135-patient double-blind, placebo-controlled Phase 3 portion of the study, in which subjects will be randomized 2:1 to receive roxadustat or placebo three-times weekly for 26 weeks. The primary endpoint for this study is percentage of patients achieving a hemoglobin response.

Roxadustat for the Treatment of Anemia in Chemotherapy Induced Anemia

We plan to initiate a Phase 2 clinical trial of roxadustat in the U.S. in chemotherapy induced anemia in the third quarter of 2019.

Table of Contents

Pamrevlumab (FG-3019) – Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF)

Pamrevlumab is our human monoclonal antibody that inhibits the activity of CTGF, a central mediator and critical common element in the progression of fibrotic and fibro-proliferative diseases. We initiated our Phase 3 clinical trial of pamrevlumab for the treatment of IPF and are screening patients in our Phase 3 clinical trial for locally advanced unresectable pancreatic cancer. We recently presented topline results from our 1-year data from our ongoing Phase 2 trial for DMD.

In the U.S., pamrevlumab has received orphan drug designation for DMD in addition to IPF and pancreatic cancer, and Fast Track designation for the treatment of both IPF patients and patients with locally advanced unresectable pancreatic cancer from the FDA.

Idiopathic Pulmonary Fibrosis

We recently began enrolling ZEPHYRUS, our double-blind, placebo-controlled Phase 3 trial of pamrevlumab in approximately 565 IPF patients. This study is powered to meet the FDA requirement of a highly statistically-significant result in the primary efficacy endpoint of change from baseline in forced vital capacity (“FVC”).

Locally Advanced Unresectable Pancreatic Cancer

We are actively screening patients for LAPIS, our double-blind placebo controlled Phase 3 trial of pamrevlumab as a neoadjuvant therapy for locally advanced unresectable pancreatic cancer. We intend to enroll approximately 260 patients, randomized 1:1 to receive either pamrevlumab, in combination with gemcitabine and nab-paclitaxel, or placebo with gemcitabine and nab-paclitaxel.

Duchenne Muscular Dystrophy

In DMD, all 21 non-ambulatory patients from our fully enrolled Phase 2 open-label single-arm trial have completed over one year of treatment with pamrevlumab. While we cannot make direct comparisons between our trial and previously published data due to, among other things, differences in subject numbers, baseline characteristics, inclusion/exclusion criteria, treatment protocols, and analysis methods, we are encouraged by the data obtained so far. Pamrevlumab was well tolerated in this study.

In June 2019 at the Parent Project Muscular Dystrophy meeting, we reported topline results from our one-year administrative analysis comparing our Phase 2 data to recent published natural disease history studies of DMD patients.

In pulmonary function tests, the results from our study indicate a potential reduction in the 1-year decline in FVC percent predicted from baseline for our pamrevlumab-treated patients when compared to FVC data of DMD patients (whether such patients were taking steroids or not) published in 2019 by Ricotti. In the 2019 Ricotti study, the DMD patients were not taking any active drug (other than steroids). All of the patients in our Phase 2 pamrevlumab trial were taking steroids. In addition, pamrevlumab showed less decline in both percent predicted forced expiratory volume as compared to previously published study results of Meier in 2016, and in percent predicted peak expiratory flow rate, compared to what was observed in the study by Ricotti in 2019.

Our data showed an increase in cardiac function, measured by mean change of left ventricular ejection fraction (“LVEF”), of 0.29% from baseline for our pamrevlumab-treated patients. Whereas, data published in 2018 by McDonald of DMD patients only on steroids showed a mean LVEF decline of 0.82% from baseline in one year. In a sub-group analysis of pamrevlumab subjects with baseline LVEF greater than 50%, the mean change was an increase in LVEF of 1.79% from baseline.

In muscle function tests, the majority of the results of this Phase 2 study showed the mean change from baseline in our pamrevlumab-treated patients were more favorable than previously published data. Our results showed a positive increase in grip-strength score in both dominant and non-dominant hands at one year of treatment with pamrevlumab, while earlier results from a 2015 study by Seferian showed a decline at one year as expected. In the performance of the upper limb (“PUL”) test specifically developed for DMD patients, our pamrevlumab-treated patients had a mean change from baseline of -1.53. In the 2019 study by Ricotti of DMD patients taking either nothing or only steroids, the annual mean change in the PUL test was -4.13. Furthermore, in our study a strong correlation between change in biceps brachii T2-mapping and change in PUL score was observed, demonstrating stabilization and even possible improvement in the muscle fibrosis burden.

Based on our administrative analysis and advice we received from expert advisors, we are planning to share these results with the FDA to discuss pivotal study design in our clinical development plan for DMD.

Table of Contents

Collaboration Partnerships for Roxadustat

Our current and future research, development, manufacturing and commercialization efforts with respect to roxadustat and our other product candidates currently in development depend on funds from our collaboration agreements with Astellas and AstraZeneca as described below.

Astellas

In June 2005, we entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (“Japan Agreement”). In April 2006, we entered into the Europe Agreement with Astellas for roxadustat for the treatment of anemia in Europe, the Commonwealth of Independent States, the Middle East, and South Africa. Under these agreements, we provide Astellas the right to develop and commercialize roxadustat for anemia indications in these territories.

We share responsibility with Astellas for clinical development activities required for the U.S. and the EU regulatory approval of roxadustat, and share equally those development costs under the agreed development plan for such activities. Astellas will be responsible for clinical development activities and all associated costs required for regulatory approval in all other countries in the Astellas territories. Astellas will own and have responsibility for regulatory filings in its territories. We are responsible, either directly or through our contract manufacturers, for the manufacture and supply of all quantities of roxadustat to be used in development and commercialization under the agreements.

The Astellas agreements will continue in effect until terminated. Either party may terminate the agreements for certain material breaches by the other party. In addition, Astellas will have the right to terminate the agreements for certain specified technical product failures, upon generic sales reaching a particular threshold, upon certain regulatory actions, or upon our entering into a settlement admitting the invalidity or unenforceability of our licensed patents. Astellas may also terminate the agreements for convenience upon advance written notice to us. In the event of any termination of the agreements, Astellas will transfer and assign to us the regulatory filings for roxadustat and will assign or license to us the relevant trademarks used with the products in the Astellas territories. Under certain terminations, Astellas is also obligated to pay us a termination fee.

Consideration under these agreements includes a total of $360.1 million in upfront and non-contingent payments, and milestone payments totaling $557.5 million, of which $542.5 million are development and regulatory milestones and $15.0 million are commercial-based milestones. Total consideration, excluding development cost reimbursement and product sales-related payments, could reach $917.6 million. The aggregate amount of such consideration received through June 30, 2019 totals $487.6 million. Additionally, under these agreements, Astellas pays 100% of the commercialization costs in its territories. Astellas will pay us a transfer price, based on net sales, in the low 20% range for our manufacture and delivery of roxadustat.

During the second quarter of 2019, we received positive topline results from analyses of pooled major adverse cardiac event (“MACE”) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA during their fiscal year 2019, which ends on March 31, 2020, following our planned NDA submission to the FDA anticipated in October of 2019. We evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019.

In addition, as of June 30, 2019, Astellas had separate investments of $80.5 million in the equity of FibroGen, Inc.

AstraZeneca

In July 2013, we entered into the U.S./RoW Agreement, a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in the U.S. and all territories not previously licensed to Astellas, except China. In July 2013, through our China subsidiary and related affiliates, we entered into the China Agreement, a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in China. Under these agreements we provide AstraZeneca the right to develop and commercialize roxadustat for anemia in these territories. We share responsibility with AstraZeneca for clinical development activities required for U.S. regulatory approval of roxadustat.

In 2015, we reached the $116.5 million cap on our initial funding obligations (during which time we shared 50% of the joint initial development costs), therefore all development and commercialization costs for roxadustat for the treatment of anemia in CKD in the U.S., Europe, Japan and all other markets outside of China have been paid by Astellas and AstraZeneca since reaching the cap.

Table of Contents

In China, FibroGen (China) Medical Technology Development Co., Ltd. (“FibroGen Beijing”) will conduct the development work for CKD anemia, will hold all of the regulatory licenses issued by China regulatory authorities, and will be primarily responsible for regulatory, clinical and manufacturing. China development costs are shared 50/50. AstraZeneca is also responsible for 100% of development expenses in all other licensed territories outside of China. Outside of China, we are responsible, through our contract manufacturers, for the manufacture and supply of all quantities of roxadustat to be used in development and commercialization under the AstraZeneca agreements.

Under the AstraZeneca agreements, we will receive upfront and subsequent non-contingent payments totaling $402.2 million. Potential milestone payments under the agreements total $1.2 billion, of which $571.0 million are development and regulatory milestones and $652.5 million are commercial-based milestones. Total consideration under the agreements, excluding development cost reimbursement, transfer price payments, royalties and profit share, could reach $1.6 billion. The aggregate amount of such consideration received through June 30, 2019 totals $444.2 million.

Under the U.S./RoW Agreement, AstraZeneca will pay for all commercialization costs in the U.S. and RoW and AstraZeneca will be responsible for the U.S. commercialization of roxadustat, with FibroGen undertaking specified promotional activities in the end-stage renal disease segment in the U.S. In addition, we will receive a transfer price for delivery of commercial product based on a percentage of net sales in the low- to mid-single digit range and AstraZeneca will pay us a tiered royalty on net sales of roxadustat in the low 20% range.

Under the China Agreement, which is conducted through FibroGen China Anemia Holdings, Ltd. (“FibroGen China”), the commercial collaboration is structured as a 50/50 profit share. AstraZeneca will conduct commercialization activities in China as well as serve as the master distributor for roxadustat and fund roxadustat launch costs in China until FibroGen Beijing has achieved profitability. At that time, AstraZeneca will recoup 50% of their historical launch costs out of initial roxadustat profits in China.

Payments under these agreements include over $500.0 million in upfront, non-contingent and other payments received or expected to be received prior to the first U.S. approval, excluding development expense reimbursement.

AstraZeneca may terminate the U.S./RoW Agreement upon specified events, including our bankruptcy or insolvency, our uncured material breach, technical product failure, or upon 180 days prior written notice at will. If AstraZeneca terminates the U.S./RoW Agreement at will, in addition to any unpaid non-contingent payments, it will be responsible for paying for a substantial portion of the post-termination development costs under the agreed development plan until regulatory approval.

AstraZeneca may terminate the China Agreement upon specified events, including our bankruptcy or insolvency, our uncured material breach, technical product failure, or upon advance prior written notice at will. If AstraZeneca terminates our China Agreement at will, it will be responsible for paying for transition costs as well as make a specified payment to FibroGen China.

In the event of any termination of the agreements, but subject to modification upon termination for technical product failure, AstraZeneca will transfer and assign to us any regulatory filings and approvals for roxadustat in the affected territories that they may hold under our agreements, grant us licenses and conduct certain transition activities.

As mentioned above, during the second quarter of 2019, we received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling our NDA submission to the FDA, which is anticipated in the third quarter of 2019. We evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the U.S./ RoW Agreement in the second quarter of 2019.

Table of Contents

Additional Information Related to Collaboration Agreements

Total cash consideration received through June 30, 2019 and potential cash consideration, other than development cost reimbursement, transfer price payments, royalties and profit share, pursuant to our existing collaboration agreements are as follows:

	Cash Received Through June 30, 2019		Additional Potential Cash Payments		Total Potential Cash Payments
	(in thousands)
Astellas--related-party:
Japan Agreement	$	77,593	$	95,000	$	172,593
Europe Agreement		410,000		335,000		745,000
Total Astellas		487,593		430,000		917,593
AstraZeneca:
U.S. / RoW Agreement		389,000		860,000		1,249,000
China Agreement		55,200		321,500		376,700
Total AstraZeneca		444,200		1,181,500		1,625,700
Total revenue	$	931,793	$	1,611,500	$	2,543,293

These collaboration agreements also provide for reimbursement of certain fully burdened research and development costs as well as direct out of pocket expenses.

RESULTS OF OPERATIONS

Revenue

	Three Months Ended June 30,				Change					Six Months Ended June 30,				Change
	2019		2018		$		%			2019		2018		$		%
	(dollars in thousands)
Revenue:
License revenue	$	150,581	$	14,323	$	136,258		951	%	$	150,581	$	14,323	$	136,258		951	%
Development and other revenue		40,985		29,629		11,356		38	%		64,848		61,553		3,295		5	%
Total revenue	$	191,566	$	43,952	$	147,614		336	%	$	215,429	$	75,876	$	139,553		184	%

Our revenue to date has been generated substantially from our collaboration agreements with Astellas and AstraZeneca.

Under our revenue recognition policy, license revenue includes amounts from upfront, non-refundable license payments and amounts allocated pursuant to the standalone selling price method from other consideration received during the periods. This revenue is generally recognized as deliverables are met and services are performed.

Development revenue include co-development and other development related services. Co-development services are recognized as revenue in the period in which they are billed to our partners, excluding China. For China co-development services, revenue is deferred until the end of the development period once all performance obligations have been satisfied. Other development related services are recognized as revenue over the non-contingent development period, ranging from 36 to 89 months, based on a proportional performance method. Other revenues consist of sales of research and development material and have been included with Development and other revenue in the condensed consolidated statements of operations, as they have not been material for any of the periods presented.

Table of Contents

We have not generated any revenues based on the sale of FDA or NMPA approved products. In the future, we may generate revenue from product sales and from collaboration agreements in the form of license fees, milestone payments, reimbursements for collaboration services and royalties on product sales. We expect that any revenues we generate will fluctuate from quarter to quarter due to the uncertain timing and amount of such payments and sales.

Total revenue increased $147.6 million, or 336% for the three months ended June 30, 2019, and increased $139.6 million, or 184% for the six months ended June 30, 2019, compared to the same periods a year ago for the reasons discussed in the sections below.

License Revenue

	Three Months Ended June 30,				Change					Six Months Ended June 30,				Change
	2019		2018		$		%			2019		2018		$		%
	(dollars in thousands)
License revenue:
Astellas	$	117,470	$	14,323	$	103,147		720	%	$	117,470	$	14,323	$	103,147		720	%
AstraZeneca		33,111		—		33,111		100	%		33,111		—		33,111		100	%
Total license revenue	$	150,581	$	14,323	$	136,258		951	%	$	150,581	$	14,323	$	136,258		951	%

License revenue increased $136.3 million, or 951%, respectively for the three and six months ended June 30, 2019 compared to the same periods a year ago.

License revenue recognized under our collaboration agreements with Astellas in the three and six months ended June 2019 was related to two regulatory milestones totaling $130.0 million associated with the planned MAA submission in Europe that were included in the transaction price during the second quarter of 2019 when these milestones became probable of being achieved. Of this amount, $117.5 million was allocated to license revenue and recognized during the second quarter of 2019.

License revenue recognized under our collaboration agreements with AstraZeneca in the three and six months ended June 2019 was related to a regulatory milestone of $50.0 million associated with the planned NDA submission in the U.S. that was included in the transaction price during the second quarter of 2019 when this milestone became probable of being achieved. Of this amount, $33.1 million was allocated to license revenue and recognized during the second quarter of 2019.

License revenue in the three and six months ended June 2018 was related to a $15.0 million regulatory milestone associated with Astellas’ expected NDA submission in Japan that was included in the transaction price during the second quarter of 2018 when this milestone became probable of being achieved. Of this amount, $14.3 million was allocated to license revenue and recognized during the second quarter of 2018.

Development and Other Revenue

	Three Months Ended June 30,				Change							Six Months Ended June 30,				Change
	2019		2018		$			%				2019		2018		$			%
	(dollars in thousands)
Development revenue:
Astellas	$	17,223	$	6,145	$	11,078			180		%	$	22,082	$	11,317	$	10,765			95		%
AstraZeneca		23,762		23,479		283			1		%		42,766		50,202		(7,436	)		(15	)	%
Total development revenue		40,985		29,624		11,361			38		%		64,848		61,519		3,329			5		%
Other revenue		—		5		(5	)		(100	)	%		—		34		(34	)		(100	)	%
Total development and other revenue	$	40,985	$	29,629	$	11,356			38		%	$	64,848	$	61,553	$	3,295			5		%

Development and other revenue increased $11.4 million, or 38% for the three months ended June 30, 2019, and $3.3 million, or 5% for the six months ended June 30, 2019, compared to the same periods a year ago.

Development revenue recognized under our collaboration agreements with Astellas increased $11.1 million, or 180% for the three months ended June 30, 2019, and $10.8 million, or 95% for the six months ended June 30, 2019, respectively primarily due to the allocated revenue of $12.0 million related to the above-mentioned $130.0 million associated with the regulatory milestones of the planned MAA submission in Europe.

Table of Contents

Development revenue recognized under our collaboration agreements with AstraZeneca remained flat for the three months ended June 30, 2019 due to the allocated revenue of $8.4 million related to the above-mentioned $50.0 million associated with the regulatory milestone of the planned NDA submission in the U.S., offset by a decrease in co-development billings related to the development of roxadustat as a result of the substantial completion of Phase 3 trials for roxadustat.

Development revenue recognized under our collaboration agreements with AstraZeneca for the six months ended June 30, 2019 decreased $7.4 million, or 15% due to a decrease in co-development billings related to the development of roxadustat as a result of the substantial completion of Phase 3 trials for roxadustat, partially offset by the allocated revenue of $8.4 million related to the above-mentioned $50.0 million associated with the regulatory milestone of the planned NDA submission in the U.S.

Operating Expenses

	Three Months Ended June 30,				Change						Six Months Ended June 30,				Change
	2019		2018		$			%			2019		2018		$			%
	(dollars in thousands)
Operating expenses
Research and development	$	52,008	$	52,138	$	(130	)		—	%	$	102,505	$	109,112	$	(6,607	)		(6	)	%
Selling, general and administrative		26,739		15,055		11,684			78	%		48,948		30,605		18,343			60		%
Total operating expenses	$	78,747	$	67,193	$	11,554			17	%	$	151,453	$	139,717	$	11,736			8		%

Total operating expenses increased $11.6 million, or 17% for the three months ended June 30, 2019, and $11.7 million, or 8% for the six months ended June 30, 2019, respectively, compared to the same periods a year ago, for the reasons discussed in the sections below.

Research and Development Expenses

Research and development expenses consist of third party research and development costs and the fully-burdened amount of costs associated with work performed under collaboration agreements. Research and development costs include employee-related expenses for research and development functions, expenses incurred under agreements with clinical research organizations, other clinical and preclinical costs and allocated direct and indirect overhead costs, such as facilities costs, information technology costs and other overhead. Research and development costs are expensed as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.

The following table summarizes our research and development expenses incurred during the three and six months ended June 30, 2019 and 2018:

		Three Months Ended June 30,				Six Months Ended June 30,
Product Candidate	Phase of Development	2019		2018		2019		2018
		(in thousands)
Roxadustat	Phase 3	$	29,492	$	33,335	$	59,633	$	70,858
Pamrevlumab	Phase 2/3		14,748		13,837		27,102		25,931
FG-5200	Preclinical		1,345		1,154		2,722		2,642
Other research and development expenses			6,423		3,812		13,048		9,681
Total research and development expenses		$	52,008	$	52,138	$	102,505	$	109,112

The program-specific expenses summarized in the table above include costs we directly attribute to our product candidates. We allocate research and development salaries, benefits, stock-based compensation and other indirect costs to our product candidates on a program-specific basis, and we include these costs in the program-specific expenses. We expect our research and development expenses to increase in the future as we advance our product candidates through clinical trials and expand our product candidate portfolio.

Table of Contents

Research and development expenses remained flat for the three months ended June 30, 2019, compared to the same period a year ago, as a result of decreases in clinical trials costs of $3.4 million, and drug development expenses of $2.5 million, offset by increases in stock-based compensation expense of $2.6 million, allocated facility related expense of $1.9 million and outside services of $1.6 million. Clinical trial costs decreased as a result of the substantial completion of Phase 3 trials for roxadustat, partially offset by the increases resulted from Phase 3 trials for pamrevlumab. Drug development expenses decreased primarily due to lower drug substance manufacturing activities related to pamrevlumab. Stock-based compensation expense increased due to the cumulative impact of stock option grant activities. Facility related expenses, as part of the allocated overhead costs, was higher due to $2.6 million amortization of finance lease ROU assets related to the adoption of ASC 842, and $1.1 million higher depreciation expenses related to the change estimated useful life for our leasehold improvements, from the building life to the shorter of the building life and remaining lease term, as a result of the adoption of ASC 842. Outside services costs increased due to higher scientific contract work related to roxadustat submission activities and higher medical affairs expenses for roxadustat in China. We expect development expenses to increase as we begin Phase 3 trials for pamrevlumab.

Research and development expenses decreased $6.6 million, or 6% for the six months ended June 30, 2019, compared to the same period a year ago, primarily due to decreases in clinical trials costs of $11.7 million, and drug development expenses of $6.2 million, partially offset by increases in stock-based compensation expense of $5.8 million, allocated facility related expense of $4.4 million and outside services of $2.4 million. Clinical trial costs decreased as a result of the substantial completion of Phase 3 trials for roxadustat, partially offset by the increases resulted from Phase 3 trials for pamrevlumab. Drug development expenses decreased primarily due to lower drug substance manufacturing activities related to pamrevlumab. Stock-based compensation expense increased due to the cumulative impact of stock option grant activities. Facility related expenses, as part of the allocated overhead costs, was higher due to $5.2 million amortization of finance lease ROU assets related to the adoption of ASC 842, and $2.2 million higher depreciation expenses related to the change estimated useful life for our leasehold improvements, from the building life to the shorter of the building life and remaining lease term, as a result of the adoption of ASC 842. Outside services costs increased due to higher scientific contract work related to roxadustat submission activities, higher medical affairs expenses for roxadustat in China and higher consulting expenses related to pamrevlumab. We expect development expenses to increase as we begin Phase 3 trials for pamrevlumab.

Selling, General and Administrative Expenses

We started to incur sales and marketing expenses in the first quarter of 2019 in China to prepare for commercial operations. Selling, general and administrative (“SG&A”) expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance, and human resource functions. SG&A expenses also include facility-related costs, professional fees, accounting and legal services, other outside services including co-promotional expenses, recruiting fees and expenses associated with obtaining and maintaining patents.

We anticipate that our SG&A expenses will increase in the future as we increase our headcount to support our potential commercialization of our product candidates. We also anticipate increased expenses, including exchange listing and SEC requirements, director and officer insurance premiums, legal, audit and tax fees, regulatory compliance programs, and investor relations costs associated with being a public company and ceasing to be an emerging growth company. Additionally, we anticipate an increase in payroll and related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our product candidates.

SG&A expenses increased $11.7 million, or 78% for the three months ended June 30, 2019, compared to the same period a year ago, primarily due to increases in outside service expenses of $7.6 million, stock-based compensation expense of $1.9 million, employee-related costs of $1.2 million, and facility related expenses of $1.1 million. Outside service expenses increased due to the co-promotional expenses incurred of our preparation for commercial operations. Stock-based compensation expense increased due to cumulative impact of stock option grant activities. Employee-related costs increased due to higher headcount primarily in the sales and marketing functions in China. Facility related expenses, as part of the allocated overhead costs, was higher due to $2.6 million amortization of finance lease ROU assets related to the adoption of ASC 842, and $1.1 million higher depreciation expenses related to the change estimated useful life for our leasehold improvements, from the building life to the shorter of the building life and remaining lease term, as a result of the adoption of ASC 842.

Table of Contents

SG&A expenses increased $18.3 million, or 60% for the six months ended June 30, 2019, compared to the same period a year ago, primarily due to increases in outside service expenses of $8.9 million, stock-based compensation expense of $4.2 million, employee-related costs of $2.2 million, and facility related expenses of $2.2 million. Outside service expenses increased due to the co-promotional expenses incurred of our preparation for commercial operations. Stock-based compensation expense increased due to cumulative impact of stock option grant activities. Employee-related costs increased due to higher headcount primarily in the sales and marketing functions in China. Facility related expenses, as part of the allocated overhead costs, was higher due to $5.2 million amortization of finance lease ROU assets related to the adoption of ASC 842, and $2.2 million higher depreciation expenses related to the change estimated useful life for our leasehold improvements, from the building life to the shorter of the building life and remaining lease term, as a result of the adoption of ASC 842.

Interest and Other Income (Expense), Net

	Three Months Ended June 30,						Change						Six Months Ended June 30,						Change
	2019			2018			$		%				2019			2018			$		%
	(dollars in thousands)
Interest and other, net:
Interest expense	$	(736	)	$	(2,750	)	$	2,014		(73	)	%	$	(1,507	)	$	(5,519	)	$	4,012		(73	)	%
Interest income and other, net		4,125			2,645			1,480		56		%		8,303			4,717			3,586		76		%
Total interest and other, net	$	3,389		$	(105	)	$	3,494		(3,328	)	%	$	6,796		$	(802	)	$	7,598		(947	)	%

Interest Expense

Before December 31, 2018, interest expense included payments made for imputed interest related to the facility lease financing obligations for our leased facilities in San Francisco and China. After adoption of ASC 842 as of January 1, 2019, the interest expense relates to our finance lease liabilities accretion primarily for our leased facilities in San Francisco and China. Interest expense also includes interest related to the Technology Development Center of the Republic of Finland product development obligations.

Interest expense decreased $2.0 million, or 73% for the three months ended June 30, 2019, and $4.0 million, or 73% for the six months ended June 30, 2019, compared to the same periods a year ago, due to the different method of interest computation of interest expense under the old and new lease accounting rules.

Interest Income and Other, Net

Interest income and other, net primarily include interest income earned on our cash, cash equivalents and investments, foreign currency transaction gains (losses), remeasurement of certain monetary assets and liabilities in non-functional currency of our subsidiaries into the functional currency, realized gains (losses) on sales of investments.

Interest income and other, net increased $1.5 million, or 56% for the three months ended June, 2019, compared to the same period a year ago, primarily due to $1.5 million higher interest earned on our cash, cash equivalents and investments associated with the higher average balances and $1.3 million higher net unrealized gain on our marketable equity investments, partially offset by $1.3 million related to a one-time realized foreign currency gain during the prior year period.

Interest income and other, net increased $3.6 million, or 76% for the six months ended June, 2019, compared to the same period a year ago, primarily due to $3.4 million higher interest earned on our cash, cash equivalents and investments associated with the higher average balances and $1.2 million higher net unrealized gain on our marketable equity investments, partially offset by $1.3 million related to a one-time realized foreign currency gain during the prior year period.

Table of Contents

Provision for Income Taxes

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
	(dollars in thousands)
Income (loss) before income taxes	$	116,208		$	(23,346	)	$	70,772		$	(64,643	)
Provision for income taxes		205			75			180			174
Effective tax rate		0.2	%		(0.3	)%		0.3	%		(0.3	)%

The provisions for income taxes for the three and six months ended June 30, 2019 and 2018 were due to foreign taxes.

Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception, we have established and continue to maintain a full valuation allowance against our deferred tax assets as we do not currently believe that realization of those assets is more likely than not.

LIQUIDITY AND CAPITAL RESOURCES

Financial Conditions

We have historically funded our operations principally from the sale of common stock (including our public offering proceeds) and from the execution of certain collaboration agreements involving license payments, milestones and reimbursement for development services.

As of June 30, 2019, we had cash and cash equivalents of $74.6 million. Cash is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting of available-for-sale debt investments, marketable equity investments, term deposit and certificate of deposit, and stated at fair value, are also available as a source of liquidity. As of June 30, 2019, we had short-term and long-term investments of $586.2 million and $10.9 million, respectively. As of June 30, 2019, a total of $26.0 million of our cash and cash equivalents was held outside of the U.S. in our foreign subsidiaries to be used primarily for our China operations.

Operating Capital Requirements

To date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one or more of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. To date, we have funded certain portions of our research and development and manufacturing efforts in China and Europe through outside parties. There is no guarantee that sufficient funds will be available to continue to fund these development efforts through commercialization or otherwise. Although our share of expenses for roxadustat will decrease as a result of AstraZeneca funding all non-China collaboration expenses not reimbursed by Astellas, we expect our research and development expenses to continue to increase as we invest in our other programs. We are subject to all the risks related to the development and commercialization of novel therapeutics, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional funding in connection with our continuing operations.

We believe that our existing cash and cash equivalents, short-term and long-term investments and accounts receivable will be sufficient to meet our anticipated cash requirements for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. However, our liquidity assumptions may change over time, and we could utilize our available financial resources sooner than we currently expect. In addition, we may elect to raise additional funds at any time through equity, equity-linked or debt financing arrangements. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth under Part II, Item 1A “Risk Factors” in this Quarterly Report on Form 10-Q. We may not be able to secure additional financing to meet our operating requirements on acceptable terms, or at all. If we raise additional funds by issuing equity or equity-linked securities, the ownership of our existing stockholders will be diluted. If we raise additional financing by the incurrence of indebtedness, we will be subject to increased fixed payment obligations and could also be subject to restrictive covenants, such as limitations on our ability to incur additional debt, and other operating restrictions that could adversely impact our ability to conduct our business. If we are unable to obtain needed additional funds, we will have to reduce our operating expenses, which would impair our growth prospects and could otherwise negatively impact our business.

Table of Contents

Cash Sources and Uses

The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods set forth below:

	Six Months Ended June 30,
	2019			2018
	(in thousands)
Net cash provided by (used in):
Operating activities	$	(6,172	)	$	(66,927	)
Investing activities		(7,717	)		29,938
Financing activities		(780	)		7,137
Effect of exchange rate changes on cash and cash equivalents		(2	)		(3	)
Net decrease in cash and cash equivalents	$	(14,671	)	$	(29,855	)

Operating Activities

Net cash used in operating activities was $6.2 million for the six months ended June 30, 2019 and consisted primarily of net income of $70.6 million adjusted for non-cash items of $42.2 million, offset by a net decrease in operating assets and liabilities of $119.0 million. The significant non-cash items included stock-based compensation expense of $34.1 million, depreciation expense of $5.5 million, amortization of finance lease ROU of $5.1 million, and net amortization of premium and discount on investments of $2.5 million. The significant items in the changes in operating assets and liabilities included decreases resulting from prepaid expenses and other current assets of $131.8 million, deferred revenue of $46.8 million, accounts payable of $5.1 million and inventories of $2.0 million, partially offset by increases resulting from accounts receivable of $57.2 million and other long-term liabilities of $8.5 million. The changes in prepaid expenses and other current assets and deferred revenue were primarily driven by a $130.0 million unbilled contract asset related to regulatory milestones under the Europe Agreement with Astellas associated with the planned MAA submission in Europe and a $50.0 million contract asset related to a regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the planned NDA submission in the U.S., which were not billable to Astellas or AstraZeneca as of June 30, 2019, net of the associated deferred revenues of $2.0 million and $50.0 million, respectively. The change in deferred revenue was also related to the recognition of revenues under our collaboration agreements with Astellas and AstraZeneca. The change in accounts payable was primarily driven by the timing of invoicing and payments. The change in inventories was due to the capitalization of inventory costs starting in June 2019 when FibroGen Beijing began productions of roxadustat for commercial sales purposes. The change in accounts receivable was primarily related to the collection of $43.9 million from Astellas for the roxadustat API delivery in December 2018 under the Japan Amendment, as well as the timing of the receipt of upfront payments and recognition of revenues under our collaboration agreements with Astellas and AstraZeneca. The change in other long-term liabilities was primarily due to the accrual of co-promotional expenses for our preparation for commercial operation that is not expected to be paid in the next year.

Net cash used in operating activities was $66.9 million for the six months ended June 30, 2018 and consisted primarily of net loss of $64.8 million adjusted for non-cash items of $27.7 million and a net decrease in operating assets and liabilities of $29.8 million. The significant non-cash items included stock-based compensation expense of $24.1 million, depreciation expense of $3.1 million, unrealized loss on our marketable equity investments of $1.1 million, and realized foreign currency gain of $1.1 million. The significant items in the changes in operating assets and liabilities included decreases resulting from accounts receivable of $21.7 million, accrued liabilities of $13.4 million, prepaid expenses and other current assets of $13.2 million, and accounts payable of $2.3 million, partially offset by an increase resulting from deferred revenue of $20.4 million. The changes in accounts receivable and deferred revenue were primarily related to a sale of roxadustat API to Astellas during the second quarter of 2018. The sale was made pursuant to a material transfer agreement in anticipation of the execution of an amendment to the Japan Agreement. The associated consideration was recorded as deferred revenue as of June 30, 2018 as control of the product had not fully transferred to Astellas as of June 30, 2018. The changes in accrued liabilities and accounts payable were primarily driven by clinical trial activities and the timing of payments. The change in prepaid expenses and other current assets was related to a contract asset related to a regulatory milestone under the Japan Agreement with Astellas associated with NDA submission in Japan, which was not billable to Astellas as of June 30, 2018.

Table of Contents

Investing Activities

Investing activities primarily consist of purchases of property and equipment, purchases of investments, and proceeds from the maturity and sale of investments.

Net cash used in investing activities was $7.7 million for the six months ended June 30, 2019 and consisted of cash used in purchases of available-for-sale securities and term deposit of $105.5 million and purchased of property and equipment of $2.2 million, partially offset by proceeds from maturities of investments of $100.0 million.

Net cash provided by investing activities was $29.9 million for the six months ended June 30, 2018 and consisted of proceeds from maturities of available-for-sale securities of $25.4 million and sales of available-for-sale securities of $8.2 million, partially offset by cash used in purchases of property and equipment of $3.7 million.

Financing Activities

Financing activities primarily reflect proceeds from the issuance of our common stock, cash paid for payroll taxes on restricted stock unit releases, and repayments of our lease liability.

Net cash used in financing activities was $0.8 million for the six months ended June 30, 2019 and consisted primarily of $8.1 million of cash paid for payroll taxes on restricted stock unit releases and $5.9 million of repayments of finance lease liabilities partially offset by $13.3 million of proceeds from the issuance of common stock upon exercise of stock options and purchases under our Employee Share Purchase Plan (“ESPP”).

Net cash provided by financing activities was $7.1 million for the six months ended June 30, 2018 and consisted primarily of $17.3 million of proceeds from the issuance of common stock upon exercise of stock options and purchases under ESPP, partially offset by $10.0 million of cash paid for payroll taxes on restricted stock unit releases.

Off-Balance Sheet Arrangements

During the three and six months ended June 30, 2019, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements.

Contractual Obligations and Commitments

There have been no material changes in our contractual obligations compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes in our critical accounting policies, estimates and judgments during the three and six months ended June 30, 2019 compared with the disclosures in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2018, except for the following:

Table of Contents

Leases

We determine if an arrangement is a lease at inception date when it is given control of the underlying assets. We elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of 12 months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.

Our building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (“ASC”) 842 - Leases (“ASC 842”) are accounted for as finance leases under the requirements of ASC 842.

Lease right-of-use (“ROU”) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not typically provide an implicit rate, we use incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. We will reassess the incremental borrowing rate periodically for application to any new leases or lease modifications or if any company-specific or general business conditions warrant.

Lease ROU assets include any lease payments made and initial direct costs incurred. We have lease agreements with lease and non-lease components. We generally account for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability.

Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms.

Recently Issued and Adopted Accounting Guidance

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“ASU 2016-02”). Under this guidance, an entity is required to recognize ROU assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which provides entities the option to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We adopted the above guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment at the beginning of the first quarter of 2019. We elected the optional transition method under the guidance, which allowed it to continue applying previous lease guidance (ASC 840) for the comparative prior year periods presentation in the year of adoption. Accordingly, we recognized a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In addition, we elected the package of transitional practical expedients permitted under the transition guidance under ASC 842, which among other things allows us to carry forward its historical lease classification, and not to reassess initial direct costs for any existing leases. Meanwhile, we did not elect the hindsight practical expedient because it has limited number of leases, lease terms are straightforward, and most of its lease renewals are undefined until negotiated. In addition, we have elected the short term accounting policy practical expedient and does not apply the balance sheet recognition requirements for short-term leases (excluding expenses relating to leases with a lease term of one month or less), by class of underlying asset to which the right of use relates. We have not elected the non-lease components practical expedient, and therefore accounts for each lease component separately from the non-lease components. Upon adoption of ASC 842, we classified our existing building leases that were previously accounted for as build-to-suit arrangements as finance leases, and applied the transition guidance. Accordingly, we derecognized the assets and liabilities previously recognized under ASC 840 build-to-suit guidance. In addition, as a result of applying the transition guidance, we also recorded an adjustment to the accumulated depreciation of related leasehold improvements to reflect a change in estimated useful life from the building life to the shorter of the building life and remaining lease term. Differences between the assets and liabilities derecognized were recorded to the opening balance of retained earnings. The adoption of ASC 842 resulted in a recognition of approximately $50.3 million in right-of-use assets and approximately $62.0 million in lease liabilities, respectively, upon adoption of this guidance, for our operating leases and finance leases. The adoption of ASC 842 had no impact to our condensed statement of operations or condensed consolidated statement of cash flows for the three and six months ended June 30, 2019. Refer to Note 1 to the condensed consolidated financial statements for details.

Table of Contents

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This guidance allows for the reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects arising from the reduction of the U.S. federal statutory income tax rate from 35% to 21%. This guidance was effective for annual reporting periods beginning after December 15, 2018, including interim periods. We adopted this guidance on January 1, 2019 using the modified retrospective approach, which resulted in a reclassification of $0.6 million, based on the aggregate portfolio approach, from accumulated other comprehensive loss to opening accumulated deficit. The adoption of this guidance had no impact to our condensed consolidated statement of operations or condensed consolidated statement of cash flows for the three and six months ended June 30, 2019. Refer to Note 1 to the condensed consolidated financial statements for details.

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, “Disclosure Update and Simplification,” amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements. Under the amendments, the changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. This analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is presented. This final rule was effective as of November 5, 2018. Accordingly, we included the condensed consolidated statements of changes in stockholders’ equity in Form 10-Q starting the first quarter of 2019.

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This guidance expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance is effective for annual reporting period beginning after December 15, 2018, including interim periods. We adopted this guidance on January 1, 2019 and the adoption of this guidance had no impact to our consolidated financial statements.

Recently Issued Accounting Guidance Not Yet Adopted

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance should be applied either retrospectively or prospectively, and is effective for annual reporting period beginning after December 15, 2019 including interim periods, with early adoption permitted. We are currently evaluating the impact on our consolidated financial statements upon adoption of this guidance.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. This guidance amends existing fair value measurement disclosure requirements by adding, changing, or removing certain disclosures. This guidance is effective for annual reporting period beginning after December 15, 2019 including interim periods, with early adoption permitted. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. We do not anticipate a material impact to our consolidated financial statements upon adoption of this guidance.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently in April 2019, the FASB issued amendments to the guidance, ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and in May 2019, ASU 2019-05, Financial Instruments – Credit Losses (Topic 326): Targeted Transition Relief. This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. ASU 2019-04 clarifies that equity instruments without readily determinable fair values for which an entity has elected the measurement alternative should be remeasured to fair value as of the date that an observable transaction occurred. ASU 2019-05 provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. The amendments should be applied on either a prospective transition or modified-retrospective approach depending on the subtopic. This guidance is effective for the annual reporting period beginning after December 15, 2019, including interim periods within that reporting period. We do not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We believe there has been no material change in our exposure to market risks as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to the company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Based on management’s evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of June 30, 2019 at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Table of Contents

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings.

ITEM 1A. RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below in addition to the other information included or incorporated by reference in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Although we have discussed all known material risks, the risks described below are not the only ones that we may face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.

We have marked with an asterisk (*) those risks described below that reflect substantive changes from the risks described under Part I, Item 1A “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2018.

Risks Related to Our Financial Condition and History of Operating Losses

We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future and may never achieve or sustain profitability. We may require additional financings in order to fund our operations.*

We are a clinical-stage biopharmaceutical company with two lead product candidates in clinical development, roxadustat in anemia in chronic kidney disease (“CKD”) and myelodysplastic syndromes (“MDS”), and pamrevlumab (FG-3019) in idiopathic pulmonary fibrosis (“IPF”), pancreatic cancer and Duchenne muscular dystrophy (“DMD”). Pharmaceutical product development is a highly risky undertaking. To date, we have focused our efforts and most of our resources on hypoxia-inducible factor (“HIF”) and fibrosis biology research, as well as developing our lead product candidates. We are not profitable and, other than in 2006 and 2007 due to income received from our Astellas Pharma Inc. (“Astellas”) collaboration, have incurred annual losses each year since our inception. We have not generated any revenue based on commercial drug product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. Our net loss for the year ended December 31, 2018 was approximately $86.4 million, and our net loss for the years ended December 31, 2017, and 2016, recast from amounts previously reported due to the adoption of the new revenue standards, were approximately $120.9 million and $58.1 million, respectively. As of June 30, 2019, we had an accumulated deficit of $637.2 million. As of June 30, 2019, we had capital resources consisting of cash, cash equivalents and short-term investments of $660.8 million plus $10.9 million of long-term investments classified as available for sale securities. Despite contractual development and cost coverage commitments from our collaboration partners, AstraZeneca AB (“AstraZeneca”) and Astellas, and the potential to receive milestone and other payments from these partners, and despite our expectation to launch commercialization efforts in China for roxadustat for the treatment of anemia caused by CKD in dialysis patients, we anticipate we will continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue our development of and seek regulatory approval for our product candidates and in our commercialization efforts. If we do not successfully develop and obtain regulatory approval for our existing or any future product candidates and effectively manufacture, market and sell any product candidates that are approved, we may never generate product sales, and even if we do generate product sales, we may never achieve or sustain profitability on a quarterly or annual basis. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital. Our failure to become and remain profitable would depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.

Table of Contents

We believe that we will continue to expend substantial resources for the foreseeable future as we continue late-stage clinical development of roxadustat, grow our operations in the People’s Republic of China (“China”), expand our clinical development efforts on pamrevlumab, seek regulatory approval, prepare for the commercialization of our product candidates, and pursue additional indications. These expenditures will include costs associated with research and development, conducting preclinical trials and clinical trials, obtaining regulatory approvals in various jurisdictions, and manufacturing and supplying products and product candidates for ourselves and our partners. In particular, in our planned Phase 3 clinical trial program for roxadustat, which we believe will be the largest Phase 3 program ever conducted for an anemia product candidate, we are expecting to enroll more than 8,000 patients for our United States (“U.S.”) and European programs alone. We are conducting this Phase 3 program in conjunction with Astellas and AstraZeneca, and we are substantially dependent on Astellas and AstraZeneca for the funding of this large program. The outcome of any clinical trial and/or regulatory approval process is highly uncertain and we are unable to fully estimate the actual costs necessary to successfully complete the development and regulatory approval process for our compounds in development and any future product candidates. We believe that the net proceeds from our 2017 public offerings, our existing cash and cash equivalents, short-term and long-term investments and accounts receivable, and expected third party collaboration revenues will allow us to fund our operating plans through at least the next 12 months. Our operating plans or third party collaborations may change as a result of many factors, which are discussed in more detail below, and other factors that may not currently be known to us, and we therefore may need to seek additional funds sooner than planned, through offerings of public or private securities, debt financings or other sources, such as royalty monetization or other structured financings. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. We may also seek additional capital due to favorable market conditions or strategic considerations even if we currently believe that we have sufficient funds for our current or future operating plans.

Our future funding requirements will depend on many factors, including, but not limited to:

•

the rate of progress in the development of our product candidates;

•

the costs of development efforts for our product candidates, such as pamrevlumab, that are not subject to reimbursement from our collaboration partners;

•

the costs necessary to obtain regulatory approvals, if any, for our product candidates in the U.S., China and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;

•

the continuation of our existing collaborations and entry into new collaborations;

•

the time and unreimbursed costs necessary to commercialize products in territories in which our product candidates are approved for sale;

•

the revenues from any future sales of our products as well as revenue earned from profit share, royalties and milestones;

•

the level of reimbursement or third party payor pricing available to our products;

•

the costs of establishing and maintaining manufacturing operations and obtaining third party commercial supplies of our products, if any, manufactured in accordance with regulatory requirements;

•

the costs we incur in maintaining domestic and foreign operations, including operations in China;

•

regulatory compliance costs;

•

the costs of our commercialization efforts for roxadustat for the treatment of anemia caused by CKD in dialysis patients in China; and

•

the costs we incur in the filing, prosecution, maintenance and defense of our extensive patent portfolio and other intellectual property rights.

Additional funds may not be available when we require them, or on terms that are acceptable to us. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate our research and development efforts or other operations or activities that may be necessary to commercialize our product candidates.

Table of Contents

All of our recent revenue has been earned from collaboration partners for our product candidates under development.

Substantially all of our revenues recognized in recent years have been from our collaboration partners.

We will require substantial additional capital to achieve our development and commercialization goals, which for our lead product candidate, roxadustat, is currently contemplated to be provided under our existing third party collaborations with Astellas and AstraZeneca.

If either or both of these collaborations were to be terminated, we could require significant additional capital in order to proceed with development and commercialization of our product candidates, including with respect to our expected commercialization for roxadustat for the treatment of anemia caused by CKD in dialysis patients in China, or we may require additional partnering in order to help fund such development and commercialization. If adequate funds or partners are not available to us on a timely basis or on favorable terms, we may be required to delay, limit, reduce or terminate our research and development efforts or other operations.

If we are unable to continue to progress our development efforts and achieve milestones under our collaboration agreements, our revenues may decrease and our activities may fail to lead to commercial products.

Substantially all of our revenues to date have been, and a significant portion of our future revenues are expected to be, derived from our existing collaboration agreements. Revenues from research and development collaborations depend upon continuation of the collaborations, reimbursement of development costs, the achievement of milestones and royalties and profits from our product sales, if any, derived from future products developed from our research. If we are unable to successfully advance the development of our product candidates or achieve milestones, revenues under our collaboration agreements will be substantially less than expected.

Risks Related to the Development and Commercialization of Our Product Candidates

We are substantially dependent on the success of our lead product candidate, roxadustat, and our second compound in development, pamrevlumab.*

To date, we have invested a substantial portion of our efforts and financial resources in the research and development of roxadustat and pamrevlumab. While we have received approval of our New Drug Application (“NDA”) for roxadustat in China for CKD anemia in dialysis patients, we will need to make substantial additional investments in both the development and commercialization of roxadustat worldwide and in various indications. Our near-term prospects, including maintaining our existing collaborations with Astellas and AstraZeneca, will depend heavily on successful development and commercialization of roxadustat, including obtaining regulatory approvals for the commercialization of roxadustat for anemia associated with CKD in the U.S., Europe, and Japan.

Our other lead product candidate, pamrevlumab, is currently in clinical development for IPF, pancreatic cancer and DMD. Pamrevlumab requires substantial further development and investment. We do not have a collaboration partner for support of this compound, and, while we have promising open-label safety data and potential signals of efficacy, we would need to complete larger and more extensive controlled clinical trials to validate the results to date in order to continue further development of this product candidate. In addition, although there are many potentially promising indications beyond IPF, pancreatic cancer and DMD, we are still exploring indications for which further development of, and investment for, pamrevlumab may be appropriate. Accordingly, the costs and time to complete development and related risks are currently unknown. Moreover, pamrevlumab is a monoclonal antibody, which may require experience and expertise that we may not currently possess as well as financial resources that are potentially greater than those required for our small molecule lead compound, roxadustat.

The clinical and commercial success of roxadustat and pamrevlumab will depend on a number of factors, many of which are beyond our control, and we may be unable to complete the development or commercialization of roxadustat or pamrevlumab.*

The clinical and commercial success of roxadustat and pamrevlumab will depend on a number of factors, including the following:

•

the timely completion of data analyses from our Phase 3 clinical trials for roxadustat, which will depend substantially upon requirements for such trials imposed by the U.S. Food and Drug Administration (“FDA”) and other regulatory agencies and bodies and the continued commitment and coordinated and timely performance by our third party collaboration partners, AstraZeneca and Astellas;

•

the timely initiation and completion of our clinical trials for pamrevlumab, including in IPF, pancreatic cancer and DMD;

•

our ability to demonstrate the safety and efficacy of our product candidates to the satisfaction of the relevant regulatory authorities;

Table of Contents

•

the ultimate approval criteria (which may include non-inferiority margins and statistical analyses methods), indications, patient populations, and ultimate benefit-risk analysis used by regulatory authorities in their approval processes;

•

whether we are required by the FDA or other regulatory authorities to conduct additional clinical trials, and the scope and nature of such clinical trials, prior to approval to market our products;

•

the timely receipt of necessary marketing approvals from the FDA and foreign regulatory authorities, including pricing and reimbursement determinations;

•

the ability to successfully commercialize our product candidates, if approved, for marketing and sale by the FDA or foreign regulatory authorities, whether alone or in collaboration with others;

•

our ability and the ability of our third party manufacturing partners to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability;

•

our success in educating health care providers and patients about the benefits, risks, administration and use of our product candidates, if approved;

•

acceptance of our product candidates, if approved, as safe and effective by patients and the healthcare community;

•

the success of efforts to enter into relationships with large dialysis organizations involving the administration of roxadustat to dialysis patients;

•

the achievement and maintenance of compliance with all regulatory requirements applicable to our product candidates;

•

the maintenance of an acceptable safety profile of our products following any approval;

•

the availability, perceived advantages, relative cost, relative safety, and relative efficacy of alternative and competitive treatments;

•

our ability to obtain and sustain an adequate level of pricing or reimbursement for our products by third party payors;

•

our ability to enforce successfully our intellectual property rights for our product candidates and against the products of potential competitors; and

•

our ability to avoid or succeed in third party patent interference or patent infringement claims.

Many of these factors are beyond our control. Accordingly, we cannot assure you that we will ever be able to achieve profitability through the sale of, or royalties from, our product candidates. If we or our collaboration partners are not successful in obtaining approval for and commercializing our product candidates, or are delayed in completing those efforts, our business and operations would be adversely affected.

If our commercialization efforts for roxadustat in China are unsuccessful, our business, financial condition and results of operations will be materially harmed.

We have invested and continue to invest a significant portion of our efforts and financial resources in the development, approval and now commercialization of roxadustat for the treatment of anemia caused by CKD in dialysis patients in China, as well as in other indications and other geographic regions. With the marketing authorization received from the National Medical Products Administration (“NMPA”) of roxadustat for the treatment of anemia caused by CKD in dialysis patients in China, we plan to launch commercialization efforts in China in the third quarter of 2019 with our commercialization partner AstraZeneca.

Our success of commercialization of roxadustat in China will depend on numerous factors in China, including:

•

our success in the marketing, sales, and distribution of the product along with our collaboration partner AstraZeneca;

•

our success in negotiating a cost effective reimbursed price with the government in China;

•

acceptance of roxadustat by state-owned and state-controlled hospitals, physicians, patients and the healthcare community;

•

acceptance of pricing and placement of roxadustat on China’s Medical Insurance Catalogs. Refer to “Business – Government Regulation – Regulation in China”;

•

successfully establishing and maintaining commercial manufacturing with third parties;

Table of Contents

•

successfully manufacturing our drug substances and drug products through our subsidiary FibroGen (China) Medical Technology Development Co., Ltd. (“FibroGen Beijing”);

•

receiving market authorization for roxadustat for anemia caused by CKD in non-dialysis patients;

•

our success in arranging for and passing the inspection of our clinical sites by the NMPA;

•

whether AstraZeneca is able to recruit and retain adequate numbers of effective sales and marketing personnel for the sale of roxadustat;

•

whether we can compete successfully as a new entrant in the treatment of anemia caused by CKD in dialysis patients in China; and

•

whether we will maintain sufficient funding to cover the costs and expenses associated with creating and sustaining a capable sales and marketing organization and related commercial infrastructure.

Successful commercialization of roxadustat will require significant resources and time, and there is a risk that we may not successfully commercialize roxadustat. If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize roxadustat and generate revenues, which would deprive us from additional working capital and would materially harm our business. If we do not successfully commercialize roxadustat in China, our collaboration partners and third parties may also lose confidence in our ability to execute in commercialization efforts and become less likely to collaborate with us, and our business may be harmed.

As a Company, we have no commercialization experience, and the time and resources to develop such experience are significant. If we fail to achieve and sustain commercial success for roxadustat in China, either directly or with AstraZeneca, our business would be harmed.

Commercializing roxadustat in China with AstraZeneca will require us to establish commercialization systems, including but not limited to, medical affairs, sales, pharmacovigilance, supply-chain, and distribution capabilities to perform our portion of the collaborative efforts. These efforts will require resources and time. In particular, significant resources may be necessary to successfully market, sell and distribute roxadustat to patients with anemia caused by CKD in dialysis patients. If we, along with AstraZeneca, are not successful in setting our marketing, pricing and reimbursement strategy, facilitating adoption by hospitals in China, recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing roxadustat, which would adversely affect our business and financial condition.

As we evolve from a company primarily involved in research and development to a company potentially involved in commercialization, we may encounter difficulties in managing our growth and expanding our operations successfully.

If we are successful in advancing roxadustat and our other product candidates through the development stage towards commercialization, we will need to expand our organization, including adding marketing and sales capabilities or continuing to contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will also need to manage our existing and additional relationships with various collaborative partners, suppliers and other third parties. Future growth will impose significant added responsibilities on our organization, in particular on management. Our future financial performance and our ability to commercialize roxadustat and our other product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we may not be able to manage our growth efforts effectively, and hire, train and integrate additional management, administrative and sales and marketing personnel, and our failure to accomplish any of these activities could prevent us from successfully growing our Company.

Table of Contents

Although FibroGen Beijing obtained regulatory approval for roxadustat in China in December 2018, we may be unable to obtain regulatory approval for our product candidates in other countries, or such approval may be delayed or limited, due to a number of factors, many of which are beyond our control.

The clinical trials and the manufacturing of our product candidates are and will continue to be, and the marketing of our product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the U.S. and in other countries where we intend to develop and, if approved, market any product candidates. Before obtaining regulatory approval for the commercial sale of any product candidate, we must demonstrate through extensive preclinical trials and clinical trials that the product candidate is safe and effective for use in each indication for which approval is sought. The regulatory review and approval process is expensive and requires substantial resources and time, and in general very few product candidates that enter development receive regulatory approval. In addition, our collaboration partners for roxadustat have final control over development decisions in their respective territories and they may make decisions with respect to development or regulatory authorities that delay or limit the potential approval of roxadustat, or increase the cost of development or commercialization. Accordingly, we may be unable to successfully develop or commercialize roxadustat or pamrevlumab or any of our other product candidates.

Even though FibroGen Beijing obtained regulatory approval for roxadustat in China, we have not obtained regulatory approval for any of our product candidates in other countries and it is possible that roxadustat and pamrevlumab will never receive regulatory approval in other countries. Other regulatory authorities may take actions or impose requirements that delay, limit or deny approval of roxadustat or pamrevlumab for many reasons, including, among others:

•

our failure to adequately demonstrate to the satisfaction of regulatory authorities that roxadustat is safe and effective in treating anemia in CKD or that pamrevlumab is safe and effective in treating IPF, pancreatic cancer or DMD;

•

our failure to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

•

the determination by regulatory authorities that additional clinical trials are necessary to demonstrate the safety and efficacy of roxadustat or pamrevlumab, or that ongoing clinical trials need to be modified in design, size, conduct or implementation;

•

our product candidates may exhibit an unacceptable safety signal as they advance through clinical trials, in particular controlled Phase 3 trials;

•

the clinical research organizations (“CROs”) that conduct clinical trials on our behalf may take actions outside of our control that materially adversely impact our clinical trials;

•

we or third party contractors manufacturing our product candidates may not maintain current good manufacturing practices (“cGMP”), successfully pass inspection or meet other applicable manufacturing regulatory requirements;

•

regulatory authorities may not agree with our interpretation of the data from our preclinical trials and clinical trials;

•

collaboration partners may not perform or complete their clinical programs in a timely manner, or at all; or

•

principal investigators may determine that one or more serious adverse events (“SAEs”), is related or possibly related to roxadustat, and any such determination may adversely affect our ability to obtain regulatory approval, whether or not the determination is correct.

Any of these factors, many of which are beyond our control, could jeopardize our or our collaboration partners’ abilities to obtain regulatory approval for and successfully market roxadustat. Because our business and operations in the near-term are almost entirely dependent upon roxadustat, any significant delays or impediments to regulatory approval could have a material adverse effect on our business and prospects.

In China, the NMPA required that FibroGen Beijing conduct three clinical studies as a post-approval commitment: (i) a post-approval safety study in 2,000 patients; (ii) a drug-intensive monitoring study in 1,000 patients; and (iii) a dosing optimization study in approximately 300 patients on dialysis. Furthermore, in the U.S., we also expect to be required to perform additional clinical trials in order to obtain approval or as a condition to maintaining approval due to post-marketing requirements. If the FDA requires a risk evaluation and mitigation strategy (“REMS”), for any of our product candidates if approved, the substantial cost and expense of complying with a REMS or other post-marketing requirements may limit our ability to successfully commercialize our product candidates.

Table of Contents

Preclinical, Phase 1 and Phase 2 clinical trial results may not be indicative of the results that may be obtained in larger, controlled Phase 3 clinical trials required for approval.*

Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical and early clinical trials, which are often highly variable and use small sample sizes, may not be predictive of similar results in humans or in larger, controlled clinical trials, and successful results from early or small clinical trials may not be replicated or show as favorable an outcome, even if successful.

We have conducted a limited number of Phase 2 clinical trials with pamrevlumab. We have conducted a randomized placebo-controlled study in 103 IPF patients with sub-studies in an additional 57 IPF patients comparing pamrevlumab to one of two standards of care, an open-label Phase 2 dose escalation study of pamrevlumab for IPF in 89 patients and a randomized double-blind placebo controlled study for liver fibrosis in subjects with hepatitis B, we are currently conducting an open-label randomized, active-control, neoadjuvant Phase 2 trial in pancreatic cancer combining pamrevlumab with nab-paclitaxel plus gemcitabine in 37 patients, and we are currently in a Phase 2 open-label trial of pamrevlumab for DMD in 21 non-ambulatory patients. We cannot be sure that the results we have received to date from these trials will be substantiated in larger, well-controlled Phase 3 clinical trials, that larger trials will demonstrate the safety and efficacy of pamrevlumab for these or other indications, that further studies will provide benefits over existing approved products or that new safety issues will not be uncovered in further trials. In addition, while we believe that the limited animal and human studies conducted to date suggest that pamrevlumab has the potential to arrest or reverse fibrosis and reduce tumor mass in some patients or diseases, we cannot be sure that these results will be indicative of the effects of pamrevlumab in larger human trials. In addition, the IPF and pancreatic cancer patient populations are extremely ill and routinely experience SAEs, including death, which may be attributed to pamrevlumab in a manner that negatively impacts the safety profile of our product candidate. If the additional clinical trials that we are planning or are currently conducting for pamrevlumab do not show favorable efficacy results or result in safety concerns, or if we do not meet our clinical endpoints with statistical significance, or demonstrate an acceptable risk-benefit profile, we may be prevented from or delayed in obtaining regulatory approval for pamrevlumab in one or both of these indications.

In the past we developed an earlier generation product candidate aimed at treating anemia in CKD that resulted in a clinical hold for a safety signal seen in that product in Phase 2 clinical trials. The clinical hold applied to that product candidate and roxadustat was lifted for both product candidates after submission of the requested information to the FDA. While we have not seen similar safety concerns involving roxadustat to date, some of the safety concerns associated with the treatment of patients with anemia in CKD using erythropoiesis stimulating agents (“ESAs”) did not emerge for many years until placebo-controlled studies had been conducted in large numbers of patients. And while the data monitoring committee for our U.S. and Europe Phase 3 anemia trials has consistently determined that our trials should continue without modification to the protocol, safety issues may still be discovered upon review of unblinded major adverse cardiac event (“MACE”) or other data. The biochemical pathways that we believe are affected by roxadustat are implicated in a variety of biological processes and disease conditions, and it is possible that the use of roxadustat to treat larger numbers of patients will demonstrate unanticipated adverse effects, including possible drug interactions, which may negatively impact the safety profile, use and market acceptance of roxadustat. We studied the potential interaction between roxadustat and three statins (atorvastatin, rosuvastatin and simvastatin), which are used to lower levels of lipids in the blood. An adverse effect associated with increased statin plasma concentration is myopathy, which typically presents in a form of myalgia. The studies indicated the potential for increased exposure to those statins when roxadustat is taken simultaneously with those statins and suggested the need for statin dose reductions for patients receiving higher statin doses. We performed additional clinical pharmacology studies to evaluate if the effect of any such interaction could be minimized or eliminated by a modification of the dosing schedule that would separate the administration of roxadustat and the statin by up to 10 hours, however, such studies showed no minimization of effect. It is possible that the potential for interaction between roxadustat and statins could lead to label provisions for statins or roxadustat relating, for example, to dose scheduling or recommended statin dose limitations. In CKD patients, statin therapy is often initiated earlier than treatment for anemia, and risks of myopathy have been shown to decrease with increased time on drug. While we believe the prior statin treatment history of such patients at established doses may reduce the risk of adverse effects from any interaction with roxadustat and facilitate any appropriate dose adjustments, we cannot be sure that this will be the case.

Our Phase 3 trials include a MACE safety endpoint, which is a composite endpoint designed to identify major safety concerns, in particular relating to cardiovascular events such as cardiovascular death, myocardial infarction and stroke. The European Medicines Agency (“EMA”) is requiring MACE+ as a safety endpoint which, in addition to the MACE components, incorporates measurements of hospitalization rates due to heart failure or unstable angina. The EMA will also review MACE results. The FDA has also informed us that the MACE endpoint will need to be evaluated separately for our Phase 3 trials in non-dialysis-dependent (“NDD”)-CKD patients and our Phase 3 trials in dialysis-dependent (“DD”)-CKD patients. The MACE endpoint is being evaluated in pooled analysis across Phase 3 studies of similar study populations and requires demonstration of non-inferiority relative to comparator, which means that the MACE event rate in roxadustat-treated patients must have less than a specified probability of exceeding the rate in the comparator trial by a specified hazard ratio.

Table of Contents

The number of patients necessary in order to permit a statistical analysis with adequate ability to detect the relative risk of MACE or MACE+ events in different arms of the trial, referred to as statistical power, depends on a number of factors, including the rate at which MACE or MACE+ events occur per patient-year in the trial, treatment duration of the patients, the achieved hazard ratios, the rates of discontinuation, and the required statistical power and confidence intervals.

In addition, we cannot be sure that the potential advantages we believe roxadustat may have for treatment of patients with anemia in CKD, as compared to the use of ESAs, will be substantiated by our larger U.S. and European Phase 3 clinical trials, or that we will be able to include a discussion of such advantages in our labeling should we obtain approval. We believe that roxadustat may have certain benefits as compared to ESAs based on the data from our Phase 2 clinical trials and China Phase 3 trials conducted to date, including safety benefits, the absence of a hypertensive effect, the potential to lower cholesterol levels and the potential to correct anemia without the use of IV iron. However, our belief that roxadustat may offer those benefits is based on a limited amount of data from our clinical trials to date, and our understanding of the likely mechanisms of action for roxadustat. Some of these benefits, such as those associated with the apparent effects on blood pressure and cholesterol, are not fully understood and, even if roxadustat receives marketing approval in additional countries beyond China, we do not expect that it will be approved for the treatment of high blood pressure or high cholesterol based on the data from our Phase 3 trials, and we may not be able to refer to any such benefits in the labeling. While the data from our Phase 2 trials suggests roxadustat may reduce low-density lipoprotein (“LDL”), and reduce the ratio of LDL to high-density lipoprotein (“HDL”), the data show it may also reduce HDL, which may be a risk to patients. In addition, causes of the safety concerns associated with the use of ESAs to achieve specified target hemoglobin levels have not been fully elucidated. While we believe that the issues giving rise to these concerns with ESAs are likely due to factors other than the hemoglobin levels achieved, we cannot be certain that roxadustat will not be associated with similar, or more severe, safety concerns.

Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we may face similar setbacks. In addition, the CKD patient population has many afflictions that may cause severe illness or death, which may be attributed to roxadustat in a manner that negatively impacts the safety profile of our product candidate. The results of our completed Phase 3 clinical trials for roxadustat demonstrated efficacy, as all primary efficacy endpoints were met with statistical significance. While we have reported topline cardiovascular safety results, the analysis of these data is ongoing; there may be unanticipated safety concerns or adverse events that prevent from or delay obtaining marketing approval for roxadustat, and even if we obtain marketing approval, any sales of roxadustat may suffer.

We do not know whether our ongoing or planned clinical trials of roxadustat or pamrevlumab will need to be redesigned based on interim results, be able to achieve sufficient enrollment or be completed on schedule, if at all.*

Clinical trials can be delayed or terminated for a variety of reasons, including delay or failure to:

•

address any physician or patient safety concerns that arise during the course of the trial;

•

obtain required regulatory or institutional review board (“IRB”) approval or guidance;

•

reach timely agreement on acceptable terms with prospective CROs and clinical trial sites;

•

recruit, enroll and retain patients through the completion of the trial;

•

maintain clinical sites in compliance with clinical trial protocols;

•

initiate or add a sufficient number of clinical trial sites; and

•

manufacture sufficient quantities of product candidate for use in clinical trials.

In addition, we could encounter delays if a clinical trial is suspended or terminated by us, by the relevant IRBs at the sites at which such trials are being conducted, or by the FDA or other regulatory authorities. A suspension or termination of clinical trials may result from any number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, changes in laws or regulations, or a principal investigator’s determination that a serious adverse event could be related to our product candidates. Any delays in completing our clinical trials will increase the costs of the trial, delay the product candidate development and approval process and jeopardize our ability to commence marketing and generate revenues. Any of these occurrences may materially and adversely harm our business and operations and prospects.

Table of Contents

Our product candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential.

Undesirable side effects caused by our product candidates or that may be identified as related to our product candidates by physician investigators conducting our clinical trials or even competing products in development that utilize a similar mechanism of action or act through a similar biological disease pathway could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. Adverse events and SAEs that emerge during treatment with our product candidates or other compounds acting through similar biological pathways may be deemed to be related to our product candidate and may result in:

•

our Phase 3 clinical trial development plan becoming longer and more extensive;

•

regulatory authorities increasing the data and information required to approve our product candidates and imposing other requirements; and

•

our collaboration partners terminating our existing agreements.

The occurrence of any or all of these events may cause the development of our product candidates to be delayed or terminated, which could materially and adversely affect our business and prospects. Refer to “Business — Our Development Program for Roxadustat” and “Business — Pamrevlumab for the Treatment of Fibrosis and Cancer” for a discussion of the adverse events and SAEs that have emerged in clinical trials of roxadustat and pamrevlumab.

Clinical trials of our product candidates may not uncover all possible adverse effects that patients may experience.

Clinical trials are conducted in representative samples of the potential patient population, which may have significant variability. Clinical trials are by design based on a limited number of subjects and of limited duration for exposure to the product used to determine whether, on a potentially statistically significant basis, the planned safety and efficacy of any product candidate can be achieved. As with the results of any statistical sampling, we cannot be sure that all side effects of our product candidates may be uncovered, and it may be the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration, that a more complete safety profile is identified. Further, even larger clinical trials may not identify rare serious adverse effects or the duration of such studies may not be sufficient to identify when those events may occur. There have been other products, including ESAs, for which safety concerns have been uncovered following approval by regulatory authorities. Such safety concerns have led to labeling changes or withdrawal of ESAs products from the market. While our most advanced product candidate is chemically unique from ESAs, it or any of our product candidates may be subject to similar risks. For example, roxadustat for use in anemia in CKD is being developed to address a very diverse patient population expected to have many serious health conditions at the time of administration of roxadustat, including diabetes, high blood pressure and declining kidney function.

To date we have not seen evidence of significant safety concerns with our product candidates currently in clinical trials. Patients treated with our products, if approved, may experience adverse reactions and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. If safety problems occur or are identified after our product candidates reach the market, we may, or regulatory authorities may require us to amend the labeling of our products, recall our products or even withdraw approval for our products.

We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates.

Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the rate at which we can recruit and enroll patients in testing our product candidates. Patients may be unwilling to participate in clinical trials of our product candidates for a variety of reasons, some of which may be beyond our control:

•

severity of the disease under investigation;

•

availability of alternative treatments;

•

size and nature of the patient population;

•

eligibility criteria for and design of the study in question;

•

perceived risks and benefits of the product candidate under study;

•

ongoing clinical trials of competitive agents;

Table of Contents

•

physicians’ and patients’ perceptions of the potential advantages of our product candidates being studied in relation to available therapies or other products under development;

•

our CRO’s and our trial sites’ efforts to facilitate timely enrollment in clinical trials;

•

patient referral practices of physicians; and

•

ability to monitor patients and collect patient data adequately during and after treatment.

Patients may be unwilling to participate in our clinical trials for roxadustat due to adverse events observed in other drug treatments of anemia in CKD, and patients currently controlling their disease with existing ESAs may be reluctant to participate in a clinical trial with an investigational drug. We may not be able to successfully initiate or continue clinical trials if we cannot rapidly enroll a sufficient number of eligible patients to participate in the clinical trials required by regulatory agencies. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate on-going or planned clinical trials, any of which could have a material and adverse effect on our business and prospects.

If we or third party manufacturers and other service providers on which we rely cannot manufacture sufficient quantities of our product candidates, or at sufficient quality, or perform other services we require, we may experience delays in development, regulatory approval, launch or commercialization.

Completion of our clinical trials and commercialization of our product candidates require access to, or development of, facilities to manufacture and manage our product candidates at sufficient yields and at commercial scale. Although we have entered into commercial supply agreements for the manufacture of some of our raw materials, we have not yet entered into commercial supply agreements with all of our third-party manufacturers. We are continuing to negotiate and expect to enter into commercial supply agreements and other supply management agreements with third-party manufacturers, but we may not be able to enter into these agreements with satisfactory terms or on a timely manner.

We have limited experience manufacturing or managing third parties in manufacturing any of our product candidates in the volumes that are expected to be necessary to support large-scale clinical trials and sales. In addition, we have limited experience forecasting supply requirements or coordinating supply chain (including export management) for launch or commercialization, which is a complex process involving our third-party manufacturers and logistics providers, and for roxadustat, our collaboration partners. We may not be able to accurately forecast supplies for commercial launch, or do so in a timely manner and our efforts to establish these manufacturing and supply chain management capabilities may not meet our requirements as to quantities, scale-up, yield, cost, potency or quality in compliance with cGMP.

We have a limited amount of roxadustat and pamrevlumab in storage, limited capacity reserved at our third-party manufacturers, and there are long lead times required to manufacture and scale-up the manufacture of additional supply, as required for both late-stage clinical trials, post-approval trials, and commercial supply. If we are unable to forecast, order or manufacture sufficient quantities of roxadustat or pamrevlumab on a timely basis, it may delay our development, launch or commercialization in some or all indications we are currently pursuing. For example, prior to agreement with regulatory authorities on the scope of our Phase 3 IPF trial design, there is uncertainty as to whether our supply plans will meet our clinical requirements in a timely manner. Any delay or interruption in the supply of our product candidates or products could have a material adverse effect on our business and operations.

Our clinical trials must be conducted with product produced under applicable cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We, and even an experienced third party manufacturer, may encounter difficulties in production. Difficulties may include:

•

costs and challenges associated with scale-up and attaining sufficient manufacturing yields, in particular for biologic products such as pamrevlumab, which is a monoclonal antibody;

•

supply chain issues, including coordination of multiple contractors in our supply chain and securing necessary licenses (such as export licenses);

•

the timely availability and shelf life requirements of raw materials and supplies;

•

quality control and quality assurance;

•

shortages of qualified personnel and capital required to manufacture large quantities of product;

Table of Contents

•

compliance with regulatory requirements that vary in each country where a product might be sold;

•

capacity or forecasting limitations and scheduling availability in contracted facilities; and

•

natural disasters, such as floods, storms, earthquakes, tsunamis, and droughts, or accidents such as fire, that affect facilities, possibly limit or postpone production, and increase costs.

The FDA and EMA will do their own benefit risk analysis and may reach a different conclusion than we or our partners have internally, and these regulatory authorities may base their approval decision on different analyses, data, and statistical methods than ours.*

Even if we believe we have achieved certain results based on a totality of the evidence, such as superiority or non-inferiority, in certain endpoints, populations or subpopulations, or using certain statistical methods of analysis, the FDA and EMA will each conduct their own benefit-risk analysis and may reach different conclusions, using different statistical methods, different endpoints or definitions thereof, or different patient populations or sub-populations, and regulatory authorities may change their approvability criteria based on their internal analyses and discussions with expert advisors. Regulatory authorities may approve roxadustat for fewer or more limited indications than we request, or may grant approval contingent on the performance of costly post-approval clinical trials. While we will present to regulatory authorities certain pre-specified and not pre-specified sub-populations and sub-group analyses (for example, incident dialysis), multiple secondary endpoints, and multiple analytical methods (such as long-term follow up analyses), including adjusted and censored data, regulatory authorities may reject these analyses, methods, or even parts of our trial design or certain data from our studies, the rationale for our pre-specified non-inferiority margins or other portions of our statistical analysis plans. In addition, even if we are able to provide positive data with respect to certain analyses, such as incident dialysis, estimated glomerular filtration rate, hepcidin, or quality of life measures, regulatory authorities may not include such claims on any approved labeling for roxadustat, which may limit the commercialization or market opportunity for roxadustat. Further, initial topline results reported for certain studies (such as reduction of transfusion risk or hemoglobin response in the presence of inflammation), may not be representative of the data seen in all studies or may not be sustained upon further analyses or after more wide-spread use upon commercialization. The failure to obtain regulatory approval, or any label, population or other approval limitations in any jurisdiction, may significantly limit our ability to generate revenues, and any failure to obtain such approval for all of the indications and labeling claims we deem desirable could reduce our potential revenue.

Positive topline results from our Phase 3 clinical trials assessing the safety and efficacy of roxadustat may not be indicative of additional results or results for roxadustat in other indications.*

There are multiple key and secondary endpoints as well as sub-group analyses in both dialysis and non-dialysis in the U.S. and multiple secondary endpoints in addition to MACE+ as well as sub-group analyses in dialysis and non-dialysis in Europe. We continue to analyze these additional endpoints from the Phase 3 clinical trials of roxadustat in anemia of CKD, as well as from the pooled analyses, some of which may have a bearing on the safety or efficacy of roxadustat. The topline results we have reported thus far may not be indicative of these additional results. In addition, results in these CKD-anemia indications may not be indicative of our clinical trials in other indications or the safety, efficacy, or approvability of roxadustat in other indications.

Even if we are able to obtain regulatory approval of our product candidates, the label we obtain may limit the indicated uses for which our product candidates may be marketed.*

With respect to roxadustat, regulatory approvals, if obtained at all, could limit the approved indicated uses for which roxadustat may be marketed. For example, ESAs have been subject to significant safety warnings, including the “Black Box” warnings on their labels. Refer to “Business — Roxadustat for the Treatment of Anemia in Chronic Kidney Disease — Limitations of the Current Standard of Care for Anemia in CKD” in our annual report on Form 10-K for the year ended December 31, 2018. In addition, in the past, an approved ESA was voluntarily withdrawn due to serious safety issues discovered after approval. The safety concerns relating to ESAs may result in labeling for roxadustat containing similar warnings even if our Phase 3 clinical trials do not suggest that roxadustat has similar safety issues. Even if the label for roxadustat does not contain all of the warnings contained in the “Black Box” warning for ESAs, the label for roxadustat may contain other warnings or limit the market opportunity or approved indications for roxadustat. These warnings could include warnings against exceeding specified hemoglobin targets and other warnings that derive from the lack of clarity regarding the safety issues associated with ESAs, even if our Phase 3 clinical trials do not themselves raise safety concerns.

Table of Contents

As an organization, we have not successfully commercialized any drug product. Therefore, we may not be able to efficiently execute our development and commercialization plans.

We are currently conducting Phase 3 clinical trials for pamrevlumab and roxadustat. The conduct of Phase 3 clinical trials and the submission of a successful NDA is a complicated process. As an organization, we have limited experience in preparing, submitting and prosecuting regulatory filings, and have not received approval for an NDA before outside of China where we received marketing authorization in December 2018 from the NMPA for the treatment of anemia caused by CKD in dialysis patients. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to NDA submission and approval of roxadustat or for any other product candidate we are developing, even if our earlier stage clinical trials are successful. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials would prevent us from or delay us in commercializing roxadustat or any other product candidate we are developing.

In addition, in order for any Phase 3 clinical trial to support an NDA submission for approval, the FDA and foreign regulatory authorities require compliance with regulations and standards, including good clinical practices (“GCP”) requirements for designing, conducting, monitoring, recording, analyzing, and reporting the results of clinical trials to ensure that the data and results from trials are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Although we rely on third parties to conduct our clinical trials, we as the sponsor remain responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan and protocol under legal and regulatory requirements, including GCP. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs, trial sites, principal investigators or other third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory authorities may require us to exclude the use of patient data from our clinical trials not conducted in compliance with GCP or perform additional clinical trials before approving our marketing applications. They may even reject our application for approval or refuse to accept our future applications for an extended time period. For example in China in March 2016, the State Drug Administration, now known as the NMPA issued guidance related to its clinical trial data integrity regulations. While trial sites and CROs bear liability for the accuracy and authenticity of data they are directly responsible for, the sponsor ultimately bears full responsibility for submitted clinical data and the drug application dossier. Fraudulent clinical data could result in a ban in China of a sponsor’s product-related NDA applications for three years and other NDA applications for one year. We have taken extensive steps to ensure the integrity of our China clinical data. In China, the clinical site inspections confirmed our compliance with GCP regulations and supported our approval. However, we cannot assure you that upon inspection by a regulatory authority in other regions, such regulatory authority will determine that any of our clinical trials comply with GCP requirements or that our results will be deemed authentic or may be used in support of our regulatory submissions.

If we are unable to establish sales, marketing and distribution capabilities or enter into or maintain agreements with third parties to market and sell our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.

We do not have a sales or marketing infrastructure and have no experience in the sales, marketing or distribution of pharmaceutical products in any country. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales and marketing capabilities or make and maintain our existing arrangements with third parties to perform these services at a level sufficient to support our commercialization efforts.

To the extent that we would undertake sales and marketing of any of our products directly, there are risks involved with establishing our own sales, marketing and distribution capabilities. Factors that may inhibit our efforts to commercialize our products on our own include:

•

our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;

•

the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;

•

our inability to effectively manage geographically dispersed sales and marketing teams;

•

the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and

•

unforeseen costs and expenses associated with creating an independent sales and marketing organization.

Table of Contents

With respect to roxadustat, we are dependent on the commercialization capabilities of our collaboration partners, AstraZeneca and Astellas. If either such partner were to terminate its agreement with us, we would have to commercialize on our own or with another third party. We will have limited or little control over the commercialization efforts of such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products, if any, effectively. If they are not successful in commercializing our product candidates, our business and financial condition would suffer.

We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than we do.*

The development and commercialization of new pharmaceutical products is highly competitive. Our future success depends on our ability to achieve and maintain a competitive advantage with respect to the development and commercialization of our product candidates. Our objective is to discover, develop and commercialize new products with superior efficacy, convenience, tolerability, and safety. We expect that in many cases, the products that we commercialize will compete with existing, market-leading products of companies that have large, established commercial organizations.

If roxadustat is approved and launched commercially, competing drugs are expected to include ESAs, particularly in those patient segments where ESAs are used. Currently available ESAs include epoetin alfa (EPOGEN^®, marketed by Amgen Inc. in the U.S., Procrit^® and Erypo^®/Eprex^®, marketed by Johnson & Johnson Inc., and Espo ^® marketed by Kyowa Hakko Kirin in Japan and China), darbepoetin (Amgen/Kyowa Hakko Kirin’s Aranesp^® and NESP^®) and Mircera ^® marketed by Hoffmann-La Roche (“Roche”) outside of the U.S. and by Vifor Pharma (“Vifor”), a Roche licensee, in the U.S. and Puerto Rico, as well as biosimilar versions of these currently marketed ESA products. ESAs have been used in the treatment of anemia in CKD for more than 20 years, serving a significant majority of DD-CKD patients. While NDD-CKD patients who are not under the care of nephrologists, including those with diabetes and hypertension, do not typically receive ESAs and are often left untreated, some patients under nephrology care may be receiving ESA therapy. It may be difficult to encourage healthcare providers and patients to switch to roxadustat from products with which they have become familiar.

We may also face competition from potential new anemia therapies currently in clinical development, including in those patient segments not currently addressed by ESAs. Companies such as GlaxoSmithKline plc (“GSK”), Bayer Corporation (“Bayer”), Akebia Therapeutics, Inc. (“Akebia”), and Japan Tobacco, are currently developing HIF prolyl hydroxylase (“HIF-PH”) inhibitors for anemia in CKD indications. Akebia is currently conducting Phase 3 studies in NDD–CKD and DD-CKD, as well as additional Phase 1 and Phase 2 studies. In Japan, Mitsubishi Tanabe Pharmaceutical Corporation (“Mitsubishi Tanabe”), Akebia’s collaboration partner, submitted an NDA for treatment of anemia in CKD patients on dialysis and not on dialysis, supported by the Phase 3 studies conducted by Mitsubishi Tanabe in Japan. GSK is conducting global Phase 3 studies in NDD-CKD and DD-CKD. In Japan, GSK has completed two Phase 3 studies in hemodialysis-dependent CKD patients and one Phase 3 study in CKD patients not on dialysis or on peritoneal dialysis. GSK and Kyowa Hakko Kirin announced in November 2018 that the two companies signed a strategic commercialization deal in Japan for daprodustat. Bayer has completed global Phase 2 studies and announced in May 2017 its HIF-PH inhibitor is now in continued development in Japan only, and its Japan Phase 3 studies in NDD-CKD and DD-CKD are expected to complete in the second half of 2019. Japan Tobacco is also conducting Phase 3 studies in NDD-CKD and DD-CKD in Japan only. Some of these product candidates may enter the market prior to roxadustat.

In addition, there are other companies developing biologic therapies for the treatment of other anemia indications that we may also seek to pursue in the future, including anemia of MDS. For example, Acceleron Pharma Inc. and its partner Celgene Corporation (“Celgene”) announced in April 2019 that Celgene has submitted a Biologics License Application (“BLA”) for luspatercept for the treatment of adult patients with very low to intermediate risk of MDS-associated anemia who have ring sideroblasts and require red blood cell transfusions, and beta-thalassemia-associated anemia who require red blood cell transfusions. Celgene’s plan to submit a marketing approval application for luspatercept in the European Union (“EU”) in the second quarter of 2019. There may also be new therapies for renal-related diseases that could limit the market or level of reimbursement available for roxadustat if and when it is commercialized.

Table of Contents

In China, biosimilars of epoetin alfa are offered by Chinese pharmaceutical companies such as EPIAO marketed by 3SBio Inc. as well as more than 15 other local manufacturers. We may also face competition by HIF-PH inhibitors from other companies such as Akebia, Bayer, and GSK, which was authorized by the NMPA to conduct trials in China to support its ex-China regulatory filings. Furthermore, while it is too early to understand how the NMPA will implement its recently approved guidelines to allow multinational companies to use their ex-China clinical data in their NDAs in China, these guidelines could in theory allow competitors to accelerate their NDA applications in China. Akebia announced in December 2015 that it has entered into a development and commercialization partnership with Mitsubishi Tanabe for its HIF-PH inhibitor vadadustat in Japan, Taiwan, South Korea, India, and certain other countries in Asia, and announced in April 2017 an expansion of their U.S. collaboration with Otsuka to add markets, including China. 3SBio Inc. also announced in 2016 its plan to begin a Phase 1 clinical trial of a HIF-PH inhibitor for the China market, and two Chinese domestic companies, Jiangsu Hengrui Medicine Co., Ltd. and Guangdong Sunshine Health Investment Co., Ltd., have announced they also secured the NMPA approval to conduct clinical trials for their respective HIF-PH inhibitors.

The first biosimilar ESAs, Pfizer’s Retacrit® (epoetin zeta), entered the U.S. market in November 2018. Market penetration of Retacrit® (epoetin zeta) and the potential addition of other biosimilar ESAs, currently under development, may alter the competitive and pricing landscape of anemia therapy in DD-CKD patients under the end stage renal disease bundle. The patents for Amgen’s epoetin alfa, EPOGEN, expired in 2004 in the EU, and the final material patents in the U.S. expired in May 2015. Several biosimilar versions of currently marketed ESAs are available for sale in the EU, China and other territories. In the U.S., a few ESA biosimilars are currently under development. Sandoz, a division of Novartis, markets Binocrit^® (epoetin alfa) in Europe and may file a biosimilar BLA in the U.S.

The majority of the current CKD anemia market focuses on dialysis patients, who visit dialysis centers on a regular basis, typically three-times a week, and anemia therapies are administered as part of the visit. Two of the largest operators of dialysis clinics in the U.S., DaVita Healthcare Partners Inc. (“DaVita”) and Fresenius Medical Care AG & Co. KGaA (“Fresenius”), collectively provide dialysis care to approximately 70% of U.S. dialysis patients, and therefore have historically won long-term contracts including rebate terms with Amgen. In January 2017, DaVita entered into a new 6-year sourcing and supply agreement with Amgen that is effective through 2022. Fresenius’ contract with Amgen expired in 2015, and Fresenius is now administering Mircera^® in a significant portion of its U.S. dialysis patients since Mircera was made available by Vifor. Successful penetration of this market may require a significant agreement with Fresenius or DaVita on favorable terms and on a timely basis.

If pamrevlumab is approved and launched commercially to treat IPF, competing drugs are expected to include Roche’s Esbriet® (pirfenidone) and Boehringer Ingelheim Pharma GmbH & Co. KG’s Ofev® (nintedanib). Nintedanib is also in development for non-small cell lung cancer and ovarian cancer. Other potential competitive product candidates in development for IPF include Biogen-Idec’s BG-00011, Galapagos NV’s GLPG1690 and GLPG1205, Kadmon Holdings, Inc.’s KD025, Prometic Life Sciences Inc.’s PBI-4050, and Promedior Inc.’s PRM-151. Galapagos initiated a Phase 3 study for GLPG 1690 in December 2018.

If pamrevlumab is approved and launched commercially to treat locally advanced pancreatic cancer patients who are not candidates for surgical resection, pamrevlumab may face competition from agents seeking approval in combination with gemcitibine and nab-paclitaxel from companies such as NewLink Genetics Corporation and Halozyme Therapeutics, Inc. Gemcitabine and/or nab-paclitaxel are the current standard of care in the first-line treatment of metastatic pancreatic cancer. Celgene Corporation’s Abraxane^® (nab-paclitaxel) was launched in the U.S. and Europe in 2013 and 2014, and was the first drug approved in this disease in nearly a decade.

If pamrevlumab is approved and launched commercially to treat DMD, pamrevlumab may face competition for some patients from Sarepta Therapeutics, Inc. (“Sarepta”) with Exondys 51® (eteplirsen), approved in the U.S. for patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping, and from PTC Therapeutics’ drug ataluren approved in ambulatory patients in Europe. We may also face competition from Sarepta’s golodirsen, currently under NDA review in the U.S., and agents currently in development for DMD, including PTC Therapeutics’ ataluren, Santhera Pharmaceuticals’ idebone, Catabasis Pharmaceuticals’ edasalonexent, Capricor Therapeutics’ CAP-1002, and Sarepta’s casimersen and other gene therapies, if and when these agents are approved and launched.

The success of any or all of these potential competitive products may negatively impact the development and potential for success of pamrevlumab. In addition, any competitive products that are on the market or in development may compete with pamrevlumab for patient recruitment and enrollment for clinical trials or may force us to change our clinical trial design, including, in order to compare pamrevlumab against another drug, which may be the new standard of care.

Table of Contents

If FG-5200 is approved and launched in China to treat corneal blindness resulting from partial thickness corneal damage without active inflammation and infection, it is likely to compete with other products designed to treat corneal damage. For example, in April 2015, a subsidiary of China Regenerative Medicine International Limited received approval for their acellular porcine cornea stroma medical device to treat patients in China with corneal ulcers and in April 2016, Guangzhou Yourvision Biotech Co. Ltd, a subsidiary of Guanhao Biotech, received approval for their acellular porcine cornea medical device to treat patients in China with infectious keratitis that does not respond to drug treatment.

Moreover, many of our competitors have significantly greater resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients, manufacturing pharmaceutical products, and commercialization. In the potential anemia market for roxadustat, for example, large and established companies such as Amgen and Roche, among others, compete aggressively to maintain their market shares. In particular, the currently marketed ESA products are supported by large pharmaceutical companies that have greater experience and expertise in commercialization in the anemia market, including in securing reimbursement, government contracts and relationships with key opinion leaders; conducting testing and clinical trials; obtaining and maintaining regulatory approvals and distribution relationships to market products; and marketing approved products. These companies also have significantly greater scale research and marketing capabilities than we do and may also have products that have been approved or are in later stages of development, and have collaboration agreements in our target markets with leading dialysis companies and research institutions. These competitors have in the past successfully prevented new and competing products from entering the anemia market, and we expect that their resources will represent challenges for us and our collaboration partners, AstraZeneca and Astellas. If we and our collaboration partners are not able to compete effectively against existing and potential competitors, our business and financial condition may be materially and adversely affected.

Our future commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, third party payors and others in the health care community.

Even if we obtain marketing approval for roxadustat, pamrevlumab or any other product candidates that we may develop or acquire in the future in all indications and geographic regions, these product candidates may not gain market acceptance among physicians, third party payors, patients and others in the health care community. Market acceptance of any approved product, including in roxadustat for the treatment of anemia caused by CKD in dialysis patients in China, depends on a number of other factors, including:

•

the clinical indications for which the product is approved and the labeling required by regulatory authorities for use with the product, including any warnings that may be required in the labeling;

•

acceptance by physicians and patients of the product as a safe and effective treatment and the willingness of the target patient population to try new therapies and of physicians to prescribe new therapies;

•

the cost, safety, efficacy and convenience of treatment in relation to alternative treatments;

•

the restrictions on the use of our products together with other medications, if any;

•

the availability of adequate coverage and reimbursement or pricing by third party payors and government authorities;

•

the ability of treatment providers, such as dialysis clinics, to enter into relationships with us without violating their existing agreement; and

•

the effectiveness of our sales and marketing efforts.

Table of Contents

No or limited reimbursement or insurance coverage of our approved products, if any, by third party payors may render our products less attractive to patients and healthcare providers.

Market acceptance and sales of any approved products will depend significantly on reimbursement or coverage of our products by the Chinese government or third party payors, and may be affected by existing and future healthcare reform measures or prices of related products for which the government or third party reimbursement applies. Coverage and reimbursement by the government or a third party payor may depend upon a number of factors, including the payor’s determination that use of a product is:

•

a covered benefit under its health plan;

•

safe, effective and medically necessary;

•

appropriate for the specific patient;

•

cost-effective; and

•

neither experimental nor investigational.

The review and publication cycle for the Chinese government to update their reimbursement lists (national or provincial) is unpredictable and is outside our control.

Obtaining coverage and reimbursement approval for a product from a government or other third party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor, which we may not be able to provide. Furthermore, the reimbursement policies of third party payors may significantly change in a manner that renders our clinical data insufficient for adequate reimbursement or otherwise limits the successful marketing of our products. Even if we obtain coverage for our product candidates, third party payors may not establish adequate reimbursement amounts, which may reduce the demand for, or the price of, our products. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain of our products.

Price controls may limit the price at which products such as roxadustat, if approved, are sold. For example, reference pricing is used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or our partner may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available products in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unacceptable levels, we or our partner may elect not to commercialize our products in such countries, and our business and financial condition could be adversely affected.

Table of Contents

Risks Related to Our Reliance on Third Parties

If our collaborations with Astellas or AstraZeneca were terminated, or if Astellas or AstraZeneca were to prioritize other initiatives over their collaborations with us, whether as a result of a change of control or otherwise, our ability to successfully develop and commercialize our lead product candidate, roxadustat, would suffer.

We have entered into collaboration agreements with respect to the development and commercialization of our lead product candidate, roxadustat, with Astellas and AstraZeneca. These agreements provide for reimbursement of our development costs by our collaboration partners and also provide for commercialization of roxadustat throughout the major territories of the world.

Our agreements with Astellas and AstraZeneca provide each of them with the right to terminate their respective agreements with us, upon the occurrence of negative clinical results, delays in the development and commercialization of our product candidates or adverse regulatory requirements or guidance. The termination of any of our collaboration agreements would require us to fund and perform the further development and commercialization of roxadustat in the affected territory, or pursue another collaboration, which we may be unable to do, either of which could have an adverse effect on our business and operations. In addition, each of those agreements provides our respective partners the right to terminate any of those agreements upon written notice for convenience. Moreover, if Astellas or AstraZeneca, or any successor entity, were to determine that their collaborations with us are no longer a strategic priority, or if either of them or a successor were to reduce their level of commitment to their collaborations with us, our ability to develop and commercialize roxadustat could suffer. In addition, some of our collaborations are exclusive and preclude us from entering into additional collaboration agreements with other parties in the area or field of exclusivity.

If we fail to establish and maintain strategic collaborations related to our product candidates, we will bear all of the risk and costs related to the development and commercialization of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise at significant cost. This in turn may negatively affect the development of our other product candidates as we direct resources to our most advanced product candidates.

Conflicts with our collaboration partners could jeopardize our collaboration agreements and our ability to commercialize product candidates.

Our collaboration partners have certain rights to control decisions regarding the development and commercialization of our product candidates with respect to which they are providing funding. If we have a disagreement over strategy and activities, our plans for obtaining approval may be revised and negatively affect the anticipated timing and potential for success of our product candidates. Even if a product under a collaboration agreement is approved, we will remain substantially dependent on the commercialization strategy and efforts of our collaboration partners, and neither of our collaboration partners has experience in commercialization of a novel drug such as roxadustat in the dialysis market.

With respect to our collaboration agreements for roxadustat, there are additional complexities in that we and our collaboration partners, Astellas and AstraZeneca, must reach consensus on our Phase 3 development program. Multi-party decision-making is complex and involves significant time and effort, and there can be no assurance that the parties will cooperate or reach consensus, or that one or both of our partners will not ask to proceed independently in some or all of their respective territories or functional areas of responsibility in which the applicable collaboration partner would otherwise be obligated to cooperate with us. Any disputes or lack of cooperation with us by either Astellas or AstraZeneca may negatively impact the timing or success of our planned Phase 3 clinical studies.

We intend to conduct proprietary research programs in specific disease areas that are not covered by our collaboration agreements. Our pursuit of such opportunities could, however, result in conflicts with our collaboration partners in the event that any of our collaboration partners takes the position that our internal activities overlap with those areas that are exclusive to our collaboration agreements, and we should be precluded from such internal activities. Moreover, disagreements with our collaboration partners could develop over rights to our intellectual property. In addition, our collaboration agreements may have provisions that give rise to disputes regarding the rights and obligations of the parties. Any conflict with our collaboration partners could lead to the termination of our collaboration agreements, delay collaborative activities, reduce our ability to renew agreements or obtain future collaboration agreements or result in litigation or arbitration and would negatively impact our relationship with existing collaboration partners.

Certain of our collaboration partners could also become our competitors in the future. If our collaboration partners develop competing products, fail to obtain necessary regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of our product candidates, the development and commercialization of our product candidates and products could be delayed.

Table of Contents

We rely on third parties for the conduct of most of our preclinical and clinical trials for our product candidates, and if our third party contractors do not properly and successfully perform their obligations under our agreements with them, we may not be able to obtain or may be delayed in receiving regulatory approvals for our product candidates.

We rely heavily on university, hospital, dialysis centers and other institutions and third parties, including the principal investigators and their staff, to carry out our clinical trials in accordance with our clinical protocols and designs. We also rely on a number of third party CROs to assist in undertaking, managing, monitoring and executing our ongoing clinical trials, including those for roxadustat. We expect to continue to rely on CROs, clinical data management organizations, medical institutions and clinical investigators to conduct our development efforts in the future, including our Phase 3 development program for roxadustat. We compete with many other companies for the resources of these third parties, and large pharmaceutical companies often have significantly more extensive agreements and relationships with such third party providers, and such third party providers may prioritize the requirements of such large pharmaceutical companies over ours. The third parties on whom we rely may terminate their engagements with us at any time, which may cause delay in the development and commercialization of our product candidates. If any such third party terminates its engagement with us or fails to perform as agreed, we may be required to enter into alternative arrangements, which would result in significant cost and delay to our product development program. Moreover, our agreements with such third parties generally do not provide assurances regarding employee turnover and availability, which may cause interruptions in the research on our product candidates by such third parties.

Moreover, while our reliance on these third parties for certain development and management activities will reduce our control over these activities, it will not relieve us of our responsibilities. For example, the FDA and foreign regulatory authorities require compliance with regulations and standards, including GCP requirements for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical trials to ensure that the data and results from trials are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Although we rely on third parties to conduct our clinical trials, we, as the sponsor, remain responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan and protocol under legal and regulatory requirements, including GCP. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites.

If any of our CROs, trial sites, principal investigators or other third parties fail to comply with applicable GCP requirements, other regulations, trial protocol or other requirements under their agreements with us, the quality or accuracy of the data they obtain may be compromised or unreliable, and the trials of our product candidates may not meet regulatory requirements. If trials do not meet regulatory requirements or if these third parties need to be replaced, the development of our product candidates may be delayed, suspended or terminated, regulatory authorities may require us to exclude the use of patient data from our approval applications or perform additional clinical trials before approving our marketing applications. Regulatory authorities may even reject our application for approval or refuse to accept our future applications for an extended time period. We cannot assure that upon inspection by a regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements or that our results may be used in support of our regulatory submissions. If any of these events occur, we may not be able to obtain regulatory approval for our product candidates on a timely basis, at a reasonable cost, or at all.

We currently rely, and expect to continue to rely, on third parties to conduct many aspects of our clinical studies and product manufacturing, and these third parties may not perform satisfactorily.

We do not have operating manufacturing facilities at this time other than our roxadustat and FG-5200 manufacturing facility in China, and our current commercial manufacturing facility plans in China are not expected to satisfy the requirements necessary to support development and commercialization outside of China. Other than in and for China specifically, we do not expect to independently manufacture our products. We currently rely, and expect to continue to rely, on third parties to scale-up, manufacture and supply roxadustat and our other product candidates outside of China. Risks arising from our reliance on third party manufacturers include:

•

reduced control and additional burdens of oversight as a result of using third party manufacturers for all aspects of manufacturing activities, including regulatory compliance and quality control and quality assurance;

•

termination of manufacturing agreements, termination fees associated with such termination, or nonrenewal of manufacturing agreements with third parties may negatively impact our planned development and commercialization activities;

•

the possible misappropriation of our proprietary technology, including our trade secrets and know-how; and

•

disruptions to the operations of our third party manufacturers or suppliers unrelated to our product, including the merger, acquisition, or bankruptcy of a manufacturer or supplier or a catastrophic event affecting our manufacturers or suppliers.

Table of Contents

Any of these events could lead to development delays or failure to obtain regulatory approval, or affect our ability to successfully commercialize our product candidates. Some of these events could be the basis for action by the FDA or another regulatory authority, including injunction, recall, seizure or total or partial suspension of production.

The facilities used by our contract manufacturers to manufacture our product candidates must pass inspections by the FDA and other regulatory authorities. Although, except for China, we do not control the manufacturing operations of, and expect to remain completely dependent on, our contract manufacturers for manufacture of drug substance and finished drug product, we are ultimately responsible for ensuring that our product candidates are manufactured in compliance with cGMP requirements. If our contract manufacturers cannot successfully manufacture material that conforms to our or our collaboration partners’ specifications, or the regulatory requirements of the FDA or other regulatory authorities, we may not be able to secure and/or maintain regulatory approval for our product candidates and our development or commercialization plans may be delayed. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. In addition, although our longer-term agreements are expected to provide for requirements to meet our quantity and quality requirements to manufacture our products candidates for clinical studies and commercial sale, we will have minimal direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel and we expect to rely on our audit rights to ensure that those qualifications are maintained to meet our requirements. If our contract manufacturers’ facilities do not pass inspection by regulatory authorities, or if regulatory authorities do not approve these facilities for the manufacture of our products, or withdraw any such approval in the future, we would need to identify and qualify alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our products, if approved. Moreover, any failure of our third party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us or adverse regulatory consequences, including clinical holds, warnings or untitled letters, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which would be expected to significantly and adversely affect supplies of our products to us and our collaboration partners.

Any of our third party manufacturers may terminate their engagement with us at any time and we have not yet entered into any commercial supply agreements for the manufacture of active pharmaceutical ingredients (“APIs”) or drug products. With respect to roxadustat, AstraZeneca and Astellas have certain rights to assume manufacturing of roxadustat and the existence of those rights may limit our ability to enter into favorable long-term supply agreements, if at all, with other third party manufacturers. In addition, our product candidates and any products that we may develop may compete with other product candidates and products for access and prioritization to manufacture. Certain third party manufacturers may be contractually prohibited from manufacturing our product due to non-compete agreements with our competitors or a commitment to grant another party priority relative to our products. There are a limited number of third party manufacturers that operate under cGMP and that might be capable of manufacturing to meet our requirements. Due to the limited number of third party manufacturers with the contractual freedom, expertise, required regulatory approvals and facilities to manufacture our products on a commercial scale, identifying and qualifying a replacement third party manufacturer would be expensive and time-consuming and may cause delay or interruptions in the production of our product candidates or products, which in turn may delay, prevent or impair our development and commercialization efforts.

We have a letter agreement with IRIX Pharmaceuticals, Inc. (“IRIX”), a third party manufacturer that we have used in the past, pursuant to which we agreed to negotiate a single source manufacturing agreement that included a right of first negotiation for the cGMP manufacture of HIF-PH inhibitors, including roxadustat, provided that IRIX is able to match any third party bids within 5%. The exclusive right to manufacture extends for five years after approval of an NDA for those compounds, and any agreement would provide that no minimum amounts would be specified until appropriate by forecast and that we and a commercialization partner would have the rights to contract with independent third parties that exceed IRIX’s internal manufacturing capabilities or in the event that we or our commercialization partner determines for reasons of continuity of supply and security that such a need exists, provided that IRIX would supply no less than 65% of the product if it is able to provide this level of supply. Subsequent to the letter agreement, we and IRIX have entered into several additional service agreements. IRIX has requested in writing that we honor the letter agreement with respect to the single source manufacturing agreement, and if we were to enter into any such exclusive manufacturing agreement, there can be no assurance that IRIX will not assert a claim for right to manufacture roxadustat or that IRIX could manufacture roxadustat successfully and in accordance with applicable regulations for a commercial product and the specifications of our collaboration partners. In 2015, Patheon Pharmaceuticals Inc., a business unit of DPx Holdings B.V. (“Patheon”), acquired IRIX, and in 2017 ThermoFisher Scientific Inc. acquired Patheon.

If any third party manufacturer terminates its engagement with us or fails to perform as agreed, we may be required to find replacement manufacturers, which would result in significant cost and delay to our development programs. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur significant delays and added costs in identifying, qualifying and contracting with any such third party or potential second source manufacturer. In any event, with any third party manufacturer we expect to enter into technical transfer agreements and share our know-how with the third party manufacturer, which can be time-consuming and may result in delays. These delays could result in a suspension or delay of marketing roxadustat.

Table of Contents

Certain of the components of our product candidates are acquired from single-source suppliers and have been purchased without long-term supply agreements. The loss of any of these suppliers, or their failure to supply us with supplies of sufficient quantity and quality to complete our drug substance or finished drug product of acceptable quality and an acceptable price, would materially and adversely affect our business.

We do not have an alternative supplier of certain components of our product candidates. To date, we have used purchase orders for the supply of materials that we use in our product candidates. We may be unable to enter into long-term commercial supply arrangements with our vendors, or do so on commercially reasonable terms, which could have a material adverse impact upon our business. In addition, we currently rely on our contract manufacturers to purchase from third-party suppliers some of the materials necessary to produce our product candidates. We do not have direct control over the acquisition of those materials by our contract manufacturers. Moreover, we currently do not have any agreements for the commercial production of those materials.

The logistics of our supply chain, which include shipment of materials and intermediates from countries such as China and India add additional time and risk (including risk of loss) to the manufacture of our product candidates. While we have in the past maintained sufficient inventory of materials, API, and drug product to meet our and our collaboration partners’ needs for roxadustat to date, the lead time and regulatory approvals required to source from and into countries outside of the U.S. increase the risk of delay and potential shortages of supply.

Risks Related to Our Intellectual Property

If our efforts to protect our proprietary technologies are not adequate, we may not be able to compete effectively in our market.

We rely upon a combination of patents, trade secret protection and contractual arrangements to protect the intellectual property related to our technologies. We will only be able to protect our products and proprietary information and technology by preventing unauthorized use by third parties to the extent that our patents, trade secrets, and contractual position allow us to do so. Any disclosure to or misappropriation by third parties of our trade secrets or confidential information could compromise our competitive position. Moreover, we are involved in, have in the past been involved in, and may in the future be involved in legal or administrative proceedings involving our intellectual property initiated by third parties, and which proceedings can result in significant costs and commitment of management time and attention. As our product candidates continue in development, third parties may attempt to challenge the validity and enforceability of our patents and proprietary information and technologies.

We also are involved in, have in the past been involved in, and may in the future be involved in initiating legal or administrative proceedings involving the product candidates and intellectual property of our competitors. These proceedings can result in significant costs and commitment of management time and attention, and there can be no assurance that our efforts would be successful in preventing or limiting the ability of our competitors to market competing products.

Composition-of-matter patents relating to the API are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection not limited to any one method of use. Method-of-use patents protect the use of a product for the specified method(s), and do not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. We rely on a combination of these and other types of patents to protect our product candidates, and there can be no assurance that our intellectual property will create and sustain the competitive position of our product candidates.

Biotechnology and pharmaceutical product patents involve highly complex legal and scientific questions and can be uncertain. Any patent applications that we own or license may fail to result in issued patents. Even if patents do successfully issue from our applications, third parties may challenge their validity or enforceability, which may result in such patents being narrowed, invalidated, or held unenforceable. Even if our patents and patent applications are not challenged by third parties, those patents and patent applications may not prevent others from designing around our claims and may not otherwise adequately protect our product candidates. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, competitors with significantly greater resources could threaten our ability to commercialize our product candidates. Discoveries are generally published in the scientific literature well after their actual development, and patent applications in the U.S. and other countries are typically not published until 18 months after their filing, and in some cases are never published. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned and licensed patents or patent applications, or that we or our licensors were the first to file for patent protection covering such inventions. Subject to meeting other requirements for patentability, for U.S. patent applications filed prior to March 16, 2013, the first to invent the claimed invention is entitled to receive patent protection for that invention while, outside the U.S., the first to file a patent application encompassing the invention is entitled to patent protection for the invention. The U.S. moved to a “first to file” system under the Leahy-Smith America Invents Act (“AIA”), effective March 16, 2013. This system also includes procedures for challenging issued patents and pending patent applications, which creates additional uncertainty. We may become involved in opposition or interference proceedings challenging our patents and patent applications or the patents and patent applications of others, and the outcome of any such proceedings are highly uncertain. An unfavorable outcome in any such proceedings could reduce the scope of or invalidate our patent rights, allow third parties to commercialize our technology and compete directly with us, or result in our inability to manufacture, develop or commercialize our product candidates without infringing the patent rights of others.

Table of Contents

In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how, information, or technology that is not covered by our patents. Although our agreements require all of our employees to assign their inventions to us, and we require all of our employees, consultants, advisors and any third parties who have access to our trade secrets, proprietary know-how and other confidential information and technology to enter into appropriate confidentiality agreements, we cannot be certain that our trade secrets, proprietary know-how and other confidential information and technology will not be subject to unauthorized disclosure or that our competitors will not otherwise gain access to or independently develop substantially equivalent trade secrets, proprietary know-how and other information and technology. Furthermore, the laws of some foreign countries, in particular, China, where we have operations, do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property globally. If we are unable to prevent unauthorized disclosure of our intellectual property related to our product candidates and technology to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business and operations.

Intellectual property disputes with third parties and competitors may be costly and time consuming, and may negatively affect our competitive position.*

Our commercial success may depend on our avoiding infringement of the patents and other proprietary rights of third parties as well as on enforcing our patents and other proprietary rights against third parties. Pharmaceutical and biotechnology intellectual property disputes are characterized by complex, lengthy and expensive litigation over patents and other intellectual property rights. We may initiate or become party to or be threatened with future litigation or other proceedings regarding intellectual property rights with respect to our product candidates and competing products.

As our product candidates progress toward commercialization, we or our collaboration partners may be subject to patent infringement claims from third parties. We attempt to ensure that our product candidates do not infringe third party patents and other proprietary rights. However, the patent landscape in competitive product areas is highly complex, and there may be patents of third parties of which we are unaware that may result in claims of infringement. Accordingly, there can be no assurance that our product candidates do not infringe proprietary rights of third parties, and parties making claims against us may seek and obtain injunctive or other equitable relief, which could potentially block further efforts to develop and commercialize our product candidates including roxadustat or pamrevlumab. Any litigation involving defense against claims of infringement, regardless of the merit of such claims, would involve substantial litigation expense and would be a substantial diversion of management time.

We may consider administrative proceedings and other means for challenging third party patents and patent applications. An unfavorable outcome in any such challenge could require us to cease using the related technology and to attempt to license rights to it from the prevailing third party, which may not be available on commercially reasonable terms, if at all, in which case our business could be harmed.

We intend, if necessary, to vigorously enforce our intellectual property in order to protect the proprietary position of our product candidates, including roxadustat and pamrevlumab. In addition, our collaboration partners who have been granted licenses to our patents may also have rights related to enforcement of those patents. Active efforts to enforce our patents by us or by our partners may include litigation, administrative proceedings, or both, depending on the potential benefits that might be available from those actions and the costs associated with undertaking those efforts against third parties. We carefully review and monitor publicly available information regarding products that may be competitive with our product candidates and assert our intellectual property rights where appropriate. For example, we previously prevailed in an administrative challenge initiated by a major biopharmaceutical company regarding our intellectual property rights, maintaining our intellectual property in all relevant scope, and will continue to protect and enforce our intellectual property rights. In addition, our partner Astellas has recently initiated quia timet infringement actions against Akebia and GSK based on our specific patents in the United Kingdom in response to actions taken by Akebia and GSK against those patents, as further detailed below.

Table of Contents

Third parties may also challenge our patents and patent applications, through interference, reexamination, inter partes review, and post-grant review proceedings before the U.S. Patent and Trademark Office (“USPTO”) or through comparable proceedings in other territories. For example, Akebia and others have filed oppositions against certain European patents within our HIF anemia-related technologies patent portfolio. In three of these proceedings, for FibroGen European Patent Nos. 1463823, 1633333, and 2322155, the European Patent Office has handed down decisions unfavorable to FibroGen. In a fourth of these proceedings, the European Patent Office issued a decision favorable to FibroGen, maintaining FibroGen European Patent No. 2322153 in amended form. All of these decisions are currently under appeal, and these four patents are valid and enforceable pending resolution of the appeals. The ultimate outcomes of such proceedings remain uncertain, and ultimate resolution of the appeals may take two years or longer. In addition, Akebia recently filed oppositions against FibroGen European Patent Nos. 2289531 and 2298301. As mentioned above, Akebia and GSK have also initiated actions in the United Kingdom against the United Kingdom counterparts of each of these European patents, and GSK has filed for a declaration of non-infringement of certain United Kingdom patents (corresponding to FibroGen European Patent Nos. 2322153 and 2322155) with respect to its daprodustat product. Akebia is also pursuing invalidation actions against corresponding patents in Canada and in Japan. While we believe the ultimate outcome of all proceedings will be that these FibroGen patents will be upheld in relevant part, we note that narrowing or even revocation of any of these patents would not affect our exclusivity for roxadustat or our freedom-to-operate with respect to use of roxadustat for the treatment of anemia.

Oppositions have also recently been filed against our European Patent No. 2872488, which claims a crystalline form of roxadustat.

Furthermore, there is a risk that any public announcements concerning the status or outcomes of intellectual property litigation or administrative proceedings may adversely affect the price of our stock. If securities analysts or our investors interpret such status or outcomes as negative or otherwise creating uncertainty, our common stock price may be adversely affected.

Our reliance on third parties and agreements with collaboration partners requires us to share our trade secrets, which increases the possibility that a competitor may discover them or that our trade secrets will be misappropriated or disclosed.

Our reliance on third party contractors to develop and manufacture our product candidates is based upon agreements that limit the rights of the third parties to use or disclose our confidential information, including our trade secrets and know-how. Despite the contractual provisions, the need to share trade secrets and other confidential information increases the risk that such trade secrets and information are disclosed or used, even if unintentionally, in violation of these agreements. In the highly competitive markets in which our product candidates are expected to compete, protecting our trade secrets, including our strategies for addressing competing products, is imperative, and any unauthorized use or disclosure could impair our competitive position and may have a material adverse effect on our business and operations.

In addition, our collaboration partners are larger, more complex organizations than ours, and the risk of inadvertent disclosure of our proprietary information may be increased despite their internal procedures and contractual obligations in place with our collaboration partners. Despite our efforts to protect our trade secrets and other confidential information, a competitor’s discovery of such trade secrets and information could impair our competitive position and have an adverse impact on our business.

We have an extensive worldwide patent portfolio. The cost of maintaining our patent protection is high and maintaining our patent protection requires continuous review and compliance in order to maintain worldwide patent protection. We may not be able to effectively maintain our intellectual property position throughout the major markets of the world.

The USPTO and foreign patent authorities require maintenance fees and payments as well as continued compliance with a number of procedural and documentary requirements. Noncompliance may result in abandonment or lapse of the subject patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance may result in reduced royalty payments for lack of patent coverage in a particular jurisdiction from our collaboration partners or may result in competition, either of which could have a material adverse effect on our business.

We have made, and will continue to make, certain strategic decisions in balancing costs and the potential protection afforded by the patent laws of certain countries. As a result, we may not be able to prevent third parties from practicing our inventions in all countries throughout the world, or from selling or importing products made using our inventions in and into the U.S. or other countries. Third parties may use our technologies in territories in which we have not obtained patent protection to develop their own products and, further, may infringe our patents in territories which provide inadequate enforcement mechanisms, even if we have patent protection. Such third party products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Table of Contents

The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the U.S., and we may encounter significant problems in securing and defending our intellectual property rights outside the U.S.

Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries, particularly certain developing countries such as China, do not always favor the enforcement of patents, trade secrets, and other intellectual property rights, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop infringement of our patents, misappropriation of our trade secrets, or marketing of competing products in violation of our proprietary rights. In China, our intended establishment of significant operations will depend in substantial part on our ability to effectively enforce our intellectual property rights in that country. Proceedings to enforce our intellectual property rights in foreign countries could result in substantial costs and divert our efforts and attention from other aspects of our business, and could put our patents in these territories at risk of being invalidated or interpreted narrowly, or our patent applications at risk of not being granted, and could provoke third parties to assert claims against us. We may not prevail in all legal or other proceedings that we may initiate and, if we were to prevail, the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Intellectual property rights do not address all potential threats to any competitive advantage we may have.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:

•

Others may be able to make compounds that are the same as or similar to our current or future product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed.

•

We or any of our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed.

•

We or any of our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions.

•

Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.

•

The prosecution of our pending patent applications may not result in granted patents.

•

Granted patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.

•

Patent protection on our product candidates may expire before we are able to develop and commercialize the product, or before we are able to recover our investment in the product.

•

Our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for such activities, as well as in countries in which we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in markets where we intend to market our product candidates.

Table of Contents

Roxadustat is considered a Class 2 substance on the 2019 World Anti-Doping Agency Prohibited List which could limit sales and increase security and distribution costs for us and our partners, particularly in China.

Roxadustat is considered a Class 2 substance on the World Anti-Doping Agency (“WADA”) Prohibited List. There are enhanced security and distribution procedures we and our collaboration partners and third-party contractors will have to take to limit the risk of loss of product in the supply chain. As a result, our distribution, manufacturing and sales costs for roxadustat, as well as for our partners, will be increased which will reduce profitability. In addition there is a risk of reduced sales due to patient access to this drug. This is particularly the case in China where we will not be able to sell roxadustat in private pharmacies due to the WADA classification. While private pharmacies only represent approximately 10% of the market in China, this will negatively affect sales and therefore the profitability of roxadustat and the Company as a whole.

The existence of counterfeit pharmaceutical products in pharmaceutical markets may compromise our brand and reputation and have a material adverse effect on our business, operations and prospects.

Counterfeit products, including counterfeit pharmaceutical products, are a significant problem, particularly in China. Counterfeit pharmaceuticals are products sold or used for research under the same or similar names, or similar mechanism of action or product class, but which are sold without proper licenses or approvals, and are often lower cost, lower quality, different potency, or have different ingredients or formulations, and have the potential to damage the reputation for quality and effectiveness of the genuine product. Such products may be used for indications or purposes that are not recommended or approved or for which there is no data or inadequate data with regard to safety or efficacy. Such products divert sales from genuine products. If counterfeit pharmaceuticals illegally sold or used for research result in adverse events or side effects to consumers, we may be associated with any negative publicity resulting from such incidents. Consumers may buy counterfeit pharmaceuticals that are in direct competition with our pharmaceuticals, which could have an adverse impact on our revenues, business and results of operations. In addition, the use of counterfeit products could be used in non-clinical or clinical studies, or could otherwise produce undesirable side effects or adverse events that may be attributed to our products as well, which could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. With respect to China, although the government has recently been increasingly active in policing counterfeit pharmaceuticals, there is not yet an effective counterfeit pharmaceutical regulation control and enforcement system in China. As a result, we may not be able to prevent third parties from selling or purporting to sell our products in China. The proliferation of counterfeit pharmaceuticals has grown in recent years and may continue to grow in the future. The existence of and any increase in the sales and production of counterfeit pharmaceuticals, or the technological capabilities of counterfeiters, could negatively impact our revenues, brand reputation, business and results of operations.

Risks Related to Government Regulation

The regulatory approval process is highly uncertain and we may not obtain regulatory approval for the commercialization of our product candidates.

The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. Except in China, We have not obtained regulatory approval for any product candidate, and it is possible that neither roxadustat nor pamrevlumab, nor any future product candidates we may discover, in-license or acquire and seek to develop in the future, will obtain regulatory approval in countries other than China.

Our product candidates could fail to receive regulatory approval from the FDA or other regulatory authorities for many reasons, including:

•

disagreement over the design or implementation of our clinical trials;

•

failure to demonstrate that a product candidate is safe and effective for its proposed indication;

•

failure of clinical trials to meet the level of statistical significance required for approval;

•

failure to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

•

disagreement over our interpretation of data from preclinical studies or clinical trials;

•

disagreement over whether to accept efficacy results from clinical trial sites outside the U.S. where the standard of care is potentially different from that in the U.S.;

•

the insufficiency of data collected from clinical trials of our present or future product candidates to support the submission and filing of an NDA or other submission or to obtain regulatory approval;

Table of Contents

•

disapproval of the manufacturing processes or facilities of either our manufacturing plant or third party manufacturers with whom we contract for clinical and commercial supplies; or

•

changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.

The FDA or other regulatory authorities may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program altogether. Even if we do obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we request, approval may be contingent on the performance of costly post-marketing clinical trials, or approval may require labeling that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. In addition, if our product candidates produce undesirable side effects or safety issues, the FDA may require the establishment of REMS or other regulatory authorities may require the establishment of a similar strategy, that may restrict distribution of our approved products, if any, and impose burdensome implementation requirements on us. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

Even if we believe our current or planned clinical trials are successful, regulatory authorities may not agree that our completed clinical trials provide adequate data on safety or efficacy. Approval by one regulatory authority does not ensure approval by any other regulatory authority. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. We may not be able to file for regulatory approvals and even if we file we may not receive the necessary approvals to commercialize our product candidates in any market.

If our product candidates obtain marketing approval, we will be subject to more extensive healthcare laws, regulation and enforcement and our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.

If we obtain approval in the U.S. for any of our product candidates, the regulatory requirements applicable to our operations, in particular our sales and marketing efforts, will increase significantly with respect to our operations and the potential for civil and criminal enforcement by the federal government and the states and foreign governments will increase with respect to the conduct of our business. The laws that may affect our operations in the U.S. include:

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;

•

federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third party payors that are false or fraudulent;

•

the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;

•

HIPAA, as amended by Health Information Technology and Clinical Health Act, and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information;

•

the federal physician sunshine requirements under the Patient Protection and Affordable Care Act (“PPACA”), which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare and Medicaid Services (“CMS”), information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;

Table of Contents

•

foreign and state law equivalents of each of the above federal laws, such as the U.S. Foreign Corrupt Practices Act (“FCPA”), anti-kickback and false claims laws that may apply to items or services reimbursed by any third party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts; and

•

the Trade Agreements Act (“TAA”), which requires that drugs sold to the U.S. Government must be manufactured in the U.S. or in TAA approved and designated countries. Drugs manufactured in countries not approved under the TAA, may not be sold to the U.S. without specific regulatory approval. We have little experience with this regulation and there is a risk that drugs made from Chinese-made API may not be sold to an entity of the U.S. such as the Veterans Health Administration (“VA”) due to our inability to obtain regulatory approval. While there have been recent VA policy changes that appear to allow for sale of drugs from non-TAA approved countries, this policy may change or there may be additional policies or legislation that affect our ability to sell drug to the U.S. Government.

The scope of these laws and our lack of experience in establishing the compliance programs necessary to comply with this complex and evolving regulatory environment increases the risks that we may unknowingly violate the applicable laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could materially adversely affect our ability to operate our business and our financial results.

The impact of recent U.S. healthcare reform, its potential partial or full repeal, and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model.

The commercial potential for our approved products could be affected by changes in healthcare spending and policy in the U.S. and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.

In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (“MMA”) altered Medicare coverage and payments for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. The MMA also provided authority for limiting the number of drugs that will be covered in any therapeutic class and as a result, we expect that there will be additional pressure to reduce costs. For example, the CMS in implementing the MMA has enacted regulations that reduced capitated payments to dialysis providers. These cost reduction initiatives and other provisions of the MMA could decrease the scope of coverage and the price that may be received for any approved dialysis products and could seriously harm our business and financial condition. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may cause a similar reduction in payments from private payors. Similar regulations or reimbursement policies have been enacted in many international markets which could similarly impact the commercial potential for our products.

Under the Medicare Improvements for Patients and Providers Act (“MIPPA”), a basic case-mix adjusted composite, or bundled, payment system commenced in January 2011 and transitioned fully by January 2014 to a single reimbursement rate for drugs and all services furnished by renal dialysis centers for Medicare beneficiaries with end-stage renal disease. Specifically, under MIPPA the bundle now covers drugs, services, lab tests and supplies under a single treatment base rate for reimbursement by the CMS based on the average cost per treatment, including the cost of ESAs and IV iron doses, typically without adjustment for usage. It is unknown whether roxadustat, if approved in the U.S., will be included in the payment bundle. Under MIPPA, agents that have no IV equivalent in the bundle are currently expected to be excluded from the bundle until 2025. If roxadustat were included in the bundle, it may reduce the price that could be charged for roxadustat, and therefore potentially limit our profitability. Based on roxadustat’s differentiated mechanism of action and therapeutic effects, and discussions with our collaboration partner, we currently believe that roxadustat might not be included in the bundle. If roxadustat is reimbursed outside of the bundle, it may potentially limit or delay market penetration of roxadustat.

Table of Contents

More recently, the PPACA was enacted in 2010 with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The PPACA, among other things, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D. In addition, other legislative changes have been proposed and adopted in the U.S. since the PPACA was enacted. On August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect on April 1, 2013.

It is likely that federal and state legislatures within the U.S. and foreign governments will continue to consider changes to existing healthcare legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:

•

the demand for any products that may be approved for sale;

•

the price and profitability of our products;

•

pricing, coverage and reimbursement applicable to our products;

•

the ability to successfully position and market any approved product; and

•

the taxes applicable to our pharmaceutical product revenues.

Some of the provisions of the PPACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, that while not a law, is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of the PPACA. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Congress also could consider subsequent legislation to replace elements of the Affordable Care Act that are repealed. Given these possibilities and others we may not anticipate, the full extent to which our business, results of operations and financial condition could be adversely affected by the recent proposed legislation and the Executive Order is uncertain. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.

Furthermore, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the regulatory approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent regulatory approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.

We may not be able to conduct, or contract others to conduct, animal testing in the future, which could harm our research and development activities.

Certain laws and regulations relating to drug development require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed.

Table of Contents

Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could result in significant liability for us and harm our reputation.

We are exposed to the risk of employee fraud or other misconduct, including intentional failure to:

•

comply with FDA regulations or similar regulations of comparable foreign regulatory authorities;

•

provide accurate information to the FDA or comparable foreign regulatory authorities;

•

comply with manufacturing standards we have established;

•

comply with privacy laws protecting personal information;

•

comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities;

•

comply with the FCPA and other anti-bribery laws;

•

report financial information or data accurately;

•

or disclose unauthorized activities to us.

Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, delays in clinical trials, or serious harm to our reputation. We have adopted a code of conduct for our directors, officers and employees, but it is not always possible to identify and deter employee misconduct. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could harm our business, results of operations, financial condition and cash flows, including through the imposition of significant fines or other sanctions.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations applicable to our operations in the U.S. and foreign countries. These current or future laws and regulations may impair our research, development or manufacturing efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Risks Related to Our International Operations

We are establishing international operations and seeking approval to commercialize our product candidates outside of the U.S., in particular in China, and a number of risks associated with international operations could materially and adversely affect our business.

We expect to be subject to a number of risks related with our international operations, many of which may be beyond our control. These risks include:

•

different regulatory requirements for drug approvals in foreign countries;

•

different standards of care in various countries that could complicate the evaluation of our product candidates;

•

different U.S. and foreign drug import and export rules;

•

reduced protection for intellectual property rights in certain countries;

Table of Contents

•

changes in tariffs, trade barriers and regulatory requirements;

•

different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;

•

economic weakness, including inflation, or political instability in particular foreign economies and markets;

•

compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

•

compliance with the FCPA, and other anti-corruption and anti-bribery laws;

•

U.S. and foreign taxes, including withholding of payroll taxes;

•

foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;

•

workforce uncertainty in countries where labor unrest is more common than in the U.S.;

•

production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;

•

a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;

•

potential liability resulting from development work conducted by foreign distributors; and

•

business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.

The pharmaceutical industry in China is highly regulated and such regulations are subject to change.

The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. Refer to “Business — Government Regulation — Regulation in China” for a discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent years, the regulatory framework in China regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or commercialization of our product candidates in China. For example, the NMPA recently adopted the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines, and accordingly imposed regulatory oversight earlier in our production process for roxadustat manufactured and sold in China. The change in regulatory starting material triggered an extension of the inspection to our contract manufacturer STA, which was successfully completed in October 2018. In addition, Chinese authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry, in some cases launching industry-wide investigations, oftentimes appearing to focus on foreign companies. The costs and time necessary to respond to an investigation can be material. Any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in China.

We plan to use our own manufacturing facilities in China to produce roxadustat API, roxadustat drug product, and FG-5200 corneal implants. As an organization, we have limited experience in the construction, licensure, and operation of a manufacturing plant, and accordingly we cannot assure you we will be able to meet regulatory requirements to operate our plant and to sell our products.

We have two manufacturing facilities in China, with one located in Beijing and the other in Cangzhou, Hebei. In December 2018, we received the Manufacturing License for Drug Substance and Drug Product for roxadustat and GMP certification for our Beijing facility that allows us to manufacture limited commercial quantities of roxadustat capsules. We are currently planning on manufacturing commercial-scale API at our Cangzhou facility, and expect to receive a license to produce roxadustat API at that site in the second half of 2019. However, as an organization, we have limited experience licensing and operating commercial manufacturing facilities.

We will be obligated to comply with continuing cGMP requirements and there can be no assurance that we will receive and maintain all of the appropriate licenses required to manufacture our product candidates for clinical and commercial use in China. In addition, we and our product suppliers must continually spend time, money and effort in production, record-keeping and quality assurance and appropriate controls in order to ensure that any products manufactured in our facilities meet applicable specifications and other requirements for product safety, efficacy and quality and there can be no assurance that our efforts will succeed for licensure or continue to be successful in meeting these requirements.

Table of Contents

We would require separate approval for the manufacture of FG-5200. In addition, we may convert the existing manufacturing process of FG-5200 to a semi-automated process, which may require us to show that implants from our new manufacturing process are comparable to the implants from our existing manufacturing process. There can be no assurance that we will successfully receive licensure and maintain approval for the manufacture of FG-5200, either of which would be expected to delay or preclude our ability to develop FG-5200 in China and may materially adversely affect our business and operations and prospects in China.

Manufacturing facilities in China are subject to periodic unannounced inspections by the NMPA and other regulatory authorities. We expect to depend on these facilities for our product candidates and business operations in China. Natural disasters or other unanticipated catastrophic events, including power interruptions, water shortages, storms, fires, earthquakes, terrorist attacks, government appropriation of our facilities, and wars, could significantly impair our ability to operate our manufacturing facilities. Certain equipment, records and other materials located in these facilities would be difficult to replace or would require substantial replacement lead time that would impact our ability to successfully commercialize our product candidates in China. The occurrence of any such event could materially and adversely affect our business, financial condition, results of operations, cash flows and prospects.

In addition to manufacturing, we are responsible for pharmacovigilance, medical affairs, and management of the third party distribution logistics for roxadustat in China. We have no experience in these areas as a company, and accordingly we cannot assure you we will be able to meet regulatory requirements or operate in these capacities successfully.

We are responsible for commercial manufacturing, pharmacovigilance, medical affairs, and management of the third party distribution logistics for roxadustat commercial activities in China. While we have been increasing our staffing in these areas, as a company, we have no experience managing or operating these functions for a commercial product and there can be no guarantee that we will do so efficiently or effectively. Mistakes or delays in these areas could limit our ability to successfully commercialize roxadustat in China, could limit our eventual market penetration, sales and profitability, and could subject us to significant liability in China.

Our decision to launch roxadustat in China prior to approval in the U.S. or Europe is largely unprecedented and could be subject to significant risk, delay and expense.*

Even though our subsidiary FibroGen Beijing has received marketing authorization for roxadustat for anemia caused by CKD in dialysis patients, we have not yet received approval in non-dialysis patients, and are awaiting the results from the Chinese authorities’ completed inspection of our Phase 3 non-dialysis clinical trial sites.

We are currently expecting non-dialysis patients to be added to our approved dialysis label for roxadustat in China in the third quarter of 2019, and are planning on launching in the third quarter of 2019, however, it is possible that unforeseen delays in the China regulatory process could have a material adverse effect on our development and commercialization of roxadustat in China.

In addition we are required to conduct a 2,000 subject post-approval safety study to demonstrate the long-term safety of roxadustat and conduct intensive drug monitoring in an additional 1,000 patients, as well as provide period reporting to the authorities on GMP and quality compliance at our manufacturing facilities. If safety issues arise in this study, or generally after commercialization, our commercialization plans and profitability in China could be negatively impacted.

We and our collaboration partner in China, AstraZeneca, may experience difficulties in successfully generating sales of roxadustat in China.*

We and AstraZeneca have a profit sharing arrangement with respect to roxadustat in China and any difficulties we may experience in generating sales will affect our bottom line. Difficulties may be related to our ability to obtain reasonable pricing, reimbursement, hospital listing, and tendering, or other difficulties related to distribution, marketing, and sales efforts in China. Sales of roxadustat in China may be limited due to the complex nature of the healthcare system, low average personal income, pricing controls, still developing infrastructure and potentially rapid competition from other products. The government has committed to updating the National Reimbursement Drug List (“NRDL”) in 2019. Previous updates to the NRDL occurred in 2017 and 2009. In addition, there were also NRDL price negotiations in 2018 for oncology drugs. Admission to the NRDL depends on a number of factors, including on-market experience, scale of patient adoption, physician endorsement, cost effectiveness and budget impact. Given that roxadustat was approved at the end of 2018, we may or may not qualify for the NRDL update in 2019. In particular, if we are unable to obtain reimbursement for roxadustat through the 2019 update to the NRDL, we may have to wait a substantial period of time before the reimbursement drug list is updated again. Without government reimbursement, many patients will not be able to afford roxadustat, since private commercial health insurance is rare, and our business and operations could be adversely affected. Therefore reimbursement and obtaining hospital listing is critical to roxadustat’s near-term commercial success in China.

Table of Contents

The market for treatment of anemia in CKD in China is highly competitive.

Although we have now received approval for roxadustat for the treatment of anemia caused by CKD in dialysis patients in China, and even if roxadustat receives approval for anemia caused by CKD in non-dialysis patients, it faces intense competition in the market for treatment of anemia in CKD. Roxadustat would compete with ESAs, which are offered by established multinational pharmaceutical companies such as Kyowa Hakko Kirin China Pharmaceutical Co., Ltd., Roche and Chinese pharmaceutical companies such as 3SBio Inc. and Di’ao Group Chengdu Diao Jiuhong Pharmaceutical Factory. Many of these competitors have substantially greater name recognition, scientific, financial, and marketing resources, as well as established distribution capabilities. Many of our competitors have more resources to develop or acquire, and more experience in developing or acquiring, new products and in creating market awareness for those products. Many of these competitors have significantly more experience than we have in navigating the Chinese regulatory framework regarding the development, manufacturing and marketing of drugs in China, as well as in marketing and selling anemia products in China. Additionally, we believe that most patients with anemia in CKD in China are currently being treated with traditional Chinese medicine, which is widely accepted and highly prevalent in China. Traditional Chinese medicine treatments are often oral and thus convenient and low-cost, and practitioners of traditional Chinese medicine are numerous and accessible in China. As a result, it may be difficult to persuade patients with anemia in CKD to switch from traditional Chinese medicine to roxadustat.

The Chinese government is implementing a new “Two Invoices” regulation which could affect the way we structure our distributorship relationships in China for roxadustat.

The Chinese government is implementing new regulations that impact distribution of pharmaceutical products in China. These regulations generally require that at most two invoices may be issued throughout the distribution chain. Failure to comply with the “Two-Invoices” regulations would prevent us from accessing the market in China. We are planning on modifying the distribution responsibilities under the China Agreement between AstraZeneca and FibroGen such that FibroGen would engage distributors and a third party logistics provider, and both companies will work together to manage the distribution network. FibroGen China Anemia Holdings, Ltd (“FibroGen China”) has never managed distribution of pharmaceutical products, and this new distribution structure may impose higher costs or limit or delay our ability to sell products to our principal customers, and may limit the near term sales of our products.

There is no assurance that roxadustat will be included in the Medical Insurance Catalogs.

Eligible participants in the national basic medical insurance program in China, which consists of mostly urban residents, are entitled to reimbursement from the social medical insurance fund for up to the entire cost of medicines that are included in the Medical Insurance Catalogs. Refer to “Business — Government Regulation — Regulation in China.” We believe that the inclusion of a drug in the Medical Insurance Catalogs can substantially improve the sales of a drug in China. The Ministry of Labor and Social Security in China (“MLSS”) together with other government authorities, select medicines to be included in the Medical Insurance Catalogs based on a variety of factors, including treatment requirements, frequency of use, effectiveness and price. The MLSS also occasionally removes medicines from such catalogs. There can be no assurance that roxadustat will be included, and once included, remain in the Medical Insurance Catalogs. The exclusion or removal of roxadustat from the Medical Insurance Catalogs may materially and adversely affect sales of roxadustat.

Even if FG-5200 can be manufactured successfully and achieve regulatory approval, we may not achieve commercial success.

We have not yet received a license to manufacture FG-5200 in our Beijing manufacturing facility or at scale, and we will have to show that FG-5200 produced in our China manufacturing facility meets the applicable regulatory requirements. There can be no assurance that we can meet these requirements or that FG-5200 can be approved for development, manufacture and sale in China.

Even if we are able to manufacture and develop FG-5200 as a medical device in China, the size and length of any potential clinical trials required for approval are uncertain and we are unable to predict the time and investment required to obtain regulatory approval. Moreover, even if FG-5200 can be successfully developed for approval in China, our product candidate would require extensive training and investment in assisting physicians in the use of FG-5200.

The retail prices of any product candidates that we develop may be subject to control, including periodic downward adjustment, by Chinese government authorities.

The price for pharmaceutical products is highly regulated in China, both at the national and provincial level. Price controls may reduce prices to levels significantly below those that would prevail in less regulated markets, or limit the volume of products that may be sold, either of which may have a material and adverse effect on potential revenues from sales of roxadustat in China. Moreover, the process and timing for the implementation of price restrictions is unpredictable, which may cause potential revenues from the sales of roxadustat to fluctuate from period to period.

Table of Contents

If our planned business activities in China fall within a restricted category under the China Catalog for Guidance for Foreign Investment, we will need to operate in China through a variable interest entity (“VIE”) structure.

The China Catalog for Guidance for Foreign Investment sets forth the industries and sectors that the Chinese government encourages and restricts with respect to foreign investment and participation. The Catalog for Guidance for Foreign Investment is subject to revision from time to time by the China Ministry of Commerce. While we currently do not believe the development and marketing of roxadustat falls within a restricted category under the Catalog for Guidance for Foreign Investment, if roxadustat does fall under such a restricted category, we will need to operate in China through a VIE structure. A VIE structure involves a wholly foreign-owned enterprise that would control and receive the economic benefits of a domestic Chinese company through various contractual relationships. Such a structure would subject us to a number of risks that may have an adverse effect on our business, including that the Chinese government may determine that such contractual arrangements do not comply with applicable regulations, Chinese tax authorities may require us to pay additional taxes, shareholders of our VIEs may have potential conflicts of interest with us, and we may lose the ability to use and enjoy assets held by our VIEs that are important to the operations of our business if such entities go bankrupt or become subject to dissolution or liquidation proceedings. VIE structures in China have come under increasing scrutiny from accounting firms and the Securities and Exchange Commission (“SEC”) staff. If we do attempt to use a VIE structure and are unsuccessful in structuring it so as to qualify as a VIE, we would not be able to consolidate the financial statements of the VIE with our financial statements, which could have a material adverse effect on our operating results and financial condition.

FibroGen Beijing would be subject to restrictions on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements.

We plan to conduct all of our business in China through FibroGen China and FibroGen Beijing. We may rely on dividends and royalties paid by FibroGen Beijing for a portion of our cash needs, including the funds necessary to service any debt we may incur and to pay our operating expenses. The payment of dividends by FibroGen Beijing is subject to limitations. Regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China. FibroGen Beijing is not permitted to distribute any profits until losses from prior fiscal years have been recouped and in any event must maintain certain minimum capital requirements. FibroGen Beijing is also required to set aside at least 10.0% of its after-tax profit based on Chinese accounting standards each year to its statutory reserve fund until the cumulative amount of such reserves reaches 50.0% of its registered capital. Statutory reserves are not distributable as cash dividends. In addition, if FibroGen Beijing incurs debt on its own behalf in the future, the agreements governing such debt may restrict its ability to pay dividends or make other distributions to us. As of June 30, 2019, approximately $5.1 million of our cash and cash equivalents is held in China.

Any capital contributions from us to FibroGen Beijing must be approved by the Ministry of Commerce in China, and failure to obtain such approval may materially and adversely affect the liquidity position of FibroGen Beijing.

The Ministry of Commerce in China or its local counterpart must approve the amount and use of any capital contributions from us to FibroGen Beijing, and there can be no assurance that we will be able to complete the necessary government registrations and obtain the necessary government approvals on a timely basis, or at all. If we fail to do so, we may not be able to contribute additional capital to fund our Chinese operations, and the liquidity and financial position of FibroGen Beijing may be materially and adversely affected.

We may be subject to currency exchange rate fluctuations and currency exchange restrictions with respect to our operations in China, which could adversely affect our financial performance.

If roxadustat is approved for sale in China, most of our product sales will occur in local Chinese currency and our operating results will be subject to volatility from currency exchange rate fluctuations. To date, we have not hedged against the risks associated with fluctuations in exchange rates and, therefore, exchange rate fluctuations could have an adverse impact on our future operating results. Changes in value of the Renminbi against the U.S. dollar, Euro and other currencies is affected by, among other things, changes in China’s political and economic conditions. Currently, the Renminbi is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. Any significant currency exchange rate fluctuations may have a material adverse effect on our business and financial condition.

Table of Contents

In addition, the Chinese government imposes controls on the convertibility of the Renminbi into foreign currencies and the remittance of foreign currency out of China for certain transactions. Shortages in the availability of foreign currency may restrict the ability of FibroGen Beijing to remit sufficient foreign currency to pay dividends or other payments to us, or otherwise satisfy their foreign currency-denominated obligations. Under existing Chinese foreign exchange regulations, payments of current account items, including profit distributions, interest payments and balance of trade, can be made in foreign currencies without prior approval from the State Administration of Foreign Exchange (“SAFE”) by complying with certain procedural requirements. However, approval from SAFE or its local branch is required where Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The Chinese government may also at its discretion restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign currency to satisfy our operational requirements, our liquidity and financial position may be materially and adversely affected.

Because FibroGen Beijing’s funds are held in banks that do not provide insurance, the failure of any bank in which FibroGen Beijing deposits its funds could adversely affect our business.

Banks and other financial institutions in China do not provide insurance for funds held on deposit. As a result, in the event of a bank failure, FibroGen Beijing may not have access to funds on deposit. Depending upon the amount of money FibroGen Beijing maintains in a bank that fails, its inability to have access to cash could materially impair its operations.

We may be subject to tax inefficiencies associated with our offshore corporate structure.

The tax regulations of the U.S. and other jurisdictions in which we operate are extremely complex and subject to change. New laws, new interpretations of existing laws, such as the Base Erosion Profit Shifting project initiated by the Organization for Economic Co-operation and Development, and any legislation proposed by the relevant taxing authorities, or limitations on our ability to structure our operations and intercompany transactions may lead to inefficient tax treatment of our revenue, profits, royalties, and distributions, if any are achieved.

In addition, we and our foreign subsidiaries have various intercompany transactions. We may not be able to obtain certain benefits under relevant tax treaties to avoid double taxation on certain transactions among our subsidiaries. If we are not able to avail ourselves to the tax treaties, we could be subject to additional taxes, which could adversely affect our financial condition and results of operations.

On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (“Tax Act”) that instituted fundamental changes to the taxation of multinational corporations. The Tax Act includes changes to the taxation of foreign earnings by implementing a dividend exemption system, expansion of the current anti-deferral rules, a minimum tax on low-taxed foreign earnings and new measures to deter base erosion. The Tax Act also includes a permanent reduction in the corporate tax rate to 21%, repeal of the corporate alternative minimum tax, expensing of capital investment, and limitation of the deduction for interest expense. Furthermore, as part of the transition to the new tax system, a one-time transition tax is imposed on a U.S. shareholder’s historical undistributed earnings of foreign affiliates. Although the Tax Act is generally effective January 1, 2018, GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017.

As a result of the impacts of the Tax Act, the SEC provided guidance that allows us to record provisional amounts for those impacts, with the requirement that the accounting be completed in a period not to exceed one year from the date of enactment. As of December 31, 2018, we completed our analysis of the accounting for the tax effects of the Tax Act and no material adjustments were recognized as of December 31, 2018. The primary impact of the Tax Act relates to the re-measurement of deferred tax assets and liabilities resulting from the change in the corporate tax rate (“Corporate Tax Rate Change”), which was recorded as of December 2017. Developing interpretations of the provisions of the Tax Act, changes to U.S. Treasury regulations, administrative interpretations, or court decisions interpreting the Tax Act in the future periods may require further adjustments to our analysis.

Table of Contents

Our foreign operations, particularly those in China, are subject to significant risks involving the protection of intellectual property.

We seek to protect the products and technology that we consider important to our business by pursuing patent applications in China and other countries, relying on trade secrets or pharmaceutical regulatory protection or employing a combination of these methods. We note that the filing of a patent application does not mean that we will be granted a patent, or that any patent eventually granted will be as broad as requested in the patent application or will be sufficient to protect our technology. There are a number of factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent applications not to be granted, including known or unknown prior art, deficiencies in the patent application, or lack of originality of the technology. Furthermore, the terms of our patents are limited. The patents we hold and the patents that may be granted from our currently pending patent applications have, absent any patent term adjustment or extension, a twenty-year protection period starting from the date of application.

Intellectual property rights and confidentiality protections in China may not be as effective as those in the U.S. or other countries for many reasons, including lack of procedural rules for discovery and evidence, low damage awards, and lack of judicial independence. Implementation and enforcement of China intellectual property laws have historically been deficient and ineffective and may be hampered by corruption and local protectionism. Policing unauthorized use of proprietary technology is difficult and expensive, and we may need to resort to litigation to enforce or defend patents issued to us or to determine the enforceability and validity of our proprietary rights or those of others. The experience and capabilities of China courts in handling intellectual property litigation varies and outcomes are unpredictable. An adverse determination in any such litigation could materially impair our intellectual property rights and may harm our business.

We are subject to laws and regulations governing corruption, which will require us to develop, maintain, and implement costly compliance programs.

We must comply with a wide range of laws and regulations to prevent corruption, bribery, and other unethical business practices, including the FCPA, anti-bribery and anti-corruption laws in other countries, particularly China. The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.

Anti-bribery laws prohibit us, our employees, and some of our agents or representatives from offering or providing any personal benefit to covered government officials to influence their performance of their duties or induce them to serve interests other than the missions of the public organizations in which they serve. Certain commercial bribery rules also prohibit offering or providing any personal benefit to employees and representatives of commercial companies to influence their performance of their duties or induce them to serve interests other than their employers. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.

Compliance with these anti-bribery laws is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the anti-bribery laws present particular challenges in the pharmaceutical industry because in many countries including China, hospitals are state-owned or operated by the government, and doctors and other hospital employees are considered foreign government officials. Furthermore, in certain countries (China in particular), hospitals and clinics are permitted to sell pharmaceuticals to their patients and are primary or significant distributors of pharmaceuticals. Certain payments to hospitals in connection with clinical studies, procurement of pharmaceuticals and other work have been deemed to be improper payments to government officials that have led to vigorous anti-bribery law enforcement actions and heavy fines in multiple jurisdictions, particularly in the U.S. and China.

It is not always possible to identify and deter violations, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.

Table of Contents

In the pharmaceutical industry, corrupt practices include, among others, acceptance of kickbacks, bribes or other illegal gains or benefits by the hospitals and medical practitioners from pharmaceutical manufacturers, distributors or their third party agents in connection with the prescription of certain pharmaceuticals. If our employees, affiliates, distributors or third party marketing firms violate these laws or otherwise engage in illegal practices with respect to their sales or marketing of our products or other activities involving our products, we could be required to pay damages or heavy fines by multiple jurisdictions where we operate, which could materially and adversely affect our financial condition and results of operations. The Chinese government has also sponsored anti-corruption campaigns from time to time, which could have a chilling effect on any future marketing efforts by us to new hospital customers. There have been recent occurrences in which certain hospitals have denied access to sales representatives from pharmaceutical companies because the hospitals wanted to avoid the perception of corruption. If this attitude becomes widespread among our potential customers, our ability to promote our products to hospitals may be adversely affected.

As we expand our operations in China and other jurisdictions internationally, we will need to increase the scope of our compliance programs to address the risks relating to the potential for violations of the FCPA and other anti-bribery and anti-corruption laws. Our compliance programs will need to include policies addressing not only the FCPA, but also the provisions of a variety of anti-bribery and anti-corruption laws in multiple foreign jurisdictions, including China, provisions relating to books and records that apply to us as a public company, and include effective training for our personnel throughout our organization. The creation and implementation of anti-corruption compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. Violation of the FCPA and other anti-corruption laws can result in significant administrative and criminal penalties for us and our employees, including substantial fines, suspension or debarment from government contracting, prison sentences, or even the death penalty in extremely serious cases in certain countries. The SEC also may suspend or bar us from trading securities on U.S. exchanges for violation of the FCPA’s accounting provisions. Even if we are not ultimately punished by government authorities, the costs of investigation and review, distraction of our personnel, legal defense costs, and harm to our reputation could be substantial and could limit our profitability or our ability to develop or commercialize our product candidates. In addition, if any of our competitors are not subject to the FCPA, they may engage in practices that will lead to their receipt of preferential treatment from foreign hospitals and enable them to secure business from foreign hospitals in ways that are unavailable to us.

Uncertainties with respect to the China legal system could have a material adverse effect on us.

The legal system of China is a civil law system primarily based on written statutes. Unlike in a common law system, prior court decisions may be cited for reference but are not binding. Because the China legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties, which may limit legal protections available to us. Moreover, decision makers in the China judicial system have significant discretion in interpreting and implementing statutory and contractual terms, which may render it difficult for FibroGen Beijing to enforce the contracts it has entered into with our business partners, customers and suppliers. Different government departments may have different interpretations of certain laws and regulations, and licenses and permits issued or granted by one government authority may be revoked by a higher government authority at a later time. Navigating the uncertainty and change in the China legal system will require the devotion of significant resources and time, and there can be no assurance that our contractual and other rights will ultimately be enforced.

Changes in China’s economic, political or social conditions or government policies could have a material adverse effect on our business and operations.*

Chinese society and the Chinese economy continue to undergo significant change. Changes in the regulatory structure, regulations, and economic policies of the Chinese government could have a material adverse effect on the overall economic growth of China, which could adversely affect our ability to conduct business in China. The Chinese government continues to adjust economic policies to promote economic growth. Some of these measures benefit the overall Chinese economy, but may also have a negative effect on us. For example, our financial condition and results of operations in China may be adversely affected by government control over capital investments or changes in tax regulations. As the Chinese pharmaceutical industry grows and evolves, the Chinese government may also implement measures to change the regulatory structure and structure of foreign investment in this industry. We are unable to predict the frequency and scope of such policy changes and structural changes, any of which could materially and adversely affect FibroGen Beijing’s development and commercialization timelines, liquidity, access to capital, and its ability to conduct business in China. Any failure on our part to comply with changing government regulations and policies could result in the loss of our ability to develop and commercialize our product candidates in China. In addition, the changing government regulations and policies could result in delays and cost increases to our development, manufacturing, approval, and commercialization timelines in China.

Table of Contents

Our operations in China subject us to various Chinese labor and social insurance laws, and our failure to comply with such laws may materially and adversely affect our business, financial condition and results of operations.

We are subject to China Labor Contract Law, which provides strong protections for employees and imposes many obligations on employers. The Labor Contract Law places certain restrictions on the circumstances under which employers may terminate labor contracts and require economic compensation to employees upon termination of employment, among other things. In addition, companies operating in China are generally required to contribute to labor union funds and the mandatory social insurance and housing funds. Any failure by us to comply with Chinese labor and social insurance laws may subject us to late fees, fines and penalties, or cause the suspension or termination of our ability to conduct business in China, any of which could have a material and adverse effect on business, results of operations and prospects.

Recent developments relating to the United Kingdom’s referendum vote in favor of leaving the EU could adversely affect us.

The United Kingdom held a referendum on June 23, 2016 in which a majority voted for the United Kingdom’s withdrawal from the EU, commonly referred to as “Brexit”. As a result of this vote, negotiations are expected to commence to determine the terms of the United Kingdom’s withdrawal from the EU as well as its relationship with the EU going forward, including the terms of trade between the United Kingdom and the EU. The effects of the United Kingdom’s withdrawal from the EU, and the perceptions as to its impact, are expected to be far-reaching and may adversely affect business activity and economic conditions in Europe and globally and could continue to contribute to instability in global financial markets, including foreign exchange markets. The United Kingdom’s withdrawal from the EU could also have the effect of disrupting the free movement of goods, services and people between the United Kingdom and the EU and could also lead to legal uncertainty and potentially divergent national laws and regulations as the United Kingdom determines which EU laws to replace or replicate, including laws that could impact our ability, or our collaborator’s ability in the case of roxadustat, to obtain approval of our products or sell our products in the United Kingdom. However, the full effects of such withdrawal are uncertain and will depend on any agreements the United Kingdom may make to retain access to EU markets. Lastly, as a result of the United Kingdom’s withdrawal from the EU, other European countries may seek to conduct referenda with respect to their continuing membership with the EU. Given these possibilities and others we may not anticipate, as well as the lack of comparable precedent, the full extent to which our business, results of operations and financial condition could be adversely affected by the United Kingdom’s withdrawal from the EU is uncertain.

Risks Related to the Operation of Our Business

We may encounter difficulties in managing our growth and expanding our operations successfully.

As we seek to advance our product candidates through clinical trials and commercialization, we will need to expand our development, regulatory, manufacturing, commercialization and administration capabilities or contract with third parties to provide these capabilities for us. As our operations expand and we continue to undertake the efforts and expense to operate as a public reporting company, we expect that we will need to increase the responsibilities on members of management in order to manage any future growth effectively. Our failure to accomplish any of these steps could prevent us from successfully implementing our strategy and maintaining the confidence of investors in our Company.

If we fail to attract and keep senior management and key personnel, in particular our chief executive officer, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates.

We are highly dependent on our chief executive officer, Thomas B. Neff, and other members of our senior management team. The loss of the services of Mr. Neff or any of these other individuals would be expected to significantly negatively impact the development and commercialization of our product candidates, our existing collaborative relationships and our ability to successfully implement our business strategy.

Recruiting and retaining qualified commercial, development, scientific, clinical, and manufacturing personnel are and will continue to be critical to our success, particularly as we expand our commercialization operations. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize product candidates. We may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel.

There is also significant competition, in particular in the San Francisco Bay Area, for the hiring of experienced and qualified personnel, which increases the importance of retention of our existing personnel. If we are unable to continue to attract and retain personnel with the quality and experience applicable to our product candidates, our ability to pursue our strategy will be limited and our business and operations would be adversely affected.

Table of Contents

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

We face an inherent risk of product liability as a result of the clinical testing, manufacturing and commercialization of our product candidates. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in a product, negligence, strict liability or breach of warranty. Claims could also be asserted under state consumer protection acts. If we are unable to obtain insurance coverage at levels that are appropriate to maintain our business and operations, or if we are unable to successfully defend ourselves against product liability claims, we may incur substantial liabilities or otherwise cease operations. Product liability claims may result in:

•

termination of further development of unapproved product candidates or significantly reduced demand for any approved products;

•

material costs and expenses to defend the related litigation;

•

a diversion of time and resources across the entire organization, including our executive management;

•

product recalls, withdrawals or labeling restrictions;

•

termination of our collaboration relationships or disputes with our collaboration partners; and

•

reputational damage negatively impacting our other product candidates in development.

If we fail to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims, we may not be able to continue to develop our product candidates. We maintain product liability insurance in a customary amount for the stage of development of our product candidates. Although we believe that we have sufficient coverage based on the advice of our third party advisors, there can be no assurance that such levels will be sufficient for our needs. Moreover, our insurance policies have various exclusions, and we may be in a dispute with our carrier as to the extent and nature of our coverage, including whether we are covered under the applicable product liability policy. If we are not able to ensure coverage or are required to pay substantial amounts to settle or otherwise contest the claims for product liability, our business and operations would be negatively affected.

Our business and operations would suffer in the event of computer system failures.

Despite the implementation of security measures, our internal computer systems, and those of our CROs, collaboration partners, and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We upgraded our disaster and data recovery capabilities in June 2017, however, to the extent that any disruption or security breach, in particular with our partners’ operations, results in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and it could result in a material disruption and delay of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.

We depend on sophisticated information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on our business.

We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations. The size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption. While we have recently upgraded our disaster data recovery program, a successful attack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyber-attacks are becoming more sophisticated and frequent. We have invested in our systems and the protection and recoverability of our data to reduce the risk of an intrusion or interruption, and we monitor and test our systems on an ongoing basis for any current or potential threats. There can be no assurance that these measures and efforts will prevent future interruptions or breakdowns. If we fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to these systems, we could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows.

Table of Contents

Our headquarters and data storage facilities are located near known earthquake fault zones. The occurrence of an earthquake, fire or any other catastrophic event could disrupt our operations or the operations of third parties who provide vital support functions to us, which could have a material adverse effect on our business, results of operations and financial condition.

We and some of the third party service providers on which we depend for various support functions, such as data storage, are vulnerable to damage from catastrophic events, such as power loss, natural disasters, terrorism and similar unforeseen events beyond our control. Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires.

We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.

If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place are unlikely to provide adequate protection in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.

Risks Related to Our Common Stock

The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above your purchase price.

In general, pharmaceutical, biotechnology and other life sciences company stocks have been highly volatile in the current market. The volatility of pharmaceutical, biotechnology and other life sciences company stocks is sometimes unrelated to the operating performance of particular companies and biotechnology and life science companies stocks often respond to trends and perceptions rather than financial performance. In particular, the market price of shares of our common stock could be subject to wide fluctuations in response to the following factors:

•

results of clinical trials of our product candidates, including roxadustat and pamrevlumab;

•

the timing of the release of results of and regulatory updates regarding our clinical trials;

•

the level of expenses related to any of our product candidates or clinical development programs;

•

results of clinical trials of our competitors’ products;

•

safety issues with respect to our product candidates or our competitors’ products;

•

regulatory actions with respect to our product candidates and any approved products or our competitors’ products;

•

fluctuations in our financial condition and operating results, which will be significantly affected by the manner in which we recognize revenue from the achievement of milestones under our collaboration agreements;

•

adverse developments concerning our collaborations and our manufacturers;

•

the termination of a collaboration or the inability to establish additional collaborations;

•

the publication of research reports by securities analysts about us or our competitors or our industry or negative recommendations or withdrawal of research coverage by securities analysts;

•

the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•

the ineffectiveness of our internal controls;

•

our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market;

Table of Contents

•

additions and departures of key personnel;

•

announced strategic decisions by us or our competitors;

•

changes in legislation or other regulatory developments affecting our product candidates or our industry;

•

fluctuations in the valuation of the biotechnology industry and particular companies perceived by investors to be comparable to us;

•

sales of our common stock by us, our insiders or our other stockholders;

•

speculation in the press or investment community;

•

announcement or expectation of additional financing efforts;

•

announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;

•

changes in accounting principles;

•

activities of the government of China, including those related to the pharmaceutical industry as well as industrial policy generally;

•

performance of other U.S. publicly traded companies with significant operations in China;

•

terrorist acts, acts of war or periods of widespread civil unrest;

•

natural disasters such as earthquakes and other calamities;

•

changes in market conditions for biopharmaceutical stocks;

•

changes in general market and economic conditions; and

•

the other factors described in this “Risk Factors” section.

As a result of fluctuations caused by these and other factors, comparisons of our operating results across different periods may not be accurate indicators of our future performance. Any fluctuations that we report in the future may differ from the expectations of market analysts and investors, which could cause the price of our common stock to fluctuate significantly. Moreover, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management’s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.

We have broad discretion in the use of the remaining net proceeds from our underwritten public offerings of common stock completed on April 11, 2017 (the “April 2017 Offering”) and August 24, 2017 (the “August 2017 Offering”) and may not use them effectively.

The net proceeds from the April 2017 Offering is intended to be used to fund the expansion of product development in China, including developing roxadustat in additional indications beyond CKD, manufacturing and commercialization activities, as well as for general corporate purposes. The net proceeds from the August 2017 Offering is intended to be used to fund the expansion of product development, including our development of pamrevlumab through Phase 3 trials, manufacturing and commercialization activities, as well as for general corporate purposes. These general corporate purposes, may include, among other things, funding research and development, clinical trials, vendor payables, potential regulatory submissions, hiring additional personnel and capital expenditures. However, we have no current commitments or obligations to use the net proceeds in the manner described above. Our management has broad discretion in the application of the remaining net proceeds from the April 2017 Offering and the August 2017 Offering, and could spend the remaining net proceeds in ways our stockholders may not agree with or that fails to improve our business or enhance the value of our common stock. The failure by our management to use these funds effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our product candidates.

If securities or industry analysts do not continue to publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

Table of Contents

Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.*

As of July 31, 2019, our executive officers, directors and principal stockholders, together with their respective affiliates, owned approximately 39.03% of our common stock, including shares subject to outstanding options that are exercisable within 60 days after such date and shares issuable upon settlement of restricted stock units that will vest within 60 days after such date. This percentage is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G, if any, filed with the SEC, which information may not be accurate as of April 30, 2019. Accordingly, these stockholders will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our board of directors and approval of significant corporate transactions. The interests of this group may differ from those of other stockholders and they may vote their shares in a way that is contrary to the way other stockholders vote their shares. This concentration of ownership could have the effect of entrenching our management and/or the board of directors, delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock.

Additional remedial measures that may be imposed in the proceedings instituted by the SEC against five China based accounting firms, including the Chinese affiliate of our independent registered public accounting firm, could result in our consolidated financial statements being determined to not be in compliance with the requirements of the Exchange Act.

In late 2012, the SEC commenced administrative proceedings under Rule 102(e) of its Rules of Practice and also under the Sarbanes-Oxley Act of 2002 against the Chinese affiliates of the “big four” accounting firms, including PricewaterhouseCoopers Zhong Tian CPAs Limited, the Chinese affiliate of our independent registered public accounting firm. The Rule 102(e) proceedings initiated by the SEC relate to these firms’ failure to produce documents, including audit work papers, in response to the request of the SEC pursuant to Section 106 of the Sarbanes-Oxley Act of 2002, as the auditors located in China are not in a position lawfully to produce documents directly to the SEC because of restrictions under Chinese law and specific directives issued by the China Securities Regulatory Commission (“CSRC”). The issues raised by the proceedings are not specific to our auditors or to us.

In January 2014, an administrative law judge reached an initial decision that the Chinese affiliates of the “big four” accounting firms should be barred from practicing before the SEC for a period of six months. In February 2015, the Chinese affiliates of the “big four” accounting firms each agreed to a censure and to pay a fine to the SEC to settle the dispute and avoid suspension of their ability to practice before the SEC and audit U.S.-listed companies. The settlement required the firms to follow detailed procedures and to seek to provide the SEC with access to Chinese firms’ audit documents via the CSRC. If future document productions fail to meet specified criteria, the SEC retains authority to impose a variety of additional remedial measures on the firms depending on the nature of the failure.

We cannot predict if the SEC will further review the four firms’ compliance with specified criteria or if such further review would result in the SEC imposing additional penalties such as suspensions or commencing any further administrative proceedings. Although it does not play a substantial role (as defined under PCAOB standards) in the audit of our consolidated financial statements, if PricewaterhouseCoopers Zhong Tian CPAs Limited were denied, temporarily, the ability to practice before the SEC, our ability to produce audited consolidated financial statements for our Company could be affected and we could be determined not to be in compliance with the requirements of the Exchange Act. Such a determination could ultimately lead to the delisting of our shares from the Nasdaq Global Select Market or deregistration from the SEC, or both, which would substantially reduce or effectively terminate the trading of our stock.

We may engage in future acquisitions that could disrupt our business, cause dilution to our stockholders and harm our business, results of operations, financial condition and cash flows and future prospects.

While we currently have no specific plans to acquire any other businesses, we may, in the future, make acquisitions of, or investments in, companies that we believe have products or capabilities that are a strategic or commercial fit with our present or future product candidates and business or otherwise offer opportunities for our Company. In connection with these acquisitions or investments, we may:

•

issue stock that would dilute our existing stockholders’ percentage of ownership;

•

incur debt and assume liabilities; and

•

incur amortization expenses related to intangible assets or incur large and immediate write-offs.

Table of Contents

We may not be able to complete acquisitions on favorable terms, if at all. If we do complete an acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will be viewed positively by customers, financial markets or investors. Furthermore, future acquisitions could pose numerous additional risks to our operations, including:

•

problems integrating the purchased business, products or technologies, or employees or other assets of the acquisition target;

•

increases to our expenses;

•

disclosed or undisclosed liabilities of the acquired asset or company;

•

diversion of management’s attention from their day-to-day responsibilities;

•

reprioritization of our development programs and even cessation of development and commercialization of our current product candidates;

•

harm to our operating results or financial condition;

•

entrance into markets in which we have limited or no prior experience; and

•

potential loss of key employees, particularly those of the acquired entity.

We may not be able to complete any acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition.

Provisions in our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current directors or management.

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:

•

authorize “blank check” preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;

•

create a classified board of directors whose members serve staggered three-year terms;

•

specify that special meetings of our stockholders can be called only by our board of directors pursuant to a resolution adopted by a majority of the total number of directors;

•

prohibit stockholder action by written consent;

•

establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;

•

provide that our directors may be removed prior to the end of their term only for cause;

•

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;

•

require a supermajority vote of the holders of our common stock or the majority vote of our board of directors to amend our bylaws; and

•

require a supermajority vote of the holders of our common stock to amend the classification of our board of directors into three classes and to amend certain other provisions of our certificate of incorporation.

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.

Table of Contents

Moreover, because we are incorporated in Delaware, we are governed by certain anti-takeover provisions under Delaware law which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. We are subject to the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Any provision of our amended and restated certificate of incorporation, our amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.

Changes in our tax provision or exposure to additional tax liabilities could adversely affect our earnings and financial condition.

As a multinational corporation, we are subject to income taxes in the U.S. and various foreign jurisdictions. Significant judgment is required in determining our global provision for income taxes and other tax liabilities. In the ordinary course of a global business, there are intercompany transactions and calculations where the ultimate tax determination is uncertain. Our income tax returns are subject to audits by tax authorities. Although we regularly assess the likelihood of adverse outcomes resulting from these examinations to determine our tax estimates, a final determination of tax audits or tax disputes could have an adverse effect on our results of operations and financial condition.

We are also subject to non-income taxes, such as payroll, sales, use, value-added, net worth, property, gross receipts, and goods and services taxes in the U.S., state and local, and various foreign jurisdictions. We are subject to audit and assessments by tax authorities with respect to these non-income taxes and may have exposure to additional non-income tax liabilities, which could have an adverse effect on our results of operations and financial condition.

On December 22, 2017, the U.S. enacted the Tax Act that instituted fundamental changes to the taxation of multinational corporations. The Tax Act includes changes to the taxation of foreign earnings by implementing a dividend exemption system, expansion of the current anti-deferral rules, a minimum tax on low-taxed foreign earnings and new measures to deter base erosion. The Tax Act also includes a permanent reduction in the corporate tax rate to 21%, repeal of the corporate alternative minimum tax, expensing of capital investment, and limitation of the deduction for interest expense. Furthermore, as part of the transition to the new tax system, a one-time transition tax is imposed on a U.S. shareholder’s historical undistributed earnings of foreign affiliates. Although the Tax Act is generally effective January 1, 2018, GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017.

As a result of the impact of the Tax Act, the SEC provided guidance that allows us to record provisional amounts for those affected items, with the requirement that the accounting be completed in a period not to exceed one year from the date of enactment. As of December 31, 2018, we completed our analysis of the accounting for the tax effects of the Tax Act and no material adjustments were recognized at year end. The primary impact of the Tax Act relates to the re-measurement of deferred tax assets and liabilities resulting from the Corporate Tax Rate Change, which was recorded as of December 31, 2017. Developing interpretations of the provisions of the Tax Act, changes to U.S. Treasury regulations, administrative interpretations or court decisions interpreting the Tax Act in the future periods may require further adjustments to our analysis.

Our amended and restated certificate of incorporation designates the state or federal courts located in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state and federal courts located in the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated by-laws, or (4) any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.

Table of Contents

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain and you may never receive a return on your investment.

You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future and investors seeking cash dividends should not purchase our common stock. We plan to retain any earnings to invest in our product candidates and maintain and expand our operations. Therefore, capital appreciation, or an increase in your stock price, which may never occur, may be the only way to realize any return on your investment.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Use of Proceeds from Initial Public Offering of Common Stock

On November 13, 2014, our Registration Statement on Form S-1, as amended (Reg. Nos. 333-199069 and 333-200189) was declared effective in connection with the initial public offering of our common stock. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act on November 14, 2014.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

Table of Contents

ITEM 6. EXHIBITS

Exhibit		Incorporation By Reference
Number	Exhibit Description	Form	SEC File No.	Exhibit	Filing Date

3.1	Amended and Restated Certificate of Incorporation of FibroGen, Inc.	8-K	001-36740	3.1	11/21/2014

3.2	Amended and Restated Bylaws of FibroGen, Inc.	S-1/A	333-199069	3.4	10/23/2014

4.1	Form of Common Stock Certificate.	8-K	001-36740	4.1	11/21/2014

4.2	Investor Rights Agreement by and among FibroGen, Inc. and certain of its stockholders, dated as of December 1995.	S-1	333-199069	4.2	10/01/2014

4.3	Investor Rights Agreement by and among FibroGen, Inc. and certain of its warrant holders, dated as of February 8, 2000.	S-1	333-199069	4.7	10/01/2014

4.4	Warrant to Purchase 11,076 Shares of Common Stock issued to Bristow Investments, L.P, dated as of February 8, 2000.	S-1	333-199069	4.12	10/01/2014

4.5	Common Stock Purchase Agreement by and between FibroGen, Inc. and AstraZeneca AB, dated as of October 20, 2014.	S-1/A	333-199069	4.17	10/24/2014

4.6	Shareholders’ Agreement by and among FibroGen International (Cayman) Limited and certain of its shareholders, dated as of September 8, 2017.	10-Q	001-36740	4.6	11/8/2017

10.6*+	FibroGen, Inc. Non-Employee Director Compensation Policy, as amended.	—	—	—	—

31.1*	Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).	—	—	—	—

31.2*	Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).	—	—	—	—

32.1*	Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(1)).	—	—	—	—

101.INS	Inline XBRL Instance Document	—	—	—	—

101.SCH	Inline XBRL Taxonomy Extension Schema Document	—	—	—	—

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	—	—	—	—

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	—	—	—	—

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	—	—	—	—

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	—	—	—	—

104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)	—	—	—	—

*	Filed herewith

+	Indicates a management contract or compensatory plan

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	FibroGen, Inc.

Dated: August 8, 2019	By:	/s/ Thomas B. Neff
		Thomas B. Neff
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

Dated: August 8, 2019	By:	/s/ Pat Cotroneo
		Pat Cotroneo
		Senior Vice President, Finance and Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-10.6 2 fgen-ex106_6.htm EX-10.6 fgen-ex106_6.htm

Exhibit 10.6

FibroGen, Inc.

Non-Employee Director Compensation Policy

This Non-Employee Director Compensation Policy (the “Policy”) documents the terms and conditions of the cash and equity compensation that non-employee members of the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) may earn for their service on the Board from and after the initial public offering of the common stock of FibroGen.

Eligible Directors

Only members of the Board who are not concurrently employees of FibroGen are eligible for compensation under this Policy (each such member, a “Director”). Any director may also decline compensation per policy of their affiliated entity or for any other reason prior to the start of the period of service to which the compensation relates.

Annual Cash Compensation

The annual cash compensation set forth below is payable in equal quarterly installments, in arrears, on the last day of each quarter in which the service occurred, pro-rated for any partial quarters of service. All annual cash fees are vested upon payment.

1.	Annual Board Service Retainer:

All Directors: $ 50,000

2.Annual Committee Chair Service Fee:

a.Chairman of the Audit Committee: $20,000

b.Chairman of the Compensation Committee: $ 17,500

c.Chairman of the Nominating and Governance Committee: $10,000

3.Annual Committee Member (non-Chair) Service Fee:

a.Audit Committee: $10,000

b.Compensation Committee: $7,500

c.Nominating and Governance Committee: $5,000

4.	Annual Lead Independent Director Retainer:

Lead Director: $22,500

Equity Compensation

Equity awards will be granted under the FibroGen, Inc. 2014 Equity Incentive Plan (or any successor thereto, the “Plan”). All stock options granted under this policy will be non-statutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Company common stock on the date of grant, and a term of ten (10) years from the date of grant (subject to earlier termination in connection with a termination of service or a corporate transaction as provided in the Plan). All equity awards granted under this Policy will be documented on the applicable form of equity award agreement most recently approved for use by the Board (or a duly authorized committee thereof) for Directors. The terms of the equity awards described in this Policy will be automatically adjusted upon any Capitalization Adjustment (as defined and provided for under the Plan).

Initial Grant: On the date of the Director’s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Director will be automatically, and without further action by the Board, granted stock options covering 10,400 shares of FibroGen’s common stock. Such options will vest in equal quarterly installments over three years from the grant date, subject to the Director’s Continuous Service. A Director who, in the one year prior to his or her initial election to serve on the Board as a Director, served as an employee of FibroGen or one of its subsidiaries, will not be eligible for an initial grant.

Exhibit 10.6

Annual Grant: On the date of each Company annual stockholder meeting, each person who is elected or appointed as a Director, and each other Director who continues to serve as a Director immediately after such annual stockholder meeting, will be automatically, and without further action by the Board, granted (a) stock options covering 7,800 shares of FibroGen’s common stock, and (b) RSUs covering 4,700 shares of FibroGen common stock. Such options and RSUs will vest upon the earlier of (x) June 6 of the following year and (y) the following year’s annual stockholder meeting, subject to the Director’s Continuous Service.

Prorated Annual Grants. If a Director is elected or appointed to the Board at a time other than at the annual stockholder meeting, then on the date of such election or appointment (or, if such date is not a market trading day, the first market trading day thereafter), the Director will be automatically, and without further action by the Board, granted stock options covering the number of shares of FibroGen’s common stock equal to the product of each of (x) 6,000 shares and (y) 3,700 RSUs, by (z) the Applicable Fraction (a “Prorated Annual Grant”). The Applicable Fraction means a fraction with (a) a numerator equal to the number of days between the date of the Director’s initial election or appointment to the Board and the date which is the first anniversary of the date of the most recent annual stockholder meeting occurring before the Director is elected or appointed to the Board, and (b) a denominator equal to 365.

Vesting. Vesting of awards granted under this Policy will cease if the Director resigns from the Board or otherwise ceases to serve as a Director, unless the Board determines that the circumstances warrant continuation of vesting. All equity awards granted under this Policy will vest in full immediately prior to a Change in Control (as defined in the Plan), subject to the Director’s Continuous Service (as defined in the Plan) as of the day prior to the closing of the Change in Control.

Reimbursement of Expenses

The Company will reimburse Directors for ordinary, necessary and reasonable out-of-pocket travel expenses to cover in-person attendance at and participation in Board meetings.

Philosophy

This Policy is designed to attract and retain experienced, talented individuals to serve on the Board. The Board anticipates that the Board, or a duly authorized committee thereof, will generally review Director compensation on an annual basis following the initial public offering. The Policy, as amended from time to time, may take into account the time commitment expected of Directors, best practices and market rates in Director compensation, the economic position of FibroGen, broader economic conditions, historical compensation structure, the advice of the compensation consultant that the Compensation Committee or the Board may retain from time to time, and the potential dilutive effect of equity awards on our stockholders.

Under this Policy, Directors receive cash compensation in the form of retainers to recognize their day to day contributions, the level of responsibility as well as the necessary time commitment involved in serving in a leadership role and/or on committees. Directors also receive equity compensation because we believe that stock ownership provides an incentive to act in ways that maximize long-term stockholder value. Further, we believe that stock-based awards are essential to attracting and retaining talented Board members. When options are granted, these options have an exercise price equal to not less than the fair market value of FibroGen’s Common Stock on the date of grant, so that options provide a return only if the fair market value appreciates over the period in which the option vests and remains exercisable. We believe that the vesting acceleration provided in the case of a change in control is consistent with market practices and is critical to attracting and retaining high quality Directors.

Exhibit 10.6

Adopted: September 17, 2014

Amended: March 4, 2015

Amended: February 23, 2016, Effective as of the 2016 Annual Meeting of Stockholders

Amended: June 5, 2018

Amended: June 5, 2019

EX-31.1 3 fgen-ex311_7.htm EX-31.1 fgen-ex311_7.htm

Exhibit 31.1

CERTIFICATION

I, Thomas B. Neff, certify that;

1. I have reviewed this Form 10-Q of FibroGen, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2019

/s/ Thomas B. Neff

Thomas B. Neff

Chairman of the Board and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 4 fgen-ex312_8.htm EX-31.2 fgen-ex312_8.htm

Exhibit 31.2

CERTIFICATION

I, Pat Cotroneo, certify that;

1. I have reviewed this Form 10-Q of FibroGen, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2019

/s/ Pat Cotroneo

Pat Cotroneo

Senior Vice President, Finance and Chief Financial Officer

(Principal Financial Officer)

EX-32.1 5 fgen-ex321_9.htm EX-32.1 fgen-ex321_9.htm

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Thomas B. Neff, Chief Executive Officer of FibroGen, Inc. (“the Company”), and Pat Cotroneo, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.	The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2019, to which this Certification is attached as Exhibit 32.1 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 8, 2019

In Witness Whereof, the undersigned have set their hands hereto as of the 8^th day of August, 2019.

/s/ Thomas B. Neff

/s/ Pat Cotroneo

Thomas B. Neff

Pat Cotroneo

Chairman of the Board and Chief Executive Officer

Senior Vice President, Finance and

Chief Financial Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of FibroGen, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.SCH 6 fgen-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Balance Sheet Components link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Collaboration Agreements (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Balance Sheet Components (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Significant Accounting Policies - Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impacts to Condensed Consolidated Balance Sheet Upon Adoption of 842 Guidance (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impacts to Accumulated Other Comprehensive Loss and Accumulated Deficit Upon Adoption of Guidance (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Collaboration Agreements - Astellas Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Collaboration Agreements - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Collaboration Agreements - Deferred Revenue - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Leases - Components of Lease Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)2 link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under all Non-Cancelable Operating Lease Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Leases - Schedule of Future Minimum Lease Payments on Consolidated Basis Under Company's Facility Financing Lease Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Balance Sheet Components - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Stock-Based Compensation - Schedule of Allocated Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 fgen-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 fgen-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 fgen-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date. Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Shell Company Entity Shell Company Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Common Stock Shares Outstanding Entity Common Stock Shares Outstanding Restricted time deposits noncurrent. Lease obligations noncurrent. Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Short Term Investments Accounts receivable ($4,311 and $47,210 from a related party) Accounts Receivable Net Current Inventories Inventory Net Prepaid expenses and other current assets ($127,981 and $0 from a related party) Prepaid Expense And Other Assets Current Total current assets Assets Current Restricted time deposits Restricted Time Deposits Noncurrent Long-term investments Long Term Investments Property and equipment, net Property Plant And Equipment Net Finance lease right-of-use assets Finance Lease Right Of Use Asset Other assets Other Assets Noncurrent Total assets Assets Liabilities, stockholders’ equity and non-controlling interests Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued and other current liabilities ($781 and $444 to a related party) Accrued Liabilities And Other Liabilities Deferred revenue Contract With Customer Liability Current Finance lease liabilities, current Finance Lease Liability Current Total current liabilities Liabilities Current Long-term portion of lease obligations Lease Obligations Noncurrent Product development obligations Accrued Product Development Costs Deferred rent Deferred Rent Credit Noncurrent Deferred revenue, net of current Contract With Customer Liability Noncurrent Finance lease liabilities, non-current Finance Lease Liability Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and Contingencies Commitments And Contingencies Stockholders’ equity: Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2019 and December 31, 2018 Preferred Stock Value Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2019 and December 31, 2018; 86,847 and 85,432 shares issued and outstanding at June 30, 2019 and December 31, 2018 Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Non-controlling interests Minority Interest Total equity Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total liabilities, stockholders’ equity and non-controlling interests Liabilities And Stockholders Equity Accounts receivable from related party Accounts Receivable Related Parties Current Prepaid expenses and other current assets from related party Due From Related Parties Current Accrued and other current liabilities to related party Due To Related Parties Current Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Interest and other net. Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] License Revenue [Member] License [Member] Development and other revenue. Development and Other Revenue [Member] Development And Other Revenue [Member] Statement [Line Items] Statement [Line Items] Revenue: Revenue From Contract With Customer [Abstract] Total revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total operating expenses Operating Expenses Income (loss) from operations Operating Income Loss Interest and other, net Interest And Other Net [Abstract] Interest expense Interest Expense Interest income and other, net Interest And Other Income Total interest and other, net Interest Income Expense Nonoperating Net Income (loss) before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income taxes Income Tax Expense Benefit Net income (loss) Net Income Loss Net income (loss) per share: Earnings Per Share Basic And Diluted [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Weighted average number of common shares used to calculate net income (loss) per share: Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue. Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period. Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Astellas agreements. Astellas Agreement [Member] Astellas Collaboration Agreement [Member] Collaboration services and other revenue from a related party Collaboration Services And Other Revenue License and milestone revenue from a related party License Fees And Milestones Revenue Statement Of Income And Comprehensive Income [Abstract] Net income (loss) Other comprehensive income (loss): Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Foreign currency translation adjustments Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Available-for-sale investments: Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract] Unrealized gain on investments, net of tax effect Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Other comprehensive income, net of taxes Other Comprehensive Income Loss Net Of Tax Comprehensive income (loss) Comprehensive Income Net Of Tax Shares issued from stock plans net of payroll taxes paid shares. Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Other Comprehensive Loss [Member] Accumulated Other Comprehensive Income [Member] Accumulated Deficit [Member] Retained Earnings [Member] Noncontrolling Interests [Member] Noncontrolling Interest [Member] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] ASU 2016-02 [Member] Accounting Standards Update201602 [Member] ASU 2018-02 [Member] Accounting Standards Update201802 [Member] ASU 2016-01 [Member] Accounting Standards Update201601 [Member] Balance Balance, Shares Shares Outstanding Impact of change in accounting principle upon adoption New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Net Income Change in unrealized gain or loss on investments Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Adjustment to issuance costs for Follow-on Offerings Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Shares issued from stock plans, net of payroll taxes paid Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares issued from stock plans, net of payroll taxes paid, Shares Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Balance Balance, Shares Unrealized gain loss on cash equivalents and short term equity investments. Increase decrease in lease obligations. Increase (decrease) in accrued interest for finance lease liabilities. Payments to acquire available for sale securities and term deposit. Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities [Abstract] Net income (loss) Profit Loss Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Amortization of finance lease right-of-use assets Finance Lease Right Of Use Asset Amortization Net amortization of premium and discount on investments Accretion Amortization Of Discounts And Premiums Investments Unrealized loss (gain) on cash equivalents and short-term equity investments Unrealized Gain Loss On Cash Equivalents And Short Term Equity Investments Loss (gain) on disposal of property and equipment Gain Loss On Disposition Of Assets Stock-based compensation Share Based Compensation Realized foreign currency gain Foreign Currency Transaction Gain Loss Realized Realized gain on sales of available-for-sale securities Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventories Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other assets Increase Decrease In Other Operating Assets Accounts payable Increase Decrease In Accounts Payable Accrued and other liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Lease obligations Increase Decrease In Lease Obligations Accrued interest for finance lease liabilities Increase Decrease In Accrued Interest For Finance Lease Liabilities Other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Proceeds from sale of property and equipment Proceeds From Sale Of Property Plant And Equipment Purchases of available-for-sale securities and term deposit Payments To Acquire Available For Sale Securities And Term Deposit Proceeds from sales of available-for-sale securities Proceeds From Sale Of Available For Sale Securities Proceeds from maturities of investments Proceeds From Sale Maturity And Collections Of Investments Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Financing activities Net Cash Provided By Used In Financing Activities [Abstract] Repayments of finance lease liabilities Finance Lease Principal Payments Repayments of lease obligations Repayments Of Debt And Capital Lease Obligations Cash paid for payroll taxes on restricted stock unit releases Payments Related To Tax Withholding For Share Based Compensation Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities Effect of exchange rate change on cash and cash equivalents Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Net decrease in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Total cash and cash equivalents at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Total cash and cash equivalents at end of period Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Leases [Abstract] Leases Leases Of Lessee Disclosure [Text Block] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] EX-101.PRE 10 fgen-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 fgen-10q_20190630_htm.xml IDEA: XBRL DOCUMENT 0000921299 2019-01-01 2019-06-30 0000921299 2019-07-31 0000921299 2019-06-30 0000921299 2018-12-31 0000921299 us-gaap:LicenseMember 2019-04-01 2019-06-30 0000921299 us-gaap:LicenseMember 2018-04-01 2018-06-30 0000921299 us-gaap:LicenseMember 2019-01-01 2019-06-30 0000921299 us-gaap:LicenseMember 2018-01-01 2018-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember 2019-04-01 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember 2018-04-01 2018-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember 2019-01-01 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember 2018-01-01 2018-06-30 0000921299 2019-04-01 2019-06-30 0000921299 2018-04-01 2018-06-30 0000921299 2018-01-01 2018-06-30 0000921299 fgen:AstellasCollaborationAgreementMember 2019-04-01 2019-06-30 0000921299 fgen:AstellasCollaborationAgreementMember 2018-04-01 2018-06-30 0000921299 fgen:AstellasCollaborationAgreementMember 2019-01-01 2019-06-30 0000921299 fgen:AstellasCollaborationAgreementMember 2018-01-01 2018-06-30 0000921299 us-gaap:CommonStockMember 2019-03-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000921299 us-gaap:RetainedEarningsMember 2019-03-31 0000921299 us-gaap:NoncontrollingInterestMember 2019-03-31 0000921299 2019-03-31 0000921299 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000921299 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000921299 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000921299 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0000921299 us-gaap:CommonStockMember 2019-06-30 0000921299 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000921299 us-gaap:RetainedEarningsMember 2019-06-30 0000921299 us-gaap:NoncontrollingInterestMember 2019-06-30 0000921299 us-gaap:CommonStockMember 2018-03-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000921299 us-gaap:RetainedEarningsMember 2018-03-31 0000921299 us-gaap:NoncontrollingInterestMember 2018-03-31 0000921299 2018-03-31 0000921299 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000921299 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000921299 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000921299 us-gaap:NoncontrollingInterestMember 2018-04-01 2018-06-30 0000921299 us-gaap:CommonStockMember 2018-06-30 0000921299 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000921299 us-gaap:RetainedEarningsMember 2018-06-30 0000921299 us-gaap:NoncontrollingInterestMember 2018-06-30 0000921299 2018-06-30 0000921299 us-gaap:CommonStockMember 2018-12-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000921299 us-gaap:RetainedEarningsMember 2018-12-31 0000921299 us-gaap:NoncontrollingInterestMember 2018-12-31 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:NoncontrollingInterestMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:NoncontrollingInterestMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccountingStandardsUpdate201802Member 2019-01-01 2019-06-30 0000921299 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000921299 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0000921299 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0000921299 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-06-30 0000921299 us-gaap:CommonStockMember 2017-12-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000921299 us-gaap:RetainedEarningsMember 2017-12-31 0000921299 us-gaap:NoncontrollingInterestMember 2017-12-31 0000921299 2017-12-31 0000921299 us-gaap:AccountingStandardsUpdate201601Member us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000921299 us-gaap:AccountingStandardsUpdate201601Member us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000921299 us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000921299 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0000921299 us-gaap:AccountingStandardsUpdate201601Member us-gaap:NoncontrollingInterestMember 2018-01-01 2018-06-30 0000921299 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 2018-06-30 0000921299 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000921299 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000921299 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0000921299 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-06-30 0000921299 country:JP 2019-01-01 2019-06-30 0000921299 srt:EuropeMember 2019-01-01 2019-06-30 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember 2019-01-01 2019-06-30 0000921299 fgen:DerecognitionBuildToSuitLeaseAssetsMember fgen:BuildingShellMember 2019-06-30 0000921299 fgen:DerecognitionBuildToSuitLeaseAssetsAccumulatedDepreciationMember fgen:BuildingShellMember 2019-06-30 0000921299 fgen:LeaseholdImprovementsAccumulatedDepreciationMember 2019-06-30 0000921299 fgen:RecognitionFinanceLeaseAssetsMember 2019-06-30 0000921299 fgen:RecognitionOperatingLeaseAssetsMember 2019-06-30 0000921299 fgen:DerecognitionDeferredRentCurrentMember 2019-06-30 0000921299 fgen:DerecognitionBuildToSuitLeaseLiabilitiesCurrentMember 2019-06-30 0000921299 fgen:RecognitionOperatingLeaseLiabilitiesCurrentMember 2019-06-30 0000921299 fgen:RecognitionFinanceLeaseLiabilitiesCurrentMember 2019-06-30 0000921299 fgen:DerecognitionBuildToSuitLeaseLiabilitiesNonCurrentMember 2019-06-30 0000921299 fgen:DerecognitionDeferredRentNonCurrentMember 2019-06-30 0000921299 fgen:RecognitionFinanceLeaseLiabilitiesNonCurrentMember 2019-06-30 0000921299 fgen:RecognitionOperatingLeaseLiabilitiesNonCurrentMember 2019-06-30 0000921299 fgen:CumulativeDecreaseToAccumulatedDeficitMember 2019-06-30 0000921299 2017-01-01 2017-12-31 0000921299 us-gaap:AccountingStandardsUpdate201802Member fgen:ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member 2019-01-01 0000921299 us-gaap:AccountingStandardsUpdate201802Member 2019-01-01 0000921299 country:JP fgen:AstellasCollaborationAgreementMember 2005-06-01 2009-02-28 0000921299 country:JP fgen:AstellasCollaborationAgreementMember 2005-06-01 2005-06-30 0000921299 country:JP fgen:ClinicalDevelopmentMilestonesMember fgen:AstellasCollaborationAgreementMember 2005-06-01 2005-06-30 0000921299 country:JP fgen:RegulatoryMilestonesMember fgen:AstellasCollaborationAgreementMember 2005-06-01 2005-06-30 0000921299 country:JP fgen:AstellasCollaborationAgreementMember 2019-06-30 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2006-04-01 2009-02-28 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2006-04-01 2006-04-30 0000921299 srt:EuropeMember fgen:ClinicalDevelopmentMilestonesMember fgen:AstellasCollaborationAgreementMember 2006-04-01 2006-04-30 0000921299 srt:EuropeMember fgen:RegulatoryMilestonesMember fgen:AstellasCollaborationAgreementMember 2006-04-01 2006-04-30 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-01-01 2019-06-30 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-06-30 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2018-01-01 2018-12-31 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:ClinicalDevelopmentMilestonesMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:RegulatoryMilestonesMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:DeferredApprovalMilestoneMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:DevelopmentMilestonesMember fgen:AstraZenecaAgreementsMember 2015-01-01 2015-12-31 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:AstraZenecaAgreementsMember 2019-06-30 0000921299 fgen:AstraZenecaAgreementsMember 2019-06-30 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 country:CN fgen:ClinicalDevelopmentMilestonesMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 country:CN fgen:RegulatoryMilestonesMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2019-06-30 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2019-01-01 2019-06-30 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2018-12-16 2018-12-17 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2018-12-28 2018-12-29 0000921299 us-gaap:LicenseMember country:JP fgen:AstellasCollaborationAgreementMember 2019-04-01 2019-06-30 0000921299 us-gaap:LicenseMember country:JP fgen:AstellasCollaborationAgreementMember 2018-04-01 2018-06-30 0000921299 us-gaap:LicenseMember country:JP fgen:AstellasCollaborationAgreementMember 2019-01-01 2019-06-30 0000921299 us-gaap:LicenseMember country:JP fgen:AstellasCollaborationAgreementMember 2018-01-01 2018-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember country:JP fgen:AstellasCollaborationAgreementMember 2019-04-01 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember country:JP fgen:AstellasCollaborationAgreementMember 2018-04-01 2018-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember country:JP fgen:AstellasCollaborationAgreementMember 2019-01-01 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember country:JP fgen:AstellasCollaborationAgreementMember 2018-01-01 2018-06-30 0000921299 us-gaap:LicenseMember country:JP fgen:AstellasCollaborationAgreementMember 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember country:JP fgen:AstellasCollaborationAgreementMember 2019-06-30 0000921299 country:JP 2019-04-01 2019-06-30 0000921299 us-gaap:LicenseMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-04-01 2019-06-30 0000921299 us-gaap:LicenseMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2018-04-01 2018-06-30 0000921299 us-gaap:LicenseMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-01-01 2019-06-30 0000921299 us-gaap:LicenseMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2018-01-01 2018-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-04-01 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2018-04-01 2018-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-01-01 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2018-01-01 2018-06-30 0000921299 us-gaap:LicenseMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-06-30 0000921299 srt:EuropeMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember fgen:AstellasCollaborationAgreementMember 2019-06-30 0000921299 srt:EuropeMember 2019-04-01 2019-06-30 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-04-01 2019-06-30 0000921299 us-gaap:LicenseMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-04-01 2019-06-30 0000921299 us-gaap:LicenseMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2018-04-01 2018-06-30 0000921299 us-gaap:LicenseMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-01-01 2019-06-30 0000921299 us-gaap:LicenseMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2018-01-01 2018-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-04-01 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2018-04-01 2018-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-01-01 2019-06-30 0000921299 fgen:DevelopmentAndOtherRevenueMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2018-01-01 2018-06-30 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2019-04-01 2019-06-30 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2018-04-01 2018-06-30 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2018-01-01 2018-06-30 0000921299 us-gaap:LicenseMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-06-30 0000921299 fgen:CoDevelopmentInformationSharingAndCommitteeServicesMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-06-30 0000921299 fgen:ChinaPerformanceObligationMember fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-06-30 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-06-30 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember 2019-04-01 2019-06-30 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2019-04-01 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0000921299 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember fgen:BondAndMutualFundsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember fgen:BondAndMutualFundsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember fgen:BondAndMutualFundsMember 2019-06-30 0000921299 us-gaap:FairValueMeasurementsRecurringMember fgen:BondAndMutualFundsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-06-30 0000921299 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-06-30 0000921299 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember fgen:TermDepositMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember fgen:TermDepositMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember fgen:TermDepositMember 2019-06-30 0000921299 us-gaap:FairValueMeasurementsRecurringMember fgen:TermDepositMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-06-30 0000921299 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000921299 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember fgen:BondAndMutualFundsMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember fgen:BondAndMutualFundsMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember fgen:BondAndMutualFundsMember 2018-12-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember fgen:BondAndMutualFundsMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember fgen:TermDepositMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember fgen:TermDepositMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember fgen:TermDepositMember 2018-12-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember fgen:TermDepositMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel1Member fgen:LeaseObligationsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel2Member fgen:LeaseObligationsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel3Member fgen:LeaseObligationsMember 2019-06-30 0000921299 fgen:LeaseObligationsMember 2019-06-30 0000921299 us-gaap:FairValueInputsLevel1Member fgen:LeaseObligationsMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel2Member fgen:LeaseObligationsMember 2018-12-31 0000921299 us-gaap:FairValueInputsLevel3Member fgen:LeaseObligationsMember 2018-12-31 0000921299 fgen:LeaseObligationsMember 2018-12-31 0000921299 fgen:LeaseObligationsMember us-gaap:BuildingMember 2018-12-31 0000921299 fgen:LeaseObligationsMember fgen:LongTermPropertyLeaseMember fgen:ShorensteinPropertiesLLCMember 2019-06-30 0000921299 us-gaap:BuildingMember fgen:ShorensteinPropertiesLLCMember 2019-01-01 2019-06-30 0000921299 fgen:ShorensteinPropertiesLLCMember 2019-01-01 2019-06-30 0000921299 fgen:ShorensteinPropertiesLLCMember 2019-06-30 0000921299 2018-01-01 2018-12-31 0000921299 us-gaap:BuildingMember 2019-01-01 2019-06-30 0000921299 fgen:ShorensteinPropertiesLLCMember 2006-12-31 0000921299 fgen:ShorensteinPropertiesLLCMember 2006-01-01 2006-12-31 0000921299 fgen:BeijingEconomicTechnologicalDevelopmentAreaMember 2013-12-31 0000921299 fgen:BeijingEconomicTechnologicalDevelopmentAreaMember 2013-01-01 2013-12-31 0000921299 srt:MinimumMember 2019-06-30 0000921299 srt:MaximumMember 2019-06-30 0000921299 srt:MinimumMember us-gaap:OfficeEquipmentMember 2019-06-30 0000921299 srt:MaximumMember us-gaap:OfficeEquipmentMember 2019-06-30 0000921299 us-gaap:GeographicDistributionForeignMember 2019-06-30 0000921299 us-gaap:GeographicDistributionForeignMember 2018-12-31 0000921299 us-gaap:USTreasurySecuritiesMember 2019-06-30 0000921299 fgen:TermDepositMember 2019-06-30 0000921299 us-gaap:CertificatesOfDepositMember 2019-06-30 0000921299 fgen:BondAndMutualFundsMember 2019-06-30 0000921299 us-gaap:EquitySecuritiesMember 2019-06-30 0000921299 us-gaap:USTreasurySecuritiesMember 2018-12-31 0000921299 fgen:TermDepositMember 2018-12-31 0000921299 us-gaap:CertificatesOfDepositMember 2018-12-31 0000921299 fgen:BondAndMutualFundsMember 2018-12-31 0000921299 us-gaap:EquitySecuritiesMember 2018-12-31 0000921299 us-gaap:LeaseholdImprovementsMember 2019-06-30 0000921299 us-gaap:LeaseholdImprovementsMember 2018-12-31 0000921299 fgen:BuildingShellMember 2019-06-30 0000921299 fgen:BuildingShellMember 2018-12-31 0000921299 fgen:LaboratoryEquipmentMember 2019-06-30 0000921299 fgen:LaboratoryEquipmentMember 2018-12-31 0000921299 us-gaap:MachineryAndEquipmentMember 2019-06-30 0000921299 us-gaap:MachineryAndEquipmentMember 2018-12-31 0000921299 us-gaap:ComputerEquipmentMember 2019-06-30 0000921299 us-gaap:ComputerEquipmentMember 2018-12-31 0000921299 us-gaap:FurnitureAndFixturesMember 2019-06-30 0000921299 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000921299 us-gaap:ConstructionInProgressMember 2019-06-30 0000921299 us-gaap:ConstructionInProgressMember 2018-12-31 0000921299 fgen:BuildToSuitArrangementsMember us-gaap:BuildingMember 2018-12-31 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:LeaseholdImprovementsMember 2019-06-30 0000921299 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000921299 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000921299 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000921299 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000921299 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000921299 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000921299 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000921299 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000921299 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000921299 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000921299 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000921299 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000921299 srt:MinimumMember us-gaap:StockCompensationPlanMember 2019-04-01 2019-06-30 0000921299 srt:MinimumMember us-gaap:StockCompensationPlanMember 2018-04-01 2018-06-30 0000921299 srt:MinimumMember us-gaap:StockCompensationPlanMember 2019-01-01 2019-06-30 0000921299 srt:MinimumMember us-gaap:StockCompensationPlanMember 2018-01-01 2018-06-30 0000921299 srt:MaximumMember us-gaap:StockCompensationPlanMember 2019-04-01 2019-06-30 0000921299 srt:MaximumMember us-gaap:StockCompensationPlanMember 2018-04-01 2018-06-30 0000921299 srt:MaximumMember us-gaap:StockCompensationPlanMember 2019-01-01 2019-06-30 0000921299 srt:MaximumMember us-gaap:StockCompensationPlanMember 2018-01-01 2018-06-30 0000921299 us-gaap:StockCompensationPlanMember 2019-04-01 2019-06-30 0000921299 us-gaap:StockCompensationPlanMember 2018-04-01 2018-06-30 0000921299 us-gaap:StockCompensationPlanMember 2019-01-01 2019-06-30 0000921299 us-gaap:StockCompensationPlanMember 2018-01-01 2018-06-30 0000921299 fgen:AstellasMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000921299 fgen:AstellasMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000921299 fgen:AstellasMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0000921299 fgen:AstellasMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0000921299 fgen:AstellasMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000921299 fgen:AstellasMember us-gaap:CollaborativeArrangementMember 2018-12-31 0000921299 fgen:AstellasMember fgen:APIShipmentMember fgen:AstellasCollaborationAgreementMember 2018-12-31 0000921299 srt:EuropeMember fgen:AstellasMember 2019-06-30 0000921299 srt:EuropeMember 2019-06-30 shares iso4217:USD iso4217:USD shares fgen:Segment pure fgen:Lease fgen:Milestone false 2019 Q2 FIBROGEN INC 0000921299 --12-31 Large Accelerated Filer true false

true

false

2019

P4Y1M6D

P1Y4M24D

P5Y3M18D

P5Y4M24D

P5Y3M18D

P5Y4M24D

P6M

P2Y

0.481

0.473

0.481

0.473

0.621

0.753

0.621

0.753

0.013

0.008

0.013

0.008

0.029

0.026

0.029

0.026

10-Q 2019-06-30 1-36740 DE 77-0357827 409 Illinois Street San Francisco CA 94158 415 978-1200 Common Stock, $0.01 par value FGEN NASDAQ Yes Yes false false false 86915996

74587000

89258000

586174000

532144000

4311000

47210000

6453000

63684000

1981000

127981000

136596000

4929000

805791000

690015000

4145000 4145000

10915000

55820000

44865000

127198000

44536000

4814000

3420000

915066000

880598000

4060000

9139000

781000

444000

66545000

66123000

136000

13771000

12071000

82812000

89033000

1342000 97157000 16846000 16798000

3038000

102926000

136109000

43780000

19058000

9993000

266764000

352128000

0.01

125000000

0.01

225000000

86847000

85432000

868000

854000

1265783000

1226453000

-462000

-2281000

-637158000

-715827000

629031000

509199000

19271000

648302000

528470000

915066000

880598000

117470000 14323000 117470000 14323000

150581000

14323000

150581000

14323000

17223000 6145000 22082000 11317000

40985000

29629000

64848000

61553000

191566000

43952000

215429000

75876000

52008000

52138000

102505000

109112000

26739000

15055000

48948000

30605000

78747000

67193000

151453000

139717000

112819000

-23241000

63976000

-63841000

736000

2750000

1507000

5519000

4125000

2645000

8303000

4717000

3389000

-105000

6796000

-802000

116208000

-23346000

70772000

-64643000

205000

75000

180000

174000

116003000

-23421000

70592000

-64817000

1.34

-0.28

0.82

-0.78

1.26

-0.28

0.77

-0.78

86445000

83750000

86077000

83309000

91728000

83750000

92069000

83309000

116003000

-23421000

70592000

-64817000

-180000

958000

111000

431000

655000

53000

1097000

3000

475000

1011000

1208000

434000

116478000

-22410000

71800000

-64383000

86129564

861000

1242460000

-937000

-753161000

19271000

508494000

116003000

655000

-180000

717508 7000 5681000 0 0 0 5688000

17642000

86847072

868000

1265783000

-462000

-637158000

19271000

648302000

83420625

834000

1173109000

-3622000

-670803000

19271000

518789000

-23421000

53000

958000

762219 8000 5184000 0 0 0 5192000

13231000

84182844

842000

1191524000

-2611000

-694224000

19271000

514802000

85432102

854000

1226453000

-2281000

-715827000

19271000

528470000

8688000

611000

-611000

70592000

1097000

111000

1414970 14000 5258000 0 0 0 5272000

34072000

86847072

868000

1265783000

-462000

-637158000

19271000

648302000

82498128

825000

1160094000

-1795000

-630657000

19271000

547738000

-1250000

1250000

-64817000

3000

431000

1684716 17000 7321000 0 0 0 7338000

24109000

84182844

842000

1191524000

-2611000

-694224000

19271000

514802000

70592000

-64817000

5523000

3083000

5140000

2457000

-463000

59000 -1127000

10000

-53000

34072000

24109000

1074000

87000

-57231000

21737000

1981000

131803000

13197000

200000

722000

-5079000

-2287000

917000

-13371000

-46818000

20370000

0 25000 241000 0

8519000

1135000

-6172000

-66927000

2206000

3705000

184000

105511000 98000

8167000

100000000

25390000

-7717000

29938000

5850000

202000

201000

8065000

10005000

13337000

17343000

-780000

7137000

-2000

-3000

-14671000

-29855000

89258000

673658000

74587000

643803000

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> 1.</td> <td valign="top"> Significant Accounting Policies</td></tr></table></div> Description of Operations FibroGen, Inc. (“FibroGen” or the “Company”), incorporated in 1993 in Delaware and headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China (“China”), is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (“HIF”), connective tissue growth factor (“CTGF”) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase (“HIF-PH”) activity, completing Phase 3 clinical development worldwide for the treatment of anemia in chronic kidney disease (“CKD”), with a New Drug Application (“NDA”) now approved by the National Medical Products Administration (“NMPA”) in China. The Company and its collaboration partners AstraZeneca AB (“AstraZeneca”) and Astellas Pharma Inc. (“Astellas”) are in the process of preparing an NDA for submission to the United States (“U.S.”) Food and Drug Administration (“FDA”) and a Marketing Authorization Application (“MAA”) for submission to the European Medicines Agency (“EMA”) this year. Astellas submitted an NDA for the treatment of anemia in CKD patients on dialysis in Japan in September 2018, which is currently under review by the Pharmaceuticals and Medical Devices Agency (“PMDA”). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (“MDS”). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (“IPF”), and advancing towards Phase 3 for the treatment of pancreatic cancer. Pamrevlumab is also currently in a Phase 2 trial for Duchenne muscular dystrophy (“DMD”). FibroGen is also developing a biosynthetic cornea in China. Basis of Presentation and Principles of Consolidation The condensed consolidated financial statements include the accounts of FibroGen, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. (“FibroGen China”). All inter-company transactions and balances have been eliminated in consolidation. The Company operates in one segment — the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2018 (“2018 Form 10-K”). The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2018 Form 10-K, except for the following: Leases The Company determines if an arrangement is a lease at inception date when it is given control of the underlying assets. The Company elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of 12 months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The Company’s building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (“ASC”) 842 - Leases (“ASC 842”) are accounted for as finance leases under the requirements of ASC 842. Lease right-of-use (“ROU”) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As its leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company will reassess the incremental borrowing rate periodically for application to any new leases or lease modifications or if any company-specific or general business conditions warrant. Lease ROU assets include any lease payments made and initial direct costs incurred. The Company has lease agreements with lease and non-lease components. The Company generally accounts for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms. Regarding leases denominated in a foreign currency, the related ROU assets and the corresponding ROU asset amortization costs are remeasured using the exchange rate in effect at the date of initial recognition; the related lease liabilities are remeasured using the exchange rate in effect at the end of the reporting period; the lease costs and interest expenses related to lease liability accretion are remeasured using average exchange rates for the reporting period. Finance leases are included in finance lease ROU assets, finance lease liabilities, current and non-current on the Company’s consolidated balance sheets. Operating leases are included in other assets, accrued and other current liabilities, and other long-term liabilities on the Company’s consolidated balance sheets. Inventories Inventories are stated at the lower of cost and net realizable value. The cost of inventories are determined using full absorption and standard costing, which approximates cost based on a first-in, first-out method. The Company reviews the standard costs of raw materials, work-in-process and finished goods periodically, and at least annually, to ensure that its inventories approximate current actual costs. The cost of inventories includes direct material costs, direct labor and manufacturing overhead. The Company regularly reviews the need to adjust the carrying value of excess and obsolete inventories to their estimated net realizable value, if less than cost, based primarily on its estimated forecast of product demand and product expiration period. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue and deferred revenue, estimates of accruals related to clinical trial costs, valuation allowances for deferred tax assets, and valuation and recognition of stock-based compensation. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company’s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented. Net Income (Loss) per Share The following is a reconciliation of the basic and diluted net income (loss) per share calculation for the periods presented (in thousands, except per share data): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,003</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,421</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,592</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,817</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute net income <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (loss) per share:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,445</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,750</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,077</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,309</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilutive effect of potential common shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,283</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,992</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,728</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,750</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,069</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,309</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.28</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.82</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.28</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.77</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> Diluted shares did not include 4.4 million and 3.4 million securities for the three and six months ended June 30, 2019, and 8.8 million and 8.7 million securities for the three and six months ended June 30, 2018, respectively, as they were anti-dilutive. Recently Issued and Adopted Accounting Guidance ASC 842 In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“ASU 2016-02”). Under this guidance, an entity is required to recognize ROU assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which provides entities the option to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the above guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment at the beginning of the first quarter of 2019. The Company elected the optional transition method under the guidance, which allowed it to continue applying previous lease guidance (ASC 840) for the comparative prior year periods presentation in the year of adoption. Accordingly, the Company recognized a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In addition, the Company elected the package of transitional practical expedients permitted under the transition guidance under ASC 842, which among other things allows the Company to carry forward its historical lease classification, and not to reassess initial direct costs for any existing leases. Meanwhile, the Company did not elect the hindsight practical expedient because it has limited number of leases, lease terms are straightforward, and most of its lease renewals are undefined until negotiated. In addition, the Company has elected the short term accounting policy practical expedient and does not apply the balance sheet recognition requirements for short-term leases (excluding expenses relating to leases with a lease term of one month or less), by class of underlying asset to which the right of use relates. The Company has not elected the non-lease components practical expedient, and therefore accounts for each lease component separately from the non-lease components. Upon adoption of ASC 842, the Company classified its existing building leases that were previously accounted for as build-to-suit arrangements as finance leases, and applied the transition guidance. Accordingly, the Company derecognized the assets and liabilities previously recognized under ASC 840 build-to-suit guidance. In addition, as a result of applying the transition guidance, the Company also recorded an adjustment to the accumulated depreciation of related leasehold improvements to reflect a change in estimated useful life from the building life to the shorter of the building life and remaining lease term. Differences between the assets and liabilities derecognized were recorded to the opening balance of retained earnings. The impacts to the select line items from the Company’s condensed consolidated balance sheet upon adoption of the ASC 842 guidance are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of Adjustment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New Lease Guidance Adoption Adjustment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease assets - building shell, cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,880</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease assets - building shell, <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,476</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change of useful life - leasehold improvements, <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accumulated depreciation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,877</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease ROU assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,597</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease ROU assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">730</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - deferred rent, current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(619</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(545</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease liabilities, current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,499</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term portion of lease obligations</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,613</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - deferred rent, non-current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,038</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,884</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease liabilities, non-current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative decrease to accumulated deficit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,688</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The adoption of this guidance did not have a material impact to the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the six months ended June 30, 2019. ASU 2018-02 In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This guidance allows for the reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects arising from the reduction of the U.S. federal statutory income tax rate from 35% to 21%. This guidance was effective for annual reporting period beginning after December 15, 2018, including interim periods. The Company adopted this guidance on January 1, 2019 using the modified retrospective approach. The impacts, based on the aggregate portfolio approach, to the Company’s accumulated other comprehensive loss and accumulated deficit upon adoption of this guidance are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Deficit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,281</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(715,827</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of change in accounting principle <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon adoption of ASU 2018-02</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(611</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opening balance as of January 1, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,670</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(716,438</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> The adoption of this guidance had no impact to the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the six months ended June 30, 2019. SEC Disclosure Requirement In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, “Disclosure Update and Simplification,” amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements. Under the amendments, the changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. This analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is presented. This final rule was effective as of November 5, 2018. Accordingly, the Company included the condensed consolidated statements of changes in stockholders’ equity in Form 10-Q starting the first quarter of 2019. ASU 2018-07 In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This guidance expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance was effective for annual reporting period beginning after December 15, 2018, including interim periods. The Company adopted this guidance on January 1, 2019, and the adoption of this guidance had no impact to the Company’s consolidated financial statements. Recently Issued Accounting Guidance Not Yet Adopted In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance should be applied either retrospectively or prospectively, and is effective for annual reporting period beginning after December 15, 2019 including interim periods, with early adoption permitted. The Company is currently evaluating the impact on its consolidated financial statements upon the adoption of this guidance. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. This guidance amends existing fair value measurement disclosure requirements by adding, changing, or removing certain disclosures. This guidance is effective for annual reporting period beginning after December 15, 2019 including interim periods, with early adoption permitted. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently in April 2019, the FASB issued amendments to the guidance, ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and in May 2019, ASU 2019-05, Financial Instruments – Credit Losses (Topic 326): Targeted Transition Relief. This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. ASU 2019-04 clarifies that equity instruments without readily determinable fair values for which an entity has elected the measurement alternative should be remeasured to fair value as of the date that an observable transaction occurred. ASU 2019-05 provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. The amendments should be applied on either a prospective transition or modified-retrospective approach depending on the subtopic. This guidance is effective for the annual reporting period beginning after December 15, 2019, including interim periods within that reporting period. The Company does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.

Leases The Company determines if an arrangement is a lease at inception date when it is given control of the underlying assets. The Company elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of 12 months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The Company’s building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (“ASC”) 842 - Leases (“ASC 842”) are accounted for as finance leases under the requirements of ASC 842. Lease right-of-use (“ROU”) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As its leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company will reassess the incremental borrowing rate periodically for application to any new leases or lease modifications or if any company-specific or general business conditions warrant. Lease ROU assets include any lease payments made and initial direct costs incurred. The Company has lease agreements with lease and non-lease components. The Company generally accounts for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms. Regarding leases denominated in a foreign currency, the related ROU assets and the corresponding ROU asset amortization costs are remeasured using the exchange rate in effect at the date of initial recognition; the related lease liabilities are remeasured using the exchange rate in effect at the end of the reporting period; the lease costs and interest expenses related to lease liability accretion are remeasured using average exchange rates for the reporting period. Finance leases are included in finance lease ROU assets, finance lease liabilities, current and non-current on the Company’s consolidated balance sheets. Operating leases are included in other assets, accrued and other current liabilities, and other long-term liabilities on the Company’s consolidated balance sheets.

P12M

Net Income (Loss) per Share The following is a reconciliation of the basic and diluted net income (loss) per share calculation for the periods presented (in thousands, except per share data): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,003</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,421</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,592</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,817</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute net income <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (loss) per share:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,445</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,750</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,077</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,309</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilutive effect of potential common shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,283</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,992</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,728</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,750</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,069</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,309</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.28</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.82</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.28</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.77</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> Diluted shares did not include 4.4 million and 3.4 million securities for the three and six months ended June 30, 2019, and 8.8 million and 8.7 million securities for the three and six months ended June 30, 2018, respectively, as they were anti-dilutive.

The following is a reconciliation of the basic and diluted net income (loss) per share calculation for the periods presented (in thousands, except per share data): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,003</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,421</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,592</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,817</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute net income <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (loss) per share:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,445</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,750</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,077</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,309</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilutive effect of potential common shares</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,283</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,992</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,728</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,750</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,069</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,309</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.28</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.82</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.28</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.77</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>

116003000

-23421000

70592000

-64817000

86445000

83750000

86077000

83309000

5283000

5992000

91728000

83750000

92069000

83309000

1.34

-0.28

0.82

-0.78

1.26

-0.28

0.77

-0.78

4400000

3400000

8800000

8700000

Recently Issued and Adopted Accounting Guidance ASC 842 In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“ASU 2016-02”). Under this guidance, an entity is required to recognize ROU assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which provides entities the option to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the above guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment at the beginning of the first quarter of 2019. The Company elected the optional transition method under the guidance, which allowed it to continue applying previous lease guidance (ASC 840) for the comparative prior year periods presentation in the year of adoption. Accordingly, the Company recognized a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In addition, the Company elected the package of transitional practical expedients permitted under the transition guidance under ASC 842, which among other things allows the Company to carry forward its historical lease classification, and not to reassess initial direct costs for any existing leases. Meanwhile, the Company did not elect the hindsight practical expedient because it has limited number of leases, lease terms are straightforward, and most of its lease renewals are undefined until negotiated. In addition, the Company has elected the short term accounting policy practical expedient and does not apply the balance sheet recognition requirements for short-term leases (excluding expenses relating to leases with a lease term of one month or less), by class of underlying asset to which the right of use relates. The Company has not elected the non-lease components practical expedient, and therefore accounts for each lease component separately from the non-lease components. Upon adoption of ASC 842, the Company classified its existing building leases that were previously accounted for as build-to-suit arrangements as finance leases, and applied the transition guidance. Accordingly, the Company derecognized the assets and liabilities previously recognized under ASC 840 build-to-suit guidance. In addition, as a result of applying the transition guidance, the Company also recorded an adjustment to the accumulated depreciation of related leasehold improvements to reflect a change in estimated useful life from the building life to the shorter of the building life and remaining lease term. Differences between the assets and liabilities derecognized were recorded to the opening balance of retained earnings. The impacts to the select line items from the Company’s condensed consolidated balance sheet upon adoption of the ASC 842 guidance are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of Adjustment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New Lease Guidance Adoption Adjustment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease assets - building shell, cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,880</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease assets - building shell, <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,476</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change of useful life - leasehold improvements, <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accumulated depreciation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,877</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease ROU assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,597</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease ROU assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">730</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - deferred rent, current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(619</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(545</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease liabilities, current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,499</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term portion of lease obligations</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,613</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - deferred rent, non-current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,038</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,884</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease liabilities, non-current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative decrease to accumulated deficit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,688</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The adoption of this guidance did not have a material impact to the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the six months ended June 30, 2019. ASU 2018-02 In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This guidance allows for the reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects arising from the reduction of the U.S. federal statutory income tax rate from 35% to 21%. This guidance was effective for annual reporting period beginning after December 15, 2018, including interim periods. The Company adopted this guidance on January 1, 2019 using the modified retrospective approach. The impacts, based on the aggregate portfolio approach, to the Company’s accumulated other comprehensive loss and accumulated deficit upon adoption of this guidance are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Deficit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,281</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(715,827</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of change in accounting principle <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon adoption of ASU 2018-02</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(611</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opening balance as of January 1, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,670</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(716,438</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> The adoption of this guidance had no impact to the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the six months ended June 30, 2019. SEC Disclosure Requirement In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, “Disclosure Update and Simplification,” amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements. Under the amendments, the changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. This analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is presented. This final rule was effective as of November 5, 2018. Accordingly, the Company included the condensed consolidated statements of changes in stockholders’ equity in Form 10-Q starting the first quarter of 2019. ASU 2018-07 In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This guidance expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance was effective for annual reporting period beginning after December 15, 2018, including interim periods. The Company adopted this guidance on January 1, 2019, and the adoption of this guidance had no impact to the Company’s consolidated financial statements.

The impacts to the select line items from the Company’s condensed consolidated balance sheet upon adoption of the ASC 842 guidance are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of Adjustment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New Lease Guidance Adoption Adjustment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease assets - building shell, cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,880</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease assets - building shell, <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,476</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change of useful life - leasehold improvements, <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accumulated depreciation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,877</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease ROU assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,597</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease ROU assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">730</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - deferred rent, current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(619</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(545</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease liabilities, current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease liabilities, current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,499</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term portion of lease obligations</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - build-to-suit lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,613</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition - deferred rent, non-current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,038</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - finance lease liabilities, non-current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,884</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition - operating lease liabilities, non-current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative decrease to accumulated deficit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,688</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

-53880000

13476000

-38877000

49597000

730000

-619000 -545000 404000

11499000

-95613000

-3038000

49884000

250000

8688000

0.35

0.21

The impacts, based on the aggregate portfolio approach, to the Company’s accumulated other comprehensive loss and accumulated deficit upon adoption of this guidance are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Deficit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,281</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(715,827</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of change in accounting principle <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon adoption of ASU 2018-02</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(611</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opening balance as of January 1, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,670</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(716,438</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>

-2281000

-715827000

611000

-611000

-1670000

-716438000

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> 2.</td> <td valign="top"> Collaboration Agreements </td></tr></table></div> Astellas Agreements Japan Agreement In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (“Japan Agreement”). Under this agreement, Astellas paid license fees and other consideration totaling $40.1 million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5 million in potential milestone payments, comprised of (i) up to $22.5 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii) up to $95.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii) up to approximately $15.0 million in milestone payments upon the achievement of specified commercial sales milestone. The aggregate amount of such consideration received through June 30, 2019 totals $77.6 million. Europe Agreement In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (“Europe Agreement”). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). Under the Europe Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $425.0 million in potential milestone payments, comprised of (i) up to $90.0 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii) up to $335.0 million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of such consideration received through June 30, 2019 totals $410.0 million. In the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of chemotherapy induced anemia (“CIA”). AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas. For revenue recognition purposes, the Company concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the end of 2023 to allow for development of this indication. During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiac event (“MACE”) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA during their fiscal year 2019, which ends on March 31, 2020, following the Company’s NDA submission to the FDA. The Company evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $129.5 million was recognized as revenue during the period from performance obligations satisfied or partially satisfied as of June 30, 2019. According to the Europe Agreement, these milestone payments are not billable to Astellas until the submission of an MAA, therefore this $130.0 million was recorded as an unbilled contract asset as of June 30, 2019. AstraZeneca Agreements U.S./Rest of World (“RoW”) Agreement Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (“U.S./RoW Agreement”). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i) up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events, $15.0 million of which was received in 2015 as a result of the finalization of its two audited pre-clinical carcinogenicity study reports, (ii) up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii) up to $160.0 million in milestone payments related to activity by potential competitors and (iv) up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of such consideration received through June 30, 2019 totals $389.0 million. As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company’s NDA submission to the FDA. The Company evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the U.S./ RoW Agreement in the second quarter of 2019, of which $41.6 million was recognized as revenue during the period from performance obligations satisfied or partially satisfied as of June 30, 2019. According to the U.S/RoW Agreement, this milestone payment is not billable to AstraZeneca until the Company has submitted the NDA, therefore this $50.0 million was recorded as an unbilled contract asset as of June 30, 2019. China Agreement Effective July 30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (“China Agreement”). Under the terms of the China Agreement, AstraZeneca paid upfront, non-contingent and non-refundable payments totaling $28.2 million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i) up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii) up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii) up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined) and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of such consideration received through June 30, 2019 totals $55.2 million. As mentioned above, in the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of CIA. AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas. In addition to CIA, in December 2018, anemia of chronic inflammation (“ACI”) and multiple myeloma (“MM”) have been approved for development by AstraZeneca and is expected to be fully funded by them. For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, ACI and MM under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications. On December 17, 2018, FibroGen (China) Medical Technology Development Co., Ltd. (“FibroGen Beijing”), received marketing authorization from the NMPA for roxadustat, a first-in-class HIF-PH inhibitor, for the treatment of anemia caused by CKD in patients on dialysis. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. On December 29, 2018, FibroGen Beijing received First Manufacturing Approval for a Product in the Field in the Territory, which allows production for Phase IV clinical studies, patients’ early experience programs, donation programs, as well as to supply products for testing and assessments required prior to launch. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. These milestones payments were received in the first quarter of 2019. Summary of Revenue Recognized Under the Collaboration Agreements The table below summarizes the accounting treatment for the various performance obligations pursuant to each of the Astellas and AstraZeneca agreements. License amounts identified below are included in the “License revenue” line item in the condensed consolidated statements of operations. All other elements identified below are included in the “Development and other revenue” line item in the condensed consolidated statements of operations. Amounts recognized as revenue under the Japan Agreement were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Performance Obligation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;" valign="bottom"> Japan</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.78%; border-top:solid 0.75pt #000000;" valign="top"> License revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.78%;" valign="top"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,591</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> Japan Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"> License</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,089</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,089</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,523</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,659</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> Total license and development revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,612</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,748</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> The revenue recognized under the Japan Agreement for the three months ended June 30, 2019 included an immaterial amount resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Japan Agreement includes $0.5 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period. Amounts recognized as revenue under the Europe Agreement were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Performance Obligation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom"> Europe</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%; border-top:solid 0.75pt #000000;" valign="bottom"> License revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,470</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,470</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%;" valign="bottom"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,854</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,003</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,467</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,726</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Europe Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-top:solid 0.75pt #000000;" valign="top"> License</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;" valign="top"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,304</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226,323</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:double 2.5pt transparent;" valign="top"> Total license and development revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712,255</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> *</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">714,274</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> _______________________________________________________________________________________________________ <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:2.5%;white-space:nowrap" valign="top"> * </td> <td valign="top"> Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of June 30, 2019, prepaid expenses and other current assets included a net unbilled contract asset of $128.0 million related to the Europe Agreement, which represents the net of the above-mentioned unbilled contract asset of $130.0 million, and $2.0 million of deferred revenue presented above.</td></tr></table></div> The revenue recognized under the Europe Agreement for the three months ended June 30, 2019 included an increase in revenue of $129.2 million resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Europe Agreement includes $9.4 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period. Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Performance Obligation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom"> U.S. / RoW and China</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%; border-top:solid 0.75pt #000000;" valign="top"> License revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,111</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,111</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%;" valign="top"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,762</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,479</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,766</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,202</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%;" valign="top"> China performance obligation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> U.S. / RoW and China Agreements</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.7%; border-top:solid 0.75pt #000000;" valign="top"> License</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">327,275</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">327,275</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.7%;" valign="top"> Co-development, information sharing & committee services</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">451,402</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,342</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,744</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.7%; border-bottom:solid 0.75pt transparent;" valign="top"> China performance obligation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,584</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,584</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.7%; border-bottom:double 2.5pt transparent;" valign="top"> Total license and development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">778,677</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,926</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> *</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">931,603</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> _______________________________________________________________________________________________________ <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> * </td> <td valign="top"> Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of June 30, 2019, long-term deferred revenue included $102.9 million related to the U.S./RoW and China Agreement, which represents the net of $152.9 million of deferred revenue presented above and the above-mentioned $50.0 million unbilled contract asset.</td></tr></table></div> The revenue recognized under the U.S./RoW Agreement for the three months ended June 30, 2019 included an increase in revenue of $41.9 million resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $149.4 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period, except for amounts allocated to the China performance obligation, which are expected to be recognized in a pattern consistent with estimated deliveries of the commercial drug product. Other Revenues Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for all periods presented. Deferred Revenue Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company’s collaboration partners for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. The long term portion of deferred revenue represents amounts to be recognized after one year through the end of the non-contingent performance period of the underlying performance obligations. Deferred revenue includes amounts allocated to the China unit of accounting under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China. As of December 31, 2018, such deferred revenue was included in long-term deferred revenue. As of June 30, 2019, following receipt of the Chinese Good Manufacturing Practices license by FibroGen Beijing in the second quarter of 2019, approximately $0.5 million of the related deferred revenue was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized as a result of the transfer of control of commercial drug product in China.

Astellas Agreements Japan Agreement In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (“Japan Agreement”). Under this agreement, Astellas paid license fees and other consideration totaling $40.1 million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5 million in potential milestone payments, comprised of (i) up to $22.5 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii) up to $95.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii) up to approximately $15.0 million in milestone payments upon the achievement of specified commercial sales milestone. The aggregate amount of such consideration received through June 30, 2019 totals $77.6 million. Europe Agreement In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (“Europe Agreement”). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). Under the Europe Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $425.0 million in potential milestone payments, comprised of (i) up to $90.0 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii) up to $335.0 million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of such consideration received through June 30, 2019 totals $410.0 million. In the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of chemotherapy induced anemia (“CIA”). AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas. For revenue recognition purposes, the Company concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the end of 2023 to allow for development of this indication. During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiac event (“MACE”) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA during their fiscal year 2019, which ends on March 31, 2020, following the Company’s NDA submission to the FDA. The Company evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $129.5 million was recognized as revenue during the period from performance obligations satisfied or partially satisfied as of June 30, 2019. According to the Europe Agreement, these milestone payments are not billable to Astellas until the submission of an MAA, therefore this $130.0 million was recorded as an unbilled contract asset as of June 30, 2019. AstraZeneca Agreements U.S./Rest of World (“RoW”) Agreement Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (“U.S./RoW Agreement”). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i) up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events, $15.0 million of which was received in 2015 as a result of the finalization of its two audited pre-clinical carcinogenicity study reports, (ii) up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii) up to $160.0 million in milestone payments related to activity by potential competitors and (iv) up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of such consideration received through June 30, 2019 totals $389.0 million. As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company’s NDA submission to the FDA. The Company evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the U.S./ RoW Agreement in the second quarter of 2019, of which $41.6 million was recognized as revenue during the period from performance obligations satisfied or partially satisfied as of June 30, 2019. According to the U.S/RoW Agreement, this milestone payment is not billable to AstraZeneca until the Company has submitted the NDA, therefore this $50.0 million was recorded as an unbilled contract asset as of June 30, 2019. China Agreement Effective July 30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (“China Agreement”). Under the terms of the China Agreement, AstraZeneca paid upfront, non-contingent and non-refundable payments totaling $28.2 million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i) up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii) up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii) up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined) and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of such consideration received through June 30, 2019 totals $55.2 million. As mentioned above, in the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of CIA. AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas. In addition to CIA, in December 2018, anemia of chronic inflammation (“ACI”) and multiple myeloma (“MM”) have been approved for development by AstraZeneca and is expected to be fully funded by them. For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, ACI and MM under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications. On December 17, 2018, FibroGen (China) Medical Technology Development Co., Ltd. (“FibroGen Beijing”), received marketing authorization from the NMPA for roxadustat, a first-in-class HIF-PH inhibitor, for the treatment of anemia caused by CKD in patients on dialysis. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. On December 29, 2018, FibroGen Beijing received First Manufacturing Approval for a Product in the Field in the Territory, which allows production for Phase IV clinical studies, patients’ early experience programs, donation programs, as well as to supply products for testing and assessments required prior to launch. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. These milestones payments were received in the first quarter of 2019.

40100000 132500000 22500000 95000000.0 15000000.0 77600000 320000000.0 425000000.0 90000000.0 335000000.0 0.50 low 20% range 410000000.0 2023 130000000.0

129500000

130000000.0

374000000.0 875000000.0 65000000.0 15000000.0 325000000.0 160000000.0 325000000.0 389000000.0 50000000.0

41600000

50000000.0

28200000 348500000 15000000.0 146000000.0 187500000 55200000 2024 6000000.0 6000000.0 Amounts recognized as revenue under the Japan Agreement were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Performance Obligation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;" valign="bottom"> Japan</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.78%; border-top:solid 0.75pt #000000;" valign="top"> License revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.78%;" valign="top"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,591</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

14323000

369000

1142000

615000

1591000

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> Japan Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"> License</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,089</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,089</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,523</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,659</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> Total license and development revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,612</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,748</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

74089000

74089000 14523000

136000

14659000 88612000

136000

88748000 500000 Amounts recognized as revenue under the Europe Agreement were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Performance Obligation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom"> Europe</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%; border-top:solid 0.75pt #000000;" valign="bottom"> License revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,470</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,470</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%;" valign="bottom"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,854</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,003</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,467</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,726</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

117470000

16854000

5003000

21467000

9726000

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Europe Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-top:solid 0.75pt #000000;" valign="top"> License</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;" valign="top"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,304</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226,323</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:double 2.5pt transparent;" valign="top"> Total license and development revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712,255</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> *</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">714,274</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> _______________________________________________________________________________________________________ <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:2.5%;white-space:nowrap" valign="top"> * </td> <td valign="top"> Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of June 30, 2019, prepaid expenses and other current assets included a net unbilled contract asset of $128.0 million related to the Europe Agreement, which represents the net of the above-mentioned unbilled contract asset of $130.0 million, and $2.0 million of deferred revenue presented above.</td></tr></table></div>

487951000

487951000 224304000

2019000

226323000 712255000

2019000

714274000 128000000.0

130000000.0

2000000.0

129200000

9400000 Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Agreement</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> Performance Obligation</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;" valign="bottom"> U.S. / RoW and China</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%; border-top:solid 0.75pt #000000;" valign="top"> License revenue</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,111</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,111</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%;" valign="top"> Development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,762</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,479</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,766</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,202</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.66%;" valign="top"> China performance obligation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div>

33111000

23762000

23479000

42766000

50202000

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> U.S. / RoW and China Agreements</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.7%; border-top:solid 0.75pt #000000;" valign="top"> License</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">327,275</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">327,275</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.7%;" valign="top"> Co-development, information sharing & committee services</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">451,402</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,342</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,744</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.7%; border-bottom:solid 0.75pt transparent;" valign="top"> China performance obligation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,584</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,584</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.7%; border-bottom:double 2.5pt transparent;" valign="top"> Total license and development revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">778,677</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,926</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> *</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">931,603</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> _______________________________________________________________________________________________________ <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> * </td> <td valign="top"> Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of June 30, 2019, long-term deferred revenue included $102.9 million related to the U.S./RoW and China Agreement, which represents the net of $152.9 million of deferred revenue presented above and the above-mentioned $50.0 million unbilled contract asset.</td></tr></table></div>

327275000

327275000 451402000

16342000

467744000 0

136584000

136584000 778677000

152926000

931603000

102900000

152900000

50000000.0

41900000

149400000 Other Revenues Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for all periods presented.

500000

The fair values of the Company’s financial assets that are measured on a recurring basis are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury notes and bills</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,891</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,263</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476,154</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,677</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,677</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,804</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,804</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term deposit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395,609</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,284</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630,893</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury notes and bills</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292,317</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,953</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517,270</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,484</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,484</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term deposit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,910</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,910</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303,576</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,863</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638,439</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

350891000

125263000

476154000

10677000

237000

33804000

80000000

30021000

395609000

235284000

630893000

292317000

224953000

517270000

10484000

234000

541000

80000000

29910000

303576000

334863000

638439000

The fair values of the Company’s financial liabilities that are carried at historical cost are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,745</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,745</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,105</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,105</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

1745000

98105000

96200000

1700000

P31M 2008

5000000.0

2023

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> 4.</td> <td valign="top"> Leases</td></tr></table></div> The Company currently has two building leases treated as finance leases. In 2006, the Company entered into a long-term property lease with Alexandria for its corporate headquarters in San Francisco, California, with an initial term of 15 years, scheduled to expire in 2023. The Company has an option to extend the lease for an additional 10 years through 2033. The lease contract provides for a fixed annual rent, with scheduled increases of two percent that occur on each anniversary of the rent commencement date. This lease requires the Company to pay all costs of ownership, operation, and maintenance of the premises, including without limitation all operating costs, insurance costs, and taxes. In 2013, the Company entered into a long-term property lease with Beijing Economic-Technological Development Area (“BDA”) Management Committee for a pilot plant located in Beijing Yizhuang Biomedical Park (“BYBP”) of BDA. The building is leased for an initial lease term of eight years, scheduled to expire in 2021. Renewal options are not specified within the lease contract. The lease contract provides for fixed quarterly rent payments, with scheduled increases that occur as detailed in the lease contract. This lease requires the Company to pay all operating and maintenance costs, and a fixed amount for property management fees. The Company currently has five additional real estate leases for space within a building, which are treated as operating leases. These leases have lease terms ranging from two to four years. These lease contracts provide for fixed quarterly rent payments, and require the Company to pay operating and maintenance costs, and a fixed amount for property management fees. In addition, the Company has several immaterial lease arrangements for office equipment, scientific devices and automobile leases, with contracted lease terms ranging from two to five years, treated as finance leases or operating leases, respectively. The Company’s lease assets and related lease liabilities were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,676</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,140</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets, net</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,536</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,212</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(273</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">939</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,475</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,071</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,780</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,788</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The components of lease expense were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Line Item</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.74%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right-of-use assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,571</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,140</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development, <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(237</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(824</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,106</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,854</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Supplemental cash flow information related to leases were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,053</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,850</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new lease liabilities:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,676</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,212</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Lease term and discount rate were as follows at June 30, 2019: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years):</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.43</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> Maturities of lease liabilities are as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 (Remaining six month period)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,002</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,089</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,678</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,878</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,523</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,170</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">973</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,319</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,851</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">937</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following information was previously disclosed under ASC 840 as of December 31, 2018: Future minimum lease payments under all non-cancelable operating lease obligations as of December 31, 2018 were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.82%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum payments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">717</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Future minimum lease payments, on a consolidated basis, under the Company’s facility lease financing obligations as of December 31, 2018 were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease financing <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">obligations</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,379</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,664</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,179</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,335</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,872</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum payments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,429</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

P15Y

2023

The Company has an option to extend the lease for an additional 10 years through 2033.

P10Y 2033 0.02

P8Y

2021 5

P2Y

P4Y

P2Y

P5Y

The Company’s lease assets and related lease liabilities were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,676</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,140</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets, net</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,536</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,212</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(273</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">939</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,475</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,071</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,780</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,788</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 49676000 5140000

44536000

1212000 273000

939000

45475000

12071000

591000

43780000

346000

56788000

2571000

5140000

609000

1249000

163000

289000

237000

824000

3106000

5854000

191000

1053000

5850000

49676000

1212000

0.0443

0.0474

Maturities of lease liabilities are as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 (Remaining six month period)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,002</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,089</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,678</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,878</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,523</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,170</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">973</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,319</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,851</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">937</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

7002000

313000

14089000

507000

13678000

134000

13878000

19000

12523000

61170000

973000

5319000

36000

55851000

937000

Future minimum lease payments under all non-cancelable operating lease obligations as of December 31, 2018 were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.82%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum payments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">717</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

444000

232000

25000

16000

717000

Future minimum lease payments, on a consolidated basis, under the Company’s facility lease financing obligations as of December 31, 2018 were as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease financing <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">obligations</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,379</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,664</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,179</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,335</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,872</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum payments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,429</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

14379000

14664000

14179000

14335000

12872000

70429000

<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> 5.</td> <td valign="top"> Balance Sheet Components</td></tr></table></div> Cash and Cash Equivalents Cash and cash equivalents consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,783</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,783</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury notes and bills</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,934</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,804</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,587</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,258</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> At June 30, 2019 and December 31, 2018, a total of $26.0 million and $21.9 million, respectively, of the Company’s cash and cash equivalents were held outside of the U.S. in its foreign subsidiaries to be used primarily for its China operations. Investments The Company’s investments consist of available-for-sale debt investments, marketable equity investments, a term deposit and a certificate of deposit. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding Gains</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding Losses</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury notes and bills</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">475,126</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476,154</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term deposit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,602</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,677</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595,853</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,236</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">597,089</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding Gains</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding Losses</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury notes and bills</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,296</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,336</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term deposit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,910</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,464</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,484</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587,885</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587,964</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> At June 30, 2019, all of the available-for-sale investments had contractual maturities within one year. The Company periodically reviews its available-for-sale investments and term deposit for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the three and six months ended June 30, 2019 and 2018, the Company did not recognize any other-than-temporary impairment loss. Inventories Inventories consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">797</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-progress</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,035</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The Company started capitalizing inventory costs in June 2019 when FibroGen China began productions of roxadustat for commercial sales purposes. There was no provision to write-down excess and obsolete inventory for the three months ended June 30, 2019. Prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled contract assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues from associated contracts</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unbilled contract assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,981</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,716</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,705</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,899</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,224</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,596</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,929</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The unbilled contract assets as of June 30, 2019 were related to two regulatory milestones totaling $130.0 million under the Europe Agreement with Astellas associated with the planned MAA submission in Europe, and a $50.0 million regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the planned NDA submission in the U.S. See Note 2 for details. Property and Equipment Property and equipment consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,250</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,200</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building shell</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,880</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,754</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,405</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,461</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,382</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,655</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,473</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,690</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,888</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,786</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,397</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,921</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,199</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,865</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,198</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> As of December 31, 2018, the Company had $53.9 million building shell cost and $13.5 million accumulated depreciation related to its building leases under build-to-suit arrangements. Upon the adoption of ASC 842 as of January 1, 2019, using the modified retrospective transition method, the Company derecognized these assets previously recognized under ASC 840 build-to-suit designation. Up to December 31, 2018, the leasehold improvements related to these building leases were depreciated over the life of the building under ASC 840. Upon the adoption of ASC 842, these leasehold improvements should have a useful life based on the lease term. As a result, at the adoption date, the Company recorded a cumulative adjustment of $38.9 million to the accumulated depreciation for these leasehold improvements so that their net balance equals the undepreciated amount had the useful life of the leasehold improvements always been equal to the lease terms. Refer to Note 1 for details. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical trial accruals</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,104</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,413</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related accruals</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,001</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,430</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property taxes and other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,778</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,588</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,074</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,537</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,545</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,123</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Cash and cash equivalents consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,783</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,783</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury notes and bills</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,934</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,804</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,587</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,258</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

40783000

38783000

49934000

33804000

541000

74587000

89258000

26000000.0

21900000

The Company’s investments consist of available-for-sale debt investments, marketable equity investments, a term deposit and a certificate of deposit. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding Gains</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding Losses</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury notes and bills</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">475,126</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476,154</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term deposit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,602</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,677</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595,853</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,236</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">597,089</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding Gains</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding Losses</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury notes and bills</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,296</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,336</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term deposit</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,000</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,910</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,464</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,484</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.96%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587,885</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">587,964</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

475126000

1028000

476154000

80000000

30000000

21000

30021000

10602000

75000

10677000

125000

112000

237000

595853000

1236000

597089000

467296000

109000

69000

467336000

80000000

30000000

90000

29910000

10464000

20000

10484000

125000

109000

234000

587885000

238000

159000

587964000

P1Y

Inventories consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">797</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-progress</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,035</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

797000

1035000

149000

1981000

Prepaid expenses and other current assets consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled contract assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues from associated contracts</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unbilled contract assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,981</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,716</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,705</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,899</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,224</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,596</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,929</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

180000000

52019000

127981000 0

4716000

2705000

3899000

2224000

136596000

4929000

130000000.0

50000000.0

Property and equipment consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,250</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,200</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building shell</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,880</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,754</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,405</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,461</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,382</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,655</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,473</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,778</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,690</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,888</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,786</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,397</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,921</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,199</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,865</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,198</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

101250000

101200000

53880000

16754000

16405000

8461000

8382000

6655000

6473000

5778000

5690000

1888000

367000

140786000

192397000

95921000

65199000

44865000

127198000

53900000

13500000

38900000

Accrued liabilities consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical trial accruals</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,104</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,413</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related accruals</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,001</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,430</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property taxes and other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,778</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,588</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,074</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,537</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,545</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,123</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

41104000 35413000

14001000

21430000

1778000 1095000

3588000

2648000

6074000

5537000

66545000

66123000

Stock-based compensation expense was allocated to research and development and selling, general and administrative expense as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,450</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,894</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,028</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,264</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,192</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,337</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,044</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,845</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.82%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,642</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,231</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,072</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,109</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

10450000

7894000

20028000

14264000

7192000

5337000

14044000

9845000

17642000

13231000

34072000

24109000

The assumptions used to estimate the fair value of stock options granted and purchases under the Company’s 2014 Employee Share Purchase Plan (“ESPP”) using the Black-Scholes option valuation model were as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.2</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.5</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.9</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.8</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.40</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.35</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.20</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.12</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPPs</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5 - 2.0</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5 - 2.0</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5 - 2.0</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5 - 2.0</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.1 - 62.1</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.3 - 75.3</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.1 - 62.1</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.3 - 75.3</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3 - 2.9</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8 - 2.6</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3 - 2.9</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8 - 2.6</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.07</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.25</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.65</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.67</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

0.682

0.675

0.679

0.678

0.020

0.028

0.025

0.027

24.40

31.35

33.20

32.12

19.07

15.25

19.65

13.67

134700000

139600000

20500000

25600000

800000

200000

1300000

700000

4300000

47200000

800000

400000

43800000

128000000.0

130000000.0

2000000.0

130000000.0

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Jul. 31, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	FGEN
Entity Registrant Name	FIBROGEN INC
Entity Central Index Key	0000921299
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.01 par value
Security Exchange Name	NASDAQ
Entity File Number	1-36740
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0357827
Entity Address, Address Line One	409 Illinois Street
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94158
City Area Code	415
Local Phone Number	978-1200
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock Shares Outstanding		86,915,996

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 74,587	$ 89,258
Short-term investments	586,174	532,144
Accounts receivable ($4,311 and $47,210 from a related party)	6,453	63,684
Inventories	1,981	0
Prepaid expenses and other current assets ($127,981 and $0 from a related party)	136,596	4,929
Total current assets	805,791	690,015
Restricted time deposits	4,145	4,145
Long-term investments	10,915	55,820
Property and equipment, net	44,865	127,198
Finance lease right-of-use assets	44,536	0
Other assets	4,814	3,420
Total assets	915,066	880,598
Current liabilities:
Accounts payable	4,060	9,139
Accrued and other current liabilities ($781 and $444 to a related party)	66,545	66,123
Deferred revenue	136	13,771
Finance lease liabilities, current	12,071	0
Total current liabilities	82,812	89,033
Long-term portion of lease obligations	1,342	97,157
Product development obligations	16,846	16,798
Deferred rent	0	3,038
Deferred revenue, net of current	102,926	136,109
Finance lease liabilities, non-current	43,780	0
Other long-term liabilities	19,058	9,993
Total liabilities	266,764	352,128
Commitments and Contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2019 and December 31, 2018	0	0
Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2019 and December 31, 2018; 86,847 and 85,432 shares issued and outstanding at June 30, 2019 and December 31, 2018	868	854
Additional paid-in capital	1,265,783	1,226,453
Accumulated other comprehensive loss	(462)	(2,281)
Accumulated deficit	(637,158)	(715,827)
Total stockholders’ equity	629,031	509,199
Non-controlling interests	19,271	19,271
Total equity	648,302	528,470
Total liabilities, stockholders’ equity and non-controlling interests	$ 915,066	$ 880,598

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Accounts receivable from related party	$ 4,311,000	$ 47,210,000
Prepaid expenses and other current assets from related party	127,981,000	0
Accrued and other current liabilities to related party	$ 781,000	$ 444,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	125,000,000	125,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	225,000,000	225,000,000
Common stock, shares issued	86,847,000	85,432,000
Common stock, shares outstanding	86,847,000	85,432,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue:
Total revenue	$ 191,566	$ 43,952	$ 215,429	$ 75,876
Operating expenses:
Research and development	52,008	52,138	102,505	109,112
Selling, general and administrative	26,739	15,055	48,948	30,605
Total operating expenses	78,747	67,193	151,453	139,717
Income (loss) from operations	112,819	(23,241)	63,976	(63,841)
Interest and other, net
Interest expense	(736)	(2,750)	(1,507)	(5,519)
Interest income and other, net	4,125	2,645	8,303	4,717
Total interest and other, net	3,389	(105)	6,796	(802)
Income (loss) before income taxes	116,208	(23,346)	70,772	(64,643)
Provision for income taxes	205	75	180	174
Net income (loss)	$ 116,003	$ (23,421)	$ 70,592	$ (64,817)
Net income (loss) per share:
Basic	$ 1.34	$ (0.28)	$ 0.82	$ (0.78)
Diluted	$ 1.26	$ (0.28)	$ 0.77	$ (0.78)
Weighted average number of common shares used to calculate net income (loss) per share:
Basic	86,445	83,750	86,077	83,309
Diluted	91,728	83,750	92,069	83,309
License Revenue [Member]
Revenue:
Total revenue	$ 150,581	$ 14,323	$ 150,581	$ 14,323
Development and Other Revenue [Member]
Revenue:
Total revenue	$ 40,985	$ 29,629	$ 64,848	$ 61,553

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - Astellas Agreement [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Collaboration services and other revenue from a related party	$ 17,223	$ 6,145	$ 22,082	$ 11,317
License and milestone revenue from a related party	$ 117,470	$ 14,323	$ 117,470	$ 14,323

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 116,003	$ (23,421)	$ 70,592	$ (64,817)
Other comprehensive income (loss):
Foreign currency translation adjustments	(180)	958	111	431
Available-for-sale investments:
Unrealized gain on investments, net of tax effect	655	53	1,097	3
Other comprehensive income, net of taxes	475	1,011	1,208	434
Comprehensive income (loss)	$ 116,478	$ (22,410)	$ 71,800	$ (64,383)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Noncontrolling Interests [Member]
Balance at Dec. 31, 2017	$ 547,738	$ 825	$ 1,160,094	$ (1,795)	$ (630,657)	$ 19,271
Balance, Shares at Dec. 31, 2017		82,498,128
Impact of change in accounting principle upon adoption \| ASU 2016-01 [Member]	0	$ 0	0	(1,250)	1,250	0
Net income (loss)	(64,817)	0	0	0	(64,817)	0
Change in unrealized gain or loss on investments	3	0	0	3	0	0
Foreign currency translation adjustments	431	0	0	431	0	0
Shares issued from stock plans, net of payroll taxes paid	7,338	$ 17	7,321	0	0	0
Shares issued from stock plans, net of payroll taxes paid, Shares		1,684,716
Stock-based compensation	24,109	$ 0	24,109	0	0	0
Balance at Jun. 30, 2018	514,802	$ 842	1,191,524	(2,611)	(694,224)	19,271
Balance, Shares at Jun. 30, 2018		84,182,844
Balance at Mar. 31, 2018	518,789	$ 834	1,173,109	(3,622)	(670,803)	19,271
Balance, Shares at Mar. 31, 2018		83,420,625
Net income (loss)	(23,421)	$ 0	0	0	(23,421)	0
Change in unrealized gain or loss on investments	53	0	0	53	0	0
Foreign currency translation adjustments	958	0	0	958	0	0
Shares issued from stock plans, net of payroll taxes paid	5,192	$ 8	5,184	0	0	0
Shares issued from stock plans, net of payroll taxes paid, Shares		762,219
Stock-based compensation	13,231	$ 0	13,231	0	0	0
Balance at Jun. 30, 2018	514,802	$ 842	1,191,524	(2,611)	(694,224)	19,271
Balance, Shares at Jun. 30, 2018		84,182,844
Balance at Dec. 31, 2018	528,470	$ 854	1,226,453	(2,281)	(715,827)	19,271
Balance, Shares at Dec. 31, 2018		85,432,102
Impact of change in accounting principle upon adoption \| ASU 2016-02 [Member]	8,688	$ 0	0	0	8,688	0
Impact of change in accounting principle upon adoption \| ASU 2018-02 [Member]	0	0	0	611	(611)	0
Net income (loss)	70,592	0	0	0	70,592	0
Change in unrealized gain or loss on investments	1,097	0	0	1,097	0	0
Foreign currency translation adjustments	111	0	0	111	0	0
Shares issued from stock plans, net of payroll taxes paid	5,272	$ 14	5,258	0	0	0
Shares issued from stock plans, net of payroll taxes paid, Shares		1,414,970
Stock-based compensation	34,072	$ 0	34,072	0	0	0
Balance at Jun. 30, 2019	648,302	$ 868	1,265,783	(462)	(637,158)	19,271
Balance, Shares at Jun. 30, 2019		86,847,072
Balance at Mar. 31, 2019	508,494	$ 861	1,242,460	(937)	(753,161)	19,271
Balance, Shares at Mar. 31, 2019		86,129,564
Net income (loss)	116,003	$ 0	0	0	116,003	0
Change in unrealized gain or loss on investments	655	0	0	655	0	0
Foreign currency translation adjustments	(180)	0	0	(180)	0	0
Shares issued from stock plans, net of payroll taxes paid	5,688	$ 7	5,681	0	0	0
Shares issued from stock plans, net of payroll taxes paid, Shares		717,508
Stock-based compensation	17,642	$ 0	17,642	0	0	0
Balance at Jun. 30, 2019	$ 648,302	$ 868	$ 1,265,783	$ (462)	$ (637,158)	$ 19,271
Balance, Shares at Jun. 30, 2019		86,847,072

XML 19 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities
Net income (loss)	$ 70,592	$ (64,817)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	5,523	3,083
Amortization of finance lease right-of-use assets	5,140	0
Net amortization of premium and discount on investments	(2,457)	463
Unrealized loss (gain) on cash equivalents and short-term equity investments	(59)	1,127
Loss (gain) on disposal of property and equipment	(10)	53
Stock-based compensation	34,072	24,109
Realized foreign currency gain	0	(1,074)
Realized gain on sales of available-for-sale securities	0	(87)
Changes in operating assets and liabilities:
Accounts receivable	57,231	(21,737)
Inventories	(1,981)	0
Prepaid expenses and other current assets	(131,803)	(13,197)
Other assets	(200)	(722)
Accounts payable	(5,079)	(2,287)
Accrued and other liabilities	917	(13,371)
Deferred revenue	(46,818)	20,370
Lease obligations	0	25
Accrued interest for finance lease liabilities	241	0
Other long-term liabilities	8,519	1,135
Net cash used in operating activities	(6,172)	(66,927)
Investing activities
Purchases of property and equipment	(2,206)	(3,705)
Proceeds from sale of property and equipment	0	184
Purchases of available-for-sale securities and term deposit	(105,511)	(98)
Proceeds from sales of available-for-sale securities	0	8,167
Proceeds from maturities of investments	100,000	25,390
Net cash provided by (used in) investing activities	(7,717)	29,938
Financing activities
Repayments of finance lease liabilities	(5,850)	0
Repayments of lease obligations	(202)	(201)
Cash paid for payroll taxes on restricted stock unit releases	(8,065)	(10,005)
Proceeds from issuance of common stock	13,337	17,343
Net cash provided by (used in) financing activities	(780)	7,137
Effect of exchange rate change on cash and cash equivalents	(2)	(3)
Net decrease in cash and cash equivalents	(14,671)	(29,855)
Total cash and cash equivalents at beginning of period	89,258	673,658
Total cash and cash equivalents at end of period	$ 74,587	$ 643,803

XML 20 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Significant Accounting Policies

1.	Significant Accounting Policies

Description of Operations

Basis of Presentation and Principles of Consolidation

Leases

Inventories

Use of Estimates

Net Income (Loss) per Share

The following is a reconciliation of the basic and diluted net income (loss) per share calculation for the periods presented (in thousands, except per share data):

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019		2018
Net income (loss)	$	116,003	$	(23,421	)	$	70,592	$	(64,817	)
Weighted average shares used to compute net income (loss) per share:
Basic		86,445		83,750			86,077		83,309
Dilutive effect of potential common shares		5,283		—			5,992		—
Diluted		91,728		83,750			92,069		83,309

Net income (loss) per share:
Basic	$	1.34	$	(0.28	)	$	0.82	$	(0.78	)
Diluted	$	1.26	$	(0.28	)	$	0.77	$	(0.78	)

Recently Issued and Adopted Accounting Guidance

ASC 842

The impacts to the select line items from the Company’s condensed consolidated balance sheet upon adoption of the ASC 842 guidance are as follows (in thousands):

Balance Sheet Line Item	Nature of Adjustment	New Lease Guidance Adoption Adjustment
Assets
Property and equipment, net	Derecognition - build-to-suit lease assets - building shell, cost	$	(53,880	)
	Derecognition - build-to-suit lease assets - building shell, accumulated depreciation		13,476
	Change of useful life - leasehold improvements, accumulated depreciation		(38,877	)
Finance lease right-of-use assets	Recognition - finance lease ROU assets		49,597
Other assets	Recognition - operating lease ROU assets		730
Liabilities
Accrued and other current liabilities	Derecognition - deferred rent, current		(619	)
	Derecognition - build-to-suit lease liabilities, current		(545	)
	Recognition - operating lease liabilities, current		404
Finance lease liabilities, current	Recognition - finance lease liabilities, current		11,499
Long-term portion of lease obligations	Derecognition - build-to-suit lease liabilities, non-current		(95,613	)
Deferred rent	Derecognition - deferred rent, non-current		(3,038	)
Finance lease liabilities, non-current	Recognition - finance lease liabilities, non-current		49,884
Other long-term liabilities	Recognition - operating lease liabilities, non-current		250
Stockholders’ equity
Accumulated deficit	Cumulative decrease to accumulated deficit	$	8,688

ASU 2018-02

	Accumulated Other Comprehensive Loss			Accumulated Deficit
Balance at December 31, 2018	$	(2,281	)	$	(715,827	)
Impact of change in accounting principle upon adoption of ASU 2018-02		611			(611	)
Opening balance as of January 1, 2019	$	(1,670	)	$	(716,438	)

The adoption of this guidance had no impact to the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the six months ended June 30, 2019.

SEC Disclosure Requirement

ASU 2018-07

Recently Issued Accounting Guidance Not Yet Adopted

XML 21 R10.htm IDEA: XBRL DOCUMENT

Collaboration Agreements

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration Agreements

2.	Collaboration Agreements

Astellas Agreements

Japan Agreement

Europe Agreement

AstraZeneca Agreements

U.S./Rest of World (“RoW”) Agreement

China Agreement

Summary of Revenue Recognized Under the Collaboration Agreements

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
Japan	License revenue	$	—	$	14,323	$	—	$	14,323
	Development revenue	$	369	$	1,142	$	615	$	1,591

Japan Agreement	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019		Total Consideration Through June 30, 2019
License	$	74,089	$	—	$	74,089
Development revenue		14,523		136		14,659
Total license and development revenue	$	88,612	$	136	$	88,748

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
Europe	License revenue	$	117,470	$	—	$	117,470	$	—
	Development revenue	$	16,854	$	5,003	$	21,467	$	9,726

Europe Agreement	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019			Total Consideration Through June 30, 2019
License	$	487,951	$	—		$	487,951
Development revenue		224,304		2,019			226,323
Total license and development revenue	$	712,255	$	2,019	*	$	714,274

_______________________________________________________________________________________________________

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
U.S. / RoW and China	License revenue	$	33,111	$	—	$	33,111	$	—
	Development revenue		23,762		23,479		42,766		50,202
	China performance obligation	$	—	$	—	$	—	$	—

U.S. / RoW and China Agreements	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019			Total Consideration Through June 30, 2019
License	$	327,275	$	—		$	327,275
Co-development, information sharing & committee services		451,402		16,342			467,744
China performance obligation		—		136,584			136,584
Total license and development revenue	$	778,677	$	152,926	*	$	931,603

_______________________________________________________________________________________________________

Other Revenues

Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for all periods presented.

Deferred Revenue

XML 22 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

3.	Fair Value Measurements

The fair values of the Company’s financial assets that are measured on a recurring basis are as follows (in thousands):

	June 30, 2019
	Level 1		Level 2		Level 3		Total
US treasury notes and bills	$	350,891	$	125,263	$	—	$	476,154
Bond and mutual funds		10,677		—		—		10,677
Equity investments		237		—		—		237
Money market funds		33,804		—		—		33,804
Term deposit		—		80,000		—		80,000
Certificate of deposit		—		30,021		—		30,021
Total	$	395,609	$	235,284	$	—	$	630,893

	December 31, 2018
	Level 1		Level 2		Level 3		Total
US treasury notes and bills	$	292,317	$	224,953	$	—	$	517,270
Bond and mutual funds		10,484		—		—		10,484
Equity investments		234		—		—		234
Money market funds		541		—		—		541
Term deposit		—		80,000		—		80,000
Certificate of deposit		—		29,910		—		29,910
Total	$	303,576	$	334,863	$	—	$	638,439

The fair values of the Company’s financial liabilities that are carried at historical cost are as follows (in thousands):

	June 30, 2019
	Level 1		Level 2		Level 3		Total
Lease obligations	$	—	$	—	$	1,745	$	1,745

	December 31, 2018
	Level 1		Level 2		Level 3		Total
Lease obligations	$	—	$	—	$	98,105	$	98,105

The fair values of the Company’s financial liabilities were derived by using an income approach, which required Level 3 inputs such as discounted estimated future cash flows.

There were no transfers of assets or liabilities between levels for any of the periods presented.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases

The Company currently has two building leases treated as finance leases.

The Company’s lease assets and related lease liabilities were as follows (in thousands):

	Balance Sheet Line Item	June 30, 2019
Assets
Finance:
Right-of-use assets - cost		$	49,676
Accumulated amortization			(5,140	)
Finance lease right-of-use assets, net	Finance lease right-of-use assets		44,536
Operating:
Right-of-use assets - cost			1,212
Accumulated amortization			(273	)
Operating lease right-of-use assets, net	Other assets		939
Total lease assets		$	45,475

Liabilities
Current:
Finance lease liabilities	Finance lease liabilities, current	$	12,071
Operating lease liabilities	Accrued and other current liabilities		591
Non-current:
Finance lease liabilities	Finance lease liabilities, non-current		43,780
Operating lease liabilities	Other long-term liabilities		346
Total lease liabilities		$	56,788

The components of lease expense were as follows (in thousands):

	Statement of Operations Line Item	Three Months Ended June 30, 2019			Six Months Ended June 30, 2019
Finance lease cost:
Amortization of right-of-use assets	Selling, general and administrative expenses	$	2,571		$	5,140
Interest on lease liabilities	Interest expense		609			1,249
Operating lease cost	Research and development, Selling, general and administrative expenses		163			289
Sublease income	Selling, general and administrative expenses		(237	)		(824	)
Total lease cost		$	3,106		$	5,854

Supplemental cash flow information related to leases were as follows (in thousands):

	Six Months Ended June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	191
Operating cash flows from finance leases		1,053
Financing cash flows from finance leases		5,850
Right-of-use assets obtained in exchange for new lease liabilities:
Finance leases		49,676
Operating leases	$	1,212

Lease term and discount rate were as follows at June 30, 2019:

	June 30, 2019
Weighted-average remaining lease term (years):
Finance leases		4.1
Operating leases		1.4
Weighted-average discount rate:
Finance leases		4.43	%
Operating leases		4.74	%

Maturities of lease liabilities are as follows:

Year Ending	Finance Leases			Operating Leases
2019 (Remaining six month period)	$	7,002		$	313
2020		14,089			507
2021		13,678			134
2022		13,878			19
2023		12,523			—
Total future lease payments		61,170			973
Less: Interest		(5,319	)		(36	)
Present value of lease liabilities	$	55,851		$	937

The following information was previously disclosed under ASC 840 as of December 31, 2018:

Future minimum lease payments under all non-cancelable operating lease obligations as of December 31, 2018 were as follows (in thousands):

Year Ending	Operating Leases
2019	$	444
2020		232
2021		25
2022		16
2023		—
Total minimum payments	$	717

Future minimum lease payments, on a consolidated basis, under the Company’s facility lease financing obligations as of December 31, 2018 were as follows (in thousands):

Year Ending	Lease financing obligations
2019	$	14,379
2020		14,664
2021		14,179
2022		14,335
2023		12,872
Total minimum payments	$	70,429

XML 24 R13.htm IDEA: XBRL DOCUMENT

Balance Sheet Components

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Components

5.	Balance Sheet Components

Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Cash	$	40,783	$	38,783
US treasury notes and bills		—		49,934
Money market funds		33,804		541
Total cash and cash equivalents	$	74,587	$	89,258

Investments

	June 30, 2019
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
US treasury notes and bills	$	475,126	$	1,028	$	—		$	476,154
Term deposit		80,000		—		—			80,000
Certificates of deposit		30,000		21		—			30,021
Bond and mutual funds		10,602		75		—			10,677
Equity investments		125		112		—			237
Total investments	$	595,853	$	1,236	$	—		$	597,089

	December 31, 2018
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
US treasury notes and bills	$	467,296	$	109	$	(69	)	$	467,336
Term deposit		80,000		—		—			80,000
Certificates of deposit		30,000		—		(90	)		29,910
Bond and mutual funds		10,464		20		—			10,484
Equity investments		125		109		—			234
Total investments	$	587,885	$	238	$	(159	)	$	587,964

Inventories

Inventories consisted of the following (in thousands):

	June 30, 2019
Raw materials	$	797
Work-in-progress		1,035
Finished goods		149
Total inventories	$	1,981

Prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Unbilled contract assets	$	180,000		$	—
Deferred revenues from associated contracts		(52,019	)		—
Net unbilled contract assets		127,981			—
Prepaid assets		4,716			2,705
Other current assets		3,899			2,224
Total prepaid expenses and other current assets	$	136,596		$	4,929

Property and Equipment

Property and equipment consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Leasehold improvements	$	101,250		$	101,200
Building shell		—			53,880
Laboratory equipment		16,754			16,405
Machinery		8,461			8,382
Computer equipment		6,655			6,473
Furniture and fixtures		5,778			5,690
Construction in progress		1,888			367
Total property and equipment	$	140,786		$	192,397
Less: accumulated depreciation		(95,921	)		(65,199	)
Property and equipment, net	$	44,865		$	127,198

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Preclinical and clinical trial accruals	$	41,104	$	35,413
Payroll and related accruals		14,001		21,430
Property taxes and other		1,778		1,095
Professional services		3,588		2,648
Other		6,074		5,537
Total accrued liabilities	$	66,545	$	66,123

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

6.	Stock-Based Compensation

Stock-based compensation expense was allocated to research and development and selling, general and administrative expense as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Research and development	$	10,450	$	7,894	$	20,028	$	14,264
Selling, general and administrative		7,192		5,337		14,044		9,845
Total stock-based compensation expense	$	17,642	$	13,231	$	34,072	$	24,109

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Stock Options
Expected term (in years)		5.3			5.4			5.3			5.4
Expected volatility		68.2	%		67.5	%		67.9	%		67.8	%
Risk-free interest rate		2.0	%		2.8	%		2.5	%		2.7	%
Expected dividend yield		—			—			—			—
Weighted average estimated fair value	$	24.40		$	31.35		$	33.20		$	32.12

ESPPs
Expected term (in years)	0.5 - 2.0			0.5 - 2.0			0.5 - 2.0			0.5 - 2.0
Expected volatility	48.1 - 62.1		%	47.3 - 75.3		%	48.1 - 62.1		%	47.3 - 75.3		%
Risk-free interest rate	1.3 - 2.9		%	0.8 - 2.6		%	1.3 - 2.9		%	0.8 - 2.6		%
Expected dividend yield		—			—			—			—
Weighted average estimated fair value	$	19.07		$	15.25		$	19.65		$	13.67

XML 26 R15.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

7.	Income Taxes

The provisions for income taxes for the three and six months ended June 30, 2019 and 2018 were due to foreign taxes.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2019

Related Party Transactions

8.	Related Party Transactions

XML 28 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Description of Operations

Basis of Presentation and Principles of Consolidation

Leases

Inventories

Use of Estimates

Net Income (Loss) per Share

The following is a reconciliation of the basic and diluted net income (loss) per share calculation for the periods presented (in thousands, except per share data):

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019		2018
Net income (loss)	$	116,003	$	(23,421	)	$	70,592	$	(64,817	)
Weighted average shares used to compute net income (loss) per share:
Basic		86,445		83,750			86,077		83,309
Dilutive effect of potential common shares		5,283		—			5,992		—
Diluted		91,728		83,750			92,069		83,309

Net income (loss) per share:
Basic	$	1.34	$	(0.28	)	$	0.82	$	(0.78	)
Diluted	$	1.26	$	(0.28	)	$	0.77	$	(0.78	)

Recently Issued and Adopted Accounting Guidance

ASC 842

The impacts to the select line items from the Company’s condensed consolidated balance sheet upon adoption of the ASC 842 guidance are as follows (in thousands):

Balance Sheet Line Item	Nature of Adjustment	New Lease Guidance Adoption Adjustment
Assets
Property and equipment, net	Derecognition - build-to-suit lease assets - building shell, cost	$	(53,880	)
	Derecognition - build-to-suit lease assets - building shell, accumulated depreciation		13,476
	Change of useful life - leasehold improvements, accumulated depreciation		(38,877	)
Finance lease right-of-use assets	Recognition - finance lease ROU assets		49,597
Other assets	Recognition - operating lease ROU assets		730
Liabilities
Accrued and other current liabilities	Derecognition - deferred rent, current		(619	)
	Derecognition - build-to-suit lease liabilities, current		(545	)
	Recognition - operating lease liabilities, current		404
Finance lease liabilities, current	Recognition - finance lease liabilities, current		11,499
Long-term portion of lease obligations	Derecognition - build-to-suit lease liabilities, non-current		(95,613	)
Deferred rent	Derecognition - deferred rent, non-current		(3,038	)
Finance lease liabilities, non-current	Recognition - finance lease liabilities, non-current		49,884
Other long-term liabilities	Recognition - operating lease liabilities, non-current		250
Stockholders’ equity
Accumulated deficit	Cumulative decrease to accumulated deficit	$	8,688

ASU 2018-02

	Accumulated Other Comprehensive Loss			Accumulated Deficit
Balance at December 31, 2018	$	(2,281	)	$	(715,827	)
Impact of change in accounting principle upon adoption of ASU 2018-02		611			(611	)
Opening balance as of January 1, 2019	$	(1,670	)	$	(716,438	)

The adoption of this guidance had no impact to the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the six months ended June 30, 2019.

SEC Disclosure Requirement

ASU 2018-07

Recently Issued Accounting Guidance Not Yet Adopted

Collaboration Arrangements

Astellas Agreements

Japan Agreement

Europe Agreement

AstraZeneca Agreements

U.S./Rest of World (“RoW”) Agreement

China Agreement

Other Revenues

Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for all periods presented.

Deferred Revenue

XML 29 R18.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation

The following is a reconciliation of the basic and diluted net income (loss) per share calculation for the periods presented (in thousands, except per share data):

	Three Months Ended June 30,					Six Months Ended June 30,
	2019		2018			2019		2018
Net income (loss)	$	116,003	$	(23,421	)	$	70,592	$	(64,817	)
Weighted average shares used to compute net income (loss) per share:
Basic		86,445		83,750			86,077		83,309
Dilutive effect of potential common shares		5,283		—			5,992		—
Diluted		91,728		83,750			92,069		83,309

Net income (loss) per share:
Basic	$	1.34	$	(0.28	)	$	0.82	$	(0.78	)
Diluted	$	1.26	$	(0.28	)	$	0.77	$	(0.78	)

ASU 2016-02 [Member]

Schedule of Impacts Upon Adoption of New Guidance

The impacts to the select line items from the Company’s condensed consolidated balance sheet upon adoption of the ASC 842 guidance are as follows (in thousands):

Balance Sheet Line Item	Nature of Adjustment	New Lease Guidance Adoption Adjustment
Assets
Property and equipment, net	Derecognition - build-to-suit lease assets - building shell, cost	$	(53,880	)
	Derecognition - build-to-suit lease assets - building shell, accumulated depreciation		13,476
	Change of useful life - leasehold improvements, accumulated depreciation		(38,877	)
Finance lease right-of-use assets	Recognition - finance lease ROU assets		49,597
Other assets	Recognition - operating lease ROU assets		730
Liabilities
Accrued and other current liabilities	Derecognition - deferred rent, current		(619	)
	Derecognition - build-to-suit lease liabilities, current		(545	)
	Recognition - operating lease liabilities, current		404
Finance lease liabilities, current	Recognition - finance lease liabilities, current		11,499
Long-term portion of lease obligations	Derecognition - build-to-suit lease liabilities, non-current		(95,613	)
Deferred rent	Derecognition - deferred rent, non-current		(3,038	)
Finance lease liabilities, non-current	Recognition - finance lease liabilities, non-current		49,884
Other long-term liabilities	Recognition - operating lease liabilities, non-current		250
Stockholders’ equity
Accumulated deficit	Cumulative decrease to accumulated deficit	$	8,688

ASU 2018-02 [Member]

Schedule of Impacts Upon Adoption of New Guidance

The impacts, based on the aggregate portfolio approach, to the Company’s accumulated other comprehensive loss and accumulated deficit upon adoption of this guidance are as follows (in thousands):

	Accumulated Other Comprehensive Loss			Accumulated Deficit
Balance at December 31, 2018	$	(2,281	)	$	(715,827	)
Impact of change in accounting principle upon adoption of ASU 2018-02		611			(611	)
Opening balance as of January 1, 2019	$	(1,670	)	$	(716,438	)

XML 30 R19.htm IDEA: XBRL DOCUMENT

Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2019

Japan [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
Japan	License revenue	$	—	$	14,323	$	—	$	14,323
	Development revenue	$	369	$	1,142	$	615	$	1,591

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

Japan Agreement	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019		Total Consideration Through June 30, 2019
License	$	74,089	$	—	$	74,089
Development revenue		14,523		136		14,659
Total license and development revenue	$	88,612	$	136	$	88,748

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
Europe	License revenue	$	117,470	$	—	$	117,470	$	—
	Development revenue	$	16,854	$	5,003	$	21,467	$	9,726

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

Europe Agreement	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019			Total Consideration Through June 30, 2019
License	$	487,951	$	—		$	487,951
Development revenue		224,304		2,019			226,323
Total license and development revenue	$	712,255	$	2,019	*	$	714,274

_______________________________________________________________________________________________________

U.S./RoW and China [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Performance Obligation	2019		2018		2019		2018
U.S. / RoW and China	License revenue	$	33,111	$	—	$	33,111	$	—
	Development revenue		23,762		23,479		42,766		50,202
	China performance obligation	$	—	$	—	$	—	$	—

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

U.S. / RoW and China Agreements	Cumulative Revenue Through June 30, 2019		Deferred Revenue at June 30, 2019			Total Consideration Through June 30, 2019
License	$	327,275	$	—		$	327,275
Co-development, information sharing & committee services		451,402		16,342			467,744
China performance obligation		—		136,584			136,584
Total license and development revenue	$	778,677	$	152,926	*	$	931,603

_______________________________________________________________________________________________________

XML 31 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair Values of Financial Assets Measured on Recurring Basis

The fair values of the Company’s financial assets that are measured on a recurring basis are as follows (in thousands):

	June 30, 2019
	Level 1		Level 2		Level 3		Total
US treasury notes and bills	$	350,891	$	125,263	$	—	$	476,154
Bond and mutual funds		10,677		—		—		10,677
Equity investments		237		—		—		237
Money market funds		33,804		—		—		33,804
Term deposit		—		80,000		—		80,000
Certificate of deposit		—		30,021		—		30,021
Total	$	395,609	$	235,284	$	—	$	630,893

	December 31, 2018
	Level 1		Level 2		Level 3		Total
US treasury notes and bills	$	292,317	$	224,953	$	—	$	517,270
Bond and mutual funds		10,484		—		—		10,484
Equity investments		234		—		—		234
Money market funds		541		—		—		541
Term deposit		—		80,000		—		80,000
Certificate of deposit		—		29,910		—		29,910
Total	$	303,576	$	334,863	$	—	$	638,439

Fair Values of Financial Liabilities Carried at Historical Cost

The fair values of the Company’s financial liabilities that are carried at historical cost are as follows (in thousands):

	June 30, 2019
	Level 1		Level 2		Level 3		Total
Lease obligations	$	—	$	—	$	1,745	$	1,745

	December 31, 2018
	Level 1		Level 2		Level 3		Total
Lease obligations	$	—	$	—	$	98,105	$	98,105

XML 32 R21.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Schedule of Lease Assets and Related Lease Liabilities

The Company’s lease assets and related lease liabilities were as follows (in thousands):

	Balance Sheet Line Item	June 30, 2019
Assets
Finance:
Right-of-use assets - cost		$	49,676
Accumulated amortization			(5,140	)
Finance lease right-of-use assets, net	Finance lease right-of-use assets		44,536
Operating:
Right-of-use assets - cost			1,212
Accumulated amortization			(273	)
Operating lease right-of-use assets, net	Other assets		939
Total lease assets		$	45,475

Liabilities
Current:
Finance lease liabilities	Finance lease liabilities, current	$	12,071
Operating lease liabilities	Accrued and other current liabilities		591
Non-current:
Finance lease liabilities	Finance lease liabilities, non-current		43,780
Operating lease liabilities	Other long-term liabilities		346
Total lease liabilities		$	56,788

Components of Lease Expense

The components of lease expense were as follows (in thousands):

	Statement of Operations Line Item	Three Months Ended June 30, 2019			Six Months Ended June 30, 2019
Finance lease cost:
Amortization of right-of-use assets	Selling, general and administrative expenses	$	2,571		$	5,140
Interest on lease liabilities	Interest expense		609			1,249
Operating lease cost	Research and development, Selling, general and administrative expenses		163			289
Sublease income	Selling, general and administrative expenses		(237	)		(824	)
Total lease cost		$	3,106		$	5,854

Schedule of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases were as follows (in thousands):

	Six Months Ended June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	191
Operating cash flows from finance leases		1,053
Financing cash flows from finance leases		5,850
Right-of-use assets obtained in exchange for new lease liabilities:
Finance leases		49,676
Operating leases	$	1,212

Schedule of Lease Term and Discount Rate

Lease term and discount rate were as follows at June 30, 2019:

	June 30, 2019
Weighted-average remaining lease term (years):
Finance leases		4.1
Operating leases		1.4
Weighted-average discount rate:
Finance leases		4.43	%
Operating leases		4.74	%

Schedule of Maturities of Finance and Operating Leases Liabilities

Maturities of lease liabilities are as follows:

Year Ending	Finance Leases			Operating Leases
2019 (Remaining six month period)	$	7,002		$	313
2020		14,089			507
2021		13,678			134
2022		13,878			19
2023		12,523			—
Total future lease payments		61,170			973
Less: Interest		(5,319	)		(36	)
Present value of lease liabilities	$	55,851		$	937

Schedule of Future Minimum Lease Payments Under all Non-Cancelable Operating Lease Obligations

Future minimum lease payments under all non-cancelable operating lease obligations as of December 31, 2018 were as follows (in thousands):

Year Ending	Operating Leases
2019	$	444
2020		232
2021		25
2022		16
2023		—
Total minimum payments	$	717

Schedule of Future Minimum Lease Payments on Consolidated Basis Under Company's Facility Financing Lease Obligations

Future minimum lease payments, on a consolidated basis, under the Company’s facility lease financing obligations as of December 31, 2018 were as follows (in thousands):

Year Ending	Lease financing obligations
2019	$	14,379
2020		14,664
2021		14,179
2022		14,335
2023		12,872
Total minimum payments	$	70,429

XML 33 R22.htm IDEA: XBRL DOCUMENT

Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Cash	$	40,783	$	38,783
US treasury notes and bills		—		49,934
Money market funds		33,804		541
Total cash and cash equivalents	$	74,587	$	89,258

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments

	June 30, 2019
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
US treasury notes and bills	$	475,126	$	1,028	$	—		$	476,154
Term deposit		80,000		—		—			80,000
Certificates of deposit		30,000		21		—			30,021
Bond and mutual funds		10,602		75		—			10,677
Equity investments		125		112		—			237
Total investments	$	595,853	$	1,236	$	—		$	597,089

	December 31, 2018
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
US treasury notes and bills	$	467,296	$	109	$	(69	)	$	467,336
Term deposit		80,000		—		—			80,000
Certificates of deposit		30,000		—		(90	)		29,910
Bond and mutual funds		10,464		20		—			10,484
Equity investments		125		109		—			234
Total investments	$	587,885	$	238	$	(159	)	$	587,964

Schedule of Inventory

Inventories consisted of the following (in thousands):

	June 30, 2019
Raw materials	$	797
Work-in-progress		1,035
Finished goods		149
Total inventories	$	1,981

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Unbilled contract assets	$	180,000		$	—
Deferred revenues from associated contracts		(52,019	)		—
Net unbilled contract assets		127,981			—
Prepaid assets		4,716			2,705
Other current assets		3,899			2,224
Total prepaid expenses and other current assets	$	136,596		$	4,929

Schedule of Property and Equipment

Property and equipment consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Leasehold improvements	$	101,250		$	101,200
Building shell		—			53,880
Laboratory equipment		16,754			16,405
Machinery		8,461			8,382
Computer equipment		6,655			6,473
Furniture and fixtures		5,778			5,690
Construction in progress		1,888			367
Total property and equipment	$	140,786		$	192,397
Less: accumulated depreciation		(95,921	)		(65,199	)
Property and equipment, net	$	44,865		$	127,198

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Preclinical and clinical trial accruals	$	41,104	$	35,413
Payroll and related accruals		14,001		21,430
Property taxes and other		1,778		1,095
Professional services		3,588		2,648
Other		6,074		5,537
Total accrued liabilities	$	66,545	$	66,123

XML 34 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Allocated Stock-Based Compensation Expense

Stock-based compensation expense was allocated to research and development and selling, general and administrative expense as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Research and development	$	10,450	$	7,894	$	20,028	$	14,264
Selling, general and administrative		7,192		5,337		14,044		9,845
Total stock-based compensation expense	$	17,642	$	13,231	$	34,072	$	24,109

Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Stock Options
Expected term (in years)		5.3			5.4			5.3			5.4
Expected volatility		68.2	%		67.5	%		67.9	%		67.8	%
Risk-free interest rate		2.0	%		2.8	%		2.5	%		2.7	%
Expected dividend yield		—			—			—			—
Weighted average estimated fair value	$	24.40		$	31.35		$	33.20		$	32.12

ESPPs
Expected term (in years)	0.5 - 2.0			0.5 - 2.0			0.5 - 2.0			0.5 - 2.0
Expected volatility	48.1 - 62.1		%	47.3 - 75.3		%	48.1 - 62.1		%	47.3 - 75.3		%
Risk-free interest rate	1.3 - 2.9		%	0.8 - 2.6		%	1.3 - 2.9		%	0.8 - 2.6		%
Expected dividend yield		—			—			—			—
Weighted average estimated fair value	$	19.07		$	15.25		$	19.65		$	13.67

XML 35 R24.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Additional Information (Detail) shares in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019 shares	Jun. 30, 2018 shares	Jun. 30, 2019 Segment shares	Jun. 30, 2018 shares	Dec. 31, 2017
Accounting Policies [Abstract]
Number of operating segment \| Segment			1
Short term investments maturity			12 months
Anti-dilutive shares \| shares	4.4	8.8	3.4	8.7
U.S. federal statutory income tax rate			21.00%		35.00%

XML 36 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Net income (loss)	$ 116,003	$ (23,421)	$ 70,592	$ (64,817)
Weighted average number of common shares used to calculate net income (loss) per share:
Basic	86,445	83,750	86,077	83,309
Dilutive effect of potential common shares	5,283	0	5,992	0
Diluted	91,728	83,750	92,069	83,309
Net income (loss) per share:
Basic	$ 1.34	$ (0.28)	$ 0.82	$ (0.78)
Diluted	$ 1.26	$ (0.28)	$ 0.77	$ (0.78)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 37 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Impacts to Condensed Consolidated Balance Sheet Upon Adoption of 842 Guidance (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Assets
Property and equipment, net	$ 44,865	$ 127,198
Finance lease right-of-use assets	44,536	0
Liabilities, stockholders’ equity and non-controlling interests
Finance lease liabilities, current	12,071	0
Deferred rent	0	3,038
Finance lease liabilities, non-current	43,780	0
Accumulated deficit	(637,158)	$ (715,827)
Derecognition Build to Suit Lease Assets [Member] \| Building Shell [Member]
Assets
Property and equipment, net	(53,880)
Derecognition Build to Suit Lease Assets Accumulated Depreciation [Member] \| Building Shell [Member]
Assets
Property and equipment, net	13,476
Leasehold Improvements Accumulated Depreciation [Member]
Assets
Property and equipment, net	(38,877)
Recognition Finance Lease Assets [Member]
Assets
Finance lease right-of-use assets	49,597
Recognition Operating Lease Assets [Member]
Assets
Other assets	730
Derecognition Deferred Rent Current [Member]
Liabilities, stockholders’ equity and non-controlling interests
Accrued and other current liabilities	(619)
Derecognition Build to Suit Lease Liabilities Current [Member]
Liabilities, stockholders’ equity and non-controlling interests
Accrued and other current liabilities	(545)
Recognition Operating Lease Liabilities Current [Member]
Liabilities, stockholders’ equity and non-controlling interests
Accrued and other current liabilities	404
Recognition Finance Lease Liabilities Current [Member]
Liabilities, stockholders’ equity and non-controlling interests
Finance lease liabilities, current	11,499
Derecognition Build to Suit Lease Liabilities Non Current [Member]
Liabilities, stockholders’ equity and non-controlling interests
Long-term portion of lease obligations	(95,613)
Derecognition Deferred Rent Non Current [Member]
Liabilities, stockholders’ equity and non-controlling interests
Deferred rent	(3,038)
Recognition Finance Lease Liabilities Non Current [Member]
Liabilities, stockholders’ equity and non-controlling interests
Finance lease liabilities, non-current	49,884
Recognition Operating Lease Liabilities Non Current [Member]
Liabilities, stockholders’ equity and non-controlling interests
Other long-term liabilities	250
Cumulative Decrease to Accumulated Deficit [Member]
Liabilities, stockholders’ equity and non-controlling interests
Accumulated deficit	$ 8,688

XML 38 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Impacts to Accumulated Other Comprehensive Loss and Accumulated Deficit Upon Adoption of Guidance (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Accounting Policy [Line Items]
Accumulated other comprehensive loss	$ (462)		$ (2,281)
Accumulated deficit	$ (637,158)		$ (715,827)
ASU 2018-02 [Member]
Accounting Policy [Line Items]
Accumulated other comprehensive loss		$ (1,670)
Accumulated deficit		(716,438)
Impact of change in accounting principle upon adoption of ASU 2018-02 [Member] \| ASU 2018-02 [Member]
Accounting Policy [Line Items]
Accumulated other comprehensive loss		611
Accumulated deficit		$ (611)

XML 39 R28.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Astellas Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		6 Months Ended	12 Months Ended	35 Months Ended	45 Months Ended
	Apr. 30, 2006	Jun. 30, 2005	Jun. 30, 2019	Dec. 31, 2018	Feb. 28, 2009	Feb. 28, 2009
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unbilled contract asset			$ 180,000	$ 0
Europe [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unbilled contract asset			130,000
Astellas Agreement [Member] \| Japan [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront, non-contingent and time-based payments received						$ 40,100
Potential milestone payments		$ 132,500
Commercial sales milestone		15,000
Aggregate consideration received			77,600
Astellas Agreement [Member] \| Japan [Member] \| Clinical and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments		22,500
Astellas Agreement [Member] \| Japan [Member] \| Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments		$ 95,000
Astellas Agreement [Member] \| Europe [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront, non-contingent and time-based payments received					$ 320,000
Potential milestone payments	$ 425,000
Aggregate consideration received			$ 410,000
Percentage of joint development costs committed to fund	50.00%
Additional consideration based on net sales description			low 20% range
Estimated joint development extended service period				2023
Transaction price and allocated to performance obligations			$ 130,000
Revenue during period from performance obligations			129,500
Unbilled contract asset			$ 130,000
Astellas Agreement [Member] \| Europe [Member] \| Clinical and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	$ 90,000
Astellas Agreement [Member] \| Europe [Member] \| Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	$ 335,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($) $ in Thousands				6 Months Ended	12 Months Ended
	Dec. 29, 2018	Dec. 17, 2018	Jul. 30, 2013	Jun. 30, 2019	Dec. 31, 2015	Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unbilled contract asset				$ 180,000		$ 0
AstraZeneca Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price and allocated to performance obligations				50,000
Revenue during period from performance obligations				41,600
Unbilled contract asset				50,000
AstraZeneca Agreements [Member] \| U.S./RoW [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront, non-contingent, non-refundable and time-based payments			$ 374,000
Potential milestone payments			875,000
Commercial sales milestone			325,000
Aggregate consideration received				389,000
Unbilled contract asset				50,000
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Clinical and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments			65,000
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments			325,000
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Deferred Approval Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments			160,000
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Development Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receipt of development milestone payment					$ 15,000
AstraZeneca Agreements [Member] \| China [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments			348,500
Aggregate consideration received				$ 55,200
Proceeds from upfront, non-contingent and non-refundable payments			28,200
Commercial sales and other events milestone			187,500
Estimated joint development extended service period				2024
Milestone payment, revenue recognition	$ 6,000	$ 6,000
AstraZeneca Agreements [Member] \| China [Member] \| Clinical and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments			15,000
AstraZeneca Agreements [Member] \| China [Member] \| Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments			$ 146,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	$ 191,566	$ 43,952	$ 215,429	$ 75,876
License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	150,581	14,323	150,581	14,323
Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	40,985	29,629	64,848	61,553
Astellas Agreement [Member] \| License Revenue [Member] \| Japan [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	0	14,323	0	14,323
Astellas Agreement [Member] \| License Revenue [Member] \| Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	117,470	0	117,470	0
Astellas Agreement [Member] \| Development Revenue [Member] \| Japan [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	369	1,142	615	1,591
Astellas Agreement [Member] \| Development Revenue [Member] \| Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	16,854	5,003	21,467	9,726
AstraZeneca Agreements [Member] \| China [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	0	0	0	0
AstraZeneca Agreements [Member] \| License Revenue [Member] \| U.S./RoW and China [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	33,111	0	33,111	0
AstraZeneca Agreements [Member] \| Development Revenue [Member] \| U.S./RoW and China [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue	$ 23,762	$ 23,479	$ 42,766	$ 50,202

XML 42 R31.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred Revenue	$ 52,019	$ 0
Astellas Agreement [Member] \| Japan [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	88,612
Deferred Revenue	136
Total Consideration	88,748
Astellas Agreement [Member] \| Japan [Member] \| Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	14,523
Deferred Revenue	136
Total Consideration	14,659
Astellas Agreement [Member] \| Japan [Member] \| License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	74,089
Deferred Revenue	0
Total Consideration	74,089
Astellas Agreement [Member] \| Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	712,255
Deferred Revenue	2,019
Total Consideration	714,274
Astellas Agreement [Member] \| Europe [Member] \| Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	224,304
Deferred Revenue	2,019
Total Consideration	226,323
Astellas Agreement [Member] \| Europe [Member] \| License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	487,951
Deferred Revenue	0
Total Consideration	487,951
AstraZeneca Agreements [Member] \| U.S./RoW and China [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	778,677
Deferred Revenue	152,926
Total Consideration	931,603
AstraZeneca Agreements [Member] \| U.S./RoW and China [Member] \| License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	327,275
Deferred Revenue	0
Total Consideration	327,275
AstraZeneca Agreements [Member] \| U.S./RoW and China [Member] \| Co-development, information sharing & committee services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	451,402
Deferred Revenue	16,342
Total Consideration	467,744
AstraZeneca Agreements [Member] \| U.S./RoW and China [Member] \| China performance obligation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	0
Deferred Revenue	136,584
Total Consideration	$ 136,584

XML 43 R32.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail) $ in Millions	3 Months Ended
	Jun. 30, 2019 USD ($)
Japan [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Remainder of transaction price, variable consideration from estimated future co-development billing	$ 0.5
Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Remainder of transaction price, variable consideration from estimated future co-development billing	9.4
Europe [Member] \| Astellas Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Changes in revenue due to prior period adjustment of performance obligations	129.2
U.S./RoW and China [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Remainder of transaction price, variable consideration from estimated future co-development billing	149.4
U.S./RoW and China [Member] \| AstraZeneca Agreements [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Changes in revenue due to prior period adjustment of performance obligations	$ 41.9

XML 44 R33.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Unbilled contract asset	$ 180,000	$ 0
Deferred revenue	52,019	0
Net unbilled contract asset	127,981	0
Long-term deferred revenue	102,926	$ 136,109
Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Unbilled contract asset	130,000
Astellas Agreement [Member] \| Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Unbilled contract asset	130,000
Deferred revenue	2,019
Astellas Agreement [Member] \| Europe [Member] \| Prepaid Expenses and Other Current Assets [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net unbilled contract asset	128,000
AstraZeneca Agreements [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Unbilled contract asset	50,000
AstraZeneca Agreements [Member] \| U.S./RoW [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Unbilled contract asset	50,000
Deferred revenue	152,900
Net unbilled contract asset	50,000
Long-term deferred revenue	$ 102,900

XML 45 R34.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Deferred Revenue - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Contract with Customer, Liability [Abstract]
Deferred revenue	$ 52,019	$ 0
AstraZeneca Agreements [Member] \| China [Member]
Contract with Customer, Liability [Abstract]
Deferred revenue	$ 500

XML 46 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	$ 597,089	$ 587,964
US treasury notes and bills [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	476,154	467,336
Bond and mutual funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	10,677	10,484
Equity investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	237	234
Term deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	80,000	80,000
Certificate of deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	30,021	29,910
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total fair value of financial assets	630,893	638,439
Fair Value, Measurements, Recurring [Member] \| US treasury notes and bills [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	476,154	517,270
Fair Value, Measurements, Recurring [Member] \| Bond and mutual funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	10,677	10,484
Fair Value, Measurements, Recurring [Member] \| Equity investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	237	234
Fair Value, Measurements, Recurring [Member] \| Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value disclosure	33,804	541
Fair Value, Measurements, Recurring [Member] \| Term deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	80,000	80,000
Fair Value, Measurements, Recurring [Member] \| Certificate of deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	30,021	29,910
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total fair value of financial assets	395,609	303,576
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| US treasury notes and bills [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	350,891	292,317
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Bond and mutual funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	10,677	10,484
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Equity investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	237	234
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value disclosure	33,804	541
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Term deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	0	0
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Certificate of deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	0	0
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total fair value of financial assets	235,284	334,863
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member] \| US treasury notes and bills [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	125,263	224,953
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member] \| Bond and mutual funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	0	0
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member] \| Equity investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	0	0
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member] \| Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value disclosure	0	0
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member] \| Term deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	80,000	80,000
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member] \| Certificate of deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	30,021	29,910
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total fair value of financial assets	0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| US treasury notes and bills [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Bond and mutual funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Equity investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value disclosure	0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Term deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Certificate of deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	$ 0	$ 0

XML 47 R36.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail) - Lease obligations [Member] - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities fair value disclosure	$ 1,745	$ 98,105
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities fair value disclosure	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities fair value disclosure	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities fair value disclosure	$ 1,745	$ 98,105

XML 48 R37.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Lease payment liability	$ 55,851,000
Transfers of assets from level 1 to 2	0	$ 0
Transfers of assets from level 2 to 1	0	0
Transfers of liabilities from level 1 to 2	0	0
Transfers of liabilities from level 2 to 1	0	0
Transfers of assets into level 3	0	0
Transfers of assets out of level 3	0	0
Transfers of liabilities into level 3	0	0
Transfers of liabilities out of level 3	$ 0	0
Shorenstein Properties LLC [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Lease commencement date	2008
Lease payment liability	$ 5,000,000.0
Remaining lease term	2023
Building [Member] \| Shorenstein Properties LLC [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Lease maximum expansion period	31 months
Lease obligations [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities fair value disclosure	$ 1,745,000	98,105,000
Lease obligations [Member] \| Long-term property lease [Member] \| Shorenstein Properties LLC [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities fair value disclosure	$ 1,700,000
Lease obligations [Member] \| Building [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liabilities fair value disclosure		$ 96,200,000

XML 49 R38.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Detail) - Lease	6 Months Ended	12 Months Ended
Leases - Additional Information (Detail) - Lease	Jun. 30, 2019	Dec. 31, 2013	Dec. 31, 2006
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee, operating lease, lease term	2 years
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee, operating lease, lease term	4 years
Shorenstein Properties LLC [Member]
Lessee Lease Description [Line Items]
Lessee, finance lease, initial lease term			15 years
Lessee, finance lease, expiration period			2023
Lessee, finance lease, option to extend the additional lease term			10 years
Lessee, finance lease, additional lease expiration period			2033
Percentage increases on each anniversary of rent commencement date			2.00%
Lessee, finance lease, existence of option to extend			true
Lessee, finance lease, option to extend	The Company has an option to extend the lease for an additional 10 years through 2033.
Beijing Economic-Technological Development Area [Member]
Lessee Lease Description [Line Items]
Lessee, finance lease, initial lease term		8 years
Lessee, finance lease, expiration period		2021
Lessee, finance lease, existence of option to extend		false
Building [Member]
Lessee Lease Description [Line Items]
Number of finance leases	2
Number of operating leases	5
Office Equipment [Member] \| Minimum [Member]
Lessee Lease Description [Line Items]
Lessee, operating lease, lease term	2 years
Office Equipment [Member] \| Maximum [Member]
Lessee Lease Description [Line Items]
Lessee, operating lease, lease term	5 years

XML 50 R39.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Leases [Abstract]
Right-of-use assets - cost	$ 49,676
Accumulated amortization	(5,140)
Finance lease right-of-use assets, net	44,536	$ 0
Right-of-use assets - cost	1,212
Accumulated amortization	(273)
Operating lease right-of-use assets, net	939
Total lease assets	45,475
Finance lease liabilities	12,071	0
Operating lease liabilities	591
Finance lease liabilities	43,780	$ 0
Operating lease liabilities	346
Total lease liabilities	$ 56,788

XML 51 R40.htm IDEA: XBRL DOCUMENT

Leases - Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Finance lease cost:
Amortization of right-of-use assets	$ 2,571	$ 5,140	$ 0
Interest on lease liabilities	609	1,249
Operating lease cost	163	289
Sublease income	(237)	(824)
Total lease cost	$ 3,106	$ 5,854

XML 52 R41.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 191
Operating cash flows from finance leases	1,053
Financing cash flows from finance leases	5,850	$ 0
Right-of-use assets obtained in exchange for new lease liabilities:
Finance leases	49,676
Operating leases	$ 1,212

XML 53 R42.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Lease Term and Discount Rate (Detail)	Jun. 30, 2019
Weighted-average remaining lease term (years):
Finance leases	4 years 1 month 6 days
Operating leases	1 year 4 months 24 days
Weighted-average discount rate:
Finance leases	4.43%
Operating leases	4.74%

XML 54 R43.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Maturities of Lease Liabilities (Detail) $ in Thousands	Jun. 30, 2019 USD ($)
Finance Leases
2019 (Remaining six month period)	$ 7,002
2020	14,089
2021	13,678
2022	13,878
2023	12,523
Total future lease payments	61,170
Less: Interest	(5,319)
Present value of lease liabilities	55,851
Operating Leases
2019 (Remaining six month period)	313
2020	507
2021	134
2022	19
2023	0
Total future lease payments	973
Less: Interest	(36)
Present value of lease liabilities	$ 937

XML 55 R44.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Future Minimum Lease Payments Under all Non-Cancelable Operating Lease Obligations (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 444
2020	232
2021	25
2022	16
2023	0
Total minimum payments	$ 717

XML 56 R45.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Future Minimum Lease Payments on Consolidated Basis Under Company's Facility Financing Lease Obligations (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 14,379
2020	14,664
2021	14,179
2022	14,335
2023	12,872
Total minimum payments	$ 70,429

XML 57 R46.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Cash And Cash Equivalents [Abstract]
Cash	$ 40,783	$ 38,783
US treasury notes and bills	0	49,934
Money market funds	33,804	541
Total cash and cash equivalents	$ 74,587	$ 89,258

XML 58 R47.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) Milestone	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$ 74,587,000		$ 74,587,000		$ 89,258,000
Contractual maturities of available-for-sale investments			1 year
Other-than-temporary impairment loss	0	$ 0	$ 0	$ 0
Provision to write-down excess and obsolete inventory	0		$ 0
Number of regulatory milestones \| Milestone			2
Unbilled contract assets	180,000,000		$ 180,000,000		0
Building shell cost	140,786,000		140,786,000		192,397,000
Accumulated depreciation	95,921,000		95,921,000		65,199,000
Building shell [Member]
Schedule of Available-for-sale Securities [Line Items]
Building shell cost	0		0		53,880,000
Building [Member] \| Build to suit arrangements [Member]
Schedule of Available-for-sale Securities [Line Items]
Accumulated depreciation					13,500,000
Leasehold improvements [Member]
Schedule of Available-for-sale Securities [Line Items]
Building shell cost	101,250,000		101,250,000		101,200,000
Leasehold improvements [Member] \| Accounting standards update 2016-02 [Member]
Schedule of Available-for-sale Securities [Line Items]
Accumulated depreciation	38,900,000		38,900,000
Europe [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled contract assets	130,000,000.0		130,000,000.0
Astellas Agreement [Member] \| Europe [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled contract assets	130,000,000.0		130,000,000.0
AstraZeneca Agreements [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled contract assets	50,000,000.0		50,000,000.0
AstraZeneca Agreements [Member] \| U.S./RoW [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled contract assets	50,000,000.0		50,000,000.0
Foreign subsidiaries [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$ 26,000,000.0		$ 26,000,000.0		$ 21,900,000

XML 59 R48.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 595,853	$ 587,885
Gross Unrealized Holding Gains	1,236	238
Gross Unrealized Holding Losses	0	(159)
Fair Value	597,089	587,964
US treasury notes and bills [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	475,126	467,296
Gross Unrealized Holding Gains	1,028	109
Gross Unrealized Holding Losses	0	(69)
Fair Value	476,154	467,336
Term deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	80,000	80,000
Gross Unrealized Holding Gains	0	0
Gross Unrealized Holding Losses	0	0
Fair Value	80,000	80,000
Certificate of deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	30,000	30,000
Gross Unrealized Holding Gains	21	0
Gross Unrealized Holding Losses	0	(90)
Fair Value	30,021	29,910
Bond and mutual funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	10,602	10,464
Gross Unrealized Holding Gains	75	20
Gross Unrealized Holding Losses	0	0
Fair Value	10,677	10,484
Equity investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	125	125
Gross Unrealized Holding Gains	112	109
Gross Unrealized Holding Losses	0	0
Fair Value	$ 237	$ 234

XML 60 R49.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Investments Schedule [Abstract]
Raw materials	$ 797
Work-in-progress	1,035
Finished goods	149
Total inventories	$ 1,981	$ 0

XML 61 R50.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Prepaid Expense And Other Assets Current [Abstract]
Unbilled contract assets	$ 180,000	$ 0
Deferred revenues from associated contracts	(52,019)	0
Net unbilled contract assets	127,981	0
Prepaid assets	4,716	2,705
Other current assets	3,899	2,224
Total prepaid expenses and other current assets	$ 136,596	$ 4,929

XML 62 R51.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 140,786	$ 192,397
Less: accumulated depreciation	(95,921)	(65,199)
Property and equipment, net	44,865	127,198
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	101,250	101,200
Building shell [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	0	53,880
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	16,754	16,405
Machinery [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	8,461	8,382
Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,655	6,473
Furniture and Fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	5,778	5,690
Construction in progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,888	$ 367

XML 63 R52.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Preclinical and clinical trial accruals	$ 41,104	$ 35,413
Payroll and related accruals	14,001	21,430
Property taxes and other	1,778	1,095
Professional services	3,588	2,648
Other	6,074	5,537
Total accrued liabilities	$ 66,545	$ 66,123

XML 64 R53.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Allocated Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 17,642	$ 13,231	$ 34,072	$ 24,109
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	10,450	7,894	20,028	14,264
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 7,192	$ 5,337	$ 14,044	$ 9,845

XML 65 R54.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years 3 months 18 days	5 years 4 months 24 days	5 years 3 months 18 days	5 years 4 months 24 days
Expected volatility	68.20%	67.50%	67.90%	67.80%
Risk-free interest rate	2.00%	2.80%	2.50%	2.70%
Expected dividend yield			0.00%	0.00%
Weighted average estimated fair value	$ 24.40	$ 31.35	$ 33.20	$ 32.12
2014 Employee Share Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility, minimum	48.10%	47.30%	48.10%	47.30%
Expected volatility, maximum	62.10%	75.30%	62.10%	75.30%
Risk-free interest rate, minimum	1.30%	0.80%	1.30%	0.80%
Risk-free interest rate, maximum	2.90%	2.60%	2.90%	2.60%
Expected dividend yield			0.00%	0.00%
Weighted average estimated fair value	$ 19.07	$ 15.25	$ 19.65	$ 13.67
2014 Employee Share Purchase Plan [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 months	6 months	6 months	6 months
2014 Employee Share Purchase Plan [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	2 years	2 years	2 years	2 years

XML 66 R55.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Related Party Transaction [Line Items]
Accounts receivable from related party	$ 4,311,000		$ 4,311,000		$ 47,210,000
Accrued liabilities to related party	781,000		781,000		444,000
Unbilled contract asset	180,000,000		180,000,000		0
Due from Related Parties, Current	127,981,000		127,981,000		0
Net unbilled contract asset	127,981,000		127,981,000		0
Deferred Revenue	52,019,000		52,019,000		0
Europe [Member]
Related Party Transaction [Line Items]
Unbilled contract asset	130,000,000.0		130,000,000.0
Astellas Agreement [Member] \| Europe [Member]
Related Party Transaction [Line Items]
Unbilled contract asset	130,000,000.0		130,000,000.0
Deferred Revenue	2,019,000		2,019,000
Astellas [Member] \| Europe [Member]
Related Party Transaction [Line Items]
Unbilled contract asset	130,000,000.0		130,000,000.0
Net unbilled contract asset	128,000,000.0		128,000,000.0
Deferred Revenue	2,000,000.0		2,000,000.0
Astellas [Member] \| Collaborative Arrangement [Member]
Related Party Transaction [Line Items]
Revenue related to collaboration agreements	134,700,000	$ 20,500,000	139,600,000	$ 25,600,000
Expense related to collaboration agreements	800,000	$ 200,000	1,300,000	$ 700,000
Accounts receivable from related party	4,300,000		4,300,000		47,200,000
Accrued liabilities to related party	$ 800,000		$ 800,000		400,000
Astellas [Member] \| Astellas Agreement [Member] \| API Shipment [Member]
Related Party Transaction [Line Items]
Accrued liabilities to related party					$ 43,800,000

EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�B8T_<6@@Q^\3\ITY''Q4TNL3@H:QAH(])_L0)0$YKBL9K*1 F) MW2(+7-07)LI+"*1$I%5T3!CX?P)K0.2 -"//&:G:Q1KD587'(R7Z,"TY>0!6 MB^SS2P+N9K=H#))3YYKZ?(FU9B;BH>=G)[6D*":(C)LW0/#I0^, A#V!AVIO M<,R.-I#],(ME09+NECO&WL%7E$#!Y[,2YGYV\P3UN>.E??J4=W6X/<]KV!/S M0>89P!OH79[F\FS6:/ &C*_5T[5MQ[:]('7B9#9X$\43PQ84F) JT:M28M?( M_Y=R!7=#T]30]UF1Z@/^FLO?-]>,(<630T>6N>O W;HPBA*JG!N M!.G&3\VR?34FZA[HQ 'F_Q%FR$VFAE MNK,*K7'(U!0VI8B5JH(@_@Q\#*3A8GA,WBH6N:@]45O%L#Y'Z3.L3^54MBQ/ MW]0/M3T-_:_5_!R/7L7\'+[4KMO;_ QKSB0E@"T47I@"D'503^52=H>Q U$- MP8-5%M7 %NFJV8!J,RV6)3 %!D*QW^!V]B3JMJJ:;5LWY%_7P68ZU]Y$P]WF MOE&<);$><9=9%1:K?%-08U!VWWUM\-[M_6J'N>^DV?[ZAFHRGIB&ZDD5X'3@ M;]QYF#$?6@#@WU571K5W7_W7MC ,]?755,@V]=&C=H&H:6B_YU4?"\,G^QV4 M1U=M'+1KC=9\OIO.2/(ZL#L;[JTVII&!U?_7IC7"F[D'D454R3I^@&QU"FFU MT^ LPF*L_#EY3?11 ?X>I@4=2U.!^M<$'[^ZH=E#R&PU__"OHC:\0 M+O3 11_@PJ]=O[]FI>QU0[GR:%/QV&@(L5N9XM,^M>;K3/%[:5!).GZ-2.*^ M$;+7T*!,M25*AW_)N.!XM%\ ]3#-0D>-3!VCOOV!"QB^<:MZ=+,?%:9X5VRH MC*2L*E&B:WGB"]MXW!0^.^,1!KA8]JNWT;2/&,#7[K8J-9F-:X%&L@7R/ M0]L'3*T5@:C&46',YWNH68.!WJ9^+:OX&PD1G%Z<_#V[_8WR%AP WC9TYA_* MTX$B)HS@7BSOYMEB4.[VP_+H+4'\ID9/0HQ?Z5+F\5-=IH%=%R[I#&VR3 M^@N@M]Q^;Q;\>'3D$DAS\>*H1JZ)P]NNV/_M[#'7#XGUZP@7-I M^Y+T6FIJ'!@ 2<,=$1!J6BQ6CY!G%4$(%$1Q>#229>P*R?E(Z&L2I_US/GU8 M4I\(A&Q7CSDM>TU8T*))AP8<5W)SH;#R,PLK7ZT+MB!PS+VLWEB#>S8$JLU# MV*K64<4I;0L,@J FXD&[EZV+:!LR7LO]O>B(]L94!:R36.KTYCZR-ZQ-[GCB MD%MV-%$T.J>:\$OKA#N1TV+L$='(09X'Y]@F47[X+ /N5OUW)2/DA<#C8 O[ MXM^U?H0^'"J0D.11Q1 $#$6]20HL<).B'L&FRJ6 55)?4=,M3+]E%-@M%<"N M9.<)6J>\4I#17(LL/3.4=CK30*CS;+NP35R3#*2$LVL8J!&]'$GQ?HYI9./\4>>@ )@L=#V$3 MW584JB,W(6YEN59@5[XC=0I[#@E<&W"1"P53EK@9Q5QU-"F3,G3XLB;*[VY6 MBQ:(#D 3HZ"K+F>URC9G#J"M/F!,]XA&1L!KC&+P!A\*OP]6807U\K2V-Y)K M[;Q.=D>;2;Z-Y[RC4]TVEU_V @Y/*DP].4O+TZ7-YNVRX(-%%P0TG.Q&OK_A MK;+PLWU>.<\#X-M-H2=BV'0L'>6+*Q$K^$,T[SGQ]R$+V;QQ5JSN#-35=FXO M.4_?1S.\3])SM3%](RAML3ZC=KI=,3! 7JD<1Q#4S@&YPW58LZ#-YI]JWZKR MO/:7-O 77,@W%B;^O>K; SX=M9&;&"O24>]MWV<]Q*H9&=:MBP^E,^/_P# MJ.P?0&6_"E"94R0C*YGZ,Z%0&0@")(3H[H2D0V: M\+R0O_\!Y? /*(=_0#G\ \KA'U .?YU0#@T'P[CM8##D>F@;9#KJ@(P!\K80 M@:!L^A VV;GF[&2JFXE60*$9AMQU7L-W )CE_CLD___+0 D[*FR-]+\&)9GS M!!NU!U.%9L/AV@'KD@]QN'"ANM5[4B2V326D J.T>;V?I\VJ\3M7A@'^24DZ MK[I+4X.SAS4BO]=JS3%I<(RJ,2WY&\\,?T&_M='YP(Z3T2>@S(.=[C; M2(RX:3DFU+@_5"E$@>(0.55,-.'(DSEGPMR3&8'*V-J=Z^-4)QLO2?!OS4WI MVSBP-JPIL>4V^>P+Q78T[MW[A M=39>?=R_],Y+QZ-P,HBL!9??^98YCN%L +4^#HF9XB&=%/ONOU$$&LD 3PR^ M_W_0=VD8C]+.__UU_@?//+52]UP,28,'R2"435@TGTB7*>:;ZD1 $VP2/4!" M&]W'@U U>'VI=*PPNGFX%J'=(@YC=_CLICQ%JGV*QT9PSWA;/^-[';/+7+E) M*?6FJU-Q6A]MEN=PMM:;V,ZN=W:3=A;2D]P6,[)\ 4=C#_!+9;=;$?'7)+VI M*H<3@-4K>V1YDH119.]LYROO%D_"T3#&?]+1I)/&\&G8&?3#&+1^)J]??%I/ M:OGK;^L@\+""YK-7/QY\2VL807_ITR*)1R"K!S9/B>].RZXA]$.KS2?ZDY'< M_Y0M5C\I1(1<9@!5G70 N@+P%^@0"=@5H#: 9I:VLYN< NARX6"0CJRS^.(\]QU!RUU.?/FZ@?]R9-QXM'6.]YU+R! M53+&W>.DD!CHS@EE9_DWG%?..>,':VMV3.CK&?E%-P+A=;Z4?1S9 !:MD3#F MXB2W4(@.A_NJAO.YL'23),%*W, ,6P4;SZ+PGG@:M__-B3Z)*.BX $KE!6P#$RGN !%,6#,![:;H=T- PCL"#>E:+- MW&)+S:TP_;+J1'W:K?)RM?OYZ_?DC:0&>:*Q%!Q@[M7X'9S$^9/(F!-CP[DX M!J6V?K7X^C,S/%5BJ=_&?;!R^O6/")G*J9HYU?$O1J_\ZS(((V<2_&[UUN+>!).HG[]HUJ+?A(.1D/2F=)P7./483(.TV2R M]XXW8CO!:09;+Z?>EK_3[44P6?O%N]X\-=36G^KG&>U,N/'HZ^W[#T[8Q:\# M1G"N#]2_A_+ROD^9C,.H/U!_U FKVB UI%T8$6=^XHD^F:4/DW\P%M:W>OX6 MTL8YW]R+>)>]T10MMA=-Q']%Y.EMY]H-< 9=&<5-)R!*AU:@P>S+W#D:A%': MWR=HRI'EW;'5- T'R;"C.OZV3C *875;9A>/$@Y&6'&MQME9D=I)HIR(QA(A M309@!0VLX.PI&]YOF^-Y^P0]\0@,^Z/(F?#\X#CP $[4CSIB]\R)6=%$, '' M_=:IM44:DW1H4=/\#0Z5(0SN>%U/=3\;M>W>L]?#M[.FUN5SJQ_ZKJUS8\)A M?]( VGH3M1CSO*\:+7K^V28S7!.=GHL#<]0K7MN',TCE/XQ^0L(;D2D/)#(L1X MD+:)\QM,FV>,:3AS$0G]'$L]+@Q;U0A2\3GAAA2-,12:NF7OUKNY[Q;G.QB* MIDJ>0,HS%VZL>G7YPH9T=IC@K;'4)@P\YC[5\@&0O:))U'*#W70)6*D/RJ-0 M>79?CBO5]TK[\E8TX\$^0[*G/;XU%B!Y7LEN9R\/L7H3>5(YX/S8?=:3ALEI ME14YEX)K6$NO"B&ZEXE6SW0MPZFK5C*ML"O3"GVMD((CS.-&7JF_ M<<\Y1& Y>JD[K#5+SSAITOG!'2KMC=+.#VV$N\0,-59;E-K+UK<>3.A<+0J3 M/8JK$=G:ZMO.'S&M'38+C*Y>A9_2J3^6G*?!T;4BJ^IX(%)2*=\3K :,#281 MB*Q^W,?@(H8@!_T1?HXP"VTX&L,_*7Z.\?,8/Z-;%N.1,84EI1;*8NIN2\E[ M_#:R"J8SC,((S*H):"P?\JIZ&TCIC#I60NE:1Z 7'7>NV*.AN\)[#U3<3!'Y MKD9MRW3.<[D$$BRV"\'N5[(RATO9L80%=8E3)"=#*]2(:8;<'0.(G[ 03[#? M6CA5N2$TZ!KZ"?5<)-.WE?GS['<*5),[O.R REV:\DK'2W% ME.^EUA&C5R\@>;DD_ZORP9'O1RR$,!W^>Q6<9YB)O7D*M'!]V4*$[ 6JN?^H MA;GV>SM6IIP%CW6GYO+:B_6A>7RY;IB?,IJH33H!2W+&(_3&/'FKM:GP(\GL?-&_T9"1C^J/--20Y'\[3B=]%([QCY)4IE2[D>Q5.YQB, MTC>P&Q TBI_U#X6N^&^4D6$6%IB#8P@$* CWV[,RT-! M+9)PN>,,P^K;C>',8@68BO1TF9N4$9[4EJ MT2Q@V;P?'VFO>:5_RYI^9$3J: M!W8X/\&R#R,J6 #M-1Y[G=&6P['F:&QV.%:FQS'AGUW';[.C&Q21T6 /'W<$ M!U84Q99_FS>C>16H"!/4$1+6@BGWR7#R3D8BU:HN-OY2RS(?31!MY9P 3<[N^F"$/4>3'>85W)8T2I/>R!,E=2U^ATFLNW =OK1#)&A"-@[[\"Q;PG56>I,-07.OT@;/4 M$89*313S%T9P:&!R.U#\$A&DEOGZJ3,&X1'!?Y-QW.'N98@5I6X;AL/! /Z; M@D%XOETO"]+>Z=0NON'?Z# 9@:TY"(<@JDY-Y*9"@$3PCAR/QYUD.%)KZ2,G M:="H"I*(Q0 @[&ZV0YLKIN F5!AY-$0#LW)A(S3YJHR-*["\9!"/<"BT<15 M^0SFD'[N%N^ O,3T"+PB6\"^L0#-U ="RD2ZK+(L Y;VB-Z%M>Z'NZT< MG9;?.$R##Y^OYZJ=J7F]CU^0^)_$2IB1G MX/"?("/%?:%]8B8LZ!A[^,8[N*5B6/T$5A^9+$T[DW ,Z\RL4.T@+SYL!,S$ MN?"@$J+[*(%Q1OA-#'9TOU6:PTF\7:Q$KIPH?GXO8#!J-A@WUOPD+OYYG7&" M#KS2U18(1%Y!=CL@IF+PWFJJJ:X)KL 8]QELF6P;H )4OJK\.55:()!0+ME+-\7O>6 MO"9;6HO1>:_0$,B_#)N!7WWX-:9K8KHO[HW@OVK\68$0A[ :3PB] MY&CU]7^=>GP-Q:*7G1BZE_;)M=M+!I33T8OI<]P#XPG7JH48B'C1#7#J[7_Y MB)2.>Q'\/(3GP&NFHUX"GT9(UA]:?VLB8$07Q43K?F],?P_A[Z;OOS=AHTFO MSQF4O7C G_G,3WI#US&Z P:C&YQH9#4S)'=TEF^R8GXLX19@;2XY><]1$Z+8 MV@U.L>!VV5-J (_6=LEX]R63F_R>5$COE:!H]*22X=#CXY9TD/+.<(!7/%KP M7X$8UR$B8J@PCYI^F 4'3QQK$.C!G9T=?0J(WYU)H E!V/\*_*]!:*X C0)LA[JS?%4>]?M\)'&%+-O?;W;SQ?+[W0/ M*GK0-+@<4R0%UP(2I@O<0=U = L%/^$E9!MY_-;\!S,GI6JL.U? S@*89\Y( M1BPK/=O0K-8GNP[?^@8! *P,+UDX CM!67\W:/TUEI3L/;1=OZU-JV<\4]NP M5@?FG4_P=!%7,[F9@C?9\O>7^?@?[2%\ ,GDUFO=%3\!\J,:YRR/(J8!*F M"-P'^:,1(Z*K,;3M;W?HE?L2+FI5+I-!Z\]I^\\GJ[54*OM.L;2A<;KIS.?Y M;2^(Q_2CLYP&K8##S([UHKLL'J$-EP0&A$/5R@8-[G#WR*^OCKGT[4@>7UHZ M//AZ9'M!/&V.N<7;RH>- M:+4X=O1[91.[D\^_;7)RQ]@@YXZ)U'<]LI^?W2/(/4*M9CY[-/)YT0)_3SYU M'W40H[:?&+X>CXV'1G3XL4%> E1[OU1PL6[=0:'BM%NJW M70[T5I6;!PKH?9L;OL*,7LR SWC@H?+R&8]06KA"J_]^3_(0K-4,E$C$_@9 M8FT/GUP[C,/5NISF^4R$T9_1^FGG.5]OZ--\\&/3"">3N4Z T(=4_5*J?&]N M=Y[V6A+W($RVPZ5M;9^@F)GNI_P V>EJV6$U^XRC5$N%-6YC6BJ *R>&>XUBM->,(J0,0 M%09?835(H-D&/NF$1KB:*V&FUKI2JC$LI6/1.YNE97,Y!"<'*(4(=1==\C-S MWR5A?F<*G9UB?/O9X>W\<:"M][=XSEQEZ.!_R#>H[AX??NZT)-$ZT;5&D*.7 M2MZ]4YR?LW0.S5[/[:T0JKCM,+!O">92J,(P3RUQ[2;4I&[P GRDPU_!F(:, MQRZM?%/]N$_FXT[81[ZN/;\U)-)<8=12]]"XY-YRA,:KW6J$9OQTL_JHD>&\ M]4B-EVLRA]9RAP9)&^?#!;-6NEX=T>HES\-C]AGT/_ 1ARW7@8,?L+H'CNS6 M][5H,[1_C(7"NO)YB8]XX2SV8LD#Q_R.'(QZ*>,5?:_A?AV>]3SUN[*QYWG? MC[,]#SN V5_^L._!TY['_!ILWAR1?^%POR:;Q[\RF\>_)IO'OR:;Q[\.F\>_ M-ILGWVNX7Y/-DU^9S9-?D\V37Y/-DU^'S9-78?.]C:S]("E-0\L!7]03WM<* M,Q^ZE_ZX2[W:=2[MOZ'KA-O;=G8?:6"MJ,14)S'_LV@N2LLBZI/)=347K[PI M P>M:L=-,=[D[\,C;S++)P][7,.=>SQ3=2@@.#1:D'VN+[<"Q6SW'>;<]GZ, M>5/[L[#F(E]6F[Q8RCIFO.G#A],6QF-XNL4".[L3*\Q\)1+]OI/S<>T!_W*< M C)1W) 9SY[E(OM&B#CYMQ60ASRLWF2E)&JH)6F6#/M?B7)0]_.3A;),@==X MR89G.H3TWKV?0*!+VY)TVC)XW)Q/"1K5/#/8)S*[^DSGL+4ZI_BFL ZY%;;P M6LR%<,[T!-KWW+!/L'3= 9<^>,XW[B<)"11%DL.;.=<,6HW46V7&*N0R5B/6O. MJMPEDGSIE(U$QO)[BEW<.91[)L$=F:WK<*FU1[;TKY' )4-XS*5)7+DL6>X)4^UWD)D1U^WQ:RJ):L)W;GMIRF5K-%BCG9P1N M7"AE9ZUV(RN[,9H6K.1=I/+Q2PW?N(V$OMN].^$Y8,7/".Z]#K1P,]%V(0WO M?V>[&-P7>W@?H7 @"'$KT^[BIT/$HA^<6"UZ?:3#@(4;-+A J/W!$/2%)T]- M%%X5I,(V".+4>]D.,&+GV;TT<;001"+VJ"8>:ME8PBTGQW["QP\$OA-4V*,% M]#W?N79W,W2P3ZG2\,&.=K@3/KB9-_WO[*7VZP,+[[M IG4U;G#(^&%?7^'% M7@^^=]_7;82DM:?="#[[S-/AQ#=4<\H'7EK_KL7O[1B6CC_7OZ*-<+,'4&V' M45\?R<(&:6 W7VK;95/U@(6IY,*OWJ"[F"56FU$O\W/0M;^P)%\[I*M?E#LB M 1.4NALX [OP]%6Y1G.R /8NUNSB+"L/)F/YM:B$D?8(\\F[L_*1SM*\D@WL M8.?DFUSA1#HN4FW7K'7EP4*7I?Q7T$C7)GC&1AN,(/YV6@(F)-Z.H1K3>3R> M.U6X7V'A?F95);2YI1P8P^=>CCF$NFB[VL#Z9.M9%6Q7*-F0DX=M]=CGY1I. M]R5,_[8J9D5&V*.-!&B187\)%.AG )=8_ MMDDS-63S*6!!R#K:8 U+UJ-X&:"R?OEOX,L^DQC[YV,>3*S:T'2$\LAB1 59 MT8P(M#]JK",Y6R!CFV;J_]4'&NM?CKUQ8Y^]6#X V>>LC!@'\?HVM#"&3ZOE ME&V".R48=K]>W@2GZERML61=_YKK>!>HLBU9P@)A=O=@-MKLN4";;1G9CSS[ M+&G?#@#[#+GL&63W-ML3^=6YK07VM9%S:KBOGNM)D-!$\;02])+1OHSR%MHV['R2J-[8Y()W@@O$=187 MM"YY$YAG0V B2*3W*AI[O5?RNEU>+@\&:/T2Q$UU VP(H^K]=N+]=NQ^VP 9 MZOB;?/?&OH?'O9'[90.@:/TR+R;+7J"B'B?;#NYL+(5PUR*4;B#'LSCN1>Z$ M$9.UA036N!P!T//EWJNS1X1Q MV)!>D'25^.HK5+*AVE/2.<\V H'HX#Y%%:LVE:?O6QEU%7*]?.UW35R4GX<'8]Q4]=X PCS_$^3W"TN,3! MKY.>AT_SFMB$>OX$=3?=,/69D\3%[VGZ@:0)\94E#KI=3>-"BG%S+[ '3&7" M :T)2_ -872EJ,TJ"*=LZ^&9!3+)I$+:G*I1%EFD>?3AR'OVP#L>3H54KK:O MX']7W?1)H/>L0,K8('"&/9#&-=$:E+@UCIOLP.]"J+.7V]HH+!791K,Y'A/< M8(JLI,I!#64BW$-IS*"P>YHE;'1_G3;%H9IG1ZCYN?>Y! &*L%W1YN[_S[O\CQ5?7/VY9/>O M,A7\C!IM;SL"D?-C$+DX!I%_^TX&7=O9Z6U[G6U T:JE3%/1R:UHGH/78Y\6 M"?YDWS1LK[^,#<[0:[(RC\@]?I.;0T%:IN_L$ETPP:/]P0J/%L.LY4"1X-'^ M"#EM^6M7<'RIIM\ 4$L#!!0 ( +F""$]T)$P,200 @E / >&PO M=V]R:V)O;VLN>&ULQ9I-;]LX$$#_"J'3[B%KBY+2-J@+I$VS&Z#=#>H@UX*6 M:)L(11HDU:3]]1W)<4)NK$$O4YULD?IX&HGSJ)'>WEMWM[+VCCVTVOA%M@UA M=S:;^7HK6^'_LCMIH&=M72L"++K-S.^<%(W?2AE:/>/S^>FL%]G7M M9O&"#;(.RAIH[!MNE;SWS_W](A.PPC=Y(U:+;)XQT05[J720[D($^;>SW4Z9 MS2++,[96SH=E?^QAS589U:H?LAF6_-;>_V.=^F%-$'I9.ZOUL%7?,6P$1_!/ M+;?2!54G*P:Q^B* =9&=SF&'WY17*Z55^+[(AO]:9G 6L^@TAC@X9E[DQ!A[MJ\AZ<#O*#-8TT7C8,_GFK50,<#7LOM#"U9!$D M1R#YA)!?>019()#%))#+'@XD^RR%[]Q+/-0RQ)KY!$S)I3$/CG8;9A:P-!H=];\/UJ827)BE2R#K>].WHO]P&UA3_[%E &32$YLD2M3 MVU:R&_&07E/,&3FQ-+[TC1"O:^%@GG7C!,1LF+TFA)@PJ M/V,L3!N<6!MCB?KE1>;HXPFQ3\;R]1%,3"N<6BOHR(ZGK!RS"R>V"XX93UHY M)AQ.+)QEU[;"?6=VS8X1QYB8=3BU=3#,Q#HPG<#$F9J&"O$:&1#,M/V$6*LBK M9$@T4TRT3$9>)QO%O)#K>*07F(4*8@N-3=Q.V- 38V(6*H@MA&*F%QVS4$%L MH7',\Z91(<;$+%006^AQ&OQ(!;U"CY3L"\Q"!;&%GC"7L+.FT[*W^] (%O+) M$,(L5!!;Z DSFK@_@7Y\B"OBF(7*W_/LDT9SV>UV>KA)8TS,0N5O*:$=O>@W MTL5.+S$+E<06.HKY683.P8!*'GA+S$(EL86.8EYV@ D92B5O:]#7-<060C&3 M]%YB%BJ)+33ZG+X'CS$Q"Y7$%D(P^X0?8V(6*HDMA$4SG;V7F(5*8@NA%SV] M-S$+E<06PC'C>F:%6:@BMA".&1=G*LQ"U505N0$S+LY4F(6JJ2IR+Q)2A5FH MFNA%S\LA5&$6JH@M-/YN9 M3C?Y 0 >B$ !H !X;"]?;KD_M^,VN&TYU&3\. M^]#7F]=ZGX(NEZLP3&=4CP_3F8OG[;H:GK=2+7[5PSZ5=17>CN%/-[SF)J62 MP_E-;L8%XT_>^_0_Z[O=[K!)3]WF]RFUY8N*?PNJ\'60S@Y/-! M3@^*\T&1'K2:#UK1@V[G@V[I07?S07?TH/OYH'MZD"R!C$M^$L*:K[4 KH7O MM0"PA2^V +*%;[8 M(6OM@"VA>^V +B%+[< NH5OMP"\A:^W KV5K[<"O?4* M]]KH9INOMP*]E:^W KV5K[<"O96OMP*]E:^W KV5K[<"O96OMP*]E:^W ;V- MK[BPA*^W ;V-K[D>@=^3K'8'>D:]W!'K'*SRK1 \K^7K'B=ZY MJ8>T?2G#H=WG2Y=\&OYMS03N7-Z/Z?(9YZG?[I\H7<8M*9Q?+WZ)GZ=^1(1/ M?[5X_ M02P,$% @ N8((3W>_$UO6 0 -2$ !, !;0V]N=&5N=%]4 M>7!E&ULS=I=3\(P% ;@OT)V:UCIQ_R*>*/>JHG^@;H=V,+6-FU!_/=V M$TPTF&" Y+UA;*<[Y]UHGBMN7C\V2W-_MIYEVKFU*'1MK MV,I4OYJ.-PUS3^VP)M2-"V=I039Z6*=]4 M]*]H=C9K2JILN>S2+7EPGG05:J+8M7FHM:?J)?K&S#=YG[6/C[I+C=FZ93\6 MY*?+$3]:VAU@J!QSSX=\2MY]02P$"% ,4 " "Y@@A/ M'R// \ 3 @ "P @ $ 7W)E;',O+G)E;'-02P$" M% ,4 " "Y@@A/)^B'#H( "Q $ @ 'I 9&]C M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( +F""$_BCT9"[@ "L" 1 M " 9D! !D;V-0&UL4$L! A0#% @ N8((3]SK9%\O P -@\ !@ M ( !]P@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ N8((3U G (Z5! @14 !@ ( !Y1, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N8((3SW_@T"V 0 T@, !D M ( !(RP 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ N8((3^$HLX*U 0 T@, !D ( !Y3$ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ N8((3T3% MA7RU 0 T@, !D ( !IS< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N8((3^+0F30 @ 5 8 !D M ( !&#X 'AL+W=O'-\4! W! &0 @ %/0 >&PO M=V]R:W-H965T&UL4$L! A0#% @ N8((3Y7[&,SV 0 RP4 !D ( ! MAD0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ N8((3V)"8!S3 @ 6 H !D ( !.$L 'AL+W=O&UL4$L! A0#% @ N8((3^0J$@*B M P 7A$ !D ( !U%0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N8((3R?3^V'6 P 8Q4 !D M ( !96 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ N8((3\%\@5S/ 0 M00 !D ( !^FD M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MN8((3ZJ3K34P P -0X !D ( !:W0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N8((3U@W#/-2 @ M)P< !D ( !UGT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N8((3\D7)\>5 @ L D !D M ( !OX0 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ N8((3S7:#T#] 0 =04 !D ( !VHL 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N8(( M3T;!X!GA 0 _P0 !D ( !.I8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N8((3\C0[0HK @ CP8 M !D ( !V9T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N8((3_OQ"I?( P 01, !D M ( !FJ8 'AL+W=O&PO&PO 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 M " "Y@@A/+9Y.-_D! !Z(0 &@ @ $U(P$ >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "Y@@A/=[\36]8! U M(0 $P @ %F)0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 0 ! '(1 !M)P$ ! end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 318 382 1 false 73 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 7 false false R8.htm 100070 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 8 false false R9.htm 100080 - Disclosure - Significant Accounting Policies Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Collaboration Agreements Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreements Collaboration Agreements Notes 10 false false R11.htm 100100 - Disclosure - Fair Value Measurements Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 100110 - Disclosure - Leases Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeases Leases Notes 12 false false R13.htm 100120 - Disclosure - Balance Sheet Components Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponents Balance Sheet Components Notes 13 false false R14.htm 100130 - Disclosure - Stock-Based Compensation Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 100140 - Disclosure - Income Taxes Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 15 false false R16.htm 100150 - Disclosure - Related Party Transactions Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 100160 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPolicies 17 false false R18.htm 100170 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPolicies 18 false false R19.htm 100180 - Disclosure - Collaboration Agreements (Tables) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables Collaboration Agreements (Tables) Tables http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreements 19 false false R20.htm 100190 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurements 20 false false R21.htm 100200 - Disclosure - Leases (Tables) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeases 21 false false R22.htm 100210 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponents 22 false false R23.htm 100220 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensation 23 false false R24.htm 100230 - Disclosure - Significant Accounting Policies - Additional Information (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail Significant Accounting Policies - Additional Information (Detail) Details 24 false false R25.htm 100240 - Disclosure - Significant Accounting Policies - Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail Significant Accounting Policies - Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation (Detail) Details 25 false false R26.htm 100250 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impacts to Condensed Consolidated Balance Sheet Upon Adoption of 842 Guidance (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail Summary of Significant Accounting Policies - Schedule of Impacts to Condensed Consolidated Balance Sheet Upon Adoption of 842 Guidance (Detail) Details 26 false false R27.htm 100260 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impacts to Accumulated Other Comprehensive Loss and Accumulated Deficit Upon Adoption of Guidance (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail Summary of Significant Accounting Policies - Schedule of Impacts to Accumulated Other Comprehensive Loss and Accumulated Deficit Upon Adoption of Guidance (Detail) Details 27 false false R28.htm 100270 - Disclosure - Collaboration Agreements - Astellas Agreements - Additional Information (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail Collaboration Agreements - Astellas Agreements - Additional Information (Detail) Details 28 false false R29.htm 100280 - Disclosure - Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) Details 29 false false R30.htm 100290 - Disclosure - Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) Details 30 false false R31.htm 100300 - Disclosure - Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) Details 31 false false R32.htm 100310 - Disclosure - Collaboration Agreements - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail Collaboration Agreements - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail) Details 32 false false R33.htm 100320 - Disclosure - Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail) Details 33 false false R34.htm 100330 - Disclosure - Collaboration Agreements - Deferred Revenue - Additional Information (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail Collaboration Agreements - Deferred Revenue - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail) Details 35 false false R36.htm 100350 - Disclosure - Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail) Details 36 false false R37.htm 100360 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 38 false false R39.htm 100380 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail) Details 39 false false R40.htm 100390 - Disclosure - Leases - Components of Lease Expense (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail Leases - Components of Lease Expense (Detail) Details 40 false false R41.htm 100400 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) Details 41 false false R42.htm 100410 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail Leases - Schedule of Lease Term and Discount Rate (Detail) Details 42 false false R43.htm 100420 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail Leases - Schedule of Maturities of Lease Liabilities (Detail) Details 43 false false R44.htm 100440 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under all Non-Cancelable Operating Lease Obligations (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail Leases - Schedule of Future Minimum Lease Payments Under all Non-Cancelable Operating Lease Obligations (Detail) Details 44 false false R45.htm 100450 - Disclosure - Leases - Schedule of Future Minimum Lease Payments on Consolidated Basis Under Company's Facility Financing Lease Obligations (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail Leases - Schedule of Future Minimum Lease Payments on Consolidated Basis Under Company's Facility Financing Lease Obligations (Detail) Details 45 false false R46.htm 100460 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail) Details 46 false false R47.htm 100470 - Disclosure - Balance Sheet Components - Additional Information (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail Balance Sheet Components - Additional Information (Detail) Details 47 false false R48.htm 100480 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail) Details 48 false false R49.htm 100490 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail Balance Sheet Components - Schedule of Inventory (Detail) Details 49 false false R50.htm 100500 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) Details 50 false false R51.htm 100510 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail Balance Sheet Components - Schedule of Property and Equipment (Detail) Details 51 false false R52.htm 100520 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail Balance Sheet Components - Schedule of Accrued Liabilities (Detail) Details 52 false false R53.htm 100530 - Disclosure - Stock-Based Compensation - Schedule of Allocated Stock-Based Compensation Expense (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail Stock-Based Compensation - Schedule of Allocated Stock-Based Compensation Expense (Detail) Details 53 false false R54.htm 100540 - Disclosure - Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail) Details 54 false false R55.htm 100550 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 55 false false All Reports Book All Reports fgen-10q_20190630.htm fgen-20190630.xsd fgen-20190630_cal.xml fgen-20190630_def.xml fgen-20190630_lab.xml fgen-20190630_pre.xml fgen-ex106_6.htm fgen-ex311_7.htm fgen-ex312_8.htm fgen-ex321_9.htm http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fgen-10q_20190630.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 318, "dts": { "calculationLink": { "local": [ "fgen-20190630_cal.xml" ] }, "definitionLink": { "local": [ "fgen-20190630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "fgen-10q_20190630.htm" ] }, "labelLink": { "local": [ "fgen-20190630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "fgen-20190630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "fgen-20190630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 500, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 34, "http://xbrl.sec.gov/dei/2019-01-31": 10, "total": 44 }, "keyCustom": 61, "keyStandard": 321, "memberCustom": 37, "memberStandard": 36, "nsprefix": "fgen", "nsuri": "http://www.fibrogen.com/20190630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Collaboration Agreements", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreements", "shortName": "Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Fair Value Measurements", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Leases", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Balance Sheet Components", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Stock-Based Compensation", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Income Taxes", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Related Party Transactions", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "fgen:DescriptionOfOperationsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "fgen:DescriptionOfOperationsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "fgen:ContractWithCustomerMilestoneMethodTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Collaboration Agreements (Tables)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables", "shortName": "Collaboration Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "fgen:ContractWithCustomerMilestoneMethodTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Leases (Tables)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "fgen:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_fgenSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "fgen:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_fgenSegment", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Significant Accounting Policies - Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail", "shortName": "Significant Accounting Policies - Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impacts to Condensed Consolidated Balance Sheet Upon Adoption of 842 Guidance (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Impacts to Condensed Consolidated Balance Sheet Upon Adoption of 842 Guidance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapAdjustmentsForChangeInAccountingPrincipleAxis_fgenDerecognitionBuildToSuitLeaseAssetsMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenBuildingShellMember_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impacts to Accumulated Other Comprehensive Loss and Accumulated Deficit Upon Adoption of Guidance (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Impacts to Accumulated Other Comprehensive Loss and Accumulated Deficit Upon Adoption of Guidance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_20190101", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Supplies", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Collaboration Agreements - Astellas Agreements - Additional Information (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "shortName": "Collaboration Agreements - Astellas Agreements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementAccountingPolicy", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228", "decimals": "-5", "lang": null, "name": "fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Supplies", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "shortName": "Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190630", "decimals": "-5", "lang": null, "name": "fgen:TransactionPriceAllocatedToPerformanceObligations", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "shortName": "Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ContractWithCustomerMilestoneMethodTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190401_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "shortName": "Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190630", "decimals": "-3", "lang": null, "name": "fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_20190401_20190630", "decimals": "-5", "first": true, "lang": null, "name": "fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Collaboration Agreements - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "shortName": "Collaboration Agreements - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_20190401_20190630", "decimals": "-5", "first": true, "lang": null, "name": "fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Supplies", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "shortName": "Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190630", "decimals": "-5", "lang": null, "name": "fgen:SuppliesNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Collaboration Agreements - Deferred Revenue - Additional Information (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail", "shortName": "Collaboration Agreements - Deferred Revenue - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190630", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail", "shortName": "Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail", "shortName": "Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "INF", "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtRangeAxis_srtMinimumMember_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Leases - Additional Information (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_srtRangeAxis_srtMinimumMember_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "fgen:FinanceLeaseRightOfUseAssetsCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "fgen:FinanceLeaseRightOfUseAssetsCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Leases - Components of Lease Expense (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail", "shortName": "Leases - Components of Lease Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:FinanceLeaseInterestExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail", "shortName": "Leases - Schedule of Lease Term and Discount Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under all Non-Cancelable Operating Lease Obligations (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail", "shortName": "Leases - Schedule of Future Minimum Lease Payments Under all Non-Cancelable Operating Lease Obligations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Leases - Schedule of Future Minimum Lease Payments on Consolidated Basis Under Company's Facility Financing Lease Obligations (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail", "shortName": "Leases - Schedule of Future Minimum Lease Payments on Consolidated Basis Under Company's Facility Financing Lease Obligations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail", "shortName": "Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Balance Sheet Components - Additional Information (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "shortName": "Balance Sheet Components - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "lang": "en-US", "name": "fgen:AvailableForSaleSecuritiesContractualMaturityPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "shortName": "Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail", "shortName": "Balance Sheet Components - Schedule of Inventory (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "fgen:CollaborationServicesAndOtherRevenue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "fgen:CollaborationServicesAndOtherRevenue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Supplies", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail", "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail", "shortName": "Balance Sheet Components - Schedule of Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "fgen:AccruedPreclinicalAndClinicalTrialCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail", "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "fgen:AccruedPreclinicalAndClinicalTrialCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Stock-Based Compensation - Schedule of Allocated Stock-Based Compensation Expense (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation - Schedule of Allocated Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190401_20190630", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail", "shortName": "Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190401_20190630", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190401_20190630", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190401_20190630", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)", "role": "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Significant Accounting Policies", "role": "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "fgen-10q_20190630.htm", "contextRef": "C_0000921299_20190101_20190630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 73, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "China [Member]" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "JAPAN", "terseLabel": "Japan [Member]" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "fgen_APIShipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "API shipment.", "label": "A P I Shipment [Member]", "terseLabel": "API Shipment [Member]" } } }, "localname": "APIShipmentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fgen_AccountingPolicyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounting policy.", "label": "Accounting Policy [Line Items]", "terseLabel": "Accounting Policy [Line Items]" } } }, "localname": "AccountingPolicyLineItems", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "stringItemType" }, "fgen_AccountingPolicyTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounting policy.", "label": "Accounting Policy [Table]", "terseLabel": "Accounting Policy [Table]" } } }, "localname": "AccountingPolicyTable", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "stringItemType" }, "fgen_AccruedAndOtherLiabilitiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued and other liabilities current.", "label": "Accrued And Other Liabilities Current", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "AccruedAndOtherLiabilitiesCurrent", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "monetaryItemType" }, "fgen_AccruedPreclinicalAndClinicalTrialCurrent": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Preclinical And Clinical Trial Current", "terseLabel": "Preclinical and clinical trial accruals" } } }, "localname": "AccruedPreclinicalAndClinicalTrialCurrent", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "fgen_AccruedProductDevelopmentCosts": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.", "label": "Accrued Product Development Costs", "terseLabel": "Product development obligations" } } }, "localname": "AccruedProductDevelopmentCosts", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "fgen_AdditionalConsiderationBasedOnNetSales": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The amount of additional consideration based on net sales of product as defined under a collaboration agreement.", "label": "Additional Consideration Based On Net Sales", "terseLabel": "Additional consideration based on net sales description" } } }, "localname": "AdditionalConsiderationBasedOnNetSales", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.", "label": "Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid", "terseLabel": "Shares issued from stock plans, net of payroll taxes paid" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "fgen_AstellasCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Astellas agreements.", "label": "Astellas Collaboration Agreement [Member]", "terseLabel": "Astellas Agreement [Member]" } } }, "localname": "AstellasCollaborationAgreementMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "fgen_AstellasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Astellas.", "label": "Astellas [Member]", "terseLabel": "Astellas [Member]" } } }, "localname": "AstellasMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fgen_AstraZenecaAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Astra Zeneca agreements.", "label": "Astra Zeneca Agreements [Member]", "terseLabel": "AstraZeneca Agreements [Member]" } } }, "localname": "AstraZenecaAgreementsMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" ], "xbrltype": "domainItemType" }, "fgen_AvailableForSaleSecuritiesContractualMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the maximum contractual maturity period for available-for-sale securities.", "label": "Available For Sale Securities Contractual Maturity Period", "terseLabel": "Contractual maturities of available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesContractualMaturityPeriod", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "fgen_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of presentation and principles of consolidation policy.", "label": "Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fgen_BeijingEconomicTechnologicalDevelopmentAreaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Beijing economic-technological development area.", "label": "Beijing Economic Technological Development Area [Member]", "terseLabel": "Beijing Economic-Technological Development Area [Member]" } } }, "localname": "BeijingEconomicTechnologicalDevelopmentAreaMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fgen_BondAndMutualFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond and mutual funds.", "label": "Bond And Mutual Funds [Member]", "terseLabel": "Bond and mutual funds [Member]" } } }, "localname": "BondAndMutualFundsMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "fgen_BuildToSuitArrangementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Build-to-suit arrangements.", "label": "Build To Suit Arrangements [Member]", "terseLabel": "Build to suit arrangements [Member]" } } }, "localname": "BuildToSuitArrangementsMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fgen_BuildingShellMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Building shell.", "label": "Building Shell [Member]", "terseLabel": "Building Shell [Member]", "verboseLabel": "Building shell [Member]" } } }, "localname": "BuildingShellMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_CashConsiderationReceivedUnderCollaborationAgreement": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.", "label": "Cash Consideration Received Under Collaboration Agreement", "totalLabel": "Total Consideration" } } }, "localname": "CashConsiderationReceivedUnderCollaborationAgreement", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" ], "xbrltype": "monetaryItemType" }, "fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash paid for amounts included in the measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" ], "xbrltype": "stringItemType" }, "fgen_ChinaPerformanceObligationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "China performance obligation.", "label": "China Performance Obligation [Member]", "terseLabel": "China performance obligation [Member]" } } }, "localname": "ChinaPerformanceObligationMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" ], "xbrltype": "domainItemType" }, "fgen_ClinicalDevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical development milestone.", "label": "Clinical Development Milestones [Member]", "terseLabel": "Clinical and Development Milestone [Member]" } } }, "localname": "ClinicalDevelopmentMilestonesMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "domainItemType" }, "fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Co development information sharing and committee services.", "label": "Co Development Information Sharing And Committee Services [Member]", "terseLabel": "Co-development, information sharing & committee services [Member]" } } }, "localname": "CoDevelopmentInformationSharingAndCommitteeServicesMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" ], "xbrltype": "domainItemType" }, "fgen_CollaborationServicesAndOtherRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.", "label": "Collaboration Services And Other Revenue", "terseLabel": "Collaboration services and other revenue from a related party" } } }, "localname": "CollaborationServicesAndOtherRevenue", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "fgen_CollaborativeArrangementAggregateConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of aggregate consideration receivable under collaborative arrangement.", "label": "Collaborative Arrangement Aggregate Consideration", "terseLabel": "Aggregate consideration received" } } }, "localname": "CollaborativeArrangementAggregateConsideration", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_CommercialSalesAndOtherEventsMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Commercial sales and other events milestone.", "label": "Commercial Sales And Other Events Milestone", "terseLabel": "Commercial sales and other events milestone" } } }, "localname": "CommercialSalesAndOtherEventsMilestone", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_CommercialSalesMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of milestone payments related to commercial sales under the collaborative agreement.", "label": "Commercial Sales Milestone", "terseLabel": "Commercial sales milestone" } } }, "localname": "CommercialSalesMilestone", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract with customer liability, milestone method revenue recognized.", "label": "Contract With Customer Liability Milestone Method Revenue Recognized", "terseLabel": "Milestone payment, revenue recognition" } } }, "localname": "ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_ContractWithCustomerMilestoneMethodTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with customer milestone method.", "label": "Contract With Customer Milestone Method Table [Text Block]", "terseLabel": "Summary of Revenue Recognized under Agreement" } } }, "localname": "ContractWithCustomerMilestoneMethodTableTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables" ], "xbrltype": "textBlockItemType" }, "fgen_CumulativeDecreaseToAccumulatedDeficitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative decrease to accumulated deficit.", "label": "Cumulative Decrease To Accumulated Deficit [Member]", "terseLabel": "Cumulative Decrease to Accumulated Deficit [Member]" } } }, "localname": "CumulativeDecreaseToAccumulatedDeficitMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": { "order": 10010.0, "parentTag": "fgen_CashConsiderationReceivedUnderCollaborationAgreement", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.", "label": "Cumulative Revenue License And Development Revenue Recognized", "terseLabel": "Cumulative Revenue" } } }, "localname": "CumulativeRevenueLicenseAndDevelopmentRevenueRecognized", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" ], "xbrltype": "monetaryItemType" }, "fgen_DeferredApprovalMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred approval milestone.", "label": "Deferred Approval Milestone [Member]", "terseLabel": "Deferred Approval Milestone [Member]" } } }, "localname": "DeferredApprovalMilestoneMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "domainItemType" }, "fgen_DerecognitionBuildToSuitLeaseAssetsAccumulatedDepreciationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derecognition build to suit lease assets accumulated depreciation.", "label": "Derecognition Build To Suit Lease Assets Accumulated Depreciation [Member]", "terseLabel": "Derecognition Build to Suit Lease Assets Accumulated Depreciation [Member]" } } }, "localname": "DerecognitionBuildToSuitLeaseAssetsAccumulatedDepreciationMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_DerecognitionBuildToSuitLeaseAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derecognition build to suit lease assets.", "label": "Derecognition Build To Suit Lease Assets [Member]", "terseLabel": "Derecognition Build to Suit Lease Assets [Member]" } } }, "localname": "DerecognitionBuildToSuitLeaseAssetsMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_DerecognitionBuildToSuitLeaseLiabilitiesCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derecognition build to suit lease liabilities current.", "label": "Derecognition Build To Suit Lease Liabilities Current [Member]", "terseLabel": "Derecognition Build to Suit Lease Liabilities Current [Member]" } } }, "localname": "DerecognitionBuildToSuitLeaseLiabilitiesCurrentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_DerecognitionBuildToSuitLeaseLiabilitiesNonCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derecognition build to suit lease liabilities non current.", "label": "Derecognition Build To Suit Lease Liabilities Non Current [Member]", "terseLabel": "Derecognition Build to Suit Lease Liabilities Non Current [Member]" } } }, "localname": "DerecognitionBuildToSuitLeaseLiabilitiesNonCurrentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_DerecognitionDeferredRentCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derecognition deferred rent current.", "label": "Derecognition Deferred Rent Current [Member]", "terseLabel": "Derecognition Deferred Rent Current [Member]" } } }, "localname": "DerecognitionDeferredRentCurrentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_DerecognitionDeferredRentNonCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derecognition deferred rent non current.", "label": "Derecognition Deferred Rent Non Current [Member]", "terseLabel": "Derecognition Deferred Rent Non Current [Member]" } } }, "localname": "DerecognitionDeferredRentNonCurrentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_DescriptionOfOperationsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of operations policy.", "label": "Description Of Operations Policy Policy [Text Block]", "terseLabel": "Description of Operations" } } }, "localname": "DescriptionOfOperationsPolicyPolicyTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fgen_DevelopmentAndOtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development and other revenue.", "label": "Development And Other Revenue [Member]", "terseLabel": "Development and Other Revenue [Member]", "verboseLabel": "Development Revenue [Member]" } } }, "localname": "DevelopmentAndOtherRevenueMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "fgen_DevelopmentMilestonePaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Development milestone payment received.", "label": "Development Milestone Payment Received", "terseLabel": "Receipt of development milestone payment" } } }, "localname": "DevelopmentMilestonePaymentReceived", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_DevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development milestones.", "label": "Development Milestones [Member]", "terseLabel": "Development Milestones [Member]" } } }, "localname": "DevelopmentMilestonesMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "domainItemType" }, "fgen_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.fibrogen.com/20190630", "xbrltype": "stringItemType" }, "fgen_EstimatedJointDevelopmentExtendedServicePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimated joint development extended service period.", "label": "Estimated Joint Development Extended Service Period", "terseLabel": "Estimated joint development extended service period" } } }, "localname": "EstimatedJointDevelopmentExtendedServicePeriod", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "gYearItemType" }, "fgen_FinanceLeaseAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10100.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance lease accumulated amortization.", "label": "Finance Lease Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FinanceLeaseAccumulatedAmortization", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "fgen_FinanceLeaseAndOperatingLeaseAssets": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance lease and operating lease assets.", "label": "Finance Lease And Operating Lease Assets", "totalLabel": "Total lease assets" } } }, "localname": "FinanceLeaseAndOperatingLeaseAssets", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "fgen_FinanceLeaseAndOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance lease and operating lease liability.", "label": "Finance Lease And Operating Lease Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiability", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "fgen_FinanceLeaseCommencementFallsOrNearEndOfEconomicLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance lease commencement falls or near end of economic life.", "label": "Finance Lease Commencement Falls Or Near End Of Economic Life", "terseLabel": "Finance lease commencement falls or near end of economic life" } } }, "localname": "FinanceLeaseCommencementFallsOrNearEndOfEconomicLife", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "fgen_FinanceLeaseEconomicLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance lease economic life.", "label": "Finance Lease Economic Life", "terseLabel": "Finance lease economic life" } } }, "localname": "FinanceLeaseEconomicLife", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "fgen_FinanceLeasePaymentsEqualsOrExceedsFairValueOfUnderlyingAsset": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance lease payments equals or exceeds fair value of the underlying asset.", "label": "Finance Lease Payments Equals Or Exceeds Fair Value Of Underlying Asset", "terseLabel": "Finance lease payments equals or exceeds fair value of the underlying asset" } } }, "localname": "FinanceLeasePaymentsEqualsOrExceedsFairValueOfUnderlyingAsset", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "fgen_FinanceLeaseRightOfUseAssetsCost": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10090.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance lease, right-of-use assets - cost.", "label": "Finance Lease Right Of Use Assets Cost", "terseLabel": "Right-of-use assets - cost" } } }, "localname": "FinanceLeaseRightOfUseAssetsCost", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Impact of change in accounting principle upon adoption of ASU 2018-02.", "label": "Impact Of Change In Accounting Principle Upon Adoption Of A S U201802 [Member]", "terseLabel": "Impact of change in accounting principle upon adoption of ASU 2018-02 [Member]" } } }, "localname": "ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10310.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in accrued interest for finance lease liabilities.", "label": "Increase Decrease In Accrued Interest For Finance Lease Liabilities", "terseLabel": "Accrued interest for finance lease liabilities" } } }, "localname": "IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "fgen_IncreaseDecreaseInLeaseObligations": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10300.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase decrease in lease obligations.", "label": "Increase Decrease In Lease Obligations", "terseLabel": "Lease obligations" } } }, "localname": "IncreaseDecreaseInLeaseObligations", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "fgen_InterestAndOtherNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest and other net.", "label": "Interest And Other Net [Abstract]", "terseLabel": "Interest and other, net" } } }, "localname": "InterestAndOtherNetAbstract", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "fgen_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "fgen_LeaseObligationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease obligations.", "label": "Lease Obligations [Member]", "terseLabel": "Lease obligations [Member]" } } }, "localname": "LeaseObligationsMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "domainItemType" }, "fgen_LeaseObligationsNoncurrent": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease obligations noncurrent.", "label": "Lease Obligations Noncurrent", "terseLabel": "Long-term portion of lease obligations" } } }, "localname": "LeaseObligationsNoncurrent", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "fgen_LeaseholdImprovementsAccumulatedDepreciationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leasehold improvements accumulated depreciation.", "label": "Leasehold Improvements Accumulated Depreciation [Member]", "terseLabel": "Leasehold Improvements Accumulated Depreciation [Member]" } } }, "localname": "LeaseholdImprovementsAccumulatedDepreciationMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, finance lease, additional lease expiration period.", "label": "Lessee Finance Lease Additional Lease Expiration Period", "terseLabel": "Lessee, finance lease, additional lease expiration period" } } }, "localname": "LesseeFinanceLeaseAdditionalLeaseExpirationPeriod", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "fgen_LesseeFinanceLeaseCommencementDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, finance lease commencement date.", "label": "Lessee Finance Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "localname": "LesseeFinanceLeaseCommencementDate", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "fgen_LesseeFinanceLeaseExpirationPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, finance lease, expiration period.", "label": "Lessee Finance Lease Expiration Period", "terseLabel": "Lessee, finance lease, expiration period" } } }, "localname": "LesseeFinanceLeaseExpirationPeriod", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, finance lease, option to extend the additional lease term.", "label": "Lessee Finance Lease Option To Extend Additional Lease Term", "terseLabel": "Lessee, finance lease, option to extend the additional lease term" } } }, "localname": "LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "fgen_LesseeFinanceLeaseRemainingLeaseMaximumExpansionPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, finance lease, remaining lease maximum expansion period.", "label": "Lessee Finance Lease Remaining Lease Maximum Expansion Period", "terseLabel": "Lease maximum expansion period" } } }, "localname": "LesseeFinanceLeaseRemainingLeaseMaximumExpansionPeriod", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "fgen_LesseeFinanceLeaseRemainingTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, finance lease remaining term.", "label": "Lessee Finance Lease Remaining Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeFinanceLeaseRemainingTerm", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "fgen_LicenseFeesAndMilestonesRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.", "label": "License Fees And Milestones Revenue", "terseLabel": "License and milestone revenue from a related party" } } }, "localname": "LicenseFeesAndMilestonesRevenue", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "fgen_LongTermPortionOfCapitalLeaseObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long term portion of capital lease obligations.", "label": "Long Term Portion Of Capital Lease Obligations", "terseLabel": "Long-term portion of lease obligations" } } }, "localname": "LongTermPortionOfCapitalLeaseObligations", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "monetaryItemType" }, "fgen_LongTermPropertyLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term property lease.", "label": "Long Term Property Lease [Member]", "terseLabel": "Long-term property lease [Member]" } } }, "localname": "LongTermPropertyLeaseMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fgen_NumberOfFinanceLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of finance leases.", "label": "Number Of Finance Leases", "terseLabel": "Number of finance leases" } } }, "localname": "NumberOfFinanceLeases", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "fgen_NumberOfOperatingLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating leases.", "label": "Number Of Operating Leases", "terseLabel": "Number of operating leases" } } }, "localname": "NumberOfOperatingLeases", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "fgen_NumberOfRegulatoryMilestones": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of regulatory milestones.", "label": "Number Of Regulatory Milestones", "terseLabel": "Number of regulatory milestones" } } }, "localname": "NumberOfRegulatoryMilestones", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "fgen_OperatingLeaseAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10080.0, "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating lease, accumulated amortization.", "label": "Operating Lease Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "OperatingLeaseAccumulatedAmortization", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "fgen_OperatingLeaseRightOfUseAssetsCost": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10070.0, "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating lease, right-of-use assets - cost.", "label": "Operating Lease Right Of Use Assets Cost", "terseLabel": "Right-of-use assets - cost" } } }, "localname": "OperatingLeaseRightOfUseAssetsCost", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "fgen_OtherRevenuesPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other revenues policy.", "label": "Other Revenues Policy [Text Block]", "terseLabel": "Other Revenues" } } }, "localname": "OtherRevenuesPolicyTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to acquire available for sale securities and term deposit.", "label": "Payments To Acquire Available For Sale Securities And Term Deposit", "negatedLabel": "Purchases of available-for-sale securities and term deposit" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage increases on each anniversary of rent commencement date.", "label": "Percentage Increases On Each Anniversary Of Rent Commencement Date", "terseLabel": "Percentage increases on each anniversary of rent commencement date" } } }, "localname": "PercentageIncreasesOnEachAnniversaryOfRentCommencementDate", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "fgen_PercentageOfFundingForCosts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.", "label": "Percentage Of Funding For Costs", "terseLabel": "Percentage of joint development costs committed to fund" } } }, "localname": "PercentageOfFundingForCosts", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "fgen_PotentialMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.", "label": "Potential Milestones", "terseLabel": "Potential milestone payments" } } }, "localname": "PotentialMilestones", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.", "label": "Proceeds From Upfront Non Contingent And Non Refundable Payments", "terseLabel": "Proceeds from upfront, non-contingent and non-refundable payments" } } }, "localname": "ProceedsFromUpfrontNonContingentAndNonRefundablePayments", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.", "label": "Proceeds From Upfront Non Contingent And Time Based Payments", "terseLabel": "Upfront, non-contingent and time-based payments received" } } }, "localname": "ProceedsFromUpfrontNonContingentAndTimeBasedPayments", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.", "label": "Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments", "terseLabel": "Upfront, non-contingent, non-refundable and time-based payments" } } }, "localname": "ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_PropertyTaxesAndOtherCurrent": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Property taxes and other current.", "label": "Property Taxes And Other Current", "terseLabel": "Property taxes and other" } } }, "localname": "PropertyTaxesAndOtherCurrent", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recently issued accounting guidance not yet adopted.", "label": "Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]", "terseLabel": "Recently Issued Accounting Guidance Not Yet Adopted" } } }, "localname": "RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recently issued and adopted accounting guidance.", "label": "Recently Issued And Adopted Accounting Guidance Policy [Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Guidance" } } }, "localname": "RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fgen_RecognitionFinanceLeaseAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recognition finance lease assets.", "label": "Recognition Finance Lease Assets [Member]", "terseLabel": "Recognition Finance Lease Assets [Member]" } } }, "localname": "RecognitionFinanceLeaseAssetsMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_RecognitionFinanceLeaseLiabilitiesCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recognition finance lease liabilities current.", "label": "Recognition Finance Lease Liabilities Current [Member]", "terseLabel": "Recognition Finance Lease Liabilities Current [Member]" } } }, "localname": "RecognitionFinanceLeaseLiabilitiesCurrentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_RecognitionFinanceLeaseLiabilitiesNonCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recognition finance lease liabilities non current .", "label": "Recognition Finance Lease Liabilities Non Current [Member]", "terseLabel": "Recognition Finance Lease Liabilities Non Current [Member]" } } }, "localname": "RecognitionFinanceLeaseLiabilitiesNonCurrentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_RecognitionOperatingLeaseAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recognition operating lease assets.", "label": "Recognition Operating Lease Assets [Member]", "terseLabel": "Recognition Operating Lease Assets [Member]" } } }, "localname": "RecognitionOperatingLeaseAssetsMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_RecognitionOperatingLeaseLiabilitiesCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recognition operating lease liabilities current.", "label": "Recognition Operating Lease Liabilities Current [Member]", "terseLabel": "Recognition Operating Lease Liabilities Current [Member]" } } }, "localname": "RecognitionOperatingLeaseLiabilitiesCurrentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_RecognitionOperatingLeaseLiabilitiesNonCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recognition operating lease liabilities non current.", "label": "Recognition Operating Lease Liabilities Non Current [Member]", "terseLabel": "Recognition Operating Lease Liabilities Non Current [Member]" } } }, "localname": "RecognitionOperatingLeaseLiabilitiesNonCurrentMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "fgen_RegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regulatory milestone.", "label": "Regulatory Milestones [Member]", "terseLabel": "Regulatory Milestone [Member]" } } }, "localname": "RegulatoryMilestonesMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "domainItemType" }, "fgen_RestrictedTimeDepositsNoncurrent": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restricted time deposits noncurrent.", "label": "Restricted Time Deposits Noncurrent", "terseLabel": "Restricted time deposits" } } }, "localname": "RestrictedTimeDepositsNoncurrent", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right-of-use assets obtained in exchange for new lease liabilities.", "label": "Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for new lease liabilities:" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" ], "xbrltype": "stringItemType" }, "fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of lease assets and related lease liabilities.", "label": "Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]", "terseLabel": "Schedule of Lease Assets and Related Lease Liabilities" } } }, "localname": "ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of lease term and discount rate.", "label": "Schedule Of Lease Term And Discount Rate Table [Text Block]", "terseLabel": "Schedule of Lease Term and Discount Rate" } } }, "localname": "ScheduleOfLeaseTermAndDiscountRateTableTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of maturities of finance and operating leases liabilities.", "label": "Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]", "terseLabel": "Schedule of Maturities of Finance and Operating Leases Liabilities" } } }, "localname": "ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.", "label": "Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]", "terseLabel": "Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of supplemental cash flow information related to leases.", "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares issued from stock plans net of payroll taxes paid shares.", "label": "Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares", "terseLabel": "Shares issued from stock plans, net of payroll taxes paid, Shares" } } }, "localname": "SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "fgen_ShorensteinPropertiesLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shorenstein properties LLC.", "label": "Shorenstein Properties L L C [Member]", "terseLabel": "Shorenstein Properties LLC [Member]" } } }, "localname": "ShorensteinPropertiesLLCMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fgen_ShortTermInvestmentsMaximumMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short term investments maximum maturity period.", "label": "Short Term Investments Maximum Maturity Period", "terseLabel": "Short term investments maturity" } } }, "localname": "ShortTermInvestmentsMaximumMaturityPeriod", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "fgen_SuppliesNet": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Supplies, net.", "label": "Supplies Net", "terseLabel": "Net unbilled contract asset", "totalLabel": "Net unbilled contract assets", "verboseLabel": "Net unbilled contract asset" } } }, "localname": "SuppliesNet", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "fgen_TermDepositMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term deposit.", "label": "Term Deposit [Member]", "terseLabel": "Term deposit [Member]" } } }, "localname": "TermDepositMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "fgen_TransactionPriceAllocatedToPerformanceObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Transaction price allocated to performance obligations.", "label": "Transaction Price Allocated To Performance Obligations", "terseLabel": "Transaction price and allocated to performance obligations" } } }, "localname": "TransactionPriceAllocatedToPerformanceObligations", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "fgen_UnitedStatesAndRestOfWorldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "United states and rest of world.", "label": "United States And Rest Of World [Member]", "terseLabel": "U.S./RoW [Member]" } } }, "localname": "UnitedStatesAndRestOfWorldMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" ], "xbrltype": "domainItemType" }, "fgen_UnitedStatesRestOfWorldAndChinaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "United States/Rest of World and China.", "label": "United States Rest Of World And China [Member]", "terseLabel": "U.S./RoW and China [Member]" } } }, "localname": "UnitedStatesRestOfWorldAndChinaMember", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" ], "xbrltype": "domainItemType" }, "fgen_UnrealizedGainLossOnCashEquivalentsAndShortTermEquityInvestments": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrealized gain loss on cash equivalents and short term equity investments.", "label": "Unrealized Gain Loss On Cash Equivalents And Short Term Equity Investments", "negatedLabel": "Unrealized loss (gain) on cash equivalents and short-term equity investments" } } }, "localname": "UnrealizedGainLossOnCashEquivalentsAndShortTermEquityInvestments", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Variable consideration payment received from estimated future co-development billing.", "label": "Variable Consideration Payment Received From Estimated Future Co Development Billing", "terseLabel": "Remainder of transaction price, variable consideration from estimated future co-development billing" } } }, "localname": "VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" ], "xbrltype": "monetaryItemType" }, "fgen_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted-average discount rate.", "label": "Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted-average discount rate:" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" ], "xbrltype": "stringItemType" }, "fgen_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted-average remaining lease term.", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted-average remaining lease term (years):" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.fibrogen.com/20190630", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" ], "xbrltype": "stringItemType" }, "invest_InvestmentsScheduleAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments Schedule [Abstract]" } } }, "localname": "InvestmentsScheduleAbstract", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r130", "r167", "r169", "r318", "r319" ], "lang": { "en-US": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r131", "r167", "r170", "r320", "r329", "r330" ], "lang": { "en-US": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update201601 [Member]", "terseLabel": "ASU 2016-01 [Member]" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update201602 [Member]", "terseLabel": "ASU 2016-02 [Member]", "verboseLabel": "Accounting standards update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201802Member": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2018-02 Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.", "label": "Accounting Standards Update201802 [Member]", "terseLabel": "ASU 2018-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201802Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r22", "r132", "r133", "r168" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10300.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable ($4,311 and $47,210 from a related party)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r46", "r98", "r266", "r268", "r269" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable Related Parties Current", "terseLabel": "Accounts receivable from related party" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r90" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Net amortization of premium and discount on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities And Other Liabilities", "terseLabel": "Accrued and other current liabilities ($781 and $444 to a related party)" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r9", "r10", "r40" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r155" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: accumulated depreciation", "verboseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r60", "r61", "r62" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r59", "r62", "r63", "r214" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r23" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Information by type of change in accounting principle. Does not include error corrections.", "label": "Adjustments For Change In Accounting Principle [Axis]", "terseLabel": "Adjustments for Change in Accounting Principle" } } }, "localname": "AdjustmentsForChangeInAccountingPrincipleAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r177", "r179", "r193", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r160", "r161" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs", "terseLabel": "Adjustment to issuance costs for Follow-on Offerings" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r179", "r189", "r192" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Anti-dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r128", "r291", "r309" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r54" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Total fair value of financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available For Sale Securities", "terseLabel": "Fair Value", "verboseLabel": "Investments" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r136" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Gross Unrealized Holding Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Gross Unrealized Holding Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available For Sale Securities Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.", "label": "Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments", "negatedLabel": "Realized gain on sales of available-for-sale securities" } } }, "localname": "AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r180", "r190" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r218", "r219" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r242" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases.", "label": "Capital Leases Future Minimum Payments Due", "totalLabel": "Total minimum payments" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r242" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail": { "order": 10010.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due Current", "terseLabel": "2019" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r242" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail": { "order": 10050.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due In Five Years", "terseLabel": "2023" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r242" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail": { "order": 10040.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due In Four Years", "terseLabel": "2022" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r242" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail": { "order": 10030.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due In Three Years", "terseLabel": "2021" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r242" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail": { "order": 10020.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases Future Minimum Payments Due In Two Years", "terseLabel": "2020" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsOnConsolidatedBasisUnderCompanySFacilityFinancingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r33", "r321", "r322" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": { "order": 10010.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash And Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r33", "r91" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10280.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Assets fair value disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r86", "r91", "r92" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Total cash and cash equivalents at end of period", "periodStartLabel": "Total cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r86", "r234" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Certificate of deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A change from one generally accepted accounting principle to another generally accepted accounting principle when there are two or more generally accepted accounting principles that apply or when the accounting principle formerly used is no longer generally accepted. A change in the method of applying an accounting principle that is not treated as a change in accounting estimate also is considered a change in accounting principle.", "label": "Change In Accounting Principle [Member]", "terseLabel": "Adjustments for Change in Accounting Principle" } } }, "localname": "ChangeInAccountingPrincipleMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement Accounting Policy", "terseLabel": "Collaboration Arrangements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r204", "r205", "r208" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement [Member]" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r159", "r298", "r314" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r160" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2019 and December 31, 2018; 86,847 and 85,432 shares issued and outstanding at June 30, 2019 and December 31, 2018" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r66", "r68", "r69" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r162", "r163", "r168" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10050.0, "parentTag": "fgen_SuppliesNet", "weight": -1.0 }, "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": { "order": 10020.0, "parentTag": "fgen_CashConsiderationReceivedUnderCollaborationAgreement", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "negatedLabel": "Deferred revenues from associated contracts", "terseLabel": "Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Contract With Customer Liability [Abstract]", "terseLabel": "Contract with Customer, Liability [Abstract]" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "auth_ref": [ "r164" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.", "label": "Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized", "terseLabel": "Changes in revenue due to prior period adjustment of performance obligations" } } }, "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r162", "r163", "r168" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r162", "r163", "r168" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract With Customer Liability Noncurrent", "terseLabel": "Deferred revenue, net of current", "verboseLabel": "Long-term deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRentCreditNoncurrent": { "auth_ref": [ "r44", "r239" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.", "label": "Deferred Rent Credit Noncurrent", "terseLabel": "Deferred rent" } } }, "localname": "DeferredRentCreditNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r89", "r153" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r3", "r13", "r21", "r96", "r266" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due From Related Parties Current", "terseLabel": "Prepaid expenses and other current assets from related party", "verboseLabel": "Due from Related Parties, Current" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r38", "r98", "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due To Related Parties Current", "terseLabel": "Accrued and other current liabilities to related party", "verboseLabel": "Accrued liabilities to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r75", "r103", "r110", "r111", "r112", "r113", "r117", "r301", "r316" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share Basic And Diluted [Abstract]", "terseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r75", "r103", "r110", "r111", "r112", "r113", "r117", "r301", "r316" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r93", "r114", "r115", "r116" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r234" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "terseLabel": "Effect of exchange rate change on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r199", "r200", "r201" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "U.S. federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Payroll and related accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Employee stock options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r14", "r18", "r143", "r297", "r306", "r328" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity investments [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r220", "r221", "r222", "r228" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Assets Level1 To Level2 Transfers Amount", "terseLabel": "Transfers of assets from level 1 to 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Assets Level2 To Level1 Transfers Amount", "terseLabel": "Transfers of assets from level 2 to 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r220", "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Fair Values of Financial Assets Measured on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r173", "r174", "r176", "r221", "r273" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r227", "r228" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Fair Value By Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r220", "r221", "r223", "r224", "r229" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r173", "r174", "r176", "r221", "r274" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r173", "r174", "r176", "r221", "r275" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r173", "r174", "r176", "r221", "r276" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount", "terseLabel": "Transfers of liabilities from level 1 to 2" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount", "terseLabel": "Transfers of liabilities from level 2 to 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r220", "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]", "terseLabel": "Fair Values of Financial Liabilities Carried at Historical Cost" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "auth_ref": [ "r226" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3", "terseLabel": "Transfers of liabilities into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r226" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3", "terseLabel": "Transfers of liabilities out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r226" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3", "terseLabel": "Transfers of assets into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r226" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3", "terseLabel": "Transfers of assets out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r227", "r229" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r247", "r255", "r264" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": { "order": 10020.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r249", "r258" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease Interest Payment On Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease Liabilities Payments Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r246", "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": { "order": 10040.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease Liability", "terseLabel": "Lease payment liability", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r246" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10010.0, "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability", "weight": 1.0 }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease Liability Current", "terseLabel": "Finance lease liabilities, current", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r246" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10030.0, "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability", "weight": 1.0 }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Liability Noncurrent", "terseLabel": "Finance lease liabilities, non-current", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Payments Due", "totalLabel": "Total future lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10100.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Five", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10090.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Four", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10080.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Three", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10070.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Two", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10060.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "2019 (Remaining six month period)" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": { "order": 10030.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r248", "r258" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease Principal Payments", "negatedLabel": "Repayments of finance lease liabilities", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r245" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10050.0, "parentTag": "fgen_FinanceLeaseAndOperatingLeaseAssets", "weight": 1.0 }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease Right Of Use Asset", "terseLabel": "Finance lease right-of-use assets", "totalLabel": "Finance lease right-of-use assets, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r247", "r255", "r264" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": { "order": 10010.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of finance lease right-of-use assets", "verboseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r261", "r264" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease Weighted Average Discount Rate Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r260", "r264" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease Weighted Average Remaining Lease Term1", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r231", "r232", "r233" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain Loss Realized", "negatedLabel": "Realized foreign currency gain" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r89", "r152", "r157" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain Loss On Disposition Of Assets", "negatedLabel": "Loss (gain) on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]", "terseLabel": "Geographic Distribution" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]", "terseLabel": "Geographic Distribution" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionForeignMember": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Allocation of business activity identified as foreign.", "label": "Geographic Distribution Foreign [Member]", "terseLabel": "Foreign subsidiaries [Member]" } } }, "localname": "GeographicDistributionForeignMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r73", "r103", "r289", "r299", "r317" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r127", "r202" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r88" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r88" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r88" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10290.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r88" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10320.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase Decrease In Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r88" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase Decrease In Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r88" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest And Other Income", "terseLabel": "Interest income and other, net" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r72", "r126", "r236", "r237", "r302" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income Expense Nonoperating Net", "totalLabel": "Total interest and other, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r48" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": { "order": 10030.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory Finished Goods", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r51", "r147" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10310.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r52", "r93", "r118", "r148", "r149" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory Policy [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r50" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": { "order": 10010.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Raw Materials", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r51", "r99", "r147", "r150" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Provision to write-down excess and obsolete inventory" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r49" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": { "order": 10020.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory Work In Process", "terseLabel": "Work-in-progress" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r324", "r325", "r326", "r327" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r324", "r325", "r326", "r327" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement Type [Axis]", "terseLabel": "Lease Arrangement, Type" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement Type [Domain]", "terseLabel": "Lease Arrangement, Type" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r262", "r264" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease Cost [Abstract]", "terseLabel": "Finance lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Components of Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases Of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeFinanceLeaseDescription": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Description of lessee's finance lease.", "label": "Lessee Finance Lease Description", "terseLabel": "Finance lease, description" } } }, "localname": "LesseeFinanceLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend finance lease.", "label": "Lessee Finance Lease Existence Of Option To Extend", "terseLabel": "Lessee, finance lease, existence of option to extend" } } }, "localname": "LesseeFinanceLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeFinanceLeaseOptionToExtend": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's finance lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Finance Lease Option To Extend", "terseLabel": "Lessee, finance lease, option to extend" } } }, "localname": "LesseeFinanceLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Finance Lease Term Of Contract1", "terseLabel": "Lessee, finance lease, initial lease term" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "2019 (Remaining six month period)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r263" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Lessee, operating lease, lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r293", "r312" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities, stockholders\u2019 equity and non-controlling interests" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities, stockholders\u2019 equity and non-controlling interests" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r220" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "terseLabel": "Liabilities fair value disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.", "label": "Liabilities Other Than Longterm Debt Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License Revenue [Member]", "verboseLabel": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r34" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long Term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r47", "r292", "r311" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Minority Interest", "terseLabel": "Non-controlling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": { "order": 10030.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds At Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86", "r87", "r90" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r64", "r67", "r74", "r90", "r115", "r300", "r315" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail": { "order": 10010.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome": { "auth_ref": [ "r101", "r104" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the effect of a change in accounting principle on net income.", "label": "New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Net Income", "terseLabel": "Impact of change in accounting principle upon adoption" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r256", "r264" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": { "order": 10030.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities Payments Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r246" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r246" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10020.0, "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r246" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10040.0, "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r250", "r258" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r245" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 10060.0, "parentTag": "fgen_FinanceLeaseAndOperatingLeaseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "totalLabel": "Operating lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r261", "r264" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r260", "r264" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r238", "r240" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases Future Minimum Payments Due", "totalLabel": "Total minimum payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r238", "r240" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due Current", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r238", "r240" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail": { "order": 10050.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r238", "r240" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail": { "order": 10040.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r238", "r240" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail": { "order": 10030.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r238", "r240" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderAllNonCancelableOperatingLeaseObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r40" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": { "order": 10050.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r17", "r290", "r308" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10030.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10270.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Available-for-sale investments:" } } }, "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r57", "r58", "r60" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax", "terseLabel": "Change in unrealized gain or loss on investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r56", "r235" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10030.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r65", "r68", "r70", "r160" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income Loss Net Of Tax", "totalLabel": "Other comprehensive income, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r57", "r60" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10040.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized gain on investments, net of tax effect" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other Than Temporary Impairment Losses Investments Availableforsale Securities", "terseLabel": "Other-than-temporary impairment loss" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r84" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Cash paid for payroll taxes on restricted stock unit releases" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r82" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2019 and December 31, 2018" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r31", "r32" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10320.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets ($127,981 and $0 from a related party)", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Prepaid Expense And Other Assets Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r151" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid assets" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r83" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r81" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds From Sale Maturity And Collections Of Investments", "terseLabel": "Proceeds from maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": { "auth_ref": [ "r79", "r135" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.", "label": "Proceeds From Sale Of Available For Sale Securities", "terseLabel": "Proceeds from sales of available-for-sale securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r80" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds From Sale Of Property Plant And Equipment", "terseLabel": "Proceeds from sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r64", "r67", "r85", "r128", "r129", "r211", "r212", "r213", "r216", "r217" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r154" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, gross", "verboseLabel": "Building shell cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r156", "r313" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r156" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r154" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction Expenses From Transactions With Related Party", "terseLabel": "Expense related to collaboration agreements" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r175", "r267", "r268", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "Repayments Of Debt And Capital Lease Obligations", "negatedLabel": "Repayments of lease obligations" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r197", "r198" ], "lang": { "en-US": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r197", "r198" ], "lang": { "en-US": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r196", "r331" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r161", "r310" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToCondensedConsolidatedBalanceSheetUponAdoptionOf842GuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue From Contract With Customer [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r166", "r167" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r94", "r172" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Deferred Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r76", "r323" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue From Related Parties", "terseLabel": "Revenue related to collaboration agreements" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.", "label": "Revenue Recognition Multiple Deliverable Arrangements [Table]", "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Table]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r165" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Revenue during period from performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r259", "r264" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r259", "r264" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r137", "r138", "r139", "r140", "r141", "r142", "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule Of Available For Sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule Of Cash And Cash Equivalents Table [Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r179", "r188", "r192" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r179", "r188", "r192" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Schedule of Allocated Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r105", "r106", "r107" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule Of Error Corrections And Prior Period Adjustments [Text Block]", "terseLabel": "Schedule of Impacts Upon Adoption of New Guidance" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule Of Future Minimum Lease Payments For Capital Leases Table [Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments on Consolidated Basis Under Company's Facility Financing Lease Obligations" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments Under all Non-Cancelable Operating Lease Obligations" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r28", "r29", "r30" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule Of Inventory Current Table [Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r36", "r156" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r97", "r267", "r268", "r269", "r270", "r271" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r180", "r190" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r77", "r146" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average estimated fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r178", "r181" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r183", "r191" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r18", "r294", "r295", "r297", "r307" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10290.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r45", "r160" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Stock Compensation Plan [Member]", "terseLabel": "2014 Employee Share Purchase Plan [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndPurchasesUnder2014EmployeeSharePurchasePlanDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r25", "r26", "r134" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r209", "r210", "r215" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r257", "r264" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": { "order": 10040.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_Supplies": { "auth_ref": [ "r5", "r7" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10040.0, "parentTag": "fgen_SuppliesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Supplies", "terseLabel": "Unbilled contract assets", "verboseLabel": "Unbilled contract asset" } } }, "localname": "Supplies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type Of Adoption [Member]", "terseLabel": "Type of Adoption" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactsToAccumulatedOtherComprehensiveLossAndAccumulatedDeficitUponAdoptionOfGuidanceDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstellasAgreementsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsAstrazenecaAgreementsAdditionalInformation1Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsDeferredRevenueAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderAgreementDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureCollaborationAgreementsTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentSecuritiesAtCarryingValue": { "auth_ref": [], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": { "order": 10020.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "U S Government Securities At Carrying Value", "terseLabel": "US treasury notes and bills" } } }, "localname": "USGovernmentSecuritiesAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r173", "r176", "r296" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "US treasury notes and bills [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail", "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r119", "r120", "r121", "r122", "r123", "r124", "r125" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r113" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail": { "order": 10030.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Dilutive effect of potential common shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r109", "r113" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Diluted", "totalLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r108", "r113" ], "calculation": { "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail": { "order": 10020.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract]", "terseLabel": "Weighted average number of common shares used to calculate net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.fibrogen.com/20190630/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfReconciliationOfBasicAndDilutedNetIncomeLossPerShareCalculationDetail", "http://www.fibrogen.com/20190630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874292-224272" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r332": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r333": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r334": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r335": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r336": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r337": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.26(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(7)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657190&loc=SL116659633-172590" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" } }, "version": "2.1" } ZIP 74 0001564590-19-030812-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-030812-xbrl.zip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�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
V M*;#W\WI%N<1S?"WIJ0AC0#MYQR$LF"-SWV7Y)Y.D:M&,(GT2%P61>RUM$-!R MO8F(2$D$HU$0YT5-HDT9CYK_8@P,TK$-?A@9L&Q+'*BX-R[!D8BA %?I/HUH MV0$U#6RQ'WB__U7;&M^?F 8DX.;D!^V/%?'G)_'&%NR9R'2 EGL9KC%IK6_EGE]W#E[L'E]5#M*R\WK?OW0?MNS>VQ 'M?T^A4LMKZQ MNL46VQ.:2.O81ANP2?S'&B2F,0-?Q_,C:-H0UV",^D;A*16UMTHEGJVM$LU. MPP_5D4\2&%T5XKX2P"_IC>_])E*1(ZH ^?1!&BR*'.6&F]TJ=Q]AL*)Y78" MT G06RY)"&@"&+L($FE%P\X_B2;!J>LF(-[2^W<5*&9&TX^]ES_6 M.T*V@.<-%0/;$: /LYD0A_/BFO8C/HNPPN7]>C]!XBN)ZX/HN<&?2:W&_"MB M1.""%,40R+\0[]S24!U%;J_^#O!/IJ\#E;&@MR,U LC-D2!A :6"_8$?PA?"K-#6'62\9D,-05B/Z]B6AB_I&[[Y&Z+(D.M M %N[B\NQEPU+*869#N)4_3P-Z.*GL\W6,5XG XC#& \#]!SPQ>LB$N] >:Z^ M:M5_Q 50V1/VD &*:HKWI7R5FB'0I*4F6<'0]"NOO8&,C,W66JK&;(U\\5FJ M[@0X0F'OZLT%(/_?59PK% Z!#1!JPMD+)NP$C+[N!=^7 'A#3LDJ@^F?ET#5Z##=XS MT3@-9GF6)-+@F),0<[8&(P>%&>-KJ4#SP6#"NWTRK6$1 !FO7=3>T:)D78[^ M;>:P15:J"7?.J0-PGI[]\!5N !=\CH;O-R="FV[DJ>D1K^4E&A[6/^'[9EMN]G'9%P$H>P?<0VGZ,J_48-^M-.^26V>:UP*V1 M+:5T&Z]IA6T$_+[FS<"^A^*?,O:]4SE& Y=CY'*,ME6WVQ*G7VUCG'4&S:!V MEVT,RRX;OFJ0W;*SKF]_G9G6U%KVUY%I5ZVPO_JK[2_+(#9O#AJ[?W)ST+*C M/\PZM6SSW\98MNS05MGNEL%FSI6P;7?:L[%L8W..EF6[>\(+/;\/EFPQ[5L7/+XRT'W MP M%@IU.0R D_;,LEZ2?&QM]$51E]E(63(99D@330KQ0_WCIJ1K9KFR-K=NI M?N-^MH-^Y^31T^B6AF2^I+)SDWZN'?W2^T=6(61!5"RKO3U;I_;V25&C>P^? M?,.9F\LKWH\ZI^NU\=X;K%W3UG\V/O=EA7K #Y$Z[;*EV<9;SPGU" M_-EFN]DI'7LEX-[PR#9(ME['F.; MG*3<(TGI!.$V"<+C$R<('X;61P_!<%)PCZ2@LQ=W2$P>.3'Y8+3^X,2D=3BQ M0TP^O^>NRDE!*S280\WV*"@7T'"AWQU!BWV"T)GR3E+NNZ1TH5_[T&*?I'2" M<)L$8=?%-%SH=^MQ8I\4=/;B#HG)0>?HS(E)%_K==IS8(29=>K;=Z=G+Q2!G M;.\Q3JQ @RN],NR#0<\& ^%DT!GT]P@GSR)L+Y7+B2U9501I5/QH'Z>XVJO- MXX#T_=YPQA/J\8NW;[MO+[Z5'G\"#+0 ?#/-U53G/T8&R";^!XTW\OG?J2A? M/)97OAIBVC3[+N'ERT34UP.[/6KB&[3%M!0)QW0G=R\>-J8Z]ATKY3#;9BQK&'#4AP5ST[2_E./]^G&KHNE&XM/F^W^T=68>9?>,-6T64\Q8<]>\M&EQ5%861 MK,/+OK&'C?[";E=3;:RKM]/$EH%]ST2-C3Z:B]L]Z_G'W5/K4+-OS&&C'G9: MP1&^TPK[J16._>/-C75US+%O6L'=YCBRMULGN,JI([_;ZUN'F7WC#5M%E/,6 M'/7O+1I*Q5)4<:CV2;"UT[;9D=_K'V]8 MZ-DU3=P:U&R6LYQ"L@<73B%M/ZJ<0EJW,N#DR"DD*U'C%-)NW$8Z=;0W3+-" M'1W?$Q!RZ@C1U_./SAY=N^S4T>YREA7JR.'"\\.2S@_=/M1Y<*BZZ'OS!]T'YU%Y>R"W>4LIY#L MP8532-N/*J>0UDT<.>T]NCC<*:3=Y2PK%)*[IW/J:"=0Q>6%3AW=A[Z!?WSF MXJ96HL:I(X<+QR?;@1LN5W3W=.O@Z]3I&ROQ8@,?<7&CTS=/4P3YI36HJXH@ MHZP:)L+K=YX0*?W3SN#8;L1<9V60>+&JA7R:(LBGP5.KK?8UT&0Y[UC:T:TF=-F:S7][CZZ^M(ILYWLX&2%'MN)"UVGQ6QB*!NUF%DEX[38%_AD M1\\W-E[0J3%[):@5NLSAPO')5N"FM6KS\>C9:97S;. /^F>.EVS$S<9=IY:B MS3U4-QN;;^BTOCV:Q?FPN^[#NDCLDZ#VQ#]]_N@,,V=/[*X$==K,'EPX;>:T MF=-FZ[C'9]V-30ASRLQJY]C=*SHMMDL,9:,6Z[I[Q21+#V\8\RS>? MIR(MQ,\_X9NO$"I+3GZR]L$W@]%?!3PBO-K"CXK MSO!,JDA$WC2836#GA3<)(N'!^UX\F58E_$6_DXLDP%^4F5>.X9D@C).XG'F) M"&"E49P&:0B%2#H;8YO%6%&);078UBE MXYV/X)->$&537,7+1M[YU85W=M3W@@)_^GN05D$^\_A+\%[A>W MP!L4W,P M:;1558>I'QE@'^S@HB[O4M MI^(%6 +_YHR-[_N=K@=[2N"0O@>8.AW\0!A#.)7C7 AO HN."T^D2-Q_KU+A M#;J*6A!RWQ^M6**(/Z]<(,PFJ!8T_HI@(KRIR.,L FKR9B( ZKW)?"^JA'HF MBD7F5 MB*+CK<+ZK@GMRWH(\7NNO_\#Z^^W782O'K)LR"DI6VJ2D2\ ":9 H$A/(,7" MH!C[]+^>^'<5@Z5%LAY7C=-;>(UDOX\, &=(O;#*@53#&9M 04B$>1/$(-&? M)5E1B.)''X38! BPPO^@V!EYH 991Y0HGP-X4G[&E+?P")S]<%2EM'"0 MU-^#57"_134LXBB&([+4E!IG\07')R_@F 7SDS[C:N[8&IG8 M3A;P6R4A>YWCAG@[/KE70JXAW1K"K29"*>;,CWIC.#3(K%J4/8(@D8"R,"95 M>1>78]J.7#BX%7EP([QAD*!:YW=A!X/Y'2!@JK1!)FH7L/U/@DQ=VD4Y:W(# M0*&,@R1!LAP!)7O#6?,+AAH/8$UQ6 (YU!2YP$WT[:C*45;C40""@!*"*,-W M-Q3VO<0YZ)PT=>_)/;KWRTEST#G:.&GV=XHTC:A12(;JRVTBUL&1/,\X5P>: M LX.AP"B3X3/@0>B?O3+P7?7[R\>8%U=$]V! MXKR =9'@M$$5+#.JO@8XS&#K%W^2E[U_U6VSDC>VBP]Y=AL7*&L4=5BQ+=0C MTBFX#CZ+8K4O\ W(5H;06)9SM/&7@^X!6,M)@I%>D+CZ9QFLI)\;&WT15&7V M4L8JPRQ)@FDA7JA_O/1D2+,+.SW89(^XHU[G^6/[]BU5*%\29MWWJZ)>Y^R> M<0P;3P\B!)PI^*]$U5,B G:"DN&7@Y,#"U),^B=K#Q3^!EQC!]JNR4]]Q\[ M&^T,,#8'77_CUWK?XKK.#E38(T+%WG_#@))GM:+N*/]LLQVQJ@VT'PA;Y M;,/-EZTSK&W%DS.Q[4&$5DQ]&Q13K_^H8J3]UEP8=W?ZR3JTV"'W'E'>XE26 MDY2[B5?,L'.2TCJT6"I,1BO18IT@=":CDY1[+RF=R6@?6BP* M_B[E-XX'[PVGV-K?@T*_>\,&IM;I'=F@=HZ/J67 WO#!LPA3OG*JH2C'654$ M:51LK)!V5=\;IRX>H2Z^='CN@]3%+A4QRXQ/JO[YT1MR :RL0R@Y#;25129Q M%"5B$QCY2JK#&HQL=HKTIB63-6AX=#.MKX>!'GF*^]V5I-<[\?O=1SM_CCUV M7$IAG,Q!W1&_TPW[IQN>]0?^X.C1K>L=>VRZ/Y53"TXM;#$:G%JP$BVG7?_T M]-$]X!UW[+B0XL&IQQ .9P>V8>8 MO>>/'2P(Z@TZIW:CXR#5]V. MR^G;- Y^L \#SI%S=+^W:'!ZX>#5LV[')?1M&@D_.LW@1-(^$KZM:'": 3T& MIQ@VC0.G%YQ VD>ZMQ4-3B\XC\$*)#0]!GGO\Q,-?X7?REFP;3.'3Z9MU-@X MZ$9G25_34'!98%,L5-CH^>TE#6W$B>>MD]R]09>'N=,CV #7NQ.Y4'/:U5QR M6G-AY+@!+NL'C/]*H^ZK:9826'AEG*D=W 9QPH/=;V/8:"A\#U@D'",\DRJ" M3>( ^'%AT'B95.!0[K3&QS%CA\.Z*5<3+,<9[R'U:1* KKIPHGRV ,/ M%BE@.>J!)Z8XX!L^(KQQ ,^( LDQ+L;P*B(AA /$*<-_$L1IB:/@ V]4)0D* MD(KF@WM!DF1W^&$OP%GQ14F[C,1(Y#G.F0\^>P%\MRS@/_BI* -8E'+ ?)G, MO*%(8H&7<>.@E(/H>66 23G."J'>CPL@&R"))/XDX#UX/L6E5E*#W0.[?[_\ MQY^7KR^O_\<[_^.U=W'^X?+Z_'?OXYNK]W]^O'ASM>)@ZTN%39SK;9P"1<1 MHA=9&L6(S>))#K,9EOU+,DC->D!^HXID%Q*[Y$,4?],<&"N>\A-Y-B$>+P)@ M:J!FD(H@]P 6?C)>\9#+$WJ_#+)<,>0."=@)0PV:PMUERB\O!VB(%5IH&,_J3[P$@@>'AU 5] M <3K9%CE!;U)0CL"IDRR*?U?-7D9X,E!;H^".">E /HG !D=)$5F:#00_8%7 #A" M6D2?L^/=BY-B#,KLD+:%GTPRL";I)V/;A)[CLY-.7^&'GOV^U^T\5[]!O5A, M.?$C6?GA %"!<,=%^R>=KEX3?H$874XE=W#.L4A0*I0%Z'!68<+[LW/50?K MMY4E4U1#>"0&.@ 6 -P/A5>A95 3!S(AOG$Q!G%J")DM5GCOM<5R(8G[(\(O M9WFUQ2KB.O,BX(7:F$(;YT:D>%PRIV9 ?K<"K2F2Y2#>HRHL236 5/U+VT6? MP!,"LT\ O:(E/:(5[X ]6H/6$Q\1H)'ZM(O%T![Q,YIN6(1KTKA?UDS5& % M)KB+;$C:)A_'E5E ME0O]6=A0%",(^0"PO1CU:"GM0@4$TR;59Y*&K?(TD,,*(4CP\%=86MT)#9"Q M?@G6 44,9B?9F?A,_8FQ:"C!;"2EGA"?VJ! ._!9FR^_E=7 @0XPFVN[]A M75N, Z8UQ'.J:"+//@=1A;J*=Q6)&M\! JU*R $[+X#7_Q>(*@QH=P@G,.3@ MM.DA ZEI:.F/(*MI^PF0/,.E!#Q:^ ;1K<207FL.2G.TR3I/J1(" ]++31Y, M)-_ ^4&S_$NR/6X?R3B/BT\%?#TA:01_F*?M>>[5'E@*-$EKY,%4@.49%IJ9 M)L$,'/@PJW"4 H@)R733C^LP),%(;527J1@0Y.J+?$)D%08C\+O MPS\5CLF"3E,T#>#,VG"3:"#;:CW=:[O]"W!J.-MX2O%9VH]+K1I_/1,,_X+V M;X4_Y"(4\#ZRO1($AH3 >((0_/T:(AH(Z\MP )K]<]_$?'^Z_L#N @Q;5A=Q=% M-9FR5$7*"\=!>@.+PJ->"=C2Q \'!3L/&()5'9Y$2[J1=G^!(YC$Z2=T M4W-V!>364++E.1Z-X-SQWDO+-$1 2ZL5B#[.(OK)_ #'I,B4;3FGEOL1;(#8 M,0/43QD#35\Y1O$+'[T+\N@PR;)/N"UR*;1(8@<6EF4!QN:(5'\L4YCLRHHW M 9*FD*@!\I_-2_C 2ZO)$- _Y9"AJ0'*=:(=H"HP0A'8DH;%*$%$JEJ M:;7?Y< /:]&%0!6$%[:4ZK<-!@E8B4IPA[-F(-%0Q>"W"12T*1H",W5Z MWZNC$!QK*P1Y_R #T=;(O0_ 1=[EI>]= EJ\WKGWM^_.^OWNRY]QVH\2@H94 MPBW&(0B;CX Q[RU_YN>?\.E7]&KO)<^HN9]%_V(F0.V*!"5MB$*$" V3%S1- MFX*E#HXV ):1ERZF[ &C%"O(TD962A)@PQ$B8@F_@6:/@1S(@&+?&=YL,AIM M+V;:1,2 /@/5-8ZGRDC3 I?"0&/PON#OFFVB.*E %"[?AS[K<$;K _Z(:-BQ M1C4SA/=1+]:>P[!A$RB3(H+%/J.]R2$A,.^3^$:R)IL#2,GDR#<7 /(M\Y@K M*$+@ ]@1:8D*[9H"A.D$B$ :IFRH!$-@!X 6?QU_49\(-^P;1H")-_D=S7IR M2]H:B"?30%H#QB= <9/QW302&*!H'U6IHB7IT:"1@$[:'+IK ))\H)/#PF*. MO&IKAR7C'6T2MQ:S_WZ39W? 3R S*/Y@0E<;LK"'FX!#$^:I]/;GS0[CPK(Y MRFHK#)'!L3S/.%<'F@8WXG (A/GI,!C!>5X$R1U8AP?>3P^[$K3GD#\'WC@7 MHU\.OKM^?P$_F@*3E@$_1+H2+TC6@@01&$H@Z@1FOH!U.2Q"TO/GGX)72ZS/ MKP$.\T[_BS_)R]Z_ZA:$L!85WR9V0='G*VE%H#SYLQ UH6QO&(W"-WBC2.J< M.('N_M@D(:N4XJ,SKS .7Z'GC!/28LP.[TSS+%@7YN0/Q%4)792SE%E4('TT*\4/]XZ7$B MQ%E7IF=]^X:@O(&3XTZW;]48^NU-9'JJ:=@G9U8A9$',63)/T9P[>F+#V-%! MO]._!W5[-\SZ*O[LO>-(S1N=[J/OW#8^YMK-(W6:QWI$.1UD,VJT#NK;H(-Z M1QT#2TCJT M6&3;+V4W:>[O#:O8V@Z1%-I^8\'*J-'>H.09)0!D51&D4?'H:;K;WI;2#EQL M0T_*5L6Q2\6A?XB2KZRHD#+B'-)G5 X0IS^^L+ ]Y3=2(=9@R-;Z]CVKHK85 M#0-T)/>[RX"MJ'$<<>/NWZ)9[\+Q[W9GL:%^Z:AV%WB Q=6NY.SAQGL /O>RR0[T."T-CAT9UW[$+-G_.&NY9Q$VDO"MQ4-3C&\.O5[ M WS1R9]/)/'L:OUB#5XV=I/H%-$V2#>G MB+8&54X1K:>(-C;0WBFBKY^#^C6["T=9A3W]^YTG5$O]T\[@V&[$8(<9/?
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end